

DESCRIPTION

Title of the Invention: ANTI-SIGLEC-15 ANTIBODY

Technical Field

[0001]

The present invention relates to a substance useful as a therapeutic and/or preventive agent for abnormal bone metabolism, and a method of treating and/or preventing abnormal bone metabolism.

Background Art

[0002]

Bone is known to be a dynamic organ which is continuously remodelled by repeated formation and resorption so as to change its own morphology and maintain blood calcium levels. Healthy bone maintains an equilibrium between bone formation by osteoblasts and bone resorption by osteoclasts, and bone mass is maintained constant. In contrast, when the equilibrium between bone formation and bone resorption is lost, abnormal bone metabolism such as osteoporosis occurs (WO 07/093042 and Endocrinological Review, (1992) 13, pp. 66-80).

[0003]

As factors which regulate bone metabolism, many systemic hormones and local cytokines have been reported, and these

factors collaborate with one another to form and maintain bone (WO 07/093042 and Endocrinological Review, (1996) 17, pp. 308-332). As a change in bone tissue due to aging, the occurrence of osteoporosis is widely known, but the mechanism of its occurrence encompasses various factors such as a decrease in secretion of sex hormones and an abnormality in the receptors for the hormones; variation in cytokine expression locally in bone; expression of aging genes; and osteoclast or osteoblast differentiation failure or dysfunction, and thus it is difficult to consider it as a simple age-related physiological phenomenon. Primary osteoporosis is largely divided into postmenopausal osteoporosis due to a decrease in secretion of estrogen and senile osteoporosis due to aging, but advancement of basic research on the mechanisms of regulation of bone formation and bone resorption is essential to elucidate the mechanism of its occurrence and to develop a therapeutic agent therefor.

[0004]

Osteoclasts are multinucleated cells derived from hematopoietic stem cells, and by releasing chloride ions and hydrogen ions on a bone surface to which osteoclasts adhere, osteoclasts acidify a gap between the bone surface and the osteoclasts and also secrete cathepsin K which is an acid protease or the like (American Journal of Physiology, (1991) 260, C1315-C1324). This causes degradation of calcium

phosphate, activation of acid proteases and degradation of bone matrix proteins, resulting in bone resorption.

[0005]

Osteoclast precursor cells have been found to be differentiated into osteoclasts by stimulation with RANKL (receptor activator of NF- κ B ligand) expressed on the cell membrane of osteoblasts/stromal cells present on the surface of bone (Proceedings of the National Academy of Science of the United States of America, (1998) 95, pp. 3597-3602, and Cell, (1998) 93, pp. 165-176). It has been revealed that RANKL is a membrane protein produced by osteoblasts/stromal cells, its expression is regulated by a bone resorption factor, RANKL induces differentiation of osteoclast precursor cells into mature multinucleated osteoclasts, and the like (Proceedings of the National Academy of Science of the United States of America, (1998) 95, pp. 3597-3602, and Journal of Bone and Mineral Research, (1998) 23, S222). Further, knockout mice devoid of RANKL have been found to develop an osteopetrosis-like disease, and therefore, RANKL has been proved to be a physiological osteoclast differentiation-inducing factor (Nature, (1999) 397, pp. 315-323).

[0006]

As pharmaceutical preparations for treating bone metabolism diseases or shortening the duration of treatment,

bisphosphonates, active vitamin D₃, calcitonin and derivatives thereof, hormones such as estradiol, SERMs (selective estrogen receptor modulators), ipriflavone, vitamin K₂ (menatetrenone), PTH, calcium preparations, and the like are used. However, these medicinal agents are not always satisfactory in terms of therapeutic outcome and the development of a medicinal agent with a more potent therapeutic effect has been demanded.

[0007]

The cell membranes of immune cells are covered with a dense coating of various glycans such as sialylated glycans which are recognized by various glycan-binding proteins. Sialic-acid-binding immunoglobulin-like lectins (hereinafter referred to as "siglecs") are a family of type I membrane proteins which recognize sialylated glycans and bind thereto. Many siglecs are expressed on the cell membranes of immune cells and recognize sialic acid similarly present on the cell membranes of immune cells and regulate cell interaction or cell function and are considered to be involved in immune responses (Nature Reviews Immunology, (2007) 7, pp. 255-266). However, there are also a lot of siglec molecules whose physiological functions have not been elucidated yet. Siglec-15 (Sialic-acid binding immunoglobulin-like lectin 15) is a molecule which has been newly reported to belong to the Siglecs (see, for example, Non-patent document 10) and is identical to a molecule called CD33L3 (CD33 molecule-like 3). This

molecule is highly evolutionarily conserved from fish to humans and has been found to be strongly expressed in dendritic cells and/or macrophages of human spleen and lymph nodes. Further, as a result of a binding test using a sialic acid probe, it has also been found that human Siglec-15 binds to Neu5Ac α 2-6GalNAc and that mouse Siglec-15 binds further to Neu5Ac α 2-3Gal β 1-4Glc, and the like (see, for example, Glycobiology, (2007) 17, pp. 838-846). Until recently, the physiological role of Siglec-15 had not been revealed, however, it has been reported that the expression of Siglec-15 increases with the differentiation and maturation of osteoclasts, and the differentiation of osteoclasts is inhibited by decreasing the expression of Siglec-15 by RNA interference (see, for example, WO 07/093042). Further, the effect of an anti-Siglec-15 antibody on osteoclast differentiation has been revealed for the first time in WO 09/48072 (published on April 16, 2009), however, an antibody sequence which can be administered to humans has not been elucidated yet.

Summary of the Invention

Problems that the Invention is to Solve

[0008]

An object of the invention is to provide a gene which is specifically expressed in various forms of abnormal bone metabolism which are seen in osteoporosis, rheumatoid

arthritis, cancer metastasis to bone or the like, a substance which inhibits the differentiation and maturation of osteoclasts and the activity thereof, and a therapeutic and/or preventive agent for abnormal bone metabolism.

Means for Solving the Problems

[0009]

The present inventors studied to elucidate the mechanism of osteoclast differentiation, maturation and activation in order to find a substance having a therapeutic and/or preventive effect on abnormal bone metabolism. As a result, the present inventors found that the expression of Siglec-15 gene increases with the differentiation and maturation of osteoclasts, and also found that the differentiation of osteoclasts is inhibited by an antibody which specifically binds to Siglec-15. Further, the present inventors humanized an obtained rat anti-mouse Siglec-15 antibody, and thus completed the invention.

That is, the invention includes the following inventions.

(1) An antibody which binds to a polypeptide comprising amino acid residues 39 to 165 of an amino acid sequence represented by SEQ ID NO: 2 and inhibits osteoclast formation and/or osteoclastic bone resorption, or a functional fragment of the antibody.

(2) The antibody or a functional fragment of the antibody according to (1), characterized in that:

a heavy chain sequence contains a variable region having CDRH1, CDRH2, and CDRH3, and the CDRH1 comprises an amino acid sequence represented by SEQ ID NO: 44, the CDRH2 comprises any one of amino acid sequences represented by SEQ ID NO: 45 and SEQ ID NO: 97, and the CDRH3 comprises an amino acid sequence represented by SEQ ID NO: 46; and

a light chain sequence contains a variable region having CDRL1, CDRL2, and CDRL3, and the CDRL1 comprises an amino acid sequence represented by SEQ ID NO: 47, the CDRL2 comprises an amino acid sequence represented by SEQ ID NO: 48, and the CDRL3 comprises an amino acid sequence represented by SEQ ID NO: 49.

(3) The antibody or a functional fragment of the antibody according to (2), characterized by containing a heavy chain variable region sequence comprising amino acid residues 20 to 140 of an amino acid sequence represented by SEQ ID NO: 41 and a light chain variable region sequence comprising amino acid residues 21 to 132 of an amino acid sequence represented by SEQ ID NO: 43.

(4) The functional fragment of the antibody according to any one of (1) to (3) which is selected from the group consisting of Fab, F(ab')₂, Fab' and Fv.

(5) The antibody according to any one of (1) to (3), characterized by being an scFv.

(6) The antibody or a functional fragment of the antibody according to any one of (1) to (4), characterized in that the antibody is a chimeric antibody.

(7) The antibody or a functional fragment of the antibody according to (6), characterized by comprising a heavy chain sequence comprising amino acid residues 20 to 470 of an amino acid sequence represented by SEQ ID NO: 41 and a light chain sequence comprising amino acid residues 21 to 237 of an amino acid sequence represented by SEQ ID NO: 43.

(8) The antibody or a functional fragment of the antibody according to any one of (1) to (4), and (6), characterized in that the antibody is humanized.

(9) The antibody according to (7) or (8), wherein the heavy chain has a constant region of a human immunoglobulin G2 heavy chain and the light chain has a constant region of a human immunoglobulin κ light chain.

(10) An antibody which inhibits osteoclast formation and/or osteoclastic bone resorption or a functional fragment of the antibody, wherein the antibody contains:

(a) a heavy chain variable region selected from the group consisting of the following amino acid sequences:

a1) an amino acid sequence comprising amino acid residues 20 to 140 of an amino acid sequence represented by SEQ ID NO: 51;

a2) an amino acid sequence comprising amino acid residues

20 to 140 of an amino acid sequence represented by SEQ ID NO:
53;

a3) an amino acid sequence comprising amino acid residues
20 to 140 of an amino acid sequence represented by SEQ ID NO:
55;

a4) an amino acid sequence comprising amino acid residues
20 to 140 of an amino acid sequence represented by SEQ ID NO:
57;

a5) an amino acid sequence comprising amino acid residues
20 to 140 of an amino acid sequence represented by SEQ ID NO:
59;

a6) an amino acid sequence comprising amino acid residues
20 to 140 of an amino acid sequence represented by SEQ ID NO:
99;

a7) an amino acid sequence comprising amino acid residues
20 to 140 of an amino acid sequence represented by SEQ ID NO:
101;

a8) an amino acid sequence having a homology of at least
95% with any one of the amino acid sequences selected from a1)
to a7);

a9) an amino acid sequence having a homology of at least
99% with any one of the amino acid sequences selected from a1)
to a7); and

a10) an amino acid sequence including a substitution,
deletion, or addition of one to several amino acid residues

in any one of the amino acid sequences selected from a1) to a7); and

(b) a light chain variable region selected from the group consisting of the following amino acid sequences:

b1) an amino acid sequence comprising amino acid residues 21 to 133 of an amino acid sequence represented by SEQ ID NO: 61;

b2) an amino acid sequence comprising amino acid residues 21 to 133 of an amino acid sequence represented by SEQ ID NO: 63;

b3) an amino acid sequence comprising amino acid residues 21 to 133 of an amino acid sequence represented by SEQ ID NO: 65;

b4) an amino acid sequence comprising amino acid residues 21 to 132 of an amino acid sequence represented by SEQ ID NO: 67;

b5) an amino acid sequence comprising amino acid residues 21 to 133 of an amino acid sequence represented by SEQ ID NO: 69;

b6) an amino acid sequence comprising amino acid residues 21 to 133 of an amino acid sequence represented by SEQ ID NO: 71;

b7) an amino acid sequence comprising amino acid residues 21 to 133 of an amino acid sequence represented by SEQ ID NO: 103;

b8) an amino acid sequence comprising amino acid residues 21 to 133 of an amino acid sequence represented by SEQ ID NO: 105;

b9) an amino acid sequence having a homology of at least 95% with any one of the amino acid sequences selected from b1) to b8);

b10) an amino acid sequence having a homology of at least 99% with any one of the amino acid sequences selected from b1) to b8); and

b11) an amino acid sequence including a substitution, deletion, or addition of one to several amino acid residues in any one of the amino acid sequences selected from b1) to b8).

(11) The antibody or a functional fragment of the antibody according to (10), characterized by containing a heavy chain sequence containing a heavy chain variable region comprising an amino acid sequence comprising amino acid residues 20 to 140 of an amino acid sequence represented by SEQ ID NO: 51 and a light chain sequence containing a light chain variable region comprising an amino acid sequence comprising amino acid residues 21 to 133 of an amino acid sequence represented by SEQ ID NO: 61.

(12) The antibody or a functional fragment of the antibody according to (10), characterized by containing a heavy chain sequence containing a heavy chain variable region

comprising an amino acid sequence comprising amino acid residues 20 to 140 of an amino acid sequence represented by SEQ ID NO: 53 and a light chain sequence containing a light chain variable region comprising an amino acid sequence comprising amino acid residues 21 to 133 of an amino acid sequence represented by SEQ ID NO: 63.

(13) The antibody or a functional fragment of the antibody according to (10), characterized by containing a heavy chain sequence containing a heavy chain variable region comprising an amino acid sequence comprising amino acid residues 20 to 140 of an amino acid sequence represented by SEQ ID NO: 55 and a light chain sequence containing a light chain variable region comprising an amino acid sequence comprising amino acid residues 21 to 133 of an amino acid sequence represented by SEQ ID NO: 65.

(14) The antibody or a functional fragment of the antibody according to (10), characterized by containing a heavy chain sequence containing a heavy chain variable region comprising an amino acid sequence comprising amino acid residues 20 to 140 of an amino acid sequence represented by SEQ ID NO: 55 and a light chain sequence containing a light chain variable region comprising an amino acid sequence comprising amino acid residues 21 to 132 of an amino acid sequence represented by SEQ ID NO: 67.

(15) The antibody or a functional fragment of the

antibody according to (10), characterized by containing a heavy chain sequence containing a heavy chain variable region comprising an amino acid sequence comprising amino acid residues 20 to 140 of an amino acid sequence represented by SEQ ID NO: 57 and a light chain sequence containing a light chain variable region comprising an amino acid sequence comprising amino acid residues 21 to 133 of an amino acid sequence represented by SEQ ID NO: 69.

(16) The antibody or a functional fragment of the antibody according to (10), characterized by containing a heavy chain sequence containing a heavy chain variable region comprising an amino acid sequence comprising amino acid residues 20 to 140 of an amino acid sequence represented by SEQ ID NO: 59 and a light chain sequence containing a light chain variable region comprising an amino acid sequence comprising amino acid residues 21 to 133 of an amino acid sequence represented by SEQ ID NO: 71.

(17) The antibody or a functional fragment of the antibody according to (10), characterized by containing a heavy chain sequence containing a heavy chain variable region comprising an amino acid sequence comprising amino acid residues 20 to 140 of an amino acid sequence represented by SEQ ID NO: 99 and a light chain sequence containing a light chain variable region comprising an amino acid sequence comprising amino acid residues 21 to 133 of an amino acid

sequence represented by SEQ ID NO: 69.

(18) The antibody or a functional fragment of the antibody according to (10), characterized by containing a heavy chain sequence containing a heavy chain variable region comprising an amino acid sequence comprising amino acid residues 20 to 140 of an amino acid sequence represented by SEQ ID NO: 101 and a light chain sequence containing a light chain variable region comprising an amino acid sequence comprising amino acid residues 21 to 133 of an amino acid sequence represented by SEQ ID NO: 69.

(19) The antibody or a functional fragment of the antibody according to (10), characterized by containing a heavy chain sequence containing a heavy chain variable region comprising an amino acid sequence comprising amino acid residues 20 to 140 of an amino acid sequence represented by SEQ ID NO: 99 and a light chain sequence containing a light chain variable region comprising an amino acid sequence comprising amino acid residues 21 to 133 of an amino acid sequence represented by SEQ ID NO: 103.

(20) The antibody or a functional fragment of the antibody according to (10), characterized by containing a heavy chain sequence containing a heavy chain variable region comprising an amino acid sequence comprising amino acid residues 20 to 140 of an amino acid sequence represented by SEQ ID NO: 99 and a light chain sequence containing a light

chain variable region comprising an amino acid sequence comprising amino acid residues 21 to 133 of an amino acid sequence represented by SEQ ID NO: 105.

(21) The antibody or a functional fragment of the antibody according to (10), characterized by containing a heavy chain sequence comprising amino acid residues 20 to 470 of an amino acid sequence represented by SEQ ID NO: 51 and a light chain sequence comprising amino acid residues 21 to 238 of an amino acid sequence represented by SEQ ID NO: 61.

(22) The antibody or a functional fragment of the antibody according to (10), characterized by containing a heavy chain sequence comprising amino acid residues 20 to 470 of an amino acid sequence represented by SEQ ID NO: 53 and a light chain sequence comprising amino acid residues 21 to 238 of an amino acid sequence represented by SEQ ID NO: 63.

(23) The antibody or a functional fragment of the antibody according to (10), characterized by containing a heavy chain sequence comprising amino acid residues 20 to 470 of an amino acid sequence represented by SEQ ID NO: 55 and a light chain sequence comprising amino acid residues 21 to 238 of an amino acid sequence represented by SEQ ID NO: 65.

(24) The antibody or a functional fragment of the antibody according to (10), characterized by containing a heavy chain sequence comprising amino acid residues 20 to 470 of an amino acid sequence represented by SEQ ID NO: 55 and a light

chain sequence comprising amino acid residues 21 to 237 of an amino acid sequence represented by SEQ ID NO: 67.

(25) The antibody or a functional fragment of the antibody according to (10), characterized by containing a heavy chain sequence comprising amino acid residues 20 to 470 of an amino acid sequence represented by SEQ ID NO: 57 and a light chain sequence comprising amino acid residues 21 to 238 of an amino acid sequence represented by SEQ ID NO: 69.

(26) The antibody or a functional fragment of the antibody according to (10), characterized by containing a heavy chain sequence comprising amino acid residues 20 to 470 of an amino acid sequence represented by SEQ ID NO: 59 and a light chain sequence comprising amino acid residues 21 to 238 of an amino acid sequence represented by SEQ ID NO: 71.

(27) The antibody or a functional fragment of the antibody according to (10), characterized by containing a heavy chain sequence comprising amino acid residues 20 to 466 of an amino acid sequence represented by SEQ ID NO: 99 and a light chain sequence comprising amino acid residues 21 to 238 of an amino acid sequence represented by SEQ ID NO: 69.

(28) The antibody or a functional fragment of the antibody according to (10), characterized by containing a heavy chain sequence comprising amino acid residues 20 to 466 of an amino acid sequence represented by SEQ ID NO: 101 and a light chain sequence comprising amino acid residues 21 to 238 of an

amino acid sequence represented by SEQ ID NO: 69.

(29) The antibody or a functional fragment of the antibody according to (10), characterized by containing a heavy chain sequence comprising amino acid residues 20 to 466 of an amino acid sequence represented by SEQ ID NO: 99 and a light chain sequence comprising amino acid residues 21 to 238 of an amino acid sequence represented by SEQ ID NO: 103.

(30) The antibody or a functional fragment of the antibody according to (10), characterized by containing a heavy chain sequence comprising amino acid residues 20 to 466 of an amino acid sequence represented by SEQ ID NO: 99 and a light chain sequence comprising amino acid residues 21 to 238 of an amino acid sequence represented by SEQ ID NO: 105.

(31) A pharmaceutical composition, characterized by comprising at least one of the antibodies or functional fragments of the antibodies according to (1) to (30).

(32) The pharmaceutical composition according to (31), characterized by being a therapeutic and/or preventive agent for abnormal bone metabolism.

(33) A pharmaceutical composition for treating and/or preventing abnormal bone metabolism, characterized by comprising at least one of the antibodies or functional fragments of the antibodies according to (1) to (30) and at least one member selected from the group consisting of bisphosphonates, active vitamin D₃, calcitonin and derivatives

thereof, hormones such as estradiol, SERMs (selective estrogen receptor modulators), ipriflavone, vitamin K₂ (menatetrenone), calcium preparations, PTH (parathyroid hormone), nonsteroidal anti-inflammatory agents, soluble TNF receptors, anti-TNF- α antibodies or functional fragments of the antibodies, anti-PTHrP (parathyroid hormone-related protein) antibodies or functional fragments of the antibodies, IL-1 receptor antagonists, anti-IL-6 receptor antibodies or functional fragments of the antibodies, anti-RANKL antibodies or functional fragments of the antibodies, and OCIF (osteoclastogenesis inhibitory factor).

(34) The pharmaceutical composition according to (32) or (33), wherein the abnormal bone metabolism is selected from the group consisting of osteoporosis, bone destruction accompanying rheumatoid arthritis, cancerous hypercalcemia, bone destruction accompanying multiple myeloma or cancer metastasis to bone, giant cell tumor, osteopenia, tooth loss due to periodontitis, osteolysis around a prosthetic joint, bone destruction in chronic osteomyelitis, Paget's disease of bone, renal osteodystrophy, and osteogenesis imperfecta.

(35) The pharmaceutical composition according to (34), characterized in that the abnormal bone metabolism is osteoporosis, bone destruction accompanying rheumatoid arthritis, or bone destruction accompanying cancer metastasis to bone.

(36) The pharmaceutical composition according to (35), characterized in that the abnormal bone metabolism is osteoporosis.

(37) The pharmaceutical composition according to (36), characterized in that the osteoporosis is postmenopausal osteoporosis, senile osteoporosis, secondary osteoporosis due to the use of a therapeutic agent such as a steroid or an immunosuppressant, or osteoporosis accompanying rheumatoid arthritis.

(38) A method of treating and/or preventing abnormal bone metabolism, characterized by administering at least one of the antibodies or functional fragments of the antibodies according to (1) to (30).

(39) A method of treating and/or preventing abnormal bone metabolism, characterized by simultaneously or successively administering at least one of the antibodies or functional fragments of the antibodies according to (1) to (30) and at least one member selected from the group consisting of bisphosphonates, active vitamin D₃, calcitonin and derivatives thereof, hormones such as estradiol, SERMs (selective estrogen receptor modulators), ipriflavone, vitamin K₂ (menatetrenone), calcium preparations, PTH (parathyroid hormone), nonsteroidal anti-inflammatory agents, soluble TNF receptors, anti-TNF- α antibodies or functional fragments of the antibodies, anti-PTHrP (parathyroid hormone-related protein) antibodies

or functional fragments of the antibodies, IL-1 receptor antagonists, anti-IL-6 receptor antibodies or functional fragments of the antibodies, anti-RANKL antibodies or functional fragments of the antibodies, and OCIF (osteoclastogenesis inhibitory factor).

(40) The treatment and/or prevention method according to (38) or (39), characterized in that the abnormal bone metabolism is osteoporosis, bone destruction accompanying rheumatoid arthritis, or bone destruction accompanying cancer metastasis to bone.

(41) The treatment and/or prevention method according to (40), characterized in that the abnormal bone metabolism is osteoporosis.

(42) The treatment and/or prevention method according to (41), characterized in that the osteoporosis is postmenopausal osteoporosis, senile osteoporosis, secondary osteoporosis due to the use of a therapeutic agent such as a steroid or an immunosuppressant, or osteoporosis accompanying rheumatoid arthritis.

(43) A polynucleotide encoding the antibody according to any one of (3), (7), and (10) to (30).

(44) The polynucleotide according to (43), characterized by containing a nucleotide sequence comprising nucleotides 58 to 420 of a nucleotide sequence represented by SEQ ID NO: 40 and a nucleotide sequence comprising nucleotides 61 to 396 of

a nucleotide sequence represented by SEQ ID NO: 42.

(45) The polynucleotide according to (44), characterized by containing a nucleotide sequence comprising nucleotides 58 to 1410 of a nucleotide sequence represented by SEQ ID NO: 40 and a nucleotide sequence comprising nucleotides 61 to 711 of a nucleotide sequence represented by SEQ ID NO: 42.

(46) The polynucleotide according to (43), characterized by containing:

(a) a polynucleotide selected from the group consisting of the following nucleotide sequences:

a1) a nucleotide sequence comprising nucleotides 58 to 420 of a nucleotide sequence represented by SEQ ID NO: 50;

a2) a nucleotide sequence comprising nucleotides 58 to 420 of a nucleotide sequence represented by SEQ ID NO: 52;

a3) a nucleotide sequence comprising nucleotides 58 to 420 of a nucleotide sequence represented by SEQ ID NO: 54;

a4) a nucleotide sequence comprising nucleotides 58 to 420 of a nucleotide sequence represented by SEQ ID NO: 56;

a5) a nucleotide sequence comprising nucleotides 58 to 420 of a nucleotide sequence represented by SEQ ID NO: 58;

a6) a nucleotide sequence comprising nucleotides 58 to 420 of a nucleotide sequence represented by SEQ ID NO: 98;

a7) a nucleotide sequence comprising nucleotides 58 to 420 of a nucleotide sequence represented by SEQ ID NO: 100;

a8) a nucleotide sequence of a polynucleotide which

hybridizes to a polynucleotide comprising a nucleotide sequence complementary to any one of the nucleotide sequences selected from a1) to a7) under stringent conditions; and

a9) a nucleotide sequence including a substitution, deletion, or addition of one to several nucleotides in any one of the nucleotide sequences selected from a1) to a7); and

(b) a polynucleotide selected from the group consisting of the following nucleotide sequences:

b1) a nucleotide sequence comprising nucleotides 61 to 399 of a nucleotide sequence represented by SEQ ID NO: 60;

b2) a nucleotide sequence comprising nucleotides 61 to 399 of a nucleotide sequence represented by SEQ ID NO: 62;

b3) a nucleotide sequence comprising nucleotides 61 to 399 of a nucleotide sequence represented by SEQ ID NO: 64;

b4) a nucleotide sequence comprising nucleotides 61 to 396 of a nucleotide sequence represented by SEQ ID NO: 66;

b5) a nucleotide sequence comprising nucleotides 61 to 399 of a nucleotide sequence represented by SEQ ID NO: 68;

b6) a nucleotide sequence comprising nucleotides 61 to 399 of a nucleotide sequence represented by SEQ ID NO: 70;

b7) a nucleotide sequence comprising nucleotides 61 to 399 of a nucleotide sequence represented by SEQ ID NO: 102;

b8) a nucleotide sequence comprising nucleotides 61 to 399 of a nucleotide sequence represented by SEQ ID NO: 104;

b9) a nucleotide sequence of a polynucleotide which hybridizes to a polynucleotide comprising a nucleotide sequence complementary to any one of the nucleotide sequences selected from b1) to b8) under stringent conditions; and

b10) a nucleotide sequence including a substitution, deletion, or addition of one to several nucleotides in any one of the nucleotide sequences selected from b1) to b8).

(47) The polynucleotide according to (46), characterized by containing a polynucleotide comprising a nucleotide sequence comprising nucleotides 58 to 420 of a nucleotide sequence represented by SEQ ID NO: 50, and a polynucleotide comprising a nucleotide sequence comprising nucleotides 61 to 399 of a nucleotide sequence represented by SEQ ID NO: 60.

(48) The polynucleotide according to (46), characterized by containing a polynucleotide comprising a nucleotide sequence comprising nucleotides 58 to 420 of a nucleotide sequence represented by SEQ ID NO: 52, and a polynucleotide comprising a nucleotide sequence comprising nucleotides 61 to 399 of a nucleotide sequence represented by SEQ ID NO: 62.

(49) The polynucleotide according to (46), characterized by containing a polynucleotide comprising a nucleotide sequence comprising nucleotides 58 to 420 of a nucleotide sequence represented by SEQ ID NO: 54, and a polynucleotide comprising a nucleotide sequence comprising nucleotides 61 to 399 of a nucleotide sequence represented by SEQ ID NO: 64.

(50) The polynucleotide according to (46), characterized by containing a polynucleotide comprising a nucleotide sequence comprising nucleotides 58 to 420 of a nucleotide sequence represented by SEQ ID NO: 54, and a polynucleotide comprising a nucleotide sequence comprising nucleotides 61 to 396 of a nucleotide sequence represented by SEQ ID NO: 66.

(51) The polynucleotide according to (46), characterized by containing a polynucleotide comprising a nucleotide sequence comprising nucleotides 58 to 420 of a nucleotide sequence represented by SEQ ID NO: 56, and a polynucleotide comprising a nucleotide sequence comprising nucleotides 61 to 399 of a nucleotide sequence represented by SEQ ID NO: 68.

(52) The polynucleotide according to (46), characterized by containing a polynucleotide comprising a nucleotide sequence comprising nucleotides 58 to 420 of a nucleotide sequence represented by SEQ ID NO: 58, and a polynucleotide comprising a nucleotide sequence comprising nucleotides 61 to 399 of a nucleotide sequence represented by SEQ ID NO: 70.

(53) The polynucleotide according to (46), characterized by containing a polynucleotide comprising a nucleotide sequence comprising nucleotides 58 to 420 of a nucleotide sequence represented by SEQ ID NO: 98, and a polynucleotide comprising a nucleotide sequence comprising nucleotides 61 to 399 of a nucleotide sequence represented by SEQ ID NO: 68.

(54) The polynucleotide according to (46), characterized

by containing a polynucleotide comprising a nucleotide sequence comprising nucleotides 58 to 420 of a nucleotide sequence represented by SEQ ID NO: 100, and a polynucleotide comprising a nucleotide sequence comprising nucleotides 61 to 399 of a nucleotide sequence represented by SEQ ID NO: 68.

(55) The polynucleotide according to (46), characterized by containing a polynucleotide comprising a nucleotide sequence comprising nucleotides 58 to 420 of a nucleotide sequence represented by SEQ ID NO: 98, and a polynucleotide comprising a nucleotide sequence comprising nucleotides 61 to 399 of a nucleotide sequence represented by SEQ ID NO: 102.

(56) The polynucleotide according to (46), characterized by containing a polynucleotide comprising a nucleotide sequence comprising nucleotides 58 to 420 of a nucleotide sequence represented by SEQ ID NO: 98, and a polynucleotide comprising a nucleotide sequence comprising nucleotides 61 to 399 of a nucleotide sequence represented by SEQ ID NO: 104.

(57) The polynucleotide according to (46), characterized by containing a polynucleotide comprising a nucleotide sequence comprising nucleotides 58 to 1410 of a nucleotide sequence represented by SEQ ID NO: 50, and a polynucleotide comprising a nucleotide sequence comprising nucleotides 61 to 714 of a nucleotide sequence represented by SEQ ID NO: 60.

(58) The polynucleotide according to (46), characterized by containing a polynucleotide comprising a nucleotide

sequence comprising nucleotides 58 to 1410 of a nucleotide sequence represented by SEQ ID NO: 52, and a polynucleotide comprising a nucleotide sequence comprising nucleotides 61 to 714 of a nucleotide sequence represented by SEQ ID NO: 62.

(59) The polynucleotide according to (46), characterized by containing a polynucleotide comprising a nucleotide sequence comprising nucleotides 58 to 1410 of a nucleotide sequence represented by SEQ ID NO: 54, and a polynucleotide comprising a nucleotide sequence comprising nucleotides 61 to 714 of a nucleotide sequence represented by SEQ ID NO: 64.

(60) The polynucleotide according to (46), characterized by containing a polynucleotide comprising a nucleotide sequence comprising nucleotides 58 to 1410 of a nucleotide sequence represented by SEQ ID NO: 54, and a polynucleotide comprising a nucleotide sequence comprising nucleotides 61 to 711 of a nucleotide sequence represented by SEQ ID NO: 66.

(61) The polynucleotide according to (46), characterized by containing a polynucleotide comprising a nucleotide sequence comprising nucleotides 58 to 1410 of a nucleotide sequence represented by SEQ ID NO: 56, and a polynucleotide comprising a nucleotide sequence comprising nucleotides 61 to 714 of a nucleotide sequence represented by SEQ ID NO: 68.

(62) The polynucleotide according to (46), characterized by containing a polynucleotide comprising a nucleotide sequence comprising nucleotides 58 to 1410 of a nucleotide

sequence represented by SEQ ID NO: 58, and a polynucleotide comprising a nucleotide sequence comprising nucleotides 61 to 714 of a nucleotide sequence represented by SEQ ID NO: 70.

(63) The polynucleotide according to (46), characterized by containing a polynucleotide comprising a nucleotide sequence comprising nucleotides 58 to 1398 of a nucleotide sequence represented by SEQ ID NO: 98, and a polynucleotide comprising a nucleotide sequence comprising nucleotides 61 to 714 of a nucleotide sequence represented by SEQ ID NO: 68.

(64) The polynucleotide according to (46), characterized by containing a polynucleotide comprising a nucleotide sequence comprising nucleotides 58 to 1398 of a nucleotide sequence represented by SEQ ID NO: 100, and a polynucleotide comprising a nucleotide sequence comprising nucleotides 61 to 714 of a nucleotide sequence represented by SEQ ID NO: 68.

(65) The polynucleotide according to (46), characterized by containing a polynucleotide comprising a nucleotide sequence comprising nucleotides 58 to 1398 of a nucleotide sequence represented by SEQ ID NO: 98, and a polynucleotide comprising a nucleotide sequence comprising nucleotides 61 to 714 of a nucleotide sequence represented by SEQ ID NO: 102.

(66) The polynucleotide according to (46), characterized by containing a polynucleotide comprising a nucleotide sequence comprising nucleotides 58 to 1398 of a nucleotide sequence represented by SEQ ID NO: 98, and a polynucleotide

comprising a nucleotide sequence comprising nucleotides 61 to 714 of a nucleotide sequence represented by SEQ ID NO: 104.

(67) A vector, comprising any one of the polynucleotides according to (43) to (66).

(68) A transformed host cell, comprising any one of the polynucleotides according to (43) to (66).

(69) A transformed host cell, comprising the vector according to (67).

(70) A method of producing the antibody according to any one of (3), (7), and (10) to (30), comprising culturing the host cell according to (68) or (69), and purifying an antibody from the resulting culture product.

Advantage of the Invention

[0010]

According to the invention, a therapeutic and/or preventive agent for abnormal bone metabolism whose mechanism of action is to inhibit the differentiation and maturation of osteoclasts and the bone resorption activity thereof can be obtained.

Brief Description of the Drawings

[0011]

[Fig. 1] Fig. 1 shows the results of evaluating the purity of mouse Siglec-15-His purified by HisTrap HP column

chromatography and Resource Q column chromatography through SDS-polyacrylamide electrophoresis and silver staining.

[Fig. 2] Fig. 2 shows the results of detecting the characteristics of mouse Siglec-15-His purified by HisTrap HP column chromatography and Resource Q column chromatography through SDS-polyacrylamide electrophoresis and Western blotting using an anti-V5-HRP antibody.

[Fig. 3] Fig. 3 shows the results of evaluating the purity of mouse Siglec-15-Fc purified by HiTrap Protein A column chromatography through SDS-polyacrylamide electrophoresis and silver staining.

[Fig. 4] Fig. 4 shows the results of testing the binding of a rat anti-mouse Siglec-15 monoclonal antibody to a plate having mouse Siglec-15-Fc immobilized thereon by an ELISA method. The symbol (◆) denotes #1A1 antibody, the symbol (■) denotes #3A1 antibody, the symbol (▲) denotes #8A1 antibody, the symbol (×) denotes #24A1 antibody, the symbol (●) denotes #32A1 antibody, the symbol (○) denotes #34A1 antibody, the symbol (+) denotes #39A1 antibody, the symbol (-) denotes #40A1 antibody, the symbol (—) denotes #41B1 antibody, the symbol (◇) denotes #61A1 antibody, and the symbol (□) denotes control IgG.

[Fig. 5] Fig. 5 shows the results of testing the effect of the addition of a rat anti-mouse Siglec-15 monoclonal antibody (#3A1, #8A1, or #32A1) on osteoclast differentiation

(stimulation with RANKL) of mouse bone marrow nonadherent cells. Incidentally, the rat control IgG in the drawing is a negative control common to Figs. 5 and 6.

[Fig. 6] Fig. 6 shows the results of testing the effect of the addition of a rat anti-mouse Siglec-15 monoclonal antibody (#34A1, #39A1, or #40A1) on osteoclast differentiation (stimulation with RANKL) of mouse bone marrow nonadherent cells. Incidentally, the rabbit anti-mouse Siglec-15 polyclonal antibody No. 3 in the drawing is a positive control common to Figs. 5 and 6.

[Fig. 7] Fig. 7 shows the results of evaluating the purity of human Siglec-15-His purified by HisTrap HP column chromatography and Resource Q column chromatography through SDS-polyacrylamide electrophoresis and silver staining.

[Fig. 8] Fig. 8 shows the results of evaluating the purity of human Siglec-15-Fc purified by Protein A column chromatography through SDS-polyacrylamide electrophoresis.

[Fig. 9] Fig. 9 shows the results of testing the binding of a rat anti-mouse Siglec-15 monoclonal antibody to a plate having human Siglec-15-Fc immobilized thereon by an ELISA method. The symbol (◆) denotes #1A1 antibody, the symbol (■) denotes #3A1 antibody, the symbol (▲) denotes #8A1 antibody, the symbol (×) denotes #24A1 antibody, the symbol (●) denotes #32A1 antibody, the symbol (○) denotes #34A1 antibody, the symbol (+) denotes #39A1 antibody, the symbol (-) denotes #40A1

antibody, the symbol (—) denotes #41B1 antibody, the symbol (◇) denotes #61A1 antibody, and the symbol (□) denotes control IgG.

[Fig. 10] Fig. 10 shows photomicrographs depicting, by TRAP staining, the inhibition of giant osteoclast formation from normal human osteoclast precursor cells by the addition of a rat anti-mouse Siglec-15 monoclonal antibody.

[Fig. 11] Fig. 11 shows photomicrographs depicting, by TRAP staining, the inhibition of giant osteoclast formation from normal human osteoclast precursor cells by the addition of a rat anti-mouse Siglec-15 monoclonal antibody (#32A1 antibody).

[Fig. 12] Fig. 12 is a graph showing the inhibition of the bone resorption activity of normal human osteoclasts by the addition of a rat anti-mouse Siglec-15 monoclonal antibody (#32A1 antibody) (N=6).

[Fig. 13] Fig. 13A is a graph showing the effect of increasing lumbar spine bone mineral density when a rat anti-mouse Siglec-15 monoclonal antibody was administered to ovariectomized rats for 4 weeks; and Fig. 13B is a graph showing the effect of decreasing urinary deoxypyridinoline excretion when a rat anti-mouse Siglec-15 monoclonal antibody was administered to ovariectomized rats for 4 weeks.

[Fig. 14] Fig. 14 is a graph showing that a rat anti-mouse Siglec-15 monoclonal antibody #32A1 binds to the V-set domain

of human Siglec-15 by competitive ELISA.

[Fig. 15] Fig. 15 is a graph showing that a rat #32A1 antibody and a human chimeric antibody thereof have substantially the same affinity for mouse Siglec-15-Fc by competitive ELISA.

[Fig. 16] Fig. 16 shows graphs depicting, by the enzymatic activity of TRAP, the inhibition of mouse osteoclast formation by the addition of a rat anti-mouse Siglec-15 monoclonal antibody (#32A1 antibody) and a chimeric antibody thereof (N=3).

[Fig. 17] Fig. 17 shows photomicrographs depicting, by TRAP staining, the inhibition of giant osteoclast formation from normal human osteoclast precursor cells by the addition of a human chimeric antibody of a rat anti-mouse Siglec-15 monoclonal antibody #32A1.

[Fig. 18] Fig. 18 is a view in which it was confirmed that 6 types of humanized rat anti-mouse Siglec-15 antibodies bind to mouse Siglec-15 protein in an antibody concentration-dependent manner by an ELISA method using a plate having mouse Siglec-15-Fc immobilized thereon.

[Fig. 19] Fig. 19 is a view in which it was confirmed that 6 types of humanized rat anti-mouse Siglec-15 antibodies bind to human Siglec-15 protein in an antibody concentration-dependent manner by an ELISA method using a plate having human Siglec-15-Fc immobilized thereon.

[Fig. 20] Fig. 20 shows photomicrographs depicting, by TRAP staining, the inhibition of mouse giant osteoclast formation under stimulation with $\text{TNF}\alpha$ by the addition of a rat anti-mouse Siglec-15 monoclonal antibody (#32A1 antibody) or a chimeric antibody thereof.

[Fig. 21] Fig. 21 shows graphs depicting, by the enzymatic activity of TRAP, the inhibition of mouse osteoclast formation under stimulation with $\text{TNF}\alpha$ by the addition of a rat anti-mouse Siglec-15 monoclonal antibody (#32A1 antibody) or a chimeric antibody thereof (N=3).

[Fig. 22] Fig. 22 shows graphs depicting, by the enzymatic activity of TRAP, the inhibition of rat osteoclast formation by the addition of a rat anti-mouse Siglec-15 monoclonal antibody (#8A1 or #32A1 antibody) (N=3).

[Fig. 23] Fig. 23 shows a cloned nucleotide sequence of a rat #32A1 heavy chain and an amino acid sequence thereof.

[Fig. 24] Fig. 24 shows a cloned nucleotide sequence of a rat #32A1 light chain and an amino acid sequence thereof.

[Fig. 25] Fig. 25 shows a nucleotide sequence of a #32A1 human chimeric antibody heavy chain and an amino acid sequence thereof.

[Fig. 26] Fig. 26 shows a nucleotide sequence of a #32A1 human chimeric antibody light chain and an amino acid sequence thereof.

[Fig. 27] Fig. 27 shows a nucleotide sequence of

h#32A1-T1H and an amino acid sequence thereof.

[Fig. 28] Fig. 28 shows a nucleotide sequence of h#32A1-T2H and an amino acid sequence thereof.

[Fig. 29] Fig. 29 shows a nucleotide sequence of h#32A1-T3H and an amino acid sequence thereof.

[Fig. 30] Fig. 30 shows a nucleotide sequence of h#32A1-T5H and an amino acid sequence thereof.

[Fig. 31] Fig. 31 shows a nucleotide sequence of h#32A1-T6H and an amino acid sequence thereof.

[Fig. 32] Fig. 32 shows a nucleotide sequence of h#32A1-T1L and an amino acid sequence thereof.

[Fig. 33] Fig. 33 shows a nucleotide sequence of h#32A1-T2L and an amino acid sequence thereof.

[Fig. 34] Fig. 34 shows a nucleotide sequence of h#32A1-T3L and an amino acid sequence thereof.

[Fig. 35] Fig. 35 shows a nucleotide sequence of h#32A1-T4L and an amino acid sequence thereof.

[Fig. 36] Fig. 36 shows a nucleotide sequence of h#32A1-T5L and an amino acid sequence thereof.

[Fig. 37] Fig. 37 shows a nucleotide sequence of h#32A1-T6L and an amino acid sequence thereof.

[Fig. 38] Fig. 38 shows amino acid sequences of h#32A1-T7H, h#32A1-T8H, and h#32A1-T9H.

[Fig. 39] Fig. 39 shows amino acid sequences of h#32A1-T10H, h#32A1-T11H, and h#32A1-T12H.

[Fig. 40] Fig. 40 shows amino acid sequences of h#32A1-T7L, h#32A1-T8L, h#32A1-T9L, h#32A1-T10L, and h#32A1-T11L.

[Fig. 41] Fig. 41 shows amino acid sequences of h#32A1-T12L, h#32A1-T13L, h#32A1-T14L, h#32A1-T15L, and h#32A1-T16L.

[Fig. 42] Fig. 42 shows amino acid sequences of h#32A1-T17L, h#32A1-T18L, h#32A1-T19L, h#32A1-T20L, and h#32A1-T21L.

[Fig. 43] Fig. 43 shows amino acid sequences of h#32A1-T22L, h#32A1-T23L, h#32A1-T24L, and h#32A1-T25L.

[Fig. 44] Fig. 44 shows graphs depicting, by the enzymatic activity of TRAP, the inhibition of mouse osteoclast formation by the addition of a humanized rat anti-mouse Siglec-15 antibody (h#32A1-T1, h#32A1-T2, or h#32A1-T3). Incidentally, the rat #32A1 antibody in the drawing is a positive control common to Figs. 44 and 45.

[Fig. 45] Fig. 45 shows graphs depicting, by the enzymatic activity of TRAP, the inhibition of mouse osteoclast formation by the addition of a humanized rat anti-mouse Siglec-15 antibody (h#32A1-T4, h#32A1-T5, or h#32A1-T6).

[Fig. 46] Fig. 46 shows graphs depicting, by the enzymatic activity of TRAP, the inhibition of mouse osteoclast formation by the addition of a humanized rat anti-mouse Siglec-15 antibody (h#32A1-H1-1/L5 or h#32A1-H5/L5).

Incidentally, the rat #32A1 antibody and #32A1 human chimeric antibody in the drawing are positive controls common to Figs. 46 and 47.

[Fig. 47] Fig. 47 shows graphs depicting, by the enzymatic activity of TRAP, the inhibition of mouse osteoclast formation by the addition of a humanized rat anti-mouse Siglec-15 antibody (h#32A1-H1-1/L2-16 or h#32A1-H-1/L2-15).

[Fig. 48] Fig. 48 shows graphs depicting the inhibition of the bone resorption activity of normal human osteoclasts by the addition of a humanized rat anti-mouse Siglec-15 antibody (h#32A1-T1, h#32A1-T2, h#32A1-T3, h#32A1-T4, h#32A1-T5, or h#32A1-T6). Incidentally, the rat #32A1 antibody and #32A1 human chimeric antibody in the drawing are positive controls common to Figs. 48 and 49.

[Fig. 49] Fig. 49 shows graphs depicting the inhibition of the bone resorption activity of normal human osteoclasts by the addition of a humanized rat anti-mouse Siglec-15 antibody (h#32A1-H1-1/L5, h#32A1-H5/L5, h#32A1-H1-1/L2-16, or h#32A1-H1-1/L2-15).

[Fig. 50] Fig. 50 is a thermogram obtained for determining the thermal stability of the h#32A1-H5/L5 antibody.

[Fig. 51] Fig. 51 is a thermogram obtained for determining the thermal stability of the h#32A1-H1-1/L5 antibody.

[Fig. 52] Fig. 52 is a thermogram obtained for determining the thermal stability of the h#32A1-H1-1/L2-15 antibody.

[Fig. 53] Fig. 53 is a thermogram obtained for determining the thermal stability of the h#32A1-H1-1/L2-16 antibody.

[Fig. 54] Fig. 54 shows a nucleotide sequence of h#32A1-H1-1 and the amino acid sequence thereof.

[Fig. 55] Fig. 55 shows a nucleotide sequence of h#32A1-H5 and the amino acid sequence thereof.

[Fig. 56] Fig. 56 shows a nucleotide sequence of h#32A1-L2-15 and the amino acid sequence thereof.

[Fig. 57] Fig. 57 shows a nucleotide sequence of h#32A1-L2-16 and the amino acid sequence thereof.

Mode for Carrying Out the Invention

[0012]

The term "gene" as used herein includes not only DNA, but also mRNA, cDNA, and cRNA.

[0013]

The term "polynucleotide" as used herein is used with the same meaning as a "nucleic acid" and also includes DNA, RNA, probes, oligonucleotides, and primers.

[0014]

The terms "polypeptide" and "protein" as used herein are

used without distinction.

[0015]

The term "RNA fraction" as used herein refers to a fraction containing RNA.

[0016]

The term "cell" as used herein also includes cells in an animal individual and cultured cells.

[0017]

The term "Siglec-15" as used herein is used with the same meaning as "Siglec-15 protein".

[0018]

The term "osteoclast formation" as used herein is used with the same meaning as "osteoclast differentiation" or "osteoclast maturation".

[0019]

The term "functional fragment of an antibody" as used herein refers to a partial fragment of an antibody having an antigen-binding activity and includes Fab, F(ab')₂, Fv, scFv, diabodies, linear antibodies, polyspecific antibodies formed from antibody fragments, and the like. The term also encompasses Fab' which is a monovalent fragment in a variable region of an antibody obtained by treating F(ab')₂ under reducing conditions. However, the term is not limited to these molecules as long as the fragment has a binding affinity for an antigen. Further, these functional fragments include not

only a fragment obtained by treating a full-length molecule of an antibody protein with an appropriate enzyme, but also a protein produced in an appropriate host cell using a genetically modified antibody gene.

[0020]

The term "epitope" as used herein refers to a partial peptide or a partial tertiary structure of Siglec-15 to which a specific anti-Siglec-15 antibody binds. The above-mentioned epitope which is a partial peptide of Siglec-15 can be determined by a method well known to those skilled in the art such as an immunoassay. However, the following method can be employed, for example. Various partial structures of Siglec-15 are produced. In the production of the partial structures, a known oligopeptide synthesis technique can be used. For example, a series of polypeptides having appropriately reduced lengths obtained by sequentially shortening Siglec-15 from the C terminus or N terminus are produced using a genetic recombination technique known to those skilled in the art. Thereafter, the reactivity of an antibody against these polypeptides is examined and a recognition site is roughly determined. Then, peptides having shorter lengths are synthesized and the reactivity with these peptides is examined, whereby the epitope can be determined. Further, the epitope which is a partial tertiary structure of Siglec-15 which binds to a specific Siglec-15 antibody can be determined

by specifying the amino acid residues of Siglec-15 adjacent to the antibody by an X-ray structural analysis. If a second anti-Siglec-15 antibody binds to a partial peptide or a partial tertiary structure to which a first anti-Siglec-15 antibody binds, it can be determined that the first antibody and the second antibody share the same epitope. Further, by confirming that the second anti-Siglec-15 antibody competes with the first anti-Siglec-15 antibody for the binding to Siglec-15 (that is, the second antibody inhibits the binding between Siglec-15 and the first antibody), it can be determined that the first antibody and the second antibody share the same epitope even if the sequence or structure of a specific epitope has not been determined. Further, when the first antibody and the second antibody bind to the same epitope and also the first antibody has a special effect such as an antigen-neutralizing activity, the second antibody can be expected to have the same activity.

[0021]

It is known that each heavy and light chain of an antibody molecule has three complementarity determining regions (CDRs). The complementarity determining region is also called the hypervariable domain, and is present in a variable region of each heavy and light chain of an antibody. It is a site which has unusually high variability in its primary structure, and there are three separate CDRs in the primary structure of each

heavy and light polypeptide chain. In this description, as for the complementarity determining regions of an antibody, the complementarity determining regions of the heavy chain are represented by CDRH1, CDRH2, and CDRH3 from the amino-terminal side of the amino acid sequence of the heavy chain, and the complementarity determining regions of the light chain are represented by CDRL1, CDRL2, and CDRL3 from the amino-terminal side of the amino acid sequence of the light chain. These sites are proximate to one another in the tertiary structure and determine the specificity for an antigen to which the antibody binds.

[0022]

The phrase "hybridization is performed under stringent conditions" as used herein refers to hybridization that is performed under conditions under which identification can be achieved by performing hybridization at 68°C in a commercially available hybridization solution, ExpressHyb Hybridization Solution (manufactured by Clontech, Inc.) or performing hybridization at 68°C in the presence of 0.7 to 1.0 M NaCl using a filter having DNA immobilized thereon, followed by performing washing at 68°C using 0.1 to 2 x SSC solution (1 x SSC solution is composed of 150 mM NaCl and 15 mM sodium citrate) or under conditions equivalent thereto.

[0023]

1. Siglec-15

The present inventors have found that the Siglec-15 gene is specifically expressed in giant cell tumors and have also found that the expression level of the Siglec-15 gene increases when a monocyte-derived cell line differentiates into osteoclasts.

[0024]

As for the Siglec-15 to be used in the invention, Siglec-15 is directly purified from monocytes or bone marrow cells of a human, non-human mammal (such as guinea pig, rat, mouse, rabbit, pig, sheep, cattle, or monkey) or chicken and is used, or a cell membrane fraction of the above-mentioned cells is prepared and can be used. Further, Siglec-15 can be obtained by in vitro synthesis thereof or production thereof in a host cell through genetic engineering. In the genetic engineering production, specifically, Siglec-15 cDNA is integrated into a vector capable of expressing Siglec-15 cDNA, and Siglec-15 is synthesized in a solution containing an enzyme, a substrate, and an energy substance required for transcription and translation, or another prokaryotic or eucaryotic host cell is transformed to express Siglec-15, whereby the protein can be obtained.

[0025]

The nucleotide sequence of human Siglec-15 cDNA has been registered in GenBank with an accession number of NM_213602 and is represented by SEQ ID NO: 1 in the Sequence Listing,

and its amino acid sequence is represented by SEQ ID NO: 2 in the Sequence Listing. The nucleotide sequence of mouse Siglec-15 cDNA has been registered in GenBank with an accession number of XM_884636 and is represented by SEQ ID NO: 3 in the Sequence Listing, and its amino acid sequence is represented by SEQ ID NO: 4 in the Sequence Listing. Mature human Siglec-15 from which the signal sequence has been removed corresponds to an amino acid sequence comprising amino acid residues 21 to 328 of the amino acid sequence represented by SEQ ID NO: 2. Further, mouse Siglec-15 from which the signal sequence has been removed corresponds to an amino acid sequence comprising amino acid residues 21 to 341 of the amino acid sequence represented by SEQ ID NO: 4. Incidentally, Siglec-15 is sometimes called CD33 antigen-like 3, CD33 molecule-like 3, CD33-like 3, or CD33L3, and all of these represent the same molecule.

[0026]

Siglec-15 cDNA can be obtained by, for example, a so-called PCR method in which a polymerase chain reaction (hereinafter referred to as "PCR") is performed using a cDNA library expressing Siglec-15 cDNA as a template and primers which specifically amplify Siglec-15 cDNA (Saiki, R. K., et al., Science, (1988) 239, 487-49).

[0027]

Further, a polynucleotide which hybridizes to a

polynucleotide comprising a nucleotide sequence complementary to at least one nucleotide sequence selected from the nucleotide sequences represented by SEQ ID NOS: 1 and 3 in the Sequence Listing under stringent conditions and encodes a protein having a biological activity comparable to that of Siglec-15 is also regarded as Siglec-15 cDNA. Further, a polynucleotide which is a splicing variant transcribed from the human or mouse Siglec-15 locus or a polynucleotide which hybridizes to a sequence complementary thereto under stringent conditions and encodes a protein having a biological activity comparable to that of Siglec-15 is also regarded as Siglec-15 cDNA.

[0028]

Further, a protein which comprises an amino acid sequence including substitution, deletion or addition of one or several amino acids in at least one amino acid sequence selected from the amino acid sequences represented by SEQ ID NOS: 2 and 4 in the Sequence Listing or an amino acid sequence obtained by removing the signal sequence from any of these sequences and has a biological activity comparable to that of Siglec-15 is also regarded as Siglec-15. Further, a protein which comprises an amino acid sequence encoded by a splicing variant transcribed from the human or mouse Siglec-15 locus or an amino acid sequence including a substitution, deletion or addition of one or several amino acids therein and has a biological

activity comparable to that of Siglec-15 is also regarded as Siglec-15.

[0029]

2. Detection of abnormal bone metabolism

An analysis of the expression level of the Siglec-15 gene in a group of test samples from various human bone tissues showed that the expression level of the gene significantly increases in giant cell tumor (GCT) which is a bone tumor with a large number of osteoclast-like multinucleated giant cells arising and is characterized by clinical findings of osteolytic bone destruction (Bullough et al., Atlas of Orthopedic Pathology 2nd edition, pp. 17.6-17.8, Lippincott Williams & Wilkins Publishers (1992)).

[0030]

It was also found that the expression level of the Siglec-15 gene increases when a monocyte-derived cell line is differentiated into osteoclasts.

[0031]

Accordingly, Siglec-15 is considered to be associated with human pathologies such as GCT in which bone resorption is increased. In other words, measurement of the expression level of the Siglec-15 gene and/or Siglec-15 in each cell and/or each tissue enables determination of the state of abnormal bone metabolism accompanied by overexpression of Siglec-15. The abnormal bone metabolism as used herein refers to a disorder

characterized by net bone loss, and specific examples thereof include, but are not limited to, osteoporosis (postmenopausal osteoporosis, senile osteoporosis, secondary osteoporosis due to the use of a therapeutic agent such as a steroid or an immunosuppressant, or osteoporosis accompanying rheumatoid arthritis), bone destruction accompanying rheumatoid arthritis, cancerous hypercalcemia, bone destruction accompanying multiple myeloma or cancer metastasis to bone, giant cell tumor, osteopenia, tooth loss due to periodontitis, osteolysis around a prosthetic joint, bone destruction in chronic osteomyelitis, Paget's disease of bone, renal osteodystrophy, and osteogenesis imperfecta.

[0032]

In the invention, the "test sample" to be used for examining the expression level of the Siglec-15 gene and/or Siglec-15 refers to a sample from a tissue of bone marrow, bone, prostate, testis, penis, bladder, kidney, oral cavity, pharynx, lip, tongue, gingiva, nasopharynx, esophagus, stomach, small intestine, large intestine, colon, liver, gallbladder, pancreas, nose, lung, soft tissue, skin, breast, uterus, ovary, brain, thyroid, lymph node, muscle, fat tissue or the like, or blood, a body fluid, an excretion, or the like obtained from a test subject, a clinical specimen, etc., however, in the invention, blood or bone marrow is more preferred.

[0033]

As for RANKL which is known to be associated with osteoclast differentiation, a knockout mouse has been produced, and the phenotype when the function of RANKL has been lost has been analyzed (Young-Yun Kong, et. al., Nature (1999) 397, pp. 315-323). By producing a knockout mouse devoid of Siglec-15 in the same manner as above, the phenotype when the function of Siglec-15 has been lost can be analyzed.

[0034]

3. Production of anti-Siglec-15 antibody

The antibody of the invention, which is against Siglec-15, can be obtained by immunizing an animal with Siglec-15 or an arbitrary polypeptide selected from the amino acid sequence of Siglec-15, and collecting and purifying the antibody produced in vivo, according to a common procedure. The biological species of Siglec-15 to be used as an antigen is not limited to being human, and an animal can be immunized with Siglec-15 derived from an animal other than humans such as a mouse or a rat. In this case, by examining the cross-reactivity between an antibody binding to the obtained heterologous Siglec-15 and human Siglec-15, an antibody applicable to a human disease can be selected.

[0035]

Further, a monoclonal antibody can be obtained by fusing antibody-producing cells which produce an antibody against Siglec-15 with myeloma cells to establish a hybridoma according

to a known method (for example, Kohler and Milstein, Nature, (1975) 256, pp. 495-497; Kennet, R. ed., Monoclonal Antibodies, pp. 365-367, Plenum Press, N.Y. (1980)).

[0036]

Incidentally, Siglec-15 to be used as an antigen can be obtained by genetic engineering to cause a host cell to produce the Siglec-15 gene.

[0037]

Specifically, a vector capable of expressing Siglec-15 gene is produced, and the resulting vector is transfected into a host cell to express the gene, and then the expressed Siglec-15 is purified. Hereinafter, a method of obtaining an antibody against Siglec-15 will be specifically described.

(1) Preparation of antigen

Examples of the antigen to be used for producing the anti-Siglec-15 antibody include Siglec-15, a polypeptide comprising a partial amino acid sequence containing at least 6 consecutive amino acids of Siglec-15, and a derivative obtained by adding a given amino acid sequence or carrier thereto.

[0038]

Siglec-15 can be purified directly from human tumor tissues or tumor cells and used. Further, Siglec-15 can be obtained by synthesizing it in vitro or by causing a host cell to produce it by genetic engineering.

[0039]

With respect to the genetic engineering, specifically, Siglec-15 cDNA is integrated into a vector capable of expressing Siglec-15 cDNA and Siglec-15 is synthesized in a solution containing an enzyme, a substrate, and an energy substance required for transcription and translation, or another prokaryotic or eucaryotic host cell is transformed to express Siglec-15, whereby the antigen can be obtained.

[0040]

Further, the antigen can also be obtained as a secretory protein by expressing a fusion protein obtained by ligating the extracellular domain of Siglec-15, which is a membrane protein, to the constant region of an antibody in an appropriate host-vector system.

[0041]

Siglec-15 cDNA can be obtained by, for example, a so-called PCR method in which a polymerase chain reaction (hereinafter referred to as "PCR") is performed using a cDNA library expressing Siglec-15 cDNA as a template and primers which specifically amplify Siglec-15 cDNA (see Saiki, R. K., et al., Science, (1988) 239, pp. 487-489).

[0042]

As the in vitro synthesis of the polypeptide, for example, Rapid Translation System (RTS) manufactured by Roche Diagnostics, Inc. can be exemplified, but it is not limited

thereto.

[0043]

Examples of the prokaryotic host include *Escherichia coli* and *Bacillus subtilis*. In order to transform the host cell with a target gene, the host cell is transformed using a plasmid vector containing a replicon, i.e., a replication origin derived from a species compatible with the host, and a regulatory sequence. Further, the vector preferably has a sequence capable of imposing phenotypic selectivity on the transformed cell.

[0044]

Examples of the eucaryotic host cell include vertebrate cells, insect cells, and yeast cells. As the vertebrate cells, for example, dihydrofolate reductase-deficient strains (Urlaub, G. and Chasin, L. A., *Proc. Natl. Acad. Sci. USA* (1980) 77, pp. 4126-4220) of simian COS cells (Gluzman, Y., *Cell*, (1981) 23, pp. 175-182, ATCC CRL-1650), murine fibroblasts NIH3T3 (ATCC No. CRL-1658), and Chinese hamster ovarian cells (CHO cells; ATCC: CCL-61); and the like are often used, however, they are not limited thereto.

[0045]

The thus obtained transformant can be cultured according to a common procedure, and by the culturing of the transformant, a target polypeptide is produced intracellularly or extracellularly.

[0046]

A suitable medium to be used for the culturing can be selected from various commonly used culture media depending on the employed host cell. If *Escherichia coli* is employed, for example, an LB medium supplemented with an antibiotic such as ampicillin or IPMG as needed can be used.

[0047]

A recombinant protein produced intracellularly or extracellularly by the transformant through such culturing can be separated and purified by any of various known separation methods utilizing the physical or chemical property of the protein.

[0048]

Specific examples of the methods include treatment with a common protein precipitant, ultrafiltration, various types of liquid chromatography such as molecular sieve chromatography (gel filtration), adsorption chromatography, ion exchange chromatography, and affinity chromatography, dialysis, and a combination thereof.

[0049]

Further, by attaching a tag of six histidine residues to a recombinant protein to be expressed, the protein can be efficiently purified with a nickel affinity column. Alternatively, by attaching a IgG Fc region to a recombinant protein to be expressed, the protein can be efficiently

purified with a protein A column.

By combining the above-mentioned methods, a large amount of a target polypeptide can be easily produced in high yield and high purity.

[0050]

(2) Production of anti-Siglec-15 monoclonal antibody

Examples of the antibody specifically binding to Siglec-15 include a monoclonal antibody specifically binding to Siglec-15, and a method of obtaining the antibody are as described below.

[0051]

The production of a monoclonal antibody generally requires the following operational steps of:

- (a) purifying a biopolymer to be used as an antigen;
- (b) preparing antibody-producing cells by immunizing an animal by injection of the antigen, collecting the blood, assaying its antibody titer to determine when the spleen is to be excised;
- (c) preparing myeloma cells (hereinafter referred to as "myeloma");
- (d) fusing the antibody-producing cells with the myeloma;
- (e) screening a group of hybridomas producing a target antibody;
- (f) dividing the hybridomas into single cell clones.

(cloning);

(g) optionally, culturing the hybridoma or rearing an animal implanted with the hybridoma for producing a large amount of a monoclonal antibody;

(h) examining the thus produced monoclonal antibody for biological activity and binding specificity, or assaying the same for properties as a labeled reagent; and the like.

[0052]

Hereinafter, the method of producing a monoclonal antibody will be described in detail following the above steps, however, the method is not limited thereto, and, for example, antibody-producing cells and myeloma can be used other than spleen cells.

[0053]

(a) Purification of antigen

As the antigen, Siglec-15 prepared by the method as described above or a partial peptide thereof can be used.

[0054]

Further, a membrane fraction prepared from recombinant cells expressing Siglec-15 or the recombinant cells expressing Siglec-15 themselves, and also a partial peptide of the protein of the invention chemically synthesized by a method known to those skilled in the art can also be used as the antigen.

[0055]

(b) Preparation of antibody-producing cells

The antigen obtained in step (a) is mixed with an adjuvant such as Freund's complete or incomplete adjuvant, or aluminum potassium sulfate and the resulting mixture is used as an immunogen to immunize an experimental animal. As the experimental animal, any animal used in a known hybridoma production method can be used without any trouble. Specifically, for example, a mouse, a rat, a goat, sheep, cattle, a horse, or the like can be used. However, from the viewpoint of ease of availability of myeloma cells to be fused with the extracted antibody-producing cells, a mouse or a rat is preferably used as the animal to be immunized.

[0056]

Further, the strain of mouse or rat to be used is not particularly limited, and in the case of a mouse, for example, various strains such as A, AKR, BALB/c, BDP, BA, CE, C3H, 57BL, C57BL, C57L, DBA, FL, HTH, HT1, LP, NZB, NZW, RF, R III, SJL, SWR, WB, and 129 can be used, and in the case of a rat, for example, Wistar, Low, Lewis, Sprague, Dawley, ACI, BN, Fischer, and the like can be used.

[0057]

These mice and rats are commercially available from breeders/distributors of experimental animals, for example, CLEA Japan, Inc. and Charles River Laboratories Japan, Inc.

[0058]

Among these, in consideration of compatibility of fusing

with myeloma cells as described below, in the case of a mouse, BALB/c strain, and in the case of a rat, Wistar and Low strains are particularly preferred as the animal to be immunized.

[0059]

Further, in consideration of antigenic homology between humans and mice, it is also preferred to use a mouse having decreased biological function to remove autoantibodies, that is, a mouse with an autoimmune disease.

[0060]

The age of the mouse or rat at the time of immunization is preferably 5 to 12 weeks of age, more preferably 6 to 8 weeks of age.

[0061]

In order to immunize an animal with Siglec-15 or a recombinant thereof, for example, a known method described in detail in, for example, Weir, D. M., Handbook of Experimental Immunology Vol. I. II. III., Blackwell Scientific Publications, Oxford (1987), Kabat, E. A. and Mayer, M. M., Experimental Immunochemistry, Charles C Thomas Publisher Springfield, Illinois (1964), or the like can be used.

[0062]

Among these immunization methods, a preferred specific method in the invention is, for example, as follows.

[0063]

That is, first, a membrane protein fraction serving as

the antigen or cells caused to express the antigen is/are intradermally or intraperitoneally administered to an animal.

[0064]

However, the combination of both routes of administration is preferred for increasing the immunization efficiency, and when intradermal administration is performed in the first half and intraperitoneal administration is performed in the latter half or only at the last dosing, the immunization efficiency can be particularly increased.

[0065]

The administration schedule of the antigen varies depending on the type of animal to be immunized, individual differences, or the like. However, in general, an administration schedule in which the frequency of administration of the antigen is 3 to 6 times and the dosing interval is 2 to 6 weeks is preferred, and an administration schedule in which the frequency of administration of the antigen is 3 to 4 times and the dosing interval is 2 to 4 weeks is more preferred.

[0066]

Further, the dose of the antigen varies depending on the type of animal to be immunized, individual differences, or the like, however, the dose is generally set to 0.05 to 5 mg, preferably about 0.1 to 0.5 mg.

[0067]

A booster immunization is performed 1 to 6 weeks, preferably 2 to 4 weeks, more preferably 2 to 3 weeks after the administration of the antigen as described above.

[0068]

The dose of the antigen at the time of performing the booster immunization varies depending on the type or size of animal or the like, however, in the case of a mouse, the dose is generally set to 0.05 to 5 mg, preferably 0.1 to 0.5 mg, more preferably about 0.1 to 0.2 mg.

[0069]

Spleen cells or lymphocytes including antibody-producing cells are aseptically removed from the immunized animal 1 to 10 days, preferably 2 to 5 days, more preferably 2 to 3 days after the booster immunization.

[0070]

At this time, the antibody titer is measured, and if an animal having a sufficiently increased antibody titer is used as a supply source of the antibody-producing cells, the subsequent procedure can be carried out more efficiently.

[0071]

Examples of the method of measuring the antibody titer to be used here include an RIA method and an ELISA method, but the method is not limited thereto.

[0072]

For example, if an ELISA method is employed, the

measurement of the antibody titer in the invention can be carried out according to the procedures as described below.

[0073]

First, a purified or partially purified antigen is adsorbed onto the surface of a solid phase such as a 96-well plate for ELISA, and the surface of the solid phase having no antigen adsorbed thereto is covered with a protein unrelated to the antigen such as bovine serum albumin (hereinafter referred to as "BSA"). After washing the surface, the surface is brought into contact with a serially-diluted sample (for example, mouse serum) as a primary antibody to allow the antibody in the sample to bind to the antigen.

[0074]

Further, as a secondary antibody, an antibody labeled with an enzyme against a mouse antibody is added and is allowed to bind to the mouse antibody. After washing, a substrate for the enzyme is added and a change in absorbance which occurs due to color development induced by degradation of the substrate or the like is measured and the antibody titer is calculated based on the measurement.

[0075]

The separation of the antibody-producing cells from the spleen cells or lymphocytes can be carried out according to a known method (for example, Kohler et al., *Nature* (1975), 256, p. 495; Kohler et al., *Eur. J. Immunol.* (1977), 6, p. 511;

Milstein et al., Nature (1977), 266, p. 550; Walsh, Nature (1977), 266, p. 495).

[0076]

For example, in the case of spleen cells, a general method in which the antibody-producing cells are separated by homogenizing the spleen to obtain cells through filtration with a stainless steel mesh and suspending the cells in Eagle's Minimum Essential Medium (MEM) can be employed.

[0077]

(c) Preparation of myeloma cells (hereinafter referred to as "myeloma")

The myeloma cells to be used for cell fusion are not particularly limited and suitable cells can be selected from known cell lines. However, in consideration of convenience when a hybridoma is selected from fused cells, it is preferred to use an HGPRT (hypoxanthine-guanine phosphoribosyl transferase) deficient strain whose selection procedure has been established.

[0078]

More specifically, examples of the HGPRT-deficient strain include X63-Ag8(X63), NS1-ANS/1(NS1), P3X63-Ag8.U1(P3U1), X63-Ag8.653(X63.653), SP2/0-Ag14(SP2/0), MPC11-45.6TG1.7(45.6TG), F0, S149/5XXO, and BU.1 derived from mice; 210.RSY3.Ag.1.2.3(Y3) derived from rats; and U266AR(SKO-007), GM1500-GTG-A12(GM1500), UC729-6,

LICR-LOW-HMy2(HMy2) and 8226AR/NIP4-1(NP41) derived from humans.

[0079]

These HGPRT-deficient strains are available from, for example, the American Type Culture Collection (ATCC) or the like.

[0080]

These cell strains are subcultured in an appropriate medium such as an 8-azaguanine medium [a medium obtained by adding 8-azaguanine to an RPMI-1640 medium supplemented with glutamine, 2-mercaptoethanol, gentamicin, and fetal calf serum (hereinafter referred to as "FCS")]; Iscove's Modified Dulbecco's Medium (hereinafter referred to as "IMDM"), or Dulbecco's Modified Eagle Medium (hereinafter referred to as "DMEM"). In this case, 3 to 4 days before performing cell fusion, the cells are subcultured in a normal medium [for example, an ASF104 medium (manufactured by Ajinomoto Co., Ltd.) containing 10% FCS] to obtain not less than 2×10^7 cells on the day of cell fusion.

[0081]

(d) Cell fusion

Fusion between the antibody-producing cells and the myeloma cells can be appropriately performed according to a known method (Weir, D. M. Handbook of Experimental Immunology Vol. I. II. III., Blackwell Scientific Publications, Oxford

(1987), Kabat, E. A. and Mayer, M. M., Experimental Immunochemistry, Charles C Thomas Publisher, Springfield, Illinois (1964), etc.), under conditions such that the survival rate of cells is not excessively reduced.

[0082]

As such a method, a chemical method in which the antibody-producing cells and the myeloma cells are mixed in a solution containing a polymer such as polyethylene glycol at a high concentration, a physical method using electric stimulation, or the like can be used.

[0083]

Among these methods, a specific example of the chemical method is as described below.

That is, in the case where polyethylene glycol is used in the solution containing a polymer at a high concentration, the antibody-producing cells and the myeloma cells are mixed in a solution of polyethylene glycol having a molecular weight of 1500 to 6000, more preferably 2000 to 4000 at a temperature of from 30 to 40°C, preferably from 35 to 38°C for 1 to 10 minutes, preferably 5 to 8 minutes.

[0084]

(e) Selection of a group of hybridomas

The method of selecting hybridomas obtained by the above-mentioned cell fusion is not particularly limited. Usually, an HAT (hypoxanthine, aminopterin, thymidine)

selection method (Kohler et al., Nature (1975), 256, p. 495; Milstein et al., Nature (1977), 266, p. 550) is used.

[0085]

This method is effective when hybridomas are obtained using the myeloma cells of an HGPRT-deficient strain which cannot survive in the presence of aminopterin.

[0086]

That is, by culturing unfused cells and hybridomas in an HAT medium, only hybridomas resistant to aminopterin are selectively allowed to survive and proliferate.

[0087]

(f) Division into single cell clone (cloning)

As a cloning method for hybridomas, a known method such as a methylcellulose method, a soft agarose method, or a limiting dilution method can be used (see, for example, Barbara, B. M. and Stanley, M. S.: Selected Methods in Cellular Immunology, W. H. Freeman and Company, San Francisco (1980)). Among these methods, particularly, a limiting dilution method is preferred.

[0088]

In this method, a fibroblast cell strain derived from a rat fetus or feeder cells such as normal mouse spleen cells, thymus gland cells, or ascites cells are seeded on a microplate.

[0089]

Meanwhile, hybridomas are diluted in a medium to give

a cell density of 0.2 to 0.5 cells per 0.2 ml. A 0.1 ml aliquot of the diluted hybridoma suspension is added to each well and culturing is continued for about 2 weeks while replacing about 1/3 of the culture solution with fresh medium at predetermined time intervals (for example, every 3 days), whereby hybridoma clones can be proliferated.

[0090]

The hybridomas in wells for which the antibody titer has been confirmed are subjected to, for example, cloning by the limiting dilution method repeatedly 2 to 4 times. A hybridoma which has been confirmed to have a stable antibody titer is selected as an anti-Siglec-15 monoclonal antibody-producing hybridoma strain.

[0091]

Examples of the hybridoma strain thus cloned include hybridoma #32A1 described in WO 09/48072. The hybridoma #32A1 was deposited at the International Patent Organism Depositary of the National Institute of Advanced Industrial Science and Technology (located at Central 6, 1-1-1 Higashi, Tsukuba-shi, Ibaraki-ken, 305-8566, Japan) on August 28, 2008, and has been given an accession number of FERM BP-10999 under the name of anti-Siglec-15 Hybridoma #32A1. Incidentally, in this description, the antibody produced by the hybridoma #32A1 is referred to as "#32A1 antibody" or simply "#32A1". Further, antibodies obtained in the Examples of this description other

than the #32A1 antibody are also represented by the antibody names in the same manner. A partial fragment containing the heavy chain variable region of the #32A1 antibody has an amino acid sequence comprising amino acid residues 20 to 167 of SEQ ID NO: 28 in the Sequence Listing. Further, a partial fragment containing the light chain variable region sequence of the #32A1 antibody has an amino acid sequence comprising amino acid residues 21 to 139 of SEQ ID NO: 30 in the Sequence Listing.

[0092]

(g) Preparation of monoclonal antibody by culturing hybridoma

By culturing the thus selected hybridoma, a monoclonal antibody can be efficiently obtained. However, prior to culturing, it is preferred to perform screening of a hybridoma which produces a target monoclonal antibody.

[0093]

In such screening, a known method can be employed.

[0094]

The measurement of the antibody titer in the invention can be carried out by, for example, an ELISA method explained in item (b) described above.

[0095]

The hybridoma obtained by the method described above can be stored in a frozen state in liquid nitrogen or in a freezer at -80°C or below.

[0096]

After completion of cloning, the medium is changed from an HT medium to a normal medium, and the hybridoma is cultured.

[0097]

Large-scale culture is performed by rotation culture using a large culture bottle or by spinner culture.

From the supernatant obtained by the large-scale culture, a monoclonal antibody which specifically binds to the protein of the invention can be obtained by purification using a method known to those skilled in the art such as gel filtration.

[0098]

Further, the hybridoma is injected into the abdominal cavity of a mouse of the same strain as the hybridoma (for example, the above-mentioned BALB/c) or a Nu/Nu mouse to proliferate the hybridoma, whereby the ascites containing a large amount of the monoclonal antibody of the invention can be obtained.

[0099]

In the case where the hybridoma is administered in the abdominal cavity, if a mineral oil such as 2,6,10,14-tetramethyl pentadecane (pristane) is administered 3 to 7 days prior thereto, a larger amount of the ascites can be obtained.

[0100]

For example, an immunosuppressant is previously injected

into the abdominal cavity of a mouse of the same strain as the hybridoma to inactivate T cells. 20 days thereafter, 10^6 to 10^7 hybridoma clone cells are suspended in a serum-free medium (0.5 ml), and the suspension is injected into the abdominal cavity of the mouse. In general, when the abdomen is expanded and filled with the ascites, the ascites is collected from the mouse.

[0101]

By this method, the monoclonal antibody can be obtained at a concentration which is about 100 times or more higher than that in the culture solution.

[0102]

The monoclonal antibody obtained by the above-mentioned method can be purified by a method described in, for example, Weir, D. M.: Handbook of Experimental Immunology Vol. I, II, III, Blackwell Scientific Publications, Oxford (1978).

[0103]

That is, examples of the method include an ammonium sulfate precipitation method, gel filtration, ion exchange chromatography, and affinity chromatography.

[0104]

As a simple purification method, a commercially available monoclonal antibody purification kit (for example, MAbTrap GII Kit manufactured by Pharmacia, Inc.) or the like can also be used.

[0105]

The thus obtained monoclonal antibody has high antigen specificity for Siglec-15.

[0106]

(h) Assay of monoclonal antibody

The isotype and subclass of the thus obtained monoclonal antibody can be determined as follows.

[0107]

First, examples of the identification method include an Ouchterlony method, an ELISA method and an RIA method.

[0108]

An Ouchterlony method is simple, but when the concentration of the monoclonal antibody is low, a condensation operation is required.

[0109]

On the other hand, when an ELISA method or an RIA method is used, by directly reacting the culture supernatant with an antigen-adsorbed solid phase and using antibodies corresponding to various types of immunoglobulin isotypes and subclasses as secondary antibodies, the isotype and subclass of the monoclonal antibody can be identified.

[0110]

In addition, as a simpler method, a commercially available identification kit (for example, Mouse Typer Kit manufactured by Bio-Rad Laboratories, Inc.) or the like can

also be used.

[0111]

Further, the quantitative determination of a protein can be performed by the Folin Lowry method and a method of calculation based on the absorbance at 280 nm [1.4 (OD 280) = Immunoglobulin 1 mg/ml].

[0112]

(3) Other antibodies

The antibody of the invention includes not only the above-mentioned monoclonal antibody against Siglec-15 but also a recombinant antibody obtained by artificial modification for the purpose of decreasing heterologous antigenicity to human such as a chimeric antibody, a humanized antibody and a human antibody. These antibodies can be produced using a known method.

[0113]

As the chimeric antibody, an antibody in which antibody variable and constant regions are derived from different species, for example, a chimeric antibody in which a mouse- or rat-derived antibody variable region is connected to a human-derived constant region can be exemplified (see Proc. Natl. Acad. Sci. USA, 81, 6851-6855, (1984)). As one example of the chimeric antibody derived from a rat anti-mouse antibody #32A1, an antibody comprising a heavy chain having an amino acid sequence comprising amino acid residues 20 to 470 of SEQ

ID NO: 41 in the Sequence Listing and a light chain having an amino acid sequence comprising amino acid residues 21 to 237 of SEQ ID NO: 43 in the Sequence Listing can be exemplified. [0114]

As the humanized antibody, an antibody obtained by integrating only a complementarity determining region (CDR) into a human-derived antibody (see Nature (1986) 321, pp. 522-525), and an antibody obtained by grafting a part of the amino acid residues of the framework as well as the CDR sequence to a human antibody by a CDR-grafting method (WO 90/07861) can be exemplified. As an example of the humanized antibody of a rat antibody #32A1, an arbitrary combination of a heavy chain containing a heavy chain variable region comprising an amino acid sequence comprising amino acid residues 20 to 140 of SEQ ID NO: 51 in the Sequence Listing, amino acid residues 20 to 140 of SEQ ID NO: 53, amino acid residues 20 to 140 of SEQ ID NO: 55, amino acid residues 20 to 140 of SEQ ID NO: 57, amino acid residues 20 to 140 of SEQ ID NO: 59, amino acid residues 20 to 140 of SEQ ID NO: 99, amino acid residues 20 to 140 of SEQ ID NO: 101, or amino acid residues 1 to 121 of any one of amino acid sequences represented by SEQ ID NOS: 72 to 77 and a light chain containing a light chain variable region comprising an amino acid sequence comprising amino acid residues 21 to 133 of SEQ ID NO: 61, amino acid residues 21 to 133 of SEQ ID NO: 63, amino acid residues 21 to 133 of SEQ

ID NO: 65, amino acid residues 21 to 132 of SEQ ID NO: 67, amino acid residues 21 to 133 of SEQ ID NO: 69, amino acid residues 21 to 133 of SEQ ID NO: 71, amino acid residues 21 to 133 of SEQ ID NO: 103, amino acid residues 21 to 133 of SEQ ID NO: 105, or amino acid residues 1 to 113 of any one of amino acid sequences represented by SEQ ID NOS: 78 to 96 can be exemplified.

[0115]

As a preferred combination, an antibody comprising a heavy chain containing a heavy chain variable region comprising an amino acid sequence comprising amino acid residues 20 to 140 of SEQ ID NO: 51 and a light chain containing a light chain variable region comprising an amino acid sequence comprising amino acid residues 21 to 133 of SEQ ID NO: 61, an antibody comprising a heavy chain containing a heavy chain variable region comprising an amino acid sequence comprising amino acid residues 20 to 140 of SEQ ID NO: 53 and a light chain containing a light chain variable region comprising an amino acid sequence comprising amino acid residues 21 to 133 of SEQ ID NO: 63, an antibody comprising a heavy chain containing a heavy chain variable region comprising an amino acid sequence comprising amino acid residues 20 to 140 of SEQ ID NO: 55 and a light chain containing a light chain variable region comprising an amino acid sequence comprising amino acid residues 21 to 133 of SEQ ID NO: 65, an antibody comprising a heavy chain containing a

heavy chain variable region comprising an amino acid sequence comprising amino acid residues 20 to 140 of SEQ ID NO: 55 and a light chain containing a light chain variable region comprising an amino acid sequence comprising amino acid residues 21 to 132 of SEQ ID NO: 67, an antibody comprising a heavy chain containing a heavy chain variable region comprising an amino acid sequence comprising amino acid residues 20 to 140 of SEQ ID NO: 57 and a light chain containing a light chain variable region comprising an amino acid sequence comprising amino acid residues 21 to 133 of SEQ ID NO: 69, an antibody comprising a heavy chain containing a heavy chain variable region comprising an amino acid sequence comprising amino acid residues 20 to 140 of SEQ ID NO: 59 and a light chain containing a light chain variable region comprising an amino acid sequence comprising amino acid residues 21 to 133 of SEQ ID NO: 71, an antibody comprising a heavy chain containing a heavy chain variable region comprising an amino acid sequence comprising amino acid residues 20 to 140 of SEQ ID NO: 99 and a light chain containing a light chain variable region comprising an amino acid sequence comprising amino acid residues 21 to 133 of SEQ ID NO: 69, an antibody comprising a heavy chain containing a heavy chain variable region comprising an amino acid sequence comprising amino acid residues 20 to 140 of SEQ ID NO: 101 and a light chain containing a light chain variable region comprising an amino acid sequence

comprising amino acid residues 21 to 133 of SEQ ID NO: 69, an antibody comprising a heavy chain containing a heavy chain variable region comprising an amino acid sequence comprising amino acid residues 20 to 140 of SEQ ID NO: 99 and a light chain containing a light chain variable region comprising an amino acid sequence comprising amino acid residues 21 to 133 of SEQ ID NO: 103, or an antibody comprising a heavy chain containing a heavy chain variable region comprising an amino acid sequence comprising amino acid residues 20 to 140 of SEQ ID NO: 99 and a light chain containing a light chain variable region comprising an amino acid sequence comprising amino acid residues 21 to 133 of SEQ ID NO: 105 can be exemplified.

[0116]

As a more preferred combination, an antibody comprising a heavy chain having an amino acid sequence comprising amino acid residues 20 to 470 of SEQ ID NO: 51 and a light chain having an amino acid sequence comprising amino acid residues 21 to 238 of SEQ ID NO: 61, an antibody comprising a heavy chain having an amino acid sequence comprising amino acid residues 20 to 470 of SEQ ID NO: 53 and a light chain having an amino acid sequence comprising amino acid residues 21 to 238 of SEQ ID NO: 63, an antibody comprising a heavy chain having an amino acid sequence comprising amino acid residues 20 to 470 of SEQ ID NO: 55 and a light chain having an amino acid sequence comprising amino acid residues 21 to 238 of SEQ ID NO: 65, an

antibody comprising a heavy chain having an amino acid sequence comprising amino acid residues 20 to 470 of SEQ ID NO: 55 and a light chain having an amino acid sequence comprising amino acid residues 21 to 237 of SEQ ID NO: 67, an antibody comprising a heavy chain having an amino acid sequence comprising amino acid residues 20 to 470 of SEQ ID NO: 57 and a light chain having an amino acid sequence comprising amino acid residues 21 to 238 of SEQ ID NO: 69, an antibody comprising a heavy chain having an amino acid sequence comprising amino acid residues 20 to 470 of SEQ ID NO: 59 and a light chain having an amino acid sequence comprising amino acid residues 21 to 238 of SEQ ID NO: 71, an antibody comprising a heavy chain having an amino acid sequence comprising amino acid residues 20 to 466 of SEQ ID NO: 99 and a light chain having an amino acid sequence comprising amino acid residues 21 to 238 of SEQ ID NO: 69, an antibody comprising a heavy chain having an amino acid sequence comprising amino acid residues 20 to 466 of SEQ ID NO: 101 and a light chain having an amino acid sequence comprising amino acid residues 21 to 238 of SEQ ID NO: 69, an antibody comprising a heavy chain having an amino acid sequence comprising amino acid residues 20 to 466 of SEQ ID NO: 99 and a light chain having an amino acid sequence comprising amino acid residues 21 to 238 of SEQ ID NO: 103, or an antibody comprising a heavy chain having an amino acid sequence comprising amino acid residues 20 to 466 of SEQ ID NO: 99 and a light chain having an amino

acid sequence comprising amino acid residues 21 to 238 of SEQ ID NO: 105 can be exemplified.

[0117]

However, the humanized antibody derived from the #32A1 antibody is not limited to the above-mentioned humanized antibodies as long as the humanized antibody has all 6 types of CDR sequences of #32A1 and has an activity of inhibiting osteoclast formation. Incidentally, the heavy chain variable region of the #32A1 antibody has CDRH1 (DYFMN) comprising an amino acid sequence represented by SEQ ID NO: 44, either one of CDRH2 (QIRNKIYTYATFYAESLEG) comprising an amino acid sequence represented by SEQ ID NO: 45 and CDRH2 (QIRNKIYTYATFYA) represented by SEQ ID NO: 97, and CDRH3 (SLTGGDYFDY) comprising an amino acid sequence represented by SEQ ID NO: 46. The CDRH2 represented by SEQ ID NO: 45 is in accordance with the Kabat definition (SEQUENCES OF PROTEINS OF IMMUNOLOGICAL INTEREST VOL. I, FIFTH EDITION (1991)). The CDRH2 represented by SEQ ID NO: 97 is made shorter by five residues at the C terminus than the Kabat definition. In the heavy chain sequence containing this CDRH2, the CDR sequence derived from a rat is made shorter and more of a human framework sequence is incorporated, and therefore, when it is administered to humans, it is much less likely to be recognized as a heterologous antigen. Further, the light chain variable region of the #32A1 antibody has CDRL1 (RASQSVTISGYSFIH)

comprising an amino acid sequence represented by SEQ ID NO: 47, CDRL2 (RASNLAS) comprising an amino acid sequence represented by SEQ ID NO: 48, and CDRL3 (QQSRKSPWT) comprising an amino acid sequence represented by SEQ ID NO: 49.

[0118]

Further, the antibody of the invention includes a human antibody. A human anti-Siglec-15 antibody refers to a human antibody having only a gene sequence of an antibody derived from a human chromosome. The human anti-Siglec-15 antibody can be obtained by a method using a human antibody-producing mouse having a human chromosome fragment containing heavy and light chain genes of a human antibody (see Tomizuka, K. et al., *Nature Genetics* (1997) 16, pp. 133-143; Kuroiwa, Y. et al., *Nucl. Acids Res.* (1998) 26, pp. 3447-3448; Yoshida, H. et al., *Animal Cell Technology: Basic and Applied Aspects* vol. 10, pp. 69-73 (Kitagawa, Y., Matuda, T. and Iijima, S. eds.), Kluwer Academic Publishers, 1999; Tomizuka, K. et al., *Proc. Natl. Acad. Sci. USA* (2000) 97, pp. 722-727, etc.).

[0119]

Such a human antibody-producing mouse can be created specifically as follows. A genetically modified animal in which endogenous immunoglobulin heavy and light chain gene loci have been disrupted, and instead, human immunoglobulin heavy and light chain gene loci have been introduced via a yeast artificial chromosome (YAC) vector or the like is created by

producing a knockout animal and a transgenic animal and mating these animals.

[0120]

Further, according to a genetic engineering technique, by using cDNAs encoding such a heavy chain and a light chain of a human antibody, respectively, and preferably a vector containing the cDNAs, eukaryotic cells are transformed, and a transformant which produces a recombinant human monoclonal antibody is cultured, whereby the antibody can also be obtained from the culture supernatant.

[0121]

Here, as the host, for example, eukaryotic cells, preferably mammalian cells such as CHO cells, lymphocytes or myeloma cells can be used.

[0122]

Further, a method of obtaining a phage display-derived human antibody screened from a human antibody library (see Wormstone, I. M. et al., *Investigative Ophthalmology & Visual Science*. (2002) 43 (7), pp. 2301-2308; Carmen, S. et al., *Briefings in Functional Genomics and Proteomics* (2002), 1 (2), pp. 189-203; Siriwardena, D. et al., *Ophthalmology* (2002) 109 (3), pp. 427-431, etc.) is also known.

[0123]

For example, a phage display method in which a variable region of a human antibody is expressed on the surface of a

phage as a single-chain antibody (scFv), and a phage which binds to an antigen is selected (Nature Biotechnology (2005), 23, (9), pp. 1105-1116) can be used.

[0124]

By analyzing the gene of the phage selected based on the binding to an antigen, a DNA sequence encoding the variable region of a human antibody which binds to an antigen can be determined.

[0125]

If the DNA sequence of scFv which binds to an antigen is determined, a human antibody can be obtained by preparing an expression vector having the sequence and introducing the vector into an appropriate host to express it (WO 92/01047, WO 92/20791, WO 93/06213, WO 93/11236, WO 93/19172, WO 95/01438, WO 95/15388, Annu. Rev. Immunol (1994) 12, pp. 433-455, Nature Biotechnology (2005) 23 (9), pp. 1105-1116).

[0126]

The antibodies obtained by the above method are evaluated for the property of binding to an antigen by the method described in Example 25 or the like, and a preferred antibody can be selected. As one example of another index when the properties of antibodies are compared, the stability of antibodies can be exemplified. The differential scanning calorimetry (DSC) shown in Example 33 is an instrument capable of rapidly and accurately measuring a thermal denaturation

midpoint temperature (T_m) which is a favorable index of relative structural stability of proteins. By measuring T_m values using DSC and comparing the values, a difference in thermal stability can be compared. It is known that the storage stability of antibodies shows some correlation with the thermal stability of antibodies (Lori Burton, et. al., *Pharmaceutical Development and Technology* (2007) 12, pp. 265-273), and a preferred antibody can be selected by using thermal stability as an index. Examples of other indices for selecting antibodies include as follows: the yield in an appropriate host cell is high and the aggregability in an aqueous solution is low. For example, an antibody which shows the highest yield does not always show high thermal stability, and therefore, it is necessary to select an antibody most suitable for administering to humans by making comprehensive evaluation based on the above-mentioned indices.

[0127]

Further, a method in which the full-length heavy and light chain sequences of an antibody are ligated using an appropriate linker, whereby a single-chain immunoglobulin is obtained is also known (Lee, H-S, et. al., *Molecular Immunology* (1999) 36, pp. 61-71; Shirmann, T. et. al., *mAbs* (2010), 2, (1) pp. 1-4). By dimerizing such a single-chain immunoglobulin, the resulting dimer can have a structure and an activity similar to those of an antibody which is a tetramer

itself. Further, the antibody of the invention may be an antibody which has a single heavy chain variable region and does not have a light chain sequence. Such an antibody is called a single domain antibody (sdAb) or a nanobody, and in fact, it is observed in camels and llamas and has been reported to have an antigen-binding affinity (Muyldemans S. et. al., Protein Eng. (1994) 7(9), 1129-35, Hamers-Casterman C. et. al., Nature (1993) 363 (6428) 446-8). It can be understood that the above-mentioned antibodies are types of functional fragments of the antibody according to the invention.

[0128]

Further, by controlling glycosylation in which a glycan is bound to the antibody of the invention, it is possible to enhance antibody-dependent cellular cytotoxic activity. As regards techniques for controlling the glycosylation of antibodies, WO 99/54342, WO 00/61739, WO 02/31140, etc. are known. However, the techniques are not limited thereto.

[0129]

In cases where an antibody is produced by first isolating an antibody gene and then introducing the gene into an appropriate host, a combination of an appropriate host and an appropriate expression vector can be used. Specific examples of the antibody gene include a combination of a gene encoding a heavy chain sequence of an antibody described in this description and a gene encoding a light chain sequence thereof.

When a host cell is transformed, it is possible to insert the heavy chain sequence gene and the light chain sequence gene into the same expression vector, and also into different expression vectors separately. In cases where eukaryotic cells are used as the host, animal cells, plant cells, and eukaryotic microorganisms can be used. As the animal cells, (1) mammalian cells, for example, dihydrofolate reductase-deficient strains (Urlaub, G. and Chasin, L. A., Proc. Natl. Acad. Sci. USA (1980) 77, pp. 4126-4220) of simian COS cells (Gluzman, Y., Cell, (1981) 23, pp. 175-182, ATCC CRL-1650), murine fibroblasts NIH3T3 (ATCC No. CRL-1658), and Chinese hamster ovarian cells (CHO cells; ATCC: CCL-61); can be exemplified. Further, in cases where prokaryotic cells are used, for example, *Escherichia coli* and *Bacillus subtilis* can be exemplified. By introducing a target antibody gene into these cells through transformation, and culturing the thus transformed cells in vitro, the antibody can be obtained. In the above-mentioned culture method, the yield may sometimes vary depending on the sequence of the antibody, and therefore, it is possible to select one which is easily produced as a pharmaceutical by using the yield as an index among the antibodies having a comparable binding activity.

[0130]

There is no limitation on isotype of the antibody of the invention, and examples thereof include IgG (IgG1, IgG2, IgG3,

IgG4), IgM, IgA (IgA1, IgA2), IgD, and IgE, and preferred examples thereof include IgG and IgM, and further, more preferred examples thereof include IgG1 and IgG2.

[0131]

Further, the antibody of the invention may be a functional fragment of the antibody having an antigen-binding site of the antibody or a modified fragment thereof. The fragment of the antibody can be obtained by treating the antibody with a protease such as papain or pepsin, or modifying the antibody gene according to a genetic engineering technique and expressing the modified gene in suitable cultured cells. Among these antibody fragments, a fragment having all or part of the functions of the full-length molecule of the antibody can be called a functional fragment of the antibody. As the functions of the antibody, generally an antigen-binding activity, an activity of neutralizing the activity of an antigen, an activity of increasing the activity of an antigen, an antibody-dependent cytotoxic activity, a complement-dependent cytotoxic activity, and a complement-dependent cellular cytotoxic activity can be exemplified. The function of the functional fragment of the antibody according to the invention is a binding activity to Siglec-15, preferably an activity of inhibiting the formation of osteoclasts, more preferably an activity of inhibiting the process of cell fusion of osteoclasts.

[0132]

Examples of the fragment of the antibody include Fab, F(ab')₂, Fv, single-chain Fv (scFv) in which Fv molecules of the heavy chain and the light chain are ligated via an appropriate linker, a diabody (diabodies), a linear antibody, and a polyspecific antibody composed of the antibody fragment. Further, Fab' which is a monovalent fragment in a variable region of an antibody obtained by treating F(ab')₂ under reducing conditions is also regarded as a fragment of the antibody.

[0133]

Further, the antibody of the invention may be a polyspecific antibody with specificity for at least two different antigens. In general, such a molecule binds to two antigens (that is, a bispecific antibody), however, the "polyspecific antibody" as used herein includes an antibody having specificity for two or more (for example, three) antigens.

[0134]

The polyspecific antibody of the invention may be a full-length antibody or a fragment of such an antibody (for example, a F(ab')₂ bispecific antibody). The bispecific antibody can be produced by ligating the heavy and light chains (HL pairs) of two types of antibodies, or can also be produced by fusing hybridomas which produce different monoclonal

antibodies to prepare bispecific antibody-producing fused cells (Millstein et al., Nature (1983) 305, pp. 537-539).

[0135]

The antibody of the invention may be a single-chain antibody (also referred to as scFv). The single-chain antibody can be obtained by ligating the heavy chain variable region and the light chain variable region of an antibody via a polypeptide linker (Pluckthun, The Pharmacology of Monoclonal Antibodies, 113 (edited by Rosenberg and Moore, Springer Verlag, New York, pp. 269-315 (1994), Nature Biotechnology (2005), 23, pp. 1126-1136). Further, a BiscFv fragment produced by ligating two scFv molecules via a polypeptide linker can also be used as the bispecific antibody.

[0136]

The method of producing a single-chain antibody is known in this technical field (see, for example, US patent Nos. 4,946,778, 5,260,203, 5,091,513, 5,455,030, etc.). In this scFv, the heavy chain variable region and the light chain variable region are ligated via a linker which does not form a conjugate, preferably via a polypeptide linker (Huston, J. S. et al., Proc. Natl. Acad. Sci. USA (1988), 85, pp. 5879-5883). In the scFv, the heavy chain variable region and the light chain variable region may be derived from the same antibody or different antibodies.

As the polypeptide linker to be used for ligating the

variable regions, for example, a given single-chain peptide composed of 12 to 19 residues is used.

[0137]

DNA encoding scFv can be obtained by performing amplification using a DNA encoding the entire amino acid sequence, or a desired partial amino acid sequence, selected from the heavy chain or the heavy chain variable region of the above-mentioned antibody and the light chain or the light chain variable region thereof as a template by a PCR method using a primer pair that defines both ends thereof, and further performing amplification by combining a DNA encoding a polypeptide linker portion and a primer pair that defines both ends thereof so as to ligate both of the ends to the heavy chain and the light chain, respectively.

[0138]

Further, once DNA encoding scFv is produced, an expression vector containing the same and a host transformed by the expression vector can be obtained according to common procedures. Further, by using the resulting host, scFv can be obtained according to common procedures. An antibody fragment thereof can be produced in a host by obtaining a gene and expressing the gene in the same manner as described above.

[0139]

The antibody of the invention may be multimerized to increase its affinity for an antigen. The antibody to be

multimerized may be one type of antibody or a plurality of antibodies which recognize a plurality of epitopes of the same antigen. As a method of multimerization of the antibody, binding of the IgG CH3 domain to two scFv molecules, binding to streptavidin, introduction of a helix-turn-helix motif and the like can be exemplified.

[0140]

The antibody of the invention may be a polyclonal antibody which is a mixture of plural types of anti-Siglec-15 antibodies having different amino acid sequences. As one example of the polyclonal antibody, a mixture of plural types of antibodies having different CDR can be exemplified. As such a polyclonal antibody, a mixture of cells which produce different antibodies is cultured, and an antibody purified from the resulting culture can be used (see WO 2004/061104).

[0141]

As a modified antibody, an antibody bound to any of various types of molecules such as polyethylene glycol (PEG) can also be used.

[0142]

Further, the antibody of the invention may be in the form of a conjugate formed between any of these antibodies and another medicinal agent (immunoconjugate). Examples of such an antibody include one in which the antibody is conjugated to a radioactive material or a compound having a

pharmacological action (Nature Biotechnology (2005) 23, pp. 1137-1146).

[0143]

The obtained antibody can be purified to homogeneity. The separation and purification of the antibody can be performed employing a conventional protein separation and purification method. For example, the antibody can be separated and purified by appropriately selecting and combining column chromatography, filter filtration, ultrafiltration, salt precipitation, dialysis, preparative polyacrylamide gel electrophoresis, isoelectric focusing electrophoresis, and the like (Strategies for Protein Purification and Characterization: A Laboratory Course Manual, Daniel R. Marshak et al. eds., Cold Spring Harbor Laboratory Press (1996); Antibodies: A Laboratory Manual. Ed Harlow and David Lane, Cold Spring Harbor Laboratory (1988)), but the method is not limited thereto.

[0144]

Examples of such chromatography include affinity chromatography, ion exchange chromatography, hydrophobic chromatography, gel filtration chromatography, reverse phase chromatography, and adsorption chromatography.

[0145]

Such chromatography can be performed employing liquid chromatography such as HPLC or FPLC.

[0146]

As a column to be used in affinity chromatography, a Protein A column and a Protein G column can be exemplified.

[0147]

For example, as a column using a Protein A column, Hyper D, POROS, Sepharose FF (Pharmacia) and the like can be exemplified.

Further, by using a carrier having an antigen immobilized thereon, the antibody can also be purified utilizing the binding property of the antibody to the antigen.

[0148]

4. Pharmaceutical containing anti-Siglec-15 antibody

From the anti-Siglec-15 antibodies obtained by the method described in the above item "3. Production of anti-Siglec-15 antibody", an antibody which neutralizes the biological activity of Siglec-15 can be obtained. Such an antibody which neutralizes the biological activity of Siglec-15 inhibits the biological activity of Siglec-15 in vivo, i.e., the differentiation and/or maturation of osteoclasts, and therefore can be used as a therapeutic and/or preventive agent for abnormal bone metabolism caused by abnormal differentiation and/or maturation of osteoclasts as a pharmaceutical. The abnormal bone metabolism may be any disorder characterized by net bone loss (osteopenia or osteolysis). In general, the treatment and/or prevention by

the anti-Siglec-15 antibody are/is applied to a case where inhibition of bone resorption is required. Examples of the abnormal bone metabolism which can be treated and/or prevented by the anti-Siglec-15 antibody include osteoporosis (postmenopausal osteoporosis, senile osteoporosis, secondary osteoporosis due to the use of a therapeutic agent such as a steroid or an immunosuppressant, or osteoporosis accompanying rheumatoid arthritis), bone destruction accompanying rheumatoid arthritis, cancerous hypercalcemia, bone destruction accompanying multiple myeloma or cancer metastasis to bone, giant cell tumor, osteopenia, tooth loss due to periodontitis, osteolysis around a prosthetic joint, bone destruction in chronic osteomyelitis, Paget's disease of bone, renal osteodystrophy, and osteogenesis imperfecta, however, the abnormal bone metabolism is not limited thereto as long as it is a disease accompanied by net bone loss caused by osteoclasts. Examples of the anti-Siglec-15 antibody to be used as the above-mentioned pharmaceutical include a chimeric antibody and a humanized antibody produced from the #32A1 antibody by the method described in item 3. "(3) Other antibodies". Further, a chimeric antibody, a humanized antibody, and a human antibody sharing the same epitope as the #32A1 antibody can also be used as a pharmaceutical. Whether a certain anti-Siglec-15 antibody shares the same epitope as the #32A1 antibody can be confirmed by observing whether or

not these antibodies bind to the same specific partial peptide of Siglec-15. Further, it can also be determined that if a certain anti-Siglec-15 antibody competes with the #32A1 antibody for binding to Siglec-15, these antibodies share the same epitope.

[0149]

The in vitro activity of the anti-Siglec-15 antibody of neutralizing the biological activity of Siglec-15 can be determined by, for example, the activity of inhibiting the differentiation of the cells which overexpress Siglec-15 into osteoclasts. For example, the anti-Siglec-15 antibody is added to RAW 264.7 cells or RAW 264 cells which are a mouse monocyte-derived cell line at various concentrations, and the activity of inhibiting the differentiation into osteoclasts by stimulation with RANKL or TNF- α can be determined. Further, the anti-Siglec-15 antibody is added to bone marrow-derived primary cultured cells at various concentrations, and the activity of inhibiting the differentiation into osteoclasts by stimulation with RANKL, TNF- α , or active vitamin D₃ can be determined. Further, the anti-Siglec-15 antibody is added to normal human osteoclast precursor cells (Normal Human Natural Osteoclast Precursor Cells, available from Sanko Junyaku Co., Ltd., Cat. No. 2T-110) at various concentrations, and the activity of inhibiting the differentiation into osteoclasts by stimulation with RANKL or M-CSF can be determined. Such

an inhibitory effect on osteoclast differentiation can be determined by using the inhibition of tartrate-resistant acid phosphatase (TRAP) activity of osteoclasts as an index. Further, the inhibitory effect on osteoclast differentiation can also be determined by using the inhibition of formation of TRAP-positive multinucleated osteoclasts, i.e., the inhibition of cell fusion of osteoclasts as an index. Further, in an experiment utilising a pit assay (Takada et al., Bone and Mineral, (1992) 17, 347-359) using femur- and/or tibia-derived cells, the in vitro activity of inhibiting the bone resorption by osteoclasts can be determined by adding the anti-Siglec-15 antibody to femur- and/or tibia-derived cells at various concentrations, and observing pit formation on a dentine slice. As a system for determining the in vitro activity of inhibiting the bone resorption by osteoclasts, it is also possible to use a plate coated with human collagen conjugated to europium. The in vivo therapeutic or preventive effect of the anti-Siglec-15 antibody on abnormal bone metabolism using an experimental animal can be confirmed by administering the anti-Siglec-15 antibody to an animal model of osteoporosis or a transgenic animal which overexpresses Siglec-15 and measuring any change in osteoclasts.

[0150]

The thus obtained antibody which neutralizes the biological activity of Siglec-15 is useful as a pharmaceutical,

particularly as a pharmaceutical composition for treating or preventing abnormal bone metabolism such as osteoporosis, bone destruction accompanying rheumatoid arthritis, or bone destruction accompanying cancer metastasis to bone, or as an antibody for immunological diagnosis of such a disease.

[0151]

In the treatment of rheumatoid arthritis (RA), a major problem is bone loss accompanying the occurrence of the disease. It has been reported that in this bone loss accompanying RA, osteoclasts play a primary role. The cytokines considered to be most important for osteoclast induction (differentiation and maturation) and activation and as the cause of bone destruction in RA are RANKL and TNF- α (Romas E. et al., Bone 30, pp. 340-346, 2002). OCIF/OPG which is a decoy receptor for RANKL can inhibit osteoclast formation induced by RANKL but does not inhibit osteoclast formation induced by TNF- α . On the other hand, the anti-Siglec-15 antibody according to the invention effectively inhibited osteoclast formation induced by both RANKL and TNF- α . Therefore, it is expected that the anti-Siglec-15 antibody of the invention can inhibit bone loss and bone destruction induced by TNF- α in RA or the like more strongly than an RANKL blocker (OCIF/OPG, an anti-RANKL antibody, or the like).

[0152]

As one example, for the treatment or prevention of

abnormal bone metabolism, the anti-Siglec-15 antibody can be administered alone or in combination with at least one other therapeutic agent for a bone-related disease. As another example, the anti-Siglec-15 antibody can be administered in combination with a therapeutically effective amount of a therapeutic agent for abnormal bone metabolism. Examples of the therapeutic agent which can be administered in combination with the anti-Siglec-15 antibody include, but are not limited to: bisphosphonates (for example, alendronate, etidronate, ibandronate, incadronate, pamidronate, risedronate, and zoledronate), active vitamin D₃, calcitonin and derivatives thereof, hormones such as estradiol, SERMs (selective estrogen receptor modulators), ipriflavone, vitamin K₂ (menatetrenone), calcium preparations, PTH (parathyroid hormone), nonsteroidal anti-inflammatory agents (for example, celecoxib and rofecoxib), soluble TNF receptors (for example, etanercept), anti-TNF- α antibodies or functional fragments of the antibodies (for example, infliximab), anti-PTHrP (parathyroid hormone-related protein) antibodies or functional fragments of the antibodies, IL-1 receptor antagonists (for example, anakinra), anti-IL-6 receptor antibodies or functional fragments of the antibodies (for example, tocilizumab), anti-RANKL antibodies or functional fragments of the antibodies (for example, denosumab), and OCIF (osteoclastogenesis inhibitory factor). Depending on the

state of abnormal bone metabolism or the intended degree of the treatment and/or prevention, two or three, or more types of medicinal agents can be administered, and these medicinal agents can be supplied all together by encapsulating them in the same preparation. These medicinal agents and the anti-Siglec-15 antibody can be supplied all together by encapsulating them in the same preparation. Further, these medicinal agents can be supplied all together by encapsulating them as a kit to be used for treatment and/or prevention. Further, these medicinal agents and the anti-Siglec-15 antibody can be supplied separately. In the case of administration in gene therapy, a gene of a proteinous therapeutic agent for a bone disease and a gene of the anti-Siglec-15 antibody can be inserted downstream of the same promoter region or different promoter regions, and can be introduced into the same vector or different vectors.

[0153]

By conjugating a therapeutic agent for a bone disease to the anti-Siglec-15 antibody or a fragment thereof, a targeted drug conjugate as described in M. C. Garnet "Targeted drug conjugates: principles and progress", Advanced Drug Delivery Reviews, (2001) 53, 171-216 can be produced. For achieving this purpose, other than the antibody molecule, any antibody fragment can be applied as long as it does not completely lose the ability to recognize osteoclasts, and

examples thereof include fragments such as Fab, F(ab')₂, and Fv. In the invention, the antibody and the fragment can be used in the same manner. The conjugate formed by the anti-Siglec-15 antibody or a fragment thereof and a therapeutic agent for a bone disease can be any of various forms described in M. C. Garnet "Targeted drug conjugates: principles and progress", *Advanced Drug Delivery Reviews*, (2001) 53, 171-216, G. T. Hermanson "Bioconjugate Techniques" Academic Press, California (1996), Putnam and J. Kopecek "Polymer Conjugates with Anticancer Activity" *Advances in Polymer Science* (1995) 122, 55-123 and the like. That is, a conjugate in which the anti-Siglec-15 antibody and a therapeutic agent for a bone disease are conjugated to each other chemically and directly or via a spacer such as an oligopeptide and a conjugate formed via an appropriate drug carrier can be exemplified. Examples of the drug carrier include a liposome and a water-soluble polymer. More specific examples of the conjugate formed via such a drug carrier include a conjugate in which the antibody and a therapeutic agent for a bone disease are incorporated in a liposome and the liposome and the antibody are conjugated to each other, and a conjugate in which a therapeutic agent for a bone disease is conjugated to a water-soluble polymer (a compound having a molecular weight of from about 1000 to 100000) chemically and directly or via a spacer such as an oligopeptide and the antibody is conjugated to the

water-soluble polymer. The conjugation of the antibody (or a fragment thereof) to a therapeutic agent for a bone disease or a drug carrier such as a liposome or a water-soluble polymer can be effected by a method known to those skilled in the art such as the method described in G. T. Hermanson "Bioconjugate Techniques" Academic Press, California (1996), Putnam and J. Kopecek "Polymer Conjugates with Anticancer Activity" Advances in Polymer Science (1995) 122, 55-123. The incorporation of a therapeutic agent for a bone disease in a liposome can be effected by a method known to those skilled in the art such as the method described in D. D. Lasic "Liposomes: From Physics to Applications" Elsevier Science Publishers B. V., Amsterdam (1993) or the like. The conjugation of a therapeutic agent for a bone disease to a water-soluble polymer can be effected by a method known to those skilled in the art such as the method described in D. Putnam and J. Kopecek "Polymer Conjugates with Anticancer Activity" Advances in Polymer Science (1995) 122, 55-123. A conjugate of the antibody (or a fragment thereof) and a proteinous therapeutic agent for a bone disease (or a fragment thereof) can be produced by methods known to those skilled in the art through genetic engineering other than the above-mentioned method.

[0154]

The invention also provides a pharmaceutical composition

containing a therapeutically and/or preventively effective amount of the anti-Siglec-15 antibody and a pharmaceutically acceptable diluent, carrier, solubilizing agent, emulsifying agent, preservative, and/or adjuvant.

[0155]

The invention also provides a pharmaceutical composition containing a therapeutically and/or preventively effective amount of the anti-Siglec-15 antibody, a therapeutically and/or preventively effective amount of at least one therapeutic agent for a bone disease, and a pharmaceutically acceptable diluent, carrier, solubilizing agent, emulsifying agent, preservative, and/or adjuvant. Examples of the therapeutic agent for a bone disease include, but are not limited to, bisphosphonates (for example, alendronate, etidronate, ibandronate, incadronate, pamidronate, risedronate, and zoledronate), active vitamin D₃, calcitonin and derivatives thereof, hormones such as estradiol, SERMs (selective estrogen receptor modulators), ipriflavone, vitamin K₂ (menatetrenone), calcium preparations, PTH (parathyroid hormone), nonsteroidal anti-inflammatory agents (for example, celecoxib and rofecoxib), soluble TNF receptors (for example, etanercept), anti-TNF- α antibodies or functional fragments of the antibodies (for example, infliximab), anti-PTHrP (parathyroid hormone-related protein) antibodies or functional fragments of the antibodies,

IL-1 receptor antagonists (for example, anakinra), anti-IL-6 receptor antibodies or functional fragments of the antibodies (for example, tocilizumab), anti-RANKL antibodies or functional fragments of the antibodies (for example, denosumab) and OCIF (osteoclastogenesis inhibitory factor).
[0156]

A substance to be used in a preparation acceptable in the pharmaceutical composition according to the invention is preferably non-toxic to a person to whom the pharmaceutical composition is to be administered in terms of the dose and concentration.

[0157]

The pharmaceutical composition of the invention can contain a substance for pharmaceutical use which is capable of changing or maintaining the pH, osmotic pressure, viscosity, transparency, color, isotonicity, aseptic condition, stability, solubility, release rate, absorption rate, and permeability thereof. Examples of such a substance for pharmaceutical use include, but are not limited to, amino acids such as glycine, alanine, glutamine, asparagine, arginine, and lysine; antimicrobial agents; antioxidants such as ascorbic acid, sodium sulfate, and sodium hydrogen sulfite; buffers such as phosphate, citrate, borate buffers, sodium hydrogen carbonate, and Tris-HCl solutions; fillers such as mannitol and glycine; chelating agents such as ethylenediamine

tetraacetate (EDTA); complexing agents such as caffeine, polyvinylpyrrolidine, β -cyclodextrin, and hydroxypropyl- β -cyclodextrin; expanders such as glucose, mannose, and dextrin; other carbohydrates such as monosaccharides and disaccharides; coloring agents; flavors; diluents; emulsifying agents; hydrophilic polymers such as polyvinylpyrrolidine; preservatives such as low molecular weight polypeptides, salt forming counter ions, benzalkonium chloride, benzoic acid, salicylic acid, thimerosal, phenethyl alcohol, methylparaben, propylparaben, chlorhexidine, sorbic acid, and hydrogen peroxide; solvents such as glycerin, propylene glycol, and polyethylene glycol; sugar alcohols such as mannitol and sorbitol; suspending agents; surfactants such as sorbitan ester, polysorbates including polysorbate 20 and polysorbate 80, Triton, tromethamine, lecithin, and cholesterol; stability enhancing agents such as sucrose and sorbitol; elasticity enhancing agents such as sodium chloride, potassium chloride, and mannitol and sorbitol; transport agents; excipients; and/or pharmaceutical adjuvants. The amount of these substances added for pharmaceutical use is preferably from 0.01 to 100 times, particularly preferably from 0.1 to 10 times the weight of the anti-Siglec-15 antibody. Those skilled in the art can appropriately determine a preferred formulation of the pharmaceutical composition in a preparation depending on the disease to which the composition

is applied, the route of administration to be applied, or the like.

[0158]

The excipient or carrier in the pharmaceutical composition may be in the form of a liquid or a solid. An appropriate excipient or carrier may be injectable water, physiological saline, an artificial cerebral spinal fluid, or other substance commonly used for parenteral administration. Further, neutral physiological saline or physiological saline containing serum albumin can also be used as a carrier. The pharmaceutical composition may contain a Tris buffer of pH 7.0 to 8.5, an acetate buffer of pH 4.0 to 5.5, or a citrate buffer of pH 3.0 to 6.2. Further, such a buffer may be supplemented with sorbitol or another compound. Examples of the pharmaceutical composition of the invention include a pharmaceutical composition containing the anti-Siglec-15 antibody and a pharmaceutical composition containing the anti-Siglec-15 antibody and at least one therapeutic agent for a bone disease. The pharmaceutical composition of the invention is prepared in the form of a lyophilized product or a liquid as a medicinal agent having a selected composition and a required purity. The pharmaceutical composition containing the anti-Siglec-15 antibody and the pharmaceutical composition containing the anti-Siglec-15 antibody and at least one therapeutic agent for abnormal bone metabolism can

also be formed into a lyophilized product using an appropriate excipient such as sucrose.

[0159]

The pharmaceutical composition of the invention can be prepared for parenteral administration or for gastrointestinal absorption through oral administration. The composition and concentration of a preparation can be determined depending on the administration method. The higher the affinity of the anti-Siglec-15 antibody contained in the pharmaceutical composition of the invention is for Siglec-15, that is, the lower the dissociation constant (K_d value) thereof is for Siglec-15, the more the anti-Siglec-15 antibody can exhibit its drug efficacy even when decreasing the dose for humans. Hence, the dose of the pharmaceutical composition of the invention for humans can also be determined based on this consideration. As for the dose, in the case where a human anti-Siglec-15 antibody is administered to humans, the antibody may be administered at a dose of from about 0.1 to 100 mg/kg once per one to 180 days.

[0160]

Examples of the dosage form of the pharmaceutical composition of the invention include injections including infusions, suppositories, transnasal agents, sublingual agents, and percutaneous absorbents.

Examples

Hereinafter, the invention will be more specifically described with reference to the Examples, however, the invention is not limited thereto. Note that the respective operations regarding gene manipulation in the following Examples were performed according to the methods described in "Molecular Cloning" (written by Sambrook, J., Fritsch, E. F. and Maniatis, T., published by Cold Spring Harbor Laboratory Press in 1989), or in the case of using commercially available reagents or kits, they are used according to the protocols attached thereto unless otherwise stated.

Example 1

[0161]

Production of soluble mouse Siglec-15 protein expression construct

A partial nucleotide sequence encoding the extracellular domain of mouse Siglec-15 protein is represented by SEQ ID NO: 5 in the Sequence Listing and an amino acid sequence thereof is represented by SEQ ID NO: 6 in the Sequence Listing. By utilizing such a partial sequence, soluble mouse Siglec-15 protein can be produced in a culture supernatant of an animal cell or the like.

[0162]

a) Amplification of soluble mouse Siglec-15 gene by PCR

As primers for amplifying the mouse Siglec-15 extracellular domain cDNA by PCR, an oligonucleotide having a sequence of 5'-ggggacaagt ttgtacaaaa aagcaggctt caccATGGAG GGGTCCCTCC AACTC-3' (mSiglec-15-ECD-F: SEQ ID NO: 7 in the Sequence Listing); and an oligonucleotide having a sequence of 5'-ggggaccact ttgtacaaga aagctgggtc TCCGGGGGCG CCGTGGAAGC GGAAC-3' (mSiglec-15-ECD-R: SEQ ID NO: 8 in the Sequence Listing) were synthesized according to a common procedure. Incidentally, these primers were designed as amplification primers for producing a gateway entry clone, such that an attB1 sequence is added to mSiglec-15-ECD-F and an attB2 sequence is added to mSiglec-15-ECD-R. The PCR was performed using this combination of primers and a polynucleotide containing an open reading frame sequence of the mouse Siglec-15 as a template according to a common procedure. The conditions for a thermal cycler were set as follows: after heating at 94°C for 5 minutes, a temperature cycle of "94°C for 0.5 minutes, 55°C for 0.5 minutes, and 68°C for 1.5 minutes" was repeated 15 times, followed by heating at 68°C for 5 minutes and incubating at 4°C.

[0163]

b) Production of entry clone by Gateway BP reaction

An entry clone into which the mouse Siglec-15 extracellular domain cDNA was integrated by the Gateway technology (Invitrogen, Inc.) employing a lambda phage

site-specific recombination system was produced by the following method. First, a BP reaction using BP Clonase was performed between the PCR product having an attB sequence at both ends produced in a) and pDNOR221 (manufactured by Invitrogen, Inc.) which is a donor vector having an attP sequence. By using this reaction solution, *Escherichia coli* DH10B was transformed, colony PCR was performed for drug-resistant clones, and the size of inserts was confirmed. Then, for a clone confirmed to have an insert with the correct size, a sequence analysis of the total DNA sequence of the insert was performed. As a result, an entry clone which is completely identical to the target nucleotide sequence (SEQ ID NO: 5 in the Sequence Listing) encoding the extracellular domain of the mouse Siglec-15 protein was obtained.

[0164]

c) Production of expression clone by Gateway LR reaction

An expression clone into which the mouse Siglec-15 extracellular domain cDNA was integrated by the Gateway technology (Invitrogen, Inc.) employing a lambda phage site-specific recombination system was produced by the following method. The entry clone produced in b) contains an insert having an attL sequence at both ends. An LR reaction using LR Clonase was performed between this entry clone and two types of destination vectors having an attR sequence. Incidentally, as the destination vectors, two types of

destination vectors: pDONM designed such that a V5 epitope tag and a 6 x His tag are added to the C terminus of the insert; and pHgFc designed such that a human Fc tag is added to the C terminus of the insert were used. By using the reaction solution obtained by the LR reaction, *Escherichia coli* DH10B was transformed, and colony PCR was performed for the obtained drug-resistant clones, and the size of inserts was confirmed. Then, for a clone confirmed to have an insert with the correct size, a sequence analysis of both ends from the insert side to the vector side was performed.

[0165]

Primer sequences for sequence analysis:

5'-tgcggtgaagg tgcagggcag-3' (mSiglec-15-ECD-seq-upstm: SEQ ID NO: 9 in the Sequence Listing)

and

5'-cctcgctg tgggtc-3' (mSiglec-15-ECD-seq-dnstm: SEQ ID NO: 10 in the Sequence Listing)

As a result of the sequence analysis, expression clones (soluble mouse Siglec-15/pDONM and soluble mouse Siglec-15/pHgFc) in which correct recombination occurred for both pDONM and pHgFc, respectively, were obtained. By transfecting the soluble mouse Siglec-15/pDONM into an animal cell or the like, mRNA having a base sequence represented by SEQ ID NO: 11 in the Sequence Listing is transcribed and translated into a protein (mouse Siglec-15-His) having an amino

acid sequence represented by SEQ ID NO: 12 in the Sequence Listing. Further, by transfecting the soluble mouse Siglec-15/phIgFc into an animal cell or the like, mRNA having a base sequence represented by SEQ ID NO: 13 in the Sequence Listing is transcribed and translated into a protein (mouse Siglec-15-Fc) having an amino acid sequence represented by SEQ ID NO: 14 in the Sequence Listing.

Example 2

[0166]

Large-scale preparation of culture solution containing soluble mouse Siglec-15 protein using 293-F cells

The two types of expression vectors (soluble mouse Siglec-15/pDONM and soluble mouse Siglec-15/phIgFc) obtained in Example 1 were prepared in an amount of about 5 mg, respectively. Incidentally, in the purification of plasmids from *Escherichia coli* cultured on a large scale, Invitrogen PureLink HiPure Plasmid Gigaprep Kit (manufactured by Invitrogen, Inc.) was used. The thus prepared plasmid was mixed with Opti-MEM (manufactured by Invitrogen, Inc.), the resulting mixture was sterilized by filtration, 10 ml of a transfection reagent 293fectin (manufactured by Invitrogen, Inc.) was added thereto, and the resulting mixture was incubated at room temperature for 20 minutes. This mixture was added to FreeStyle 293-F cells (manufactured by Invitrogen,

Inc.) cultured in Erlenmeyer flasks such that the cell density reached 1.1×10^6 cells/ml x 5 L (1 L/flask x 5 flasks) in FreeStyle 293 Expression Medium (manufactured by Invitrogen, Inc.). After the cells had been subjected to culture with agitation (125 rotations/min) at a CO₂ concentration of 8.0% for 96 hours (4 days) at 37°C, the culture solution was collected and centrifuged to prepare a culture supernatant. It is considered that in the thus prepared culture supernatant, a protein in which a V5 epitope tag and a 6 x His tag have been added to the C-terminal side of the mouse Siglec-15 extracellular domain (mouse Siglec-15-His) and a protein in which a human Fc tag has been added to the C-terminal side of the mouse Siglec-15 extracellular domain (mouse Siglec-15-Fc) are expressed, respectively.

Example 3

[0167]

Purification of mouse Siglec-15-His

a) HisTrap HP column chromatography

To 2 L of the culture solution of mouse Siglec-15-His-expressing 293F cells prepared in Example 2, 225 mL of 10 x buffer (500 mM Tris, 1.5 M NaCl, 200 mM imidazole, pH 8.0) was added, and the resulting mixture was stirred well and filtered through a Sterivex-GV filter (manufactured by Millipore Co., Ltd.). This culture solution was applied at a flow rate of

2 ml/min to a column which comprised three HisTrap HP 5 ml columns (manufactured by Amersham Biosciences, Inc.) connected in series and was previously treated with a pyrogen removing agent PyroCLEAN (manufactured by ALerCHEK, Inc.) and washed with distilled water for injection. After the column was washed with 60 ml of 50 mM Tris-HCl buffer (pH 8.0) containing 300 mM NaCl at a flow rate of 1 ml/min, a protein adsorbed to the column was eluted with 50 ml of 50 mM Tris-HCl buffer (pH 8.0) containing 300 mM NaCl and 500 mM imidazole at a flow rate of 1 ml/min. The eluate was fractionated at 1 ml per fraction into mini-sorp tubes (manufactured by Nunc, Inc.) to which 10 μ l of 10% Tween 20 had previously been added. After about 20 ml of a solution obtained by combining the fractions (fractions 14 to 20) and containing the eluted protein was concentrated to 2.5 ml with a centrifugal membrane concentrator Amicon Ultra-15 (manufactured by Millipore Co., Ltd.), the concentrate was applied to a PD-10 desalting column (manufactured by Amersham Biosciences, Inc.) which had previously been equilibrated with phosphate-buffered saline containing 0.01% Tween 20 (T-PBS), followed by elution with T-PBS, whereby 3.5 ml of a sample whose solvent was replaced with T-PBS was obtained.

[0168]

b) Resource Q column chromatography

To 3.5 ml of the sample which was purified by HisTrap

HP column chromatography and whose solvent was replaced with T-PBS, 22.5 ml of 50 mM Tris-HCl buffer (pH 7.5) containing 0.1% CHAPS was added and the resulting mixture was stirred. Then, the mixture was centrifuged at 4°C for 30 minutes at 3,000 rpm and the precipitate was removed. After the resulting supernatant was filtered through a Millex-GV filter (manufactured by Millipore Co., Ltd.), the filtrate was applied at a flow rate of 1 ml/min to a Resource Q 6 ml column (manufactured by Amersham Biosciences, Inc.) which had previously been equilibrated with 50 mM Tris-HCl buffer (pH 7.5) containing 0.1% CHAPS. Thereafter, the column was washed with this buffer at a flow rate of 1 ml/min and a protein fraction which was not adsorbed to the column was collected. A protein adsorbed to the column was eluted with 50 mM Tris-HCl buffer (pH 7.5) containing 0.1% CHAPS and 1 M NaCl at a flow rate of 1 ml/min. After 26.5 ml of the fraction which was not adsorbed to the column was concentrated to 2.0 ml with a centrifugal membrane concentrator Amicon Ultra-15 (manufactured by Millipore Co., Ltd.), the concentrate was centrifuged at 4°C for 10 minutes at 3,000 rpm and the precipitate was removed. The supernatant after centrifugation was cryopreserved at -80°C until use. The above-mentioned purification procedure (HisTrap HP column chromatography and Resource Q column chromatography) was performed by repeating it twice.

[0169]

c) Detection and purity assay of purified mouse Siglec-15-His

By using a sample prepared by the above-mentioned purification procedure (HisTrap HP column chromatography and Resource Q column chromatography), SDS-polyacrylamide electrophoresis under reducing conditions and silver staining were performed. That is, to 5 μ l of each of the samples purified by the respective purification steps, an equivalent amount of an SDS-treatment solution was added, and the resulting mixture was thermally treated at 95°C for 10 minutes. 0.3 μ l of each of the thermally treated samples was used for SDS-polyacrylamide electrophoresis. As a gel for electrophoresis, an 8-25% polyacrylamide gradient gel (manufactured by Amersham Biosciences, Inc.) was used, and the electrophoresis was performed using PhastSystem (manufactured by Amersham Biosciences, Inc.). Further, as molecular weight markers, Rainbow Molecular Weight Markers (manufactured by Amersham Biosciences, Inc.) were used. After completion of the electrophoresis, silver staining was performed using PhastGel Silver Kit (manufactured by Amersham Biosciences, Inc.) and PhastSystem. The results are shown in Fig. 1. It was shown that a protein having a molecular weight of about 35 kDa (mouse Siglec-15-His) was efficiently purified and concentrated in the protein fraction which was not adsorbed to the Resource Q column.

[0170]

Electrophoresis was performed under the same conditions except that ECL DualVue Western Blotting Markers (manufactured by Amersham Biosciences, Inc.) were used as the molecular weight markers, and the protein in the gel was transferred (blotted) to a PVDF membrane (Hybond-P, manufactured by Amersham Biosciences, Inc.) using a PhastTransfer Semi-dry Transfer Kit (manufactured by Amersham Biosciences, Inc.) and PhastSystem. This PVDF membrane was gently shaken in 10 ml of a blocking agent (BlockAce, manufactured by Snow Brand Milk Products, Co., Ltd.) containing 0.1% Tween 20 at room temperature for 1 hour. To this blocking solution, 10 μ l of S-protein HRP (manufactured by Amersham Biosciences, Inc.) and 10 μ l of an anti-V5-HRP antibody (Monoclonal Antibody to Pk-TAG-HRP, manufactured by Acris Antibodies) were added and the membrane in the solution was gently shaken at room temperature for an additional 1 hour. The PVDF membrane was washed 4 times by gently shaking it in 50 mL of phosphate-buffered saline (PBS) containing 0.01% Tween 20 for 5 minutes. After washing, the PVDF membrane was treated according to the protocol accompanying an ECL detection kit (manufactured by Amersham Biosciences, Inc.) to develop the color of the band of the protein, and the developed color was detected using an ECL Mini-Camera (manufactured by Amersham Biosciences, Inc.) and Polaroid film (Polapan 3200B,

manufactured by Polaroid, Inc.). The results are shown in Fig. 2. Also from these results, it could be confirmed that a protein which has a molecular weight of about 35 kDa (mouse Siglec-15-His) and reacts with an anti-V5-HRP antibody was efficiently purified and concentrated in the protein fraction which was not adsorbed to the Resource Q column.

[0171]

d) Measurement of protein concentration of purified mouse Siglec-15-His

For the purified mouse Siglec-15-His (the protein fraction which was not adsorbed to the Resource Q column), the protein concentration was measured with a DC protein assay kit (manufactured by Bio-Rad Laboratories, Inc.) using bovine serum albumin as a standard sample. As shown in Table 1, a total of 1.66 mg of purified mouse Siglec-15-His protein was obtained by performing the purification procedure twice.

[0172]

[Table 1]

	Protein Conc. (mg/ml)	Sample Vol. (ml)	Total protein (mg)
1st	0.475	2.0	0.95
2nd	0.354	2.0	0.71
Total			1.66

Example 4

[0173]

Purification of mouse Siglec-15-Fc

a) HiTrap Protein A column chromatography

1.8 L of the culture solution of mouse Siglec-15-Fc-expressing 293F cells prepared in Example 2 was filtered through a Sterivex-GV filter (manufactured by Millipore Co., Ltd.), and then the filtrate was applied to a HiTrap Protein A 5 ml column (manufactured by Amersham Biosciences, Inc.) which had previously been equilibrated with Dulbecco's PBS (D-PBS, manufactured by Invitrogen, Inc.) at a flow rate of 5 ml/min. After the column was washed with D-PBS at a flow rate of 5 ml/min, a protein adsorbed to the column was eluted with 50 ml of 0.1 M sodium citrate buffer (pH 3.0) at a flow rate of 5 ml/min. The eluate was fractionated at 5 ml per fraction into mini-sorp tubes (manufactured by Nunc, Inc.), and immediately thereafter, 1.3 ml of 1 M Tris was added thereto to neutralize the eluate. After a solution obtained by combining the fractions (fractions 1 and 2) in which the eluted protein was detected was concentrated to 2.5 ml with a centrifugal membrane concentrator Amicon Ultra-15 (manufactured by Millipore Co., Ltd.), the concentrate was applied to a PD-10 desalting column (manufactured by Amersham Biosciences, Inc.) which had previously been equilibrated with Otsuka Physiological Saline for Injection (TO-SS, manufactured by Otsuka Pharmaceutical Co., Ltd.) containing 0.01% Tween 20, followed by elution with TO-SS, whereby 3.5 ml of a sample whose solvent was replaced with TO-SS was

obtained. This sample was cryopreserved at -80°C until use. By using 2.9 L of a culture solution of 293F cells, the same purification procedure was performed by repeating it once more. [0174]

b) Detection and purity assay of purified mouse Siglec-15-Fc

By using a sample prepared by the above-mentioned purification procedure, SDS-polyacrylamide electrophoresis under reducing conditions and silver staining were performed. That is, to 5 μl of each of the samples purified by the respective purification steps, an equivalent amount of an SDS-treatment solution was added, and the resulting mixture was heated at 95°C for 10 minutes. 0.3 μl of a sample obtained by diluting each of the thermally treated samples to 1/300 or 1/900 with a half concentration of the SDS-treatment solution was used for SDS-polyacrylamide electrophoresis. The electrophoresis and silver staining were performed in the same manner as the purity assay of mouse Siglec-15-His described in c) of Example 3. The results are shown in Fig. 3 along with the results of examining preliminary purification conditions on a small scale (the pH of the applied culture solution was 8.9 or 7.0). It was shown that a protein having a molecular weight of about 55 kDa (mouse Siglec-15-Fc) was efficiently purified and concentrated in the protein fraction which was eluted from the HiTrap Protein A column.

[0175]

c) Measurement of protein concentration of purified mouse Siglec-15-Fc

For the purified mouse Siglec-15-Fc (the protein fraction eluted from the PD-10 desalting column), the protein concentration was measured with a DC protein assay kit (manufactured by Bio-Rad Laboratories, Inc.) using bovine serum albumin as a standard sample. As shown in Table 2, a total of 92 mg of purified mouse Siglec-15-Fc protein was obtained by performing the purification procedure twice.

[0176]

[Table 2]

	Protein Conc. (mg/ml)	Sample Vol. (ml)	Total protein (mg)
1st	8.0	3.5	28
2nd	18.5	3.5	64
Total			92

Example 5

[0177]

Establishment of rat anti-mouse Siglec-15 monoclonal antibody-producing hybridoma

a) Preparation of antigen

The mouse Siglec-15-His protein produced in Example 3 was prepared at 100 μ g/0.5 ml, and an equivalent amount of an adjuvant was added thereto and an emulsion was produced using a glass syringe. As the adjuvant, Freund's complete adjuvant

(FCA, Manufactured by Difco Laboratories, Inc.) was used only for the first immunization, and Freund's incomplete adjuvant (FICA, Manufactured by Difco Laboratories, Inc.) was used for the second immunization and thereafter.

[0178]

b) Immunization of rat

Four rats (Wistar, female, 6 weeks of age, purchased from CLEA Japan, Inc.) were used as immunized animals. The emulsion obtained in a) was injected subcutaneously and intradermally using a 27 G injection needle such that the amount of the antigen was 50 μ g per rat. Immunization was performed a total of 4 times every 7 days after the first immunization. A small amount (200 μ l) of the blood was collected from the tail vein after 7 days from the date of the 4th immunization, and an antiserum was prepared. In order to confirm the antibody titer of the antiserum, ELISA using the mouse Siglec-15-His protein that had been used as the antigen, the mouse Siglec-15-Fc protein produced in Example 4, or bovine serum albumin (BSA), each of which was immobilized, was performed. As a result, the reactivity with the mouse Siglec-15-His protein and the mouse Siglec-15-Fc protein was observed in all four rats (rat Nos. 1 to 4). On the other hand, the reactivity with BSA was not observed. From these results, it was confirmed that the antibody titer in the serum of each of the immunized rats increased, and therefore, the No. 2 rat which showed the highest

antibody titer was subjected to a cell fusion procedure.

[0179]

c) Cell fusion

Cell fusion was performed according to a common method of fusing mouse (rat) spleen cells with myeloma cells. The whole blood was collected from the heart of the rat under ether anesthesia and the rat was euthanized, and then the spleen was excised. The collected spleen cells and P3X63Ag8.653 cells (ATCC CRL 1580) which are mouse myeloma cells were subjected to cell fusion using polyethylene glycol (PEG). The resulting cells were seeded in a 96-well plate, and a medium containing hypoxanthine (H), aminopterin (A) and thymidine (T) (HAT selection medium) was added thereto, and then, the cells were cultured for 7 to 10 days. The culture supernatant was collected from 61 wells in which the survival of hybridomas obtained by cell fusion was confirmed. Then, the antibody titer was evaluated by ELISA using the mouse Siglec-15-His protein that had been used as the antigen, the mouse Siglec-15-Fc protein produced in Example 4, or BSA, each of which was immobilized, and anti-mouse Siglec-15 monoclonal antibody-producing hybridomas were screened. From the results of the screening, 12 wells showing a high antibody titer were selected and the hybridomas contained in the wells were subjected to a cloning procedure.

[0180]

d) Cloning of hybridoma

For the thus selected hybridomas, a first cloning step was performed by a limiting dilution method. After the limiting dilution, the hybridomas were cultured for 2 weeks, and the antibody titer in the culture supernatant was confirmed by ELISA using the mouse Siglec-15-Fc protein produced in Example 4 or BSA, each of which was immobilized. For 11 clones which were confirmed to be positive clones, a second cloning step was performed (in the same manner as the first cloning step), whereby 10 clones of the anti-mouse Siglec-15 monoclonal antibody-producing hybridomas (#1A1, #3A1, #8A1, #24A1, #32A1, #34A1, #39A1, #40A1, #41B1, #61A1) were established in the end. Incidentally, the hybridoma #32A1 was deposited at the International Patent Organism Depositary of the National Institute of Advanced Industrial Science and Technology (located at Central 6, 1-1-1 Higashi, Tsukuba-shi, Ibaraki-ken, 305-8566, Japan) on August 28, 2008, and has been given an accession number of FERM BP-10999 under the name of anti-Siglec-15 Hybridoma #32A1.

Example 6

[0181]

Preparation of rat anti-mouse Siglec-15 monoclonal antibody

a) Preparation of nude mouse ascites

The hybridomas established in Example 5 were cultured using TIL Media I (manufactured by Immuno-biological Laboratories Co., Ltd.) medium containing 10% FCS. Subculturing of the cells was carried out by performing a procedure in which the culture solution was diluted to about one-fourth every two to three days by using the time point when the cells were grown to about 5×10^5 cells/ml as an index. Each of the thus cultured hybridomas was intraperitoneally implanted in a nude mouse to which pristane had been intraperitoneally administered (0.2 ml/mouse) previously at 1×10^7 cells per mouse. In the implantation, three nude mice were used for each of the 10 clones of hybridomas. After the implantation, the ascites was collected when sufficient accumulation of ascites was observed, which was combined with those collected from the other two mice implanted with the same hybridoma, the amount of the ascites thus combined was measured, and the ascites was cryopreserved until purification of the antibody. The amounts of the collected ascites for the respective hybridomas were summarized in Table 3.

[0182]

[Table 3]

Hybridoma	Amount of collected ascites (ml)	Hybridoma	Amount of collected ascites (ml)
#1A1	12.5	#34A1	8.2
#3A1	8.0	#39A1	14.5
#8A1	6.0	#40A1	20.3
#24A1	7.8	#41B1	10.5
#32A1	5.5	#61A1	12.3

[0183]

b) Purification of antibody

The total amount of the collected ascites was subjected to IgG purification using a 20 ml Protein G column (manufactured by GE Healthcare, Co., Ltd.). The purified IgG was assayed for purity by gel filtration analysis (Superdex 200 column chromatography), and some of the antibodies were subjected to centrifugal membrane concentration. That is, among the purified anti-mouse Siglec-15 monoclonal antibodies, 9 types of antibodies except for the #24A1 antibody were concentrated to about one-sixth to one-eighth of the original volume by centrifuging the antibodies at 3,000 rpm for 30 to 60 minutes at 4°C using a centrifugal membrane concentrator Amicon Ultra-15 (manufactured by Millipore Co., Ltd.). Subsequently, for the #24A1 antibody and the other concentrated 9 types of antibodies, the protein concentration was measured with a DC protein assay kit (manufactured by Bio-Rad Laboratories, Inc.) using bovine serum albumin (BSA) as a standard sample. By the above-mentioned procedure, the anti-mouse Siglec-15 monoclonal antibody was prepared.

Example 7

[0184]

Evaluation of property of rat anti-mouse Siglec-15 monoclonal antibody binding to mouse Siglec-15 protein

The property of the rat anti-mouse Siglec-15 monoclonal antibody binding to mouse Siglec-15 protein was evaluated by an ELISA method. The mouse Siglec-15-Fc protein produced in Example 4 was diluted to 5 µg/ml with 0.1 M sodium carbonate buffer (pH 9.5), and the resulting solution was added to a 96-well plate (manufactured by Nalge Nunc International, Inc., Cat. No. 430341) at 100 µl/well. After the plate was left at room temperature for 1 hour, the solution was removed and a washing buffer (phosphate-buffered saline containing 0.05% Tween 20) was added at 300 µl/well and then removed. After this washing procedure was performed one more time, phosphate-buffered saline containing 25% BlockAce (manufactured by Dainippon Sumitomo Pharma Co., Ltd.) was added at 200 µl/well, and the plate was left at room temperature for 1 hour, whereby blocking was performed. The liquid was removed, and the plate was washed twice with 300 µl/well of the washing buffer. Then, each of the rat anti-mouse Siglec-15 monoclonal antibodies prepared in Example 6 or rat control IgG (manufactured by R&D Systems, Inc.) was diluted to a final concentration of from 1.28 to 20,000 ng/ml (5-fold dilution

series) with an ELISA buffer (phosphate-buffered saline containing 12.5% BlockAce and 0.05% Tween 20), and the resulting diluted antibody solution was added to the plate at 100 μ l/well. After the plate was left at room temperature for 1 hour, the liquid was removed, and the plate was washed 3 times with 300 μ l/well of the washing buffer. Subsequently, an HRP (horseradish peroxidase)-labeled goat anti-rat IgG antibody (manufactured by Beckman Coulter, Inc.) diluted to 1,000-fold with an ELISA buffer was added at 100 μ l/well, and the plate was left at room temperature for 1 hour. The liquid was removed and the plate was washed 3 times with 300 μ l/well of the washing buffer, and then, by using a color developing kit for peroxidase (manufactured by Sumitomo Bakelite Co., Ltd.), the color was developed according to the protocol accompanying the kit. After developing the color, an absorbance at 492 nm was measured using a microplate reader (manufactured by Nihon Molecular Devices Corporation). As a result, it was confirmed that all of the examined 10 test samples of the rat anti-mouse Siglec-15 monoclonal antibodies bind to the mouse Siglec-15 protein in an antibody concentration-dependent manner (Fig. 4). On the other hand, in the case of the rat control IgG, binding to the mouse Siglec-15 protein was not observed.

Example 8

[0185]

Preparation of mouse bone marrow nonadherent cells

The femur and tibia were excised from a male ddY mouse at the age of 5 to 8 weeks and soft tissues were removed. Both ends of the femur or tibia were cut off, and D-PBS was injected using a syringe with a 25-gauge injection needle to push out bone marrow cells, which were collected in a centrifugal tube. Centrifugation was performed at room temperature for 5 minutes at 100 g, and the supernatant was removed. To the resulting cell pellet, 1 ml of a hemolytic buffer (Red Blood Cell Lysing Buffer, manufactured by Sigma Co., Ltd.) was added to suspend it, and the resulting suspension was left at room temperature for 5 minutes. 20 ml of D-PBS was added thereto, and the suspension was centrifuged at room temperature for 5 minutes at 100 g, and the supernatant was removed. To the resulting cell pellet, 10 ml of MEM- α medium (manufactured by Invitrogen, Inc.) containing 5 ng/ml of M-CSF (manufactured by R&D Systems, Inc.) and 10% fetal bovine serum (FBS) was added to suspend it. Then, the resulting suspension was passed through a cell strainer (40 μ m Nylon, manufactured by BD Falcon) to remove aggregates. The resulting cells were transferred to a 75 cm² T-flask (for the attachment of adherent cells) and cultured overnight in a CO₂ incubator. After the overnight culture, the cells which did not adhere to the T-flask were recovered and used as mouse bone marrow nonadherent cells.

Example 9

[0186]

Evaluation of biological activity of rat anti-mouse Siglec-15 monoclonal antibody based on test for mouse osteoclast formation

By using all of the 10 test samples of the anti-mouse Siglec-15 monoclonal antibodies produced in Example 6, an effect on osteoclast differentiation of mouse bone marrow nonadherent cells was examined. The mouse bone marrow nonadherent cells prepared by the method of Example 8 were prepared at 1.5×10^5 cells/ml in α -MEM medium containing 10% FBS and 10 ng/ml of M-CSF (manufactured by R&D Systems, Inc.), and the resulting cell preparation was seeded in each well of a 96-well plate in an amount of 200 μ l and the cells were cultured for 2 days in a CO₂ incubator. The old culture solution in the 96-well plate was removed, and 100 μ l of MEM- α medium was added to each well, the 100 μ l of MEM- α medium containing 10% FBS to which human RANKL (RANKL, manufactured by Peprotech, Inc.) and M-CSF had been added to give final concentrations of 20 ng/ml and 10 ng/ml, respectively. To the cell culture solution, each of the rat anti-mouse Siglec-15 monoclonal antibodies produced in Example 6, a sample obtained by removing sodium azide from commercially available rat control IgG (purified rat IgG, manufactured by R&D Systems, Inc.), or a separately produced rabbit anti-mouse Siglec-15 polyclonal antibody (No.

3) was added at a concentration of from 32 to 1,000 ng/ml, and the cells were cultured for an additional 3 days in a CO₂ incubator. Incidentally, the polyclonal antibody (No. 3) is an antibody which has already been confirmed to inhibit osteoclast formation in the experimental system described in this Example. After completion of the culturing, the activity of tartrate-resistant acid phosphatase (TRAP) of the formed osteoclasts was measured by a procedure described below. The culture solution in each well of the 96-well plate was removed by suction, and 50 µl of 50 mM sodium citrate buffer (pH 6.1) containing 1% Triton X-100 was added to each well. Then, the plate was shaken for 5 minutes on a plate shaker to lyse the cells. To each well, 50 µl of a substrate solution (50 mM sodium citrate buffer (pH 6.1) containing 5 mg/ml p-nitrophenyl phosphate and 0.46% sodium tartrate) was added, and the plate was incubated at room temperature for 5 minutes. After the incubation, 50 µl of a 1 N sodium hydroxide solution was added to each well of the 96-well plate to stop the enzymatic reaction. After stopping the enzymatic reaction, an absorbance of each well at 405 nm was measured, and the obtained measurement was used as an index of TRAP activity. The results are shown in Figs. 5 and 6. A significant inhibition of TRAP activity was not observed in the case of the commercially available rat control IgG. On the other hand, a significant inhibition of TRAP activity was observed in the cases of the #32A1 antibody

added in the range of from 32 ng/ml to 1000 ng/ml, and the #8A1 antibody and the affinity-purified rabbit polyclonal No. 3 antibody added in the range of from 63 ng/ml to 1000 ng/ml. Also in the cases of the #3A1 antibody, #34A1 antibody, and #39A1 antibody, a dose-dependent inhibition of TRAP activity was observed at a relatively high concentration of 500 ng/ml or higher. The inhibition of mouse osteoclast formation by the other antibodies was not observed. From the above results, antibodies which strongly inhibit mouse osteoclast formation (osteoclast differentiation and maturation) were found among the prepared rat anti-mouse Siglec-15 monoclonal antibodies. Further, as a property common to the #3A1 antibody, #8A1 antibody, #32A1 antibody, #34A1 antibody, and #39A1 antibody, the activity of inhibiting osteoclast formation at a concentration of 1000 ng/ml, i.e., 1 μ g/ml or less can be exemplified.

Example 10

[0187]

Production of soluble human Siglec-15 protein expression construct

A partial nucleotide sequence encoding the extracellular domain of human Siglec-15 protein is represented by SEQ ID NO: 15 in the Sequence Listing and the amino acid sequence thereof is represented by SEQ ID NO: 16 in the Sequence Listing. By

utilizing such a partial sequence, soluble human Siglec-15 protein can be produced in a culture supernatant of an animal cell or the like.

[0188]

a) Amplification of soluble human Siglec-15 gene by PCR

As primers for amplifying the human Siglec-15 extracellular domain cDNA by PCR, an oligonucleotide having a sequence of 5'-ggggacaagt ttgtacaaaa aagcaggctt caccATGGAA AAGTCCATCT GGCTGC-3' (hSiglec-15-ECD-F: SEQ ID NO: 17 in the Sequence Listing); and an oligonucleotide having a sequence of 5'-ggggaccact ttgtacaaga aagctggggtc CCCGCTGGCG CCATGGAAGC GG-3' (hSiglec-15-ECD-R: SEQ ID NO: 18 in the Sequence Listing) were synthesized according to a common procedure. Incidentally, these primers were designed, as amplification primers for producing a gateway entry clone, such that an attB1 sequence is added to hSiglec-15-ECD-F and an attB2 sequence is added to hSiglec-15-ECD-R. The PCR was performed using this combination of primers and a polynucleotide containing an open reading sequence of the human Siglec-15 as a template according to a common procedure. The resulting PCR reaction solution was purified using PureLink PCR Purification Kit (manufactured by Invitrogen, Inc.).

[0189]

b) Production of entry clone by Gateway BP reaction

An entry clone into which the human Siglec-15

extracellular domain cDNA was integrated by the Gateway technology (Invitrogen, Inc.) employing a lambda phage site-specific recombination system was produced by the following method. First, a BP reaction using BP Clonase was performed between the PCR product having an attB sequence at both ends produced in a) and pDNOR221 (manufactured by Invitrogen, Inc.) which is a donor vector having an attP sequence. By using this reaction solution, *Escherichia coli* TOP10 was transformed, colony PCR was performed for drug-resistant clones, and the size of inserts was confirmed. Then, for a clone confirmed to have an insert with the correct size, a sequence analysis of the total DNA sequence of the insert was performed. As a result, an entry clone which is completely identical to the target nucleotide sequence (SEQ ID NO: 15 in the Sequence Listing) encoding the extracellular domain of the human Siglec-15 protein was obtained.

[0190]

c) Production of expression clone by Gateway LR reaction

An expression clone into which the human Siglec-15 extracellular domain cDNA was integrated by the Gateway technology (Invitrogen, Inc.) employing a lambda phage site-specific recombination system was produced by the following method. The entry clone produced in b) contains an insert having an attL sequence at both ends. An LR reaction using LR Clonase was performed between this entry clone and

two types of destination vectors having an attR sequence. Incidentally, as the destination vectors, two types of destination vectors: pDONM designed such that a V5 epitope tag and a 6 x His tag are added to the C terminus of the insert; and pHgFc designed such that a human Fc tag is added to the C terminus of the insert, were used. By using the reaction solution obtained by the LR reaction, *Escherichia coli* TOP10 was transformed, and a sequence analysis was performed for the resulting drug-resistant clones to confirm whether correct recombination occurred.

As a result of the sequence analysis, expression clones (soluble human Siglec-15/pDONM and soluble human Siglec-15/pHgFc) in which correct recombination occurred for both pDONM and pHgFc, respectively, were obtained. By transfecting the soluble human Siglec-15/pDONM into an animal cell or the like, mRNA having a base sequence represented by SEQ ID NO: 19 in the Sequence Listing is transcribed and translated into a protein (human Siglec-15-His) having an amino acid sequence represented by SEQ ID NO: 20 in the Sequence Listing. Further, by transfecting the soluble human Siglec-15/pHgFc into an animal cell or the like, mRNA having a base sequence represented by SEQ ID NO: 21 in the Sequence Listing is transcribed and translated into a protein (human Siglec-15-Fc) having an amino acid sequence represented by SEQ ID NO: 22 in the Sequence Listing.

Example 11

[0191]

Large-scale preparation of culture solution containing soluble human Siglec-15 protein using 293-F cells

a) Preparation of culture solution containing human Siglec-15-His

The soluble human Siglec-15/pDONM obtained in Example 10 was prepared in an amount of about 25 mg. Incidentally, in the purification of plasmids from *Escherichia coli* cultured on a large scale, Invitrogen PureLink HiPure Plasmid Gigaprep Kit (manufactured by Invitrogen, Inc.) was used. The thus prepared plasmid was mixed with Opti-MEM (manufactured by Invitrogen, Inc.), 50 ml of transfection reagent 293fectin (manufactured by Invitrogen, Inc.) was added thereto, and the resulting mixture was incubated at room temperature for 20 minutes. This mixture was added to FreeStyle 293-F cells (manufactured by Invitrogen, Inc.) cultured in FreeStyle 293 Expression Medium (manufactured by Invitrogen, Inc.) containing 1% penicillin-streptomycin such that the cell density reached 1.0 to 3.4×10^6 cells/ml using a 25 L bioprocess culture apparatus (WAVE Bioreactor). After the cells had been subjected to culture with agitation (30 rotations/min) at a CO_2 concentration of from 6 to 12% for 96 hours (4 days) at 37°C , the culture solution was collected and centrifuged to prepare

a culture supernatant. It is observed that in the thus prepared culture supernatant, a protein in which a V5 epitope tag and a 6 x His tag have been added to the C-terminal side of the human Siglec-15 extracellular domain (human Siglec-15-His) is expressed.

[0192]

b) Preparation of culture solution containing human Siglec-15-Fc

The soluble human Siglec-15/phIgFc obtained in Example 10 was prepared in an amount of about 5 mg. Incidentally, in the purification of plasmids from *Escherichia coli* cultured on a large scale, Invitrogen PureLink HiPure Plasmid Gigaprep Kit (manufactured by Invitrogen, Inc.) was used. The thus prepared plasmid was mixed with Opti-MEM (manufactured by Invitrogen, Inc.), followed by filter sterilization. Then, 10 ml of a transfection reagent 293fectin (manufactured by Invitrogen, Inc.) was added thereto, and the resulting mixture was incubated at room temperature for 20 minutes. This mixture was added to FreeStyle 293-F cells (manufactured by Invitrogen, Inc.) cultured in Erlenmeyer flasks such that the cell density reached 1.0 to 3.0×10^6 cells/ml x 5 L (1 L/flask x 5 flasks) in FreeStyle 293 Expression Medium (manufactured by Invitrogen, Inc.). After the cells had been subjected to culture with agitation (125 rotations/min) at a CO₂ concentration of 8.0% for 96 hours (4 days) at 37°C, the culture solution was collected

and centrifuged to prepare a culture supernatant. It is observed that in the thus prepared culture supernatant, a protein in which a human Fc tag has been added to the C-terminal side of the human Siglec-15 extracellular domain (human Siglec-15-Fc) is expressed.

Example 12

[0193]

Purification of soluble human Siglec-15 protein

a) Purification of soluble human Siglec-15-His

a-i) HisTrap HP column chromatography

To 12 L of the culture solution of 293F cells expressing human Siglec-15-His prepared in a) of Example 11, 1350 mL of 10 x buffer (500 mM Tris, 1.5 M NaCl, 200 mM imidazole, pH 8.0) was added, and the resulting mixture was stirred well and filtered through a MilliPak-60 filter (manufactured by Millipore Co., Ltd.). This culture solution was applied at a flow rate of 10 ml/min to a Ni-Sepharose HP (manufactured by Amersham Biosciences, Inc.) 100 ml column which had previously been washed with pure water (Milli-Q water). After the column had been washed with 400 ml of 50 mM Tris-HCl buffer (pH 8.0) containing 300 mM NaCl at a flow rate of 8 mL/min, a protein adsorbed to the column was eluted with 200 ml of 50 mM Tris-HCl buffer (pH 8.0) containing 300 mM NaCl and 500 mM imidazole at a flow rate of 2.5 ml/min, and the eluate was

fractionated into mini-sorp tubes (manufactured by Nunc, Inc.). In order to prevent precipitation of the protein, 8 ml of a 5 M NaCl solution was added to about 40 ml of a fraction containing the eluted protein, followed by stirring, and then the resulting mixture was concentrated to about 20 ml with a centrifugal membrane concentrator Amicon Ultra-15 (manufactured by Millipore Co., Ltd.). Insoluble matter generated during the concentration was removed by centrifugation at 3000 rpm for 30 minutes at 4°C, and 2.5 ml of the resulting supernatant was applied to a PD-10 desalting column (manufactured by Amersham Biosciences, Inc.) which had previously been equilibrated with phosphate-buffered saline containing 1 M NaCl (N-PBS), followed by elution with N-PBS, whereby 3.5 ml of a sample whose solvent was replaced with N-PBS was obtained. This procedure was performed by repeating it 7 more times, and about 28 ml of a solution of partially purified human Siglec-15-His was obtained.

[0194]

a-ii) Resource Q column chromatography

12 ml of the sample which had been purified by Ni-Sepharose HP column chromatography and whose solvent had been replaced with N-PBS was dialyzed overnight at 4°C against 50 mM Tris-HCl buffer (pH 7.5) containing 0.1% CHAPS (1 L, 3 times) and the resulting dialysate was centrifuged at 3,000 rpm for 30 minutes at 4°C, and the precipitate was removed.

After the resulting supernatant had been filtered through a Millex-GV filter (manufactured by Millipore Co., Ltd.), the filtrate was applied at a flow rate of 1 ml/min to a Resource Q 6 ml column (manufactured by Amersham Biosciences, Inc.) which had previously been equilibrated with 50 mM Tris-HCl buffer (pH 7.5) containing 0.1% CHAPS. Thereafter, the column was washed with this buffer at a flow rate of 1 ml/min and a protein fraction which was not adsorbed to the column was collected. A protein adsorbed to the column was eluted with 50 mM Tris-HCl buffer (pH 7.5) containing 0.1% CHAPS and 1 M NaCl at a flow rate of 1 ml/min. After 26.5 ml of the fraction which had not been adsorbed to the column was concentrated to 3.0 ml with a centrifugal membrane concentrator Amicon Ultra-15 (manufactured by Millipore Co., Ltd.), the concentrate was centrifuged at 3,000 rpm for 10 minutes at 4°C and the precipitate was removed. 2.5 ml of the resulting supernatant was applied to a PD-10 desalting column (manufactured by Amersham Biosciences, Inc.) which had previously been equilibrated with phosphate-buffered saline containing 50 mM arginine hydrochloride (pH 7.0, A-PBS), followed by elution with A-PBS, whereby 3.5 ml of a sample whose solvent was replaced with A-PBS was obtained. The arginine hydrochloride in the solvent of the prepared sample was added in order to prevent soluble human Siglec-15-His from precipitating. The supernatant after centrifugation was cryopreserved at -80°C

until use. The above-mentioned purification procedure (Resource Q column chromatography) was performed by repeating it twice.

[0195]

a-iii) Detection and purity assay of purified human Siglec-15-His

By using a sample prepared by the above-mentioned purification procedure (Ni-Sepharose HP column chromatography and Resource Q column chromatography), SDS-polyacrylamide electrophoresis under reducing conditions and silver staining were performed. That is, to 5 μ l of each of the samples purified by the respective purification steps, an equivalent amount of an SDS-treatment solution was added, and the resulting mixture was thermally treated at 95°C for 10 minutes. 0.3 μ l of each of the thermally treated samples was used for SDS-polyacrylamide electrophoresis. The electrophoresis procedure was performed in the same manner as in Example 3 except that Rainbow Molecular Weight Markers (manufactured by Amersham Biosciences, Inc.) were used as the molecular weight markers. After completion of the electrophoresis, silver staining was performed using a PhastGel Silver Kit (manufactured by Amersham Biosciences, Inc.) and PhastSystem. The results are shown in Fig. 7. It was shown that a protein having a molecular weight of about 35 kDa (human Siglec-15-His) was efficiently purified and concentrated in the protein

fraction which was not adsorbed to the Resource Q column.

[0196]

a-iv) Measurement of protein concentration of purified human Siglec-15-His

For the purified human Siglec-15-His (the protein fraction which was not adsorbed to the Resource Q column), the protein concentration was measured with a DC protein assay kit (manufactured by Bio-Rad Laboratories, Inc.) using bovine serum albumin as a standard sample. By performing the purification procedure twice, a total of 1.66 mg of purified human Siglec-15-His was obtained.

[0197]

b) Purification of soluble human Siglec-15-Fc

b-i) HiTrap Protein A column chromatography

1.5 L of the culture solution of 293F cells expressing human Siglec-15-Fc prepared in b) of Example 11 was filtered through a Sterivex-GV filter (manufactured by Millipore Co., Ltd.), and then the filtrate was applied at a flow rate of 5 ml/min to a HiTrap Protein A 5 ml column (manufactured by Amersham Biosciences, Inc.) which had previously been equilibrated with Dulbecco's PBS (D-PBS, manufactured by Invitrogen, Inc.). After the column had been washed with 70 ml of D-PBS at a flow rate of 5 ml/min, a protein adsorbed to the column was eluted with 24 ml of 0.1 M sodium citrate buffer (pH 3.0) at a flow rate of 1.2 ml/min. The eluate was

fractionated at 1.2 ml per fraction into mini-sorp tubes (manufactured by Nunc, Inc.), and immediately thereafter, 0.31 ml of 1 M Tris was added thereto to neutralize the eluate. A 2.5 ml aliquot of a solution (about 7.5 ml) obtained by combining the eluted protein fractions (fractions 5 to 9) was applied to a PD-10 desalting column (manufactured by Amersham Biosciences, Inc.) which had previously been equilibrated with phosphate-buffered saline containing 50 mM arginine hydrochloride (pH 7.0, A-PBS), followed by elution with A-PBS, whereby 3.5 ml of a sample whose solvent was replaced with A-PBS was obtained. This procedure was performed by repeating it twice. The arginine hydrochloride in the solvent was added in order to prevent soluble human Siglec-15-Fc from precipitating. 2.5 ml of the remaining solution of the eluted protein fractions (fractions 5 to 9) was applied to a PD-10 desalting column (manufactured by Amersham Biosciences, Inc.) which had previously been equilibrated with phosphate-buffered saline containing 1 M NaCl (pH 6.7, N-PBS), followed by elution with N-PBS, whereby 3.5 ml of a sample whose solvent was replaced with N-PBS was obtained. NaCl in the solvent in the prepared sample was added in order to prevent soluble human Siglec-15-Fc from precipitating without adding an amino group-containing compound such as arginine. The samples prepared by the above-mentioned procedure were cryopreserved at -80°C until use.

[0198]

b-ii) Detection and purity assay of purified human Siglec-15-Fc

By using the samples prepared by the above-mentioned purification procedure, SDS-polyacrylamide electrophoresis under reducing conditions and silver staining were performed. That is, to 5 μ l of each of the samples purified by the respective purification steps, an equivalent amount of an SDS-treatment solution was added, and the resulting mixture was heated at 95°C for 10 minutes. 0.3 μ l of a sample obtained by diluting each of the thermally treated samples to 1/100 or 1/300 with a half concentration of the SDS-treatment solution was used for SDS-polyacrylamide electrophoresis. The electrophoresis and silver staining were performed in the same manner as the purity assay of human Siglec-15-His described in a-iii). The results are shown in Fig. 8. It was shown that a protein having a molecular weight of about 55 kDa (human Siglec-15-Fc) was efficiently purified and concentrated in the protein fraction which was eluted from the HiTrap Protein A column.

[0199]

b-iii) Measurement of protein concentration of purified human Siglec-15-Fc

For the purified human Siglec-15-Fc (the protein fraction eluted from the PD-10 desalting column), the protein concentration was measured with a DC protein assay kit

(manufactured by Bio-Rad Laboratories, Inc.) using bovine serum albumin as a standard sample. As shown in Table 4, a total of 25.2 mg of purified human Siglec-15-Fc was obtained by performing the purification procedure twice.

[0200]

[Table 4]

	Protein Conc. (mg/ml)	Sample Vol. (ml)	Total protein (mg)
Arg-containing solvent	2.3	7.0	16.1
NaCl-containing solvent	2.6	3.5	9.1
Total			25.2

Example 13

[0201]

Evaluation of property of rat anti-mouse Siglec-15 monoclonal antibody binding to human Siglec-15 protein

The property of the rat anti-mouse Siglec-15 monoclonal antibody binding to human Siglec-15 protein was evaluated by an ELISA method. The human Siglec-15-Fc protein (subjected to replacement with A-PBS) produced in b) of Example 12 was diluted to 5 µg/ml with 0.1 M sodium carbonate buffer (pH 9.5), and the resulting solution was added to a 96-well plate (manufactured by Nalge Nunc International, Inc., Cat. No. 430341) at 100 µl/well. After the plate had been left at room temperature for 1 hour, the solution was removed and a washing buffer (phosphate-buffered saline containing 0.05% Tween 20) was added at 300 µl/well and then removed. After this washing

procedure had been performed one more time, phosphate-buffered saline containing 25% BlockAce (manufactured by Dainippon Sumitomo Pharma Co., Ltd.) was added at 200 μ l/well, and the plate was left at room temperature for 1 hour, whereby blocking was performed. The liquid was removed, and the plate was washed twice with 300 μ l/well of the washing buffer. Then, each of the rat anti-mouse Siglec-15 monoclonal antibodies prepared in Example 6 or rat control IgG (manufactured by R&D Systems, Inc.) was diluted to a final concentration of from 1.28 to 20,000 ng/ml (5-fold dilution series) with an ELISA buffer (phosphate-buffered saline containing 12.5% BlockAce and 0.05% Tween 20), and the resulting diluted antibody solution was added to the plate at 100 μ l/well. After the plate was left at room temperature for 1 hour, the liquid was removed, and the plate was washed 3 times with 300 μ l/well of the washing buffer. Subsequently, an HRP (horseradish peroxidase)-labeled goat anti-rat IgG antibody (manufactured by Beckman Coulter, Inc.) diluted to 1,000-fold with an ELISA buffer was added at 100 μ l/well, and the plate was left at room temperature for 1 hour. The liquid was removed and the plate was washed 3 times with 300 μ l/well of the washing buffer, and then, by using a color developing kit for peroxidase (manufactured by Sumitomo Bakelite Co., Ltd.), the color was developed according to the protocol accompanying the kit. After developing the color, an absorbance at 492 nm was measured

using a microplate reader (manufactured by Nihon Molecular Devices Corporation). As a result, it was confirmed that all of the examined 10 test samples of the rat anti-mouse Siglec-15 monoclonal antibodies bind to the human Siglec-15 protein in an antibody concentration-dependent manner (Fig. 9). In particular, the binding activity of 5 test samples, namely #1A1, #3A1, #24A1, #32A1, and #61A1, was high, and the binding activity of 3 test samples, namely #8A1, #34A1, and #39A1, was relatively low. On the other hand, in the case of the rat control IgG, binding to the human Siglec-15 protein was not observed. From the above results, it was shown that the rat anti-mouse Siglec-15 monoclonal antibodies prepared in Example 6 bind not only to mouse Siglec-15, but also to human Siglec-15, and moreover, it was found that some antibodies strongly bind to human Siglec-15.

Example 14

[0202]

Effect of addition of rat anti-mouse Siglec-15 monoclonal antibody on cell fusion and bone resorption activity of normal human osteoclast precursor cells (evaluation of in vitro biological activity)

Since it was confirmed that the rat anti-mouse Siglec-15 monoclonal antibodies bind also to human Siglec-15 in Example 13, the effects of these antibodies on human osteoclast

formation and bone resorption activity were examined.

[0203]

a) Effect of addition of rat anti-mouse Siglec-15 monoclonal antibody on cell fusion of osteoclasts from normal human osteoclast precursor cells (TRAP Staining)

Normal human osteoclast precursor cells (Normal Human Natural Osteoclast Precursor Cells, purchased from Sanko Junyaku Co., Ltd., Cat. No. 2T-110) were seeded in a 96-well plate at 1×10^4 cells/well according to the protocol accompanying the cells. As the medium, a minimal essential medium for osteoclast precursor cells (OPBM, purchased from Sanko Junyaku Co., Ltd., Cat. No. PT-8201) supplemented with an OPGM supplement set (purchased from Sanko Junyaku Co., Ltd., Cat. No. PT-9501) containing fetal bovine serum (final concentration: 10%), human RANKL (final concentration: 66 ng/ml), human M-CSF (final concentration: 33 ng/ml), and the like was used. To the resulting culture supernatant, each of the rat anti-mouse Siglec-15 monoclonal antibodies prepared in Example 6 or rat control IgG (manufactured by R&D Systems, Inc.) was added to give a final concentration of 30 μ g/ml, and the cells were cultured for 4 days in a CO₂ incubator. After the culturing, the supernatant was removed, and 10% neutral formalin was added to fix the cells. After fixing the cells, the cells were washed twice with distilled water, a TRAP staining solution (0.27 mM naphthol AS-MX phosphate

(manufactured by Sigma Co., Ltd.), 1.6 mM fast red violet LB salt (manufactured by Sigma Co., Ltd.), 1% dimethylformamide, 50 mM sodium tartrate, 0.1 M sodium acetate buffer (pH 5.0)) was added at 100 μ l/well, and a reaction was allowed to proceed at room temperature for 5 minutes. After the reaction, the cells were washed twice with distilled water, and then observed by microscopy (Fig. 10). As a result, the formation of giant osteoclasts resulting from a high degree of cell fusion was almost completely inhibited by the addition of the #32A1 antibody. Further, in the case of the #41B1 antibody, the formation of giant osteoclasts resulting from a high degree of cell fusion was also significantly inhibited. On the other hand, in the case of the other rat anti-mouse Siglec-15 monoclonal antibodies (the #1A1 antibody and others) and the rat control IgG, such a significant inhibition of osteoclast cell fusion was not observed. In this manner, it was revealed that multinucleation and cell fusion of TRAP-positive osteoclasts from normal human osteoclast precursor cells are inhibited by monoclonal antibodies specifically binding to the Siglec-15 protein.

[0204]

b) Effect of addition of rat anti-mouse Siglec-15 monoclonal antibody (#32A1) on cell fusion of osteoclasts from normal human osteoclast precursor cells (TRAP Staining)

Normal human osteoclast precursor cells (Normal Human

Natural Osteoclast Precursor Cells, purchased from Sanko Junyaku Co., Ltd., Cat. No. 2T-110) were seeded in a 96-well plate at 1×10^4 cells/well according to the protocol accompanying the cells. As the medium, a minimal essential medium for osteoclast precursor cells (OPBM, purchased from Sanko Junyaku Co., Ltd., Cat. No. PT-8201) supplemented with an OPGM supplement set (purchased from Sanko Junyaku Co., Ltd., Cat. No. PT-9501) containing fetal bovine serum (final concentration: 10%), human RANKL (final concentration: 68.4 ng/ml), human M-CSF (final concentration: 33 ng/ml), and the like was used. To the resulting culture supernatant, the rat anti-mouse Siglec-15 monoclonal antibody (#32A1 antibody) prepared in Example 6 was added to give a final concentration of 0.1, 0.3, 1, or 3 $\mu\text{g/ml}$, and the cells were cultured for 3 days in a CO_2 incubator. After the culturing, the supernatant was removed, and 10% neutral formalin was added to fix the cells. After fixing the cells, the cells were washed twice with distilled water, and a TRAP staining solution (0.27 mM naphthol AS-MX phosphate (manufactured by Sigma Co., Ltd.), 1.6 mM fast red violet LB salt (manufactured by Sigma Co., Ltd.), 1% dimethylformamide, 50 mM sodium tartrate, 0.1 M sodium acetate buffer (pH 5.0)) was added at 100 $\mu\text{l/well}$, and a reaction was allowed to proceed at room temperature for 5 minutes. After the reaction, the cells were washed twice with distilled water, and then, observed by microscopy (Fig. 11). As a result, the

formation of TRAP-positive multinucleated osteoclasts was inhibited in a #32A1 antibody concentration-dependent manner within the range of from 0.3 $\mu\text{g/ml}$ to 3 $\mu\text{g/ml}$.

[0205]

c) Effect of addition of rat anti-mouse Siglec-15 monoclonal antibody (#32A1) on bone resorption activity of normal human osteoclast precursor cells (Evaluation using collagen-coated plate)

It is known that osteoclasts release a protease such as cathepsin K and degrade type I collagen which is a constitutional component of bone tissue. The OsteoLyse Assay Kit (manufactured by Lonza, Inc., Cat. No. PA-1500) provides a 96-well plate coated with europium-conjugated human collagen (96-well OsteoLyse cell culture plate), and it is possible to evaluate the bone resorption activity of osteoclasts in vitro by measuring the amount of fluorescent collagen fragments released into the supernatant when osteoclasts are cultured on the plate. Normal human osteoclast precursor cells (Normal Human Natural Osteoclast Precursor Cells, purchased from Sanko Junyaku Co., Ltd., Cat. No. 2T-110) were seeded in a 96-well OsteoLyse cell culture plate at 1×10^4 cells/well according to the protocol accompanying the cells. As the medium, a minimal essential medium for osteoclast precursor cells (OPBM, purchased from Sanko Junyaku Co., Ltd., Cat. No. PT-8201) supplemented with an OPGM supplement set (purchased from Sanko

Junyaku Co., Ltd., Cat. No. PT-9501) containing fetal bovine serum (final concentration: 10%), human RANKL (final concentration: 68.4 ng/ml), human M-CSF (final concentration: 33 ng/ml), and the like was used. To the resulting culture supernatant, the rat anti-mouse Siglec-15 monoclonal antibody (#32A1 antibody) prepared in Example 6 was added to give a final concentration of 0.1, 0.3, 1, or 3 $\mu\text{g/ml}$, and the cells were cultured for 3 days in a CO_2 incubator. A 10 μl aliquot of the culture supernatant was collected, and 200 μl of Fluorophore Releasing Reagent included in the OsteoLyse Assay Kit was added thereto, and a fluorescence intensity was measured (Excitation: 340 nm, Emission: 615 nm) using a fluorescence plate reader (ARVO MX, manufactured by Perkin Elmer Inc.), whereby the amount of free fluorescent collagen fragments released in the culture supernatant was determined (Fig. 12). As a result, the amount of fluorescent collagen fragments increased by the addition of RANKL was reduced by the #32A1 antibody in a concentration-dependent manner within the range of from 0.3 $\mu\text{g/ml}$ to 3 $\mu\text{g/ml}$. From this result, it was revealed that the bone resorption activity of human osteoclasts is inhibited by the studied monoclonal antibody specifically binding to the Siglec-15 protein.

Example 15

[0206]

Evaluation of biological activity of rat anti-mouse Siglec-15 monoclonal antibody using ovariectomized rats

a) Protocol of animal experiment

The ovaries on both sides were removed from female F344 rats (obtained from Charles River Laboratories Japan, Inc.) at the age of 12 weeks, and the rats were divided into three groups: a vehicle administration group; a rat anti-mouse Siglec-15 monoclonal antibody #8A1 administration group; and a rat anti-mouse Siglec-15 monoclonal antibody #32A1 administration group. Further, one group was prepared as a sham operation group. In the antibody administration groups, the rat anti-mouse Siglec-15 monoclonal antibody #8A1 or the rat anti-mouse Siglec-15 monoclonal antibody #32A1 prepared in Example 6 was intraperitoneally administered at a dose of 1 mg/kg three times a week repeatedly for 4 weeks from the next day of the operation. In the vehicle administration group and the sham operation group, PBS containing 0.01% Tween 20 was intraperitoneally administered as the vehicle. At 4 weeks after the initiation of administration, urine was collected for 24 hours under fasting conditions, and the urine samples were stored at -80°C until measurement. After completion of the urine collection, the rats were euthanized, and the lumbar spine was excised from each rat.

[0207]

b) Measurement of lumbar spine bone mineral density

Soft tissues adhered to the excised lumbar spine were removed, and the 4th to 6th lumbar vertebrae were extracted. The extracted lumbar vertebrae were degreased and dehydrated by being shaken in ethanol and then air-dried, and the bone mineral density was measured using a bone densitometer (DCS-600EX, manufactured by Aloka Co., Ltd.). The results are shown in Fig. 13(A). A significant decrease in lumbar spine bone mineral density was observed in the ovariectomized group as compared with the sham operation group, however, in the #8A1 and #32A1 antibody administration groups, a decrease in bone mineral density due to ovariectomy was significantly inhibited.

[0208]

c) Measurement of urinary deoxypyridinoline excretion

A variety of type I collagen crosslinked metabolites sharply reflect bone metabolic turnover, particularly bone resorption. Above all, deoxypyridinoline is localized mainly in bone collagen, and therefore, is considered to be highly reliable as an index of bone resorption.

[0209]

The cryopreserved urine sample was thawed, and insoluble matter was precipitated by a centrifugal operation, whereby a supernatant was obtained. The amount of deoxypyridinoline contained in this supernatant was measured using Osteolinks "DPD" (manufactured by DS Pharma Biomedical Co., Ltd.).

Further, by using Creatinine Test Wako (manufactured by Wako Pure Chemical Industries, Ltd.), the content of creatinine in the supernatant was also measured, and the amount of deoxypyridinoline corrected for creatinine was calculated. The results are shown in Fig. 13(B). The urinary deoxypyridinoline excretion was significantly increased in the ovariectomized group as compared with the sham group, and therefore, it was indicated that in the ovariectomized rats, osteoclastic bone resorption is increased. On the other hand, in the #8A1 and #32A1 antibody administration groups, an increase in deoxypyridinoline excretion due to ovariectomy was inhibited such that the level of deoxypyridinoline excretion was comparable to that of the sham operation group. From this result, it was also confirmed in the animal models that the studied monoclonal antibodies specifically binding to Siglec-15 inhibit osteoclastic bone resorption, and it was strongly indicated that due to the inhibitory effect on bone resorption, a decrease in lumbar spine bone mineral density in the ovariectomized rats was inhibited.

Example 16

[0210]

Determination of binding site (epitope) of rat anti-mouse Siglec-15 monoclonal antibody

a) Expression and purification of human Siglec-15 V-set

domain

A DNA encoding a protein in which a His tag and a thrombin recognition sequence were attached to the N-terminal side of a human Siglec-15 V-set domain (a polypeptide comprising 39 to 165 amino acid residues of an amino acid sequence in the NCBI Protein database with the accession number of NP_998767 or an amino acid sequence represented by SEQ ID NO: 2 in the Sequence Listing) was integrated into a vector pDEST14 (Invitrogen, Inc., Cat. No. 11801-016). By using this plasmid, *Escherichia coli* Rosetta-gamiB (DE3) (Novagen, Inc., Cat. No. 71136-4) was transformed, and cultured in TB medium (Invitrogen, Inc., Cat. No. 22711-022). After culturing, the bacterial cells were homogenized by ultrasound, the resulting homogenate was centrifuged, and the supernatant was purified with a HisTrap HP column (GE Healthcare, Co., Ltd., Cat. No. 17-5247-01). Thereafter, the His tag was cleaved with thrombin, and then the human Siglec-15 V-set domain was purified using a Mono S5/50 GL column (GE Healthcare, Co., Ltd., Cat. No. 17-5168-01) and a Superdex 75 10/300 column (GE Healthcare, Co., Ltd., Cat. No. 17-5174-01) until a single band with a molecular weight of 14 kDa was obtained by electrophoresis.

[0211]

b) Purification of soluble human Siglec-15-Fc

The soluble human Siglec-15-Fc was purified by the method

described in Example 12.

[0212]

c) Competitive ELISA of human V-set domain and rat anti-mouse Siglec-15 monoclonal antibody #32A1

In a 96-well maxi-sorp plate (manufactured by Nunc, Inc., model number: 442404), 100 μ l of a goat anti-human Fc antibody (Jackson ImmunoResearch, Inc., model number: 109-005-098) (1.25 μ g/ml) was added to each well and immobilized overnight at 4°C. After the 96-well maxi-sorp plate was washed twice with PBS, 100 μ l of the soluble human Siglec-15-Fc (1 μ g/ml) was added to each well and immobilized at room temperature for 1 hour. Thereafter, 300 μ l of a 5% skim milk/PBS solution was added to each well, and blocking of the wells was performed at room temperature for 3 hours. In the meantime, 2 μ g/ml of the rat anti-mouse Siglec-15 monoclonal antibody #32A1 was mixed with an equivalent amount of 0, 0.032, 0.16, 0.8, 4, or 20 μ g/ml of the human Siglec-15 V-set domain, and a reaction was allowed to proceed at room temperature for 1.5 hours. After the 96-well maxi-sorp plate had been washed twice with PBS, 100 μ l of the mixed solution of the rat anti-mouse Siglec-15 monoclonal antibody #32A1 and the human Siglec-15 V-set domain was added thereto, and a reaction was allowed to proceed at room temperature for 1 hour. After the 96-well maxi-sorp plate had been washed 5 times with a 0.05% Tween 20 (Bio-Rad Laboratories, Inc., Cat. No. 170-6531)/PBS solution

(hereinafter referred to as "PBST solution"), 100 μ l of an HRP-labeled goat anti-rat IgG antibody (Beckman Coulter, Inc., Cat. No. 732664, diluted to 2000-fold) was added thereto, and a reaction was allowed to proceed at room temperature for 1 hour. After the plate had been washed 5 times with the PBST solution, 100 μ l of a color developing liquid of ELISA POD Substrate ABTS Kit (Nacalai Tesque Co., Ltd., Cat. No. 14351-80) was added thereto, and a reaction was allowed to proceed for 30 minutes. Then, 100 μ l of a reaction stopping solution was added thereto, and an absorbance at 405 nm was measured. The results of competitive ELISA showed that the binding of the rat anti-mouse Siglec-15 monoclonal antibody #32A1 to the immobilized human Siglec-15 is inhibited in a human V-set domain concentration-dependent manner. Accordingly, it was shown that the epitope for the rat anti-mouse Siglec-15 monoclonal antibody #32A1 is the human Siglec-15 V-set domain (a domain comprising 39 to 165 amino acid residues of an amino acid sequence in the NCBI Protein database with the accession number of NP_998767 or an amino acid sequence represented by SEQ ID NO: 2 in the Sequence Listing) (Fig. 14).

Example 17

[0213]

Amplification of cDNA encoding variable region of rat anti-mouse Siglec-15 monoclonal antibody #32A1 and base

sequence analysis thereof

a) Preparation of mRNA

The hybridoma #32A1 was cultured according to a) of Example 6. From 4×10^7 cells of the hybridoma #32A1, about 65 μ g of mRNA was prepared using a QuickPrep mRNA purification kit (GE Healthcare, Co., Ltd.).

[0214]

b) Synthesis of cDNA (5'-RACE-Ready cDNA)

The synthesis of cDNA (5'-RACE-Ready cDNA) was performed using 0.3 μ g of the mRNA prepared in a) with PrimeScript Reverse Transcriptase (TaKaRa Bio, Inc.) and SMART RACE cDNA Amplification Kit (Clontech Co., Ltd.).

[0215]

c) Amplification of cDNA of #32A1 gene heavy chain variable region by 5'-RACE PCR

As primers for amplifying the cDNA of the #32A1 heavy chain gene variable region by PCR, UPM (Universal Primer A Mix, attached to the SMART RACE cDNA Amplification Kit) and an oligonucleotide having a sequence of 5'-GGCCGGGTGGGCTACGTTGCAGGTGACGGTCTG-3' (RG2AR2: SEQ ID NO: 23 in the Sequence Listing) were used. As the UPM, one attached to the SMART RACE cDNA Amplification Kit (Clontech Co., Ltd.) was used, and the RG2AR2 was designed from the sequence of the rat heavy chain (IgG2a) constant region in the database and synthesized according to a common procedure.

The cDNA of the #32A1 heavy chain gene variable region was amplified by 5'-RACE PCR using this combination of primers and the cDNA synthesized in b) (5'-RACE-Ready cDNA) as a template. The PCR was performed using Advantage 2 PCR Kit (Clontech Co., Ltd.), and the conditions for a thermal cycler were set as follows: after heating at 94°C for 1 minute, a temperature cycle of "94°C for 0.5 minutes and 72°C for 3 minutes" was repeated 5 times, then, a temperature cycle of "94°C for 0.5 minutes, 70°C for 0.5 minutes, and 72°C for 3 minutes" was repeated 5 times, and further, a temperature cycle of "94°C for 0.5 minutes, 68°C for 0.5 minutes, and 72°C for 3 minutes" was repeated 20 times, followed by incubating at 4°C.

[0216]

d) Amplification of cDNA of #32A1 light chain gene variable region by 5'-RACE PCR

As primers for amplifying the cDNA of the #32A1 light chain gene variable region by PCR, UPM (Universal Primer A Mix, attached to the SMART RACE cDNA Amplification Kit) and an oligonucleotide having a sequence of 5'-CATGCTGTACGTGCTGTCTTTGCTGTCCTGATCAG-3' (RKR2: SEQ ID NO: 24 in the Sequence Listing) were used. As the UPM, one attached to the SMART RACE cDNA Amplification Kit (Clontech Co., Ltd.) was used, and the RKR2 was designed from the sequence of the rat light chain (κ chain) constant region in the database and

synthesized according to a common procedure.

The cDNA of the #32A1 light chain gene variable region was amplified by 5'-RACE PCR using this combination of primers and the cDNA synthesized in b) (5'-RACE-Ready cDNA) as a template. The PCR was performed using Advantage 2 PCR Kit (Clontech Co., Ltd.), and the conditions for a thermal cycler were set as follows: after heating at 94°C for 1 minute, a temperature cycle of "94°C for 0.5 minutes and 72°C for 3 minutes" was repeated 5 times, then, a temperature cycle of "94°C for 0.5 minutes, 70°C for 0.5 minutes, and 72°C for 3 minutes" was repeated 5 times, and further, a temperature cycle of "94°C for 0.5 minutes, 68°C for 0.5 minutes, and 72°C for 3 minutes" was repeated 20 times, followed by incubating at 4°C.

[0217]

e) Determination of base sequences of cDNAs of heavy and light chain variable regions

The cDNA of the heavy chain variable region amplified in c) was purified using MinElute PCR Purification Kit (QIAGEN Inc.), and then the sequence analysis of the DNA sequence was performed. As a sequencing primer, an oligonucleotide having a sequence of 5'-CTCCAGAGTTCCAGGTCACGGTGACTGGC-3' (RG2AR3: SEQ ID NO: 25 in the Sequence Listing) was designed from the sequence of the rat heavy chain (IgG2a) constant region in the database and synthesized according to a common procedure.

[0218]

The cDNA of the light chain variable region amplified in d) was purified using MinElute PCR Purification Kit (QIAGEN Inc.), and then the sequence analysis of the DNA sequence was performed. As a sequencing primer, an oligonucleotide having a sequence of 5'-TCCAGTTGCTAACTGTTCCG-3' (sqRK: SEQ ID NO: 26 in the Sequence Listing) was designed from the sequence of the rat light chain (κ chain) constant region in the database and synthesized according to a common procedure.

[0219]

The cDNA containing the heavy chain variable region obtained by the sequence analysis has a base sequence represented by SEQ ID NO: 27 in the Sequence Listing and encodes the amino acid sequence represented by SEQ ID NO: 28 in the Sequence Listing. The amino acid sequence represented by amino acid numbers 1 to 19 of SEQ ID NO: 28 corresponds to a secretory signal, the amino acid sequence represented by amino acid numbers 20 to 140 thereof corresponds to a heavy chain variable region, and the amino acid sequence represented by amino acid numbers 141 to 167 thereof corresponds to a heavy chain constant region (partial). The above-mentioned heavy chain variable region contains CDRH1 (DYFMN) comprising the amino acid sequence represented by SEQ ID NO: 44, CDRH2 (QIRNKIYTYATFYAESLEG) comprising the amino acid sequence represented by SEQ ID NO: 45, and CDRH3 (SLTGGDYFDY) comprising

the amino acid sequence represented by SEQ ID NO: 46. Further, the cDNA containing the light chain variable region has a base sequence represented by SEQ ID NO: 29 in the Sequence Listing and encodes the amino acid sequence represented by SEQ ID NO: 30 in the Sequence Listing. The amino acid sequence represented by amino acid numbers 1 to 20 of SEQ ID NO: 30 corresponds to a secretory signal, the amino acid sequence represented by amino acid numbers 21 to 132 thereof corresponds to a light chain variable region, and the amino acid sequence represented by amino acid numbers 133 to 139 thereof corresponds to a light chain constant region (partial). The above-mentioned light chain variable region contains CDRL1 (RASQSVTISGYSFIH) comprising the amino acid sequence represented by SEQ ID NO: 47, CDRL2 (RASNLAS) comprising the amino acid sequence represented by SEQ ID NO: 48, and CDRL3 (QQSRKSPWT) comprising the amino acid sequence represented by SEQ ID NO: 49.

Example 18

[0220]

Production of gene expression construct of human chimeric antibody of rat anti-mouse Siglec-15 monoclonal antibody #32A1

a) Production of universal expression vectors pEF1/FCCU-1 and pEF6KCL

a)-i) Construction of human light chain expression vector pEF6KCL

By performing PCR using a plasmid pEF6/V5-HisB (Invitrogen) as a template and also using the following primers, a DNA fragment from immediately downstream of BGHpA (2174) to SmaI (2958) (a DNA fragment containing fl origin of replication and SV40 promoter and origin, hereinafter referred to as "fragment A") was obtained.

5'-CCACGCGCCCTGTAGCGGCGCATTAAGC-3' (primer EFF1: SEQ ID NO: 31 in the Sequence Listing)

5'-AAACCCGGGAGCTTTTTCAGAAAAGCCTAGG-3' (primer EFsmaR: SEQ ID NO: 32)

The obtained fragment A and a DNA fragment (SEQ ID NO: 33, hereinafter referred to as "fragment B") containing a DNA sequence encoding a human κ chain secretory signal, a human κ chain constant region, and a human poly-A additional signal were ligated by overlapping PCR. The thus obtained DNA fragment in which the fragment A and the fragment B were ligated (hereinafter referred to as "fragment A+B") was digested with the restriction enzymes KpnI and SmaI, which was ligated to a plasmid pEF6/V5-HisB (Invitrogen) which was digested with the restriction enzymes KpnI and SmaI, whereby a human light chain expression vector pEF6KCL having a signal sequence, a cloning site, a human κ chain constant region, and a human poly-A additional signal sequence downstream of the EF1

promoter was constructed.

[0221]

a)-ii) Construction of pEF1/KCL

A DNA fragment obtained by cleaving the pEF6KCL obtained by the above-mentioned method with the restriction enzymes KpnI and SmaI was ligated to pEF1/myc-HisB (Invitrogen, Inc.) which was digested with KpnI and SmaI, whereby a plasmid pEF1/KCL was constructed.

[0222]

a)-iii) Construction of human heavy chain expression vector pEF1/FCCU-1

A DNA fragment (SEQ ID NO: 34 in the Sequence Listing) containing a DNA sequence encoding a human IgG1 signal sequence and a constant region amino acid sequence was digested with the restriction enzymes NheI and PmeI and was ligated to the plasmid pEF1/KCL which was digested with NheI and PmeI, whereby a human heavy chain expression vector pEF1/FCCU-1 having a signal sequence, a cloning site, a human heavy chain constant region, and a human poly-A additional signal sequence downstream of the EF1 promoter was constructed.

[0223]

b) Production of #32A1 human chimeric antibody heavy chain expression construct

As primers for amplifying the cDNA of the #32A1 heavy chain variable region by PCR, an oligonucleotide having a

sequence of 5'-aaagctgagcGAGGTGCAAATTTTGGAGACTGGAGGAGGC-3' (32A1HF: SEQ ID NO: 35 in the Sequence Listing) and an oligonucleotide having a sequence of 5'-aaagctgagctGACTGTGACCATGACTCCTTGGCCCCAG-3' (32A1HR: SEQ ID NO: 36 in the Sequence Listing) were synthesized according to a common procedure.

[0224]

Incidentally, in order to integrate a PCR product into pEF1/FCCU-1, these primers were designed such that a recognition sequence for the restriction enzyme BspI was added. The PCR was performed according to a common procedure using this combination of primers and the cDNA of the heavy chain variable region purified in e) of Example 17 as a template. The resulting PCR product was purified using MinElute PCR Purification Kit (QIAGEN, Inc.), and then a DNA fragment obtained by digesting the PCR product with the restriction enzyme BspI (NEW ENGLAND BIOLABS, Inc.) was inserted into the pEF1/FCCU-1 at the site cleaved with the restriction enzyme BspI, whereby a #32A1 human chimeric antibody heavy chain expression construct was constructed. The sequence of the insert was confirmed by a sequence analysis. As a primer for sequencing, an oligonucleotide having a sequence of 5'-TAATACGACTCACTATAGGG-3' (F11: SEQ ID NO: 37 in the Sequence Listing) was synthesized according to a common procedure. An expression vector in which the insert could be correctly

inserted was named "32A1H/pEF1/FCCU".

[0225]

c) Production of #32A1 human chimeric antibody light chain expression construct

As primers for amplifying the cDNA of the #32A1 light chain variable region by PCR, an oligonucleotide having a sequence of

5'-aaacatatggcGACATTGTCTTGACCCAGTCTCCTGCTTTGG-3' (32A1LF: SEQ ID NO: 38 in the Sequence Listing) and an oligonucleotide

having a sequence of

5'-aaacgtacgTCTCAATTCCAGCTTGGTGCCTCCAGCG-3' (32A1LR SEQ ID NO: 39 in the Sequence Listing) were synthesized according to a common procedure.

[0226]

Incidentally, in order to integrate a PCR product into pEF6KCL, these primers were designed such that a recognition sequence for the restriction enzyme NdeI was added to 32A1LF, and a recognition sequence for the restriction enzyme BsiWI was added to 32A1LR. The PCR was performed according to a common procedure using this combination of primers and the cDNA of the light chain variable region purified in e) of Example 17 as a template. The resulting PCR product was purified using MinElute PCR Purification Kit (QIAGEN, Inc.), and then, a DNA fragment obtained by digesting the PCR product with the restriction enzymes NdeI (TaKaRa Bio, Inc.) and BsiWI (NEW

ENGLAND BIOLABS, Inc.) was inserted into the pEF6KCL at the site cleaved with the restriction enzymes NdeI (TaKaRa Bio, Inc.) and BsiWI (NEW ENGLAND BIOLABS, Inc.), whereby a #32A1 human chimeric antibody light chain expression construct was constructed. The sequence of the insert was confirmed by a sequence analysis. As a primer for sequencing, a primer F11 represented by SEQ ID NO: 37 in the Sequence Listing was used. An expression vector in which the insert could be correctly inserted was named "32A1L/pEF6KCL".

[0227]

The #32A1 human chimeric antibody heavy chain gene produced in b) has the nucleotide sequence represented by SEQ ID NO: 40 in the Sequence Listing and encodes the amino acid sequence represented by SEQ ID NO: 41 in the Sequence Listing. The amino acid sequence represented by amino acid numbers 1 to 19 of SEQ ID NO: 41 corresponds to a secretory signal, the amino acid sequence represented by amino acid numbers 20 to 140 thereof corresponds to a heavy chain variable region, and the amino acid sequence represented by amino acid numbers 141 to 470 thereof corresponds to a heavy chain constant region. Further, the #32A1 human chimeric antibody light chain gene produced in c) has the nucleotide sequence represented by SEQ ID NO: 42 in the Sequence Listing and encodes the amino acid sequence represented by SEQ ID NO: 43 in the Sequence Listing. The amino acid sequence represented by amino acid numbers 1

to 20 of SEQ ID NO: 43 corresponds to a secretory signal, the amino acid sequence represented by amino acid numbers 21 to 132 thereof corresponds to a light chain variable region, and the amino acid sequence represented by amino acid numbers 133 to 237 thereof corresponds to a light chain constant region.

Example 19

[0228]

Preparation of human chimeric antibody of rat anti-mouse Siglec-15 monoclonal antibody #32A1

a) Production of human chimeric antibody

3×10^7 cells of 293 FreeStyle cells in logarithmic growth phase were seeded in 30 ml of fresh FreeStyle 293 Expression Medium (Invitrogen, Inc.) (four lots were prepared, in which the 30-ml culture was taken as one lot) and subjected to shaking culture (125 rpm) at 37°C in an 8% CO₂ incubator. 300 µg of polyethyleneimine (manufactured by Polyscience, Inc. #24765) was dissolved in 1 ml of Opti-Pro SFM medium (manufactured by Invitrogen, Inc.), and the resulting solution was left at room temperature for 5 minutes. The #32A1 human chimeric antibody heavy chain expression vector 32A1H/pEF1/FCCU and the #32A1 human chimeric antibody light chain expression vector 32A1L/pEF6KCL produced in Example 18 were prepared using PureLink HiPure Plasmid Kit (Invitrogen, Inc.). The 32A1H/pEF1/FCCU (15 µg) and the 32A1L/pEF6KCL (45 µg) were

suspended in 1 ml of Opti-Pro SFM medium (Invitrogen, Inc.), and the resulting suspension was added to 1 ml of the polyethyleneimine/Opti-Pro SFM mixed liquid which had been left at room temperature for 5 minutes, and the resulting mixture was left at room temperature for an additional 5 minutes. Subsequently, 2 ml of the polyethyleneimine/the expression vectors/Opti-Pro SFM mixed liquid was added to each lot of the 293 FreeStyle cell suspension, and the shaking culture was continued. After the cells were cultured for 7 days at 37°C in 8% CO₂, the culture supernatant was collected from each lot. [0229]

b) Purification of human chimeric antibody

90 ml of the culture supernatant (for three lots) obtained above was filtered through a filter (manufactured by NALGENE, Inc., #295-4545), and 0.5 ml of MabSelect SuRe (manufactured by GE Healthcare Bio-science Co., Ltd., #17-5438-01) equilibrated with PBS was added to the filtrate, and the resulting mixture was shaken overnight at 80 rpm and 10°C. On the next day, the carrier was collected and washed with PBS, and thereafter, the antibody was eluted with 1 M arginine solution (pH 4.0). The eluate was applied to a PD-10 column (manufactured by GE Healthcare Bio-science Co., Ltd., #17-0851-01) to replace the liquid with PBS, and then concentrated with Amicon Ultra-4 (manufactured by Millipore Co., Ltd., #UFC805008), whereby 1.2 ml of a human chimeric

antibody (0.98 mg/ml) was obtained. The concentration of the antibody was calculated from the measurement at 280 nm obtained using Hitachi Diode Array BioPhotometer U-0080D.

Example 20

[0230]

Evaluation of property of human chimeric antibody of rat anti-mouse Siglec-15 monoclonal antibody #32A1 binding to mouse Siglec-15 protein

The competitive inhibition of the rat #32A1 antibody against the purified human chimeric antibody prepared in Example 19 was determined by the following method. The mouse Siglec-15-Fc purified in Example 4 was diluted to 1 μ g/ml with PBS, the diluted solution was dispensed at 100 μ l/well onto an immunoplate (manufactured by Nunc, Inc., #437111), and the plate was left to stand overnight at 4°C, whereby the protein was adsorbed to the plate. On the next day, each well was washed twice with a PBS-T solution (PBS, 0.05% (v/v) Tween 20), a solution obtained by diluting skim milk (manufactured by Morinaga Milk Industry Co., Ltd.) to 5% with PBS was dispensed at 350 μ l/well, and the plate was left to stand at room temperature for 2 hours. The liquid in each well was removed, and each well was washed 3 times with the PBS-T solution. Thereafter, a mixed solution (a PBS solution containing skim milk at a final concentration of 0.5%) containing the human

chimeric antibody at 0.25 $\mu\text{g/ml}$ and the #32A1 antibody or a rat control IgG antibody (manufactured by R&D Systems, Inc., #6-001-A) at a different concentration (0 $\mu\text{g/ml}$, 0.016 $\mu\text{g/ml}$, 0.05 $\mu\text{g/ml}$, 0.16 $\mu\text{g/ml}$, 0.5 $\mu\text{g/ml}$, 1.66 $\mu\text{g/ml}$, or 5 $\mu\text{g/ml}$) was dispensed at 100 $\mu\text{l/well}$, and the plate was left to stand at room temperature for 2 hours. After each well was washed 3 times with the PBS-T solution, alkaline phosphatase-conjugated AffiniPure goat anti-human IgG (manufactured by Jackson ImmunoResearch, Inc., #109-055-097) diluted to 2500-fold with a TBS-T solution (TBS, 0.05% (v/v) Tween 20) was added at 100 $\mu\text{l/well}$, and the plate was left to stand at room temperature for 1 hour. The liquid in each well was removed, and each well was washed 5 times with the TBS-T solution. Thereafter, a fluorescent substrate solution (manufactured by Roche Co., Ltd., #11681982001) was added at 100 $\mu\text{l/well}$, and a fluorescence reaction was allowed to proceed. At 10 minutes after the addition of the fluorescent substrate solution, the fluorescence intensity was measured using a plate reader. As a result, it was shown that the #32A1 antibody inhibits the binding of the human chimeric antibody to the mouse Siglec-15-Fc in a concentration-dependent manner. Further, when the #32A1 antibody and the human chimeric antibody were mixed at the same concentration (1:1), about 40% competitive inhibition was exhibited. Therefore, it is considered that the #32A1 antibody and the human chimeric antibody have

substantially the same affinity for the mouse Siglec-15-Fc. On the other hand, the rat control IgG did not show competitive inhibition (Fig. 15).

Example 21

[0231]

Evaluation of biological activity of human chimeric antibody of rat anti-mouse Siglec-15 monoclonal antibody #32A1 based on test for mouse osteoclast formation and test for human osteoclast formation

a) Test for mouse osteoclast formation

By using the human chimeric antibody of the rat anti-mouse Siglec-15 monoclonal antibody #32A1 prepared in Example 19, the effect on osteoclast differentiation of mouse bone marrow nonadherent cells was examined. Mouse bone marrow nonadherent cells prepared by the method of Example 8 were prepared at 1.5×10^5 cells/ml in α -MEM medium containing 10% FBS and 10 ng/ml of M-CSF (manufactured by R&D Systems, Inc.), the resulting cell preparation was seeded in each well of a 96-well plate in an amount of 200 μ l and the cells were cultured for 2 days in a CO₂ incubator. The old culture solution in the 96-well plate was removed, and 100 μ l of MEM- α medium was added to each well, the 100 μ l of MEM- α medium containing 10% FBS to which human RANKL (RANKL, manufactured by Peprotech, Inc.) and M-CSF had been added to give final concentrations of 20

ng/ml and 10 ng/ml, respectively. To the cell culture solution, the rat anti-mouse Siglec-15 monoclonal antibody #32A1 produced in Example 6 or the human chimeric antibody of the rat anti-mouse Siglec-15 monoclonal antibody #32A1 prepared in Example 19 was added at a concentration of from 3 to 100 ng/ml, and the cells were cultured for an additional 3 days in a CO₂ incubator. After completion of the culturing, the activity of tartrate-resistant acid phosphatase (TRAP) of the formed osteoclasts was measured by the method described in Example 9. After stopping the enzymatic reaction, an absorbance of each well at 405 nm was measured, and the obtained measurement was used as an index of TRAP activity. The results are shown in Fig. 16. A dose-dependent inhibition of TRAP activity was observed at a concentration of 50 ng/ml or higher in the case of the #32A1 antibody and the human chimeric antibody of the rat anti-mouse Siglec-15 monoclonal antibody #32A1. From this result, it was shown that the human chimeric antibody of the rat anti-mouse Siglec-15 monoclonal antibody #32A1 has an activity of inhibiting osteoclast formation (osteoclast differentiation and maturation) substantially comparable to that of the rat #32A1 antibody.

[0232]

b) Evaluation using normal human osteoclast precursor cells (TRAP Staining)

Normal human osteoclast precursor cells (Normal Human

Natural Osteoclast Precursor Cells, purchased from Sanko Junyaku Co., Ltd., Cat. No. 2T-110) were seeded in a 96-well plate at 1×10^4 cells/well according to the protocol attached to the cells. As the medium, a minimal essential medium for osteoclast precursor cells (OPBM, purchased from Sanko Junyaku Co., Ltd., Cat. No. PT-8201) supplemented with an OPGM supplement set (purchased from Sanko Junyaku Co., Ltd., Cat. No. PT-9501) containing fetal bovine serum (final concentration: 10%), human RANKL (final concentration: 66 ng/ml), human M-CSF (final concentration: 33 ng/ml), and the like was used. To the resulting culture supernatant, the human chimeric antibody of the rat anti-mouse Siglec-15 monoclonal antibody #32A1 prepared in Example 19 was added at a final concentration of 0.3, 1, 3, or 10 $\mu\text{g/ml}$, and the cells were cultured for 3 days in a CO_2 incubator. After the culturing, the supernatant was removed, and 10% neutral formalin was added to fix the cells. After fixing the cells, the cells were washed twice with distilled water, a TRAP staining solution (0.27 mM naphthol AS-MX phosphate (manufactured by Sigma Co., Ltd.), 1.6 mM fast red violet LB salt (manufactured by Sigma Co., Ltd.), 1% dimethylformamide, 50 mM sodium tartrate, 0.1 M sodium acetate buffer (pH 5.0)) was added at 100 $\mu\text{l/well}$, and a reaction was allowed to proceed at room temperature for 5 minutes. After the reaction, the cells were washed twice with distilled water, and then observed by microscopy (Fig. 17).

As a result, the formation of TRAP-positive multinucleated osteoclasts was inhibited by the addition of the human chimeric antibody of #32A1 within the range of from 0.3 $\mu\text{g/ml}$ to 10 $\mu\text{g/ml}$.

Example 22

[0233]

Designing of humanized antibody of rat anti-mouse Siglec-15 monoclonal antibody #32A1 (1)

a) Designing of humanized version of #32A1

a)-i) Molecular modeling of variable region of #32A1

The molecular modeling of the variable region of #32A1 was performed by a method generally known as homology modeling (Methods in Enzymology, 203, 121-153, (1991)). The primary sequences (three-dimensional structures derived from the X-ray crystal structures are available) of the variable regions of human immunoglobulin registered in Protein Data Bank (Nuc. Acid Res. 35, D301-D303 (2007)) were compared with the variable region of #32A1 determined above. As a result, 1LK3 was selected as having the highest sequence homology with the variable region of the light chain of #32A1 among antibodies having a similar deletion in the framework. Further, 1AD0 was selected as having the highest sequence homology with the variable region of the heavy chain of #32A1. The three-dimensional structure of the framework region was generated by obtaining the "framework model" by combining the

coordinates of 1LK3 and 1AD0 corresponding to the light and heavy chains of #32A1. The CDRs of #32A1 were classified according to the classification of Thornton et al. (J. Mol. Biol., 263, 800-815, (1996)) as follows: CDRL1, CDRL2, CDRL3, CDRH1, and CDRH2 were assigned to clusters 15A, 7A, 9A, 10A, and 12B, respectively. CDRH3 was classified into k(8)C according to the H3-rules (FEBS letter 399, 1-8 (1996)). Then, the representative conformations of the respective CDRs were integrated into the framework model.

[0234]

Finally, in order to obtain a probable molecular model of the variable region of #32A1 in terms of energy, an energy calculation was performed for excluding disadvantageous interatomic contact. The above procedure was performed using the commercially available three-dimensional protein structure prediction program Prime and the coordinate search program MacroModel (Schrodinger, LLC).

[0235]

a)-ii) Designing of amino acid sequence of humanized #32A1

A humanized #32A1 antibody was constructed according to a method generally known as CDR grafting (Proc. Natl. Acad. Sci. USA 86, 10029-10033 (1989)). An acceptor antibody was selected in two ways based on the amino acid homology within the framework region. The sequence of the framework region

of #32A1 was compared with the sequences of all human frameworks in the Kabat Database (Nuc. Acid Res. 29, 205-206 (2001)) involving antibody amino acid sequences. As a result, an M37GO37'CL antibody was selected as an acceptor based on a sequence homology of 73% in the framework region. The amino acid residues in the framework region of M37GO37'CL were aligned with the amino acid residues of #32A1, and the positions where different amino acids were used were identified. The positions of these residues were analyzed using the three-dimensional model of #32A1 constructed above. Then, donor residues to be grafted onto the acceptor were selected according to the criteria provided by Queen et al. (Proc. Natl. Acad. Sci. USA 86, 10029-10033 (1989)).

[0236]

The sequence of the framework region of #32A1 was compared with the sequences of all human frameworks in the IgBLAST (Nuc. Acid Res. 36, D25-D30 (2007)). As a result, for the L-chain, AAB34430 was selected as an acceptor based on a sequence homology of 79% in the framework region. As for the H-chain, CAF31288 was selected as an acceptor based on a sequence homology of 78% in the framework region. In respect of the L-chain, the amino acid residues in the framework region of AAB34430, and in respect of the H-chain, the amino acid residues in the framework region of CAF31288, were aligned with the amino acid residues of #32A1, and the positions where

different amino acids were used were identified. The positions of these residues were analyzed using the three-dimensional model of #32A1 constructed above. Then, donor residues to be grafted on the acceptor were selected according to the criteria provided by Queen et al. (Proc. Natl. Acad. Sci. USA 86, 10029-10033 (1989)). In these methods, by transferring some selected donor residues to the acceptor antibody, humanized #32A1 sequences were constructed as described in the following Examples.

[0237]

b) Humanization of #32A1 heavy chain

b)-i) h#32A1-T1H-type heavy chain:

A humanized #32A1 heavy chain designed by replacing amino acid numbers 23 (isoleucine), 24 (leucine), 26 (threonine), 32 (lysine), 43 (threonine), 61 (glutamic acid), 89 (valine), 95 (aspartic acid), 96 (serine), 97 (glutamic acid), 98 (serine), 100 (valine), 104 (valine), 105 (serine), 114 (isoleucine), 118 (threonine), 134 (valine), 135 (methionine), and 140 (leucine) of the #32A1 heavy chain represented by SEQ ID NO: 28 in the Sequence Listing with leucine, valine, serine, glutamine, alanine, glycine, phenylalanine, asparagine, alanine, lysine, asparagine, leucine, methionine, asparagine, valine, alanine, threonine, leucine, and serine, respectively, was named "h#32A1-T1H-type heavy chain".

[0238]

The amino acid sequence of the h#32A1-T1H-type heavy chain is represented by SEQ ID NO: 51 in the Sequence Listing. The sequence comprising amino acid residues 1 to 19 of the amino acid sequence of SEQ ID NO: 51, the sequence comprising amino acid residues 20 to 140 thereof, and the sequence comprising amino acid residues 141 to 470 thereof correspond to the signal sequence, the heavy chain variable region, and the heavy chain constant region, respectively. A nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 51 is represented by SEQ ID NO: 50 in the Sequence Listing. The sequence comprising nucleotides 1 to 57 of the nucleotide sequence of SEQ ID NO: 50, the sequence comprising nucleotides 58 to 420 thereof, and the sequence comprising nucleotides 421 to 1410 thereof encode the signal sequence, the heavy chain variable region sequence, and the heavy chain constant region sequence, respectively. The nucleotide sequence of SEQ ID NO: 50 and the amino acid sequence of SEQ ID NO: 51 are also shown in Fig. 27.

[0239]

b)-ii) h#32A1-T2H-type heavy chain:

A humanized #32A1 heavy chain designed by replacing amino acid numbers 23 (isoleucine), 24 (leucine), 26 (threonine), 32 (lysine), 43 (threonine), 95 (aspartic acid), 96 (serine), 97 (glutamic acid), 98 (serine), 100 (valine), 104 (valine), 114 (isoleucine), 118 (threonine), 134 (valine), 135

(methionine), and 140 (leucine) of the #32A1 heavy chain represented by SEQ ID NO: 28 in the Sequence Listing with leucine, valine, serine, glutamine, alanine, asparagine, alanine, lysine, asparagine, leucine, methionine, valine, alanine, threonine, leucine, and serine, respectively, was named "h#32A1-T2H-type heavy chain".

[0240]

The amino acid sequence of the h#32A1-T2H-type heavy chain is represented by SEQ ID NO: 53 in the Sequence Listing. The sequence comprising amino acid residues 1 to 19 of the amino acid sequence of SEQ ID NO: 53, the sequence comprising amino acid residues 20 to 140 thereof, and the sequence comprising amino acid residues 141 to 470 thereof correspond to the signal sequence, the heavy chain variable region, and the heavy chain constant region, respectively. A nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 53 is represented by SEQ ID NO: 52 in the Sequence Listing. The sequence comprising nucleotides 1 to 57 of the nucleotide sequence of SEQ ID NO: 52, the sequence comprising nucleotides 58 to 420 thereof, and the sequence comprising nucleotides 421 to 1410 thereof encode the signal sequence, the heavy chain variable region sequence, and the heavy chain constant region sequence, respectively. The nucleotide sequence of SEQ ID NO: 52 and the amino acid sequence of SEQ ID NO: 53 are also shown in Fig.

[0241]

b)-iii) h#32A1-T3H-type heavy chain:

A humanized #32A1 heavy chain designed by replacing amino acid numbers 24 (leucine), 26 (threonine), 32 (lysine), 104 (valine), 114 (isoleucine), 134 (valine), 135 (methionine), and 140 (leucine) of the #32A1 heavy chain represented by SEQ ID NO: 28 in the Sequence Listing with valine, serine, glutamine, methionine, valine, threonine, leucine, and serine, respectively, was named "h#32A1-T3H-type heavy chain".

[0242]

The amino acid sequence of the h#32A1-T3H-type heavy chain is represented by SEQ ID NO: 55 in the Sequence Listing. The sequence comprising amino acid residues 1 to 19 of the amino acid sequence of SEQ ID NO: 55, the sequence comprising amino acid residues 20 to 140 thereof, and the sequence comprising amino acid residues 141 to 470 thereof correspond to the signal sequence, the heavy chain variable region, and the heavy chain constant region, respectively. The nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 55 is represented by SEQ ID NO: 54 in the Sequence Listing. The sequence comprising nucleotides 1 to 57 of the nucleotide sequence of SEQ ID NO: 54, the sequence comprising nucleotides 58 to 420 thereof, and the sequence comprising nucleotides 421 to 1410 thereof encode the signal sequence, the heavy chain variable region sequence, and the heavy chain constant region sequence,

respectively. The nucleotide sequence of SEQ ID NO: 54 and the amino acid sequence of SEQ ID NO: 55 are also shown in Fig. 29.

[0243]

b)-iv) h#32A1-T5H-type heavy chain:

A humanized #32A1 heavy chain designed by replacing amino acid numbers 23 (isoleucine), 24 (leucine), 26 (threonine), 32 (lysine), 61 (glutamic acid), 89 (valine), 95 (aspartic acid), 97 (glutamic acid), 99 (serine), 104 (valine), 105 (serine), 114 (isoleucine), 134 (valine), 135 (methionine), and 140 (leucine) of the #32A1 heavy chain represented by SEQ ID NO: 28 in the Sequence Listing with valine, valine, serine, glutamine, glycine, phenylalanine, asparagine, lysine, threonine, methionine, asparagine, valine, threonine, leucine, and serine, respectively, was named "h#32A1-T5H-type heavy chain".

[0244]

The amino acid sequence of the h#32A1-T5H-type heavy chain is represented by SEQ ID NO: 57 in the Sequence Listing. The sequence comprising amino acid residues 1 to 19 of the amino acid sequence of SEQ ID NO: 57, the sequence comprising amino acid residues 20 to 140 thereof, and the sequence comprising amino acid residues 141 to 470 thereof correspond to the signal sequence, the heavy chain variable region, and the heavy chain constant region, respectively. A nucleotide sequence

encoding the amino acid sequence of SEQ ID NO: 57 is represented by SEQ ID NO: 56 in the Sequence Listing. The sequence comprising nucleotides 1 to 57 of the nucleotide sequence of SEQ ID NO: 56, the sequence comprising nucleotides 58 to 420 thereof, and the sequence comprising nucleotides 421 to 1410 thereof encode the signal sequence, the heavy chain variable region sequence, and the heavy chain constant region sequence, respectively. The nucleotide sequence of SEQ ID NO: 56 and the amino acid sequence of SEQ ID NO: 57 are also shown in Fig. 30.

[0245]

b)-v) h#32A1-T6H-type heavy chain:

A humanized #32A1 heavy chain designed by replacing amino acid numbers 23 (isoleucine), 24 (leucine), 26 (threonine), 32 (lysine), 95 (aspartic acid), 97 (glutamic acid), 99 (serine), 104 (valine), 114 (isoleucine), 134 (valine), 135 (methionine), and 140 (leucine) of the #32A1 heavy chain represented by SEQ ID NO: 28 in the Sequence Listing with valine, valine, serine, glutamine, asparagine, lysine, threonine, methionine, valine, threonine, leucine, and serine, respectively, was named "h#32A1-T6H-type heavy chain".

[0246]

The amino acid sequence of the h#32A1-T6H-type heavy chain is represented by SEQ ID NO: 59 in the Sequence Listing. The sequence comprising amino acid residues 1 to 19 of the amino

acid sequence of SEQ ID NO: 59, the sequence comprising amino acid residues 20 to 140 thereof, and the sequence comprising amino acid residues 141 to 470 thereof correspond to the signal sequence, the heavy chain variable region, and the heavy chain constant region, respectively. A nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 59 is represented by SEQ ID NO: 58 in the Sequence Listing. The sequence comprising nucleotides 1 to 57 of the nucleotide sequence of SEQ ID NO: 58, the sequence comprising nucleotides 58 to 420 thereof, and the sequence comprising nucleotides 421 to 1410 thereof encode a signal sequence, the heavy chain variable region sequence, and the heavy chain constant region sequence, respectively. The nucleotide sequence of SEQ ID NO: 58 and the amino acid sequence of SEQ ID NO: 59 are also shown in Fig. 31.

[0247]

b)-vi) h#32A1-T7H-type heavy chain:

A humanized #32A1 heavy chain designed by replacing amino acid numbers 23 (isoleucine), 24 (leucine), 26 (threonine), 32 (lysine), 43 (threonine), 89 (valine), 95 (aspartic acid), 96 (serine), 97 (glutamic acid), 98 (serine), 100 (valine), 104 (valine), 105 (serine), 114 (isoleucine), 118 (threonine), 134 (valine), 135 (methionine), and 140 (leucine) of the #32A1 heavy chain represented by SEQ ID NO: 28 in the Sequence Listing with leucine, valine, serine, glutamine, alanine,

phenylalanine, asparagine, alanine, lysine, asparagine, leucine, methionine, asparagine, valine, alanine, threonine, leucine, and serine, respectively, was named "h#32A1-T7H-type heavy chain".

[0248]

The amino acid sequence of the h#32A1-T7H-type heavy chain is represented by SEQ ID NO: 72 in the Sequence Listing. The sequence comprising amino acid residues 1 to 121 of the amino acid sequence of SEQ ID NO: 72 and the sequence comprising amino acid residues 122 to 451 thereof correspond to the heavy chain variable region and the heavy chain constant region, respectively. The amino acid sequence of SEQ ID NO: 72 is also shown in Fig. 38.

[0249]

b)-vii) h#32A1-T8H-type heavy chain:

A humanized #32A1 heavy chain designed by replacing amino acid numbers 23 (isoleucine), 24 (leucine), 26 (threonine), 32 (lysine), 43 (threonine), 61 (glutamic acid), 95 (aspartic acid), 96 (serine), 97 (glutamic acid), 98 (serine), 100 (valine), 104 (valine), 105 (serine), 114 (isoleucine), 118 (threonine), 134 (valine), 135 (methionine), and 140 (leucine) of the #32A1 heavy chain represented by SEQ ID NO: 28 in the Sequence Listing with leucine, valine, serine, glutamine, alanine, glycine, asparagine, alanine, lysine, asparagine, leucine, methionine, asparagine, valine, alanine, threonine,

leucine, and serine, respectively, was named "h#32A1-T8H-type heavy chain".

[0250]

The amino acid sequence of the h#32A1-T8H-type heavy chain is represented by SEQ ID NO: 73 in the Sequence Listing. The sequence comprising amino acid residues 1 to 121 of the amino acid sequence of SEQ ID NO: 73 and the sequence comprising amino acid residues 122 to 451 thereof correspond to the heavy chain variable region and the heavy chain constant region, respectively. The amino acid sequence of SEQ ID NO: 73 is also shown in Fig. 38.

[0251]

b-viii) h#32A1-T9H-type heavy chain:

A humanized #32A1 heavy chain designed by replacing amino acid numbers 23 (isoleucine), 24 (leucine), 26 (threonine), 32 (lysine), 43 (threonine), 61 (glutamic acid), 89 (valine), 95 (aspartic acid), 96 (serine), 97 (glutamic acid), 98 (serine), 100 (valine), 104 (valine), 114 (isoleucine), 118 (threonine), 134 (valine), 135 (methionine), and 140 (leucine) of the #32A1 heavy chain represented by SEQ ID NO: 28 in the Sequence Listing with leucine, valine, serine, glutamine, alanine, glycine, phenylalanine, asparagine, alanine, lysine, asparagine, leucine, methionine, valine, alanine, threonine, leucine, and serine respectively, was named "h#32A1-T9H-type heavy chain".

[0252]

The amino acid sequence of the h#32A1-T9H-type heavy chain is represented by SEQ ID NO: 74 in the Sequence Listing. The sequence comprising amino acid residues 1 to 121 of the amino acid sequence of SEQ ID NO: 74 and the sequence comprising amino acid residues 122 to 451 thereof correspond to the heavy chain variable region and the heavy chain constant region, respectively. The amino acid sequence of SEQ ID NO: 74 is also shown in Fig. 38.

[0253]

b)-ix) h#32A1-T10H-type heavy chain:

A humanized #32A1 heavy chain designed by replacing amino acid numbers 23 (isoleucine), 24 (leucine), 26 (threonine), 32 (lysine), 43 (threonine), 95 (aspartic acid), 96 (serine), 97 (glutamic acid), 98 (serine), 100 (valine), 104 (valine), 105 (serine), 114 (isoleucine), 118 (threonine), 134 (valine), 135 (methionine), and 140 (leucine) of the #32A1 heavy chain represented by SEQ ID NO: 28 in the Sequence Listing with leucine, valine, serine, glutamine, alanine, asparagine, alanine, lysine, asparagine, leucine, methionine, asparagine, valine, alanine, threonine, leucine, and serine, respectively, was named "h#32A1-T10H-type heavy chain".

[0254]

The amino acid sequence of the h#32A1-T10H-type heavy chain is represented by SEQ ID NO: 75 in the Sequence Listing.

The sequence comprising amino acid residues 1 to 121 of the amino acid sequence of SEQ ID NO: 75 and the sequence comprising amino acid residues 122 to 451 thereof correspond to the heavy chain variable region and the heavy chain constant region, respectively. The amino acid sequence of SEQ ID NO: 75 is also shown in Fig. 39.

[0255]

b)-x) h#32A1-T11H-type heavy chain:

A humanized #32A1 heavy chain designed by replacing amino acid numbers 23 (isoleucine), 24 (leucine), 26 (threonine), 32 (lysine), 43 (threonine), 89 (valine), 95 (aspartic acid), 96 (serine), 97 (glutamic acid), 98 (serine), 100 (valine), 104 (valine), 114 (isoleucine), 118 (threonine), 134 (valine), 135 (methionine), and 140 (leucine) of the #32A1 heavy chain represented by SEQ ID NO: 28 in the Sequence Listing with leucine, valine, serine, glutamine, alanine, phenylalanine, asparagine, alanine, lysine, asparagine, leucine, methionine, valine, alanine, threonine, leucine, and serine, respectively, was named "h#32A1-T11H-type heavy chain".

[0256]

The amino acid sequence of the h#32A1-T11H-type heavy chain is represented by SEQ ID NO: 76 in the Sequence Listing. The sequence comprising amino acid residues 1 to 121 of the amino acid sequence of SEQ ID NO: 76 and the sequence comprising amino acid residues 122 to 451 thereof correspond to the heavy

chain variable region and the heavy chain constant region, respectively. The amino acid sequence of SEQ ID NO: 76 is also shown in Fig. 39.

[0257]

b)-xi) h#32A1-T12H-type heavy chain:

A humanized #32A1 heavy chain designed by replacing amino acid residues 23 (isoleucine), 24 (leucine), 26 (threonine), 32 (lysine), 43 (threonine), 61 (glutamic acid), 95 (aspartic acid), 96 (serine), 97 (glutamic acid), 98 (serine), 100 (valine), 104 (valine), 114 (isoleucine), 118 (threonine), 134 (valine), 135 (methionine), and 140 (leucine) of the #32A1 heavy chain represented by SEQ ID NO: 28 in the Sequence Listing with leucine, valine, serine, glutamine, alanine, glycine, asparagine, alanine, lysine, asparagine, leucine, methionine, valine, alanine, threonine, leucine, and serine, respectively, was named "h#32A1-T12H-type heavy chain".

[0258]

The amino acid sequence of the h#32A1-T12H-type heavy chain is represented by SEQ ID NO: 77 in the Sequence Listing. The sequence comprising amino acid residues 1 to 121 of the amino acid sequence of SEQ ID NO: 77 and the sequence comprising amino acid residues 122 to 451 thereof correspond to the heavy chain variable region and the heavy chain constant region, respectively. The amino acid sequence of SEQ ID NO: 77 is also shown in Fig. 39.

[0259]

c) Humanization of #32A1 light chain

c)-i) h#32A1-T1L-type light chain:

A humanized #32A1 light chain designed by replacing amino acid numbers 24 (leucine), 29 (alanine), between 29 and 30 (i.e. inserting a residue missing from the rat framework), 36 (glutamine), 41 (serine), 66 (glutamine), 68 (arginine), 81 (isoleucine), 99 (asparagine), 100 (proline), 101 (valine), 104 (aspartic acid), 106 (isoleucine), 108 (threonine), 110 (phenylalanine), 122 (alanine), 127 (leucine), 129 (leucine), 130 (arginine), and 132 (alanine) of the #32A1 light chain represented by SEQ ID NO: 30 in the Sequence Listing with methionine, aspartic acid, serine, glutamic acid, asparagine, proline, lysine, valine, serine, serine, leucine, glutamic acid, valine, valine, tyrosine, glycine, valine, isoleucine, lysine, and threonine, respectively, was named "h#32A1-T1L-type light chain".

[0260]

The amino acid sequence of the h#32A1-T1L-type light chain is represented by SEQ ID NO: 61 in the Sequence Listing. The sequence comprising amino acid residues 1 to 20 of the amino acid sequence of SEQ ID NO: 61, the sequence comprising amino acid residues 21 to 133 thereof, and the sequence comprising amino acid residues 134 to 238 thereof correspond to the signal sequence, the light chain variable region, and the light chain

constant region, respectively. A nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 61 is represented by SEQ ID NO: 60 in the Sequence Listing. The sequence comprising nucleotides 1 to 60 of the nucleotide sequence of SEQ ID NO: 60, the sequence comprising nucleotides 61 to 399 thereof, and the sequence comprising nucleotides 400 to 714 thereof encode the signal sequence, the light chain variable region sequence, and the light chain constant region sequence, respectively. The nucleotide sequence of SEQ ID NO: 60 and the amino acid sequence of SEQ ID NO: 61 are also shown in Fig. 32.

[0261]

c)-ii) h#32A1-T2L-type light chain:

A humanized #32A1 light chain designed by replacing amino acid numbers 24 (leucine), 29 (alanine), between 29 and 30 (i.e. inserting a residue missing from the rat framework), 36 (glutamine), 66 (glutamine), 81 (isoleucine), 99 (asparagine), 100 (proline), 101 (valine), 104 (aspartic acid), 106 (isoleucine), 108 (threonine), 127 (leucine), 129 (leucine), 130 (arginine), and 132 (alanine) of the #32A1 light chain represented by SEQ ID NO: 30 in the Sequence Listing with methionine, aspartic acid, serine, glutamic acid, proline, valine, serine, serine, leucine, glutamic acid, valine, valine, valine, isoleucine, lysine, and threonine, respectively, was named "h#32A1-T2L-type light chain".

[0262]

The amino acid sequence of the h#32A1-T2L-type light chain is represented by SEQ ID NO: 63 in the Sequence Listing. The sequence comprising amino acid residues 1 to 20 of the amino acid sequence of SEQ ID NO: 63, the sequence comprising amino acid residues 21 to 133 thereof, and the sequence comprising amino acid residues 134 to 238 thereof correspond to the signal sequence, the light chain variable region, and the light chain constant region, respectively. A nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 63 is represented by SEQ ID NO: 62 in the Sequence Listing. The sequence comprising nucleotides 1 to 60 of the nucleotide sequence of SEQ ID NO: 62, the sequence comprising nucleotides 61 to 399 thereof, and the sequence comprising nucleotides 400 to 714 thereof encode the signal sequence, the light chain variable region sequence, and the light chain constant region sequence, respectively. The nucleotide sequence of SEQ ID NO: 62 and the amino acid sequence of SEQ ID NO: 63 are also shown in Fig. 33.

[0263]

c)-iii) h#32A1-T3L-type light chain:

A humanized #32A1 light chain designed by replacing amino acid numbers 29 (alanine), between 29 and 30 (i.e. inserting a residue missing from the rat framework), 36 (glutamine), 99 (asparagine), 100 (proline), 101 (valine), 104 (aspartic acid),

106 (isoleucine), 127 (leucine), 129 (leucine), 130 (arginine), and 132 (alanine) of the #32A1 light chain represented by SEQ ID NO: 30 in the Sequence Listing with aspartic acid, serine, glutamic acid, serine, serine, leucine, glutamic acid, valine, valine, isoleucine, lysine, and threonine, respectively, was named "h#32A1-T3L-type light chain".

[0264]

The amino acid sequence of the h#32A1-T3L-type light chain is represented by SEQ ID NO: 65 in the Sequence Listing. The sequence comprising amino acid residues 1 to 20 of the amino acid sequence of SEQ ID NO: 65, the sequence comprising amino acid residues 21 to 133 thereof, and the sequence comprising amino acid residues 134 to 238 thereof correspond to the signal sequence, the light chain variable region, and the light chain constant region, respectively. A nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 65 is represented by SEQ ID NO: 64 in the Sequence Listing. The sequence comprising nucleotides 1 to 60 of the nucleotide sequence of SEQ ID NO: 64, the sequence comprising nucleotides 61 to 399 thereof, and the sequence comprising nucleotides 400 to 714 thereof encode the signal sequence, the light chain variable region sequence, and the light chain constant region sequence, respectively. The nucleotide sequence of SEQ ID NO: 64 and the amino acid sequence of SEQ ID NO: 65 are also shown in Fig. 34.

[0265]

c)-iv) h#32A1-T4L-type light chain:

A humanized #32A1 light chain designed by replacing amino acid numbers 36 (glutamine), 99 (asparagine), 100 (proline), 101 (valine), 104 (aspartic acid), 106 (isoleucine), 129 (leucine), 130 (arginine), and 132 (alanine) of the #32A1 light chain represented by SEQ ID NO: 30 in the Sequence Listing with glutamic acid, serine, serine, leucine, glutamic acid, valine, isoleucine, lysine, and threonine, respectively, was named "h#32A1-T4L-type light chain".

[0266]

The amino acid sequence of the h#32A1-T4L-type light chain is represented by SEQ ID NO: 67 in the Sequence Listing. The sequence comprising amino acid residues 1 to 20 of the amino acid sequence of SEQ ID NO: 67, the sequence comprising amino acid residues 21 to 132 thereof, and the sequence comprising amino acid residues 133 to 237 thereof correspond to the signal sequence, the light chain variable region, and the light chain constant region, respectively. A nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 67 is represented by SEQ ID NO: 66 in the Sequence Listing. The sequence comprising nucleotides 1 to 60 of the nucleotide sequence of SEQ ID NO: 66, the sequence comprising nucleotides 61 to 396 thereof, and the sequence comprising nucleotides 397 to 711 thereof encode the signal sequence, the light chain variable

region sequence, and the light chain constant region sequence, respectively. The nucleotide sequence of SEQ ID NO: 66 and the amino acid sequence of SEQ ID NO: 67 are also shown in Fig. 35.

[0267]

c)-v) h#32A1-T5L-type light chain:

A humanized #32A1 light chain designed by replacing amino acid numbers 29 (alanine), between 29 and 30 (i.e. inserting a residue missing from the rat framework), 36 (glutamine), 41 (serine), 66 (glutamine), 68 (arginine), 99 (asparagine), 100 (proline), 101 (valine), 104 (aspartic acid), 106 (isoleucine), 110 (phenylalanine), 122 (alanine), 123 (glycine), 127 (leucine), 129 (leucine), 130 (arginine), and 132 (alanine) of the #32A1 light chain represented by SEQ ID NO: 30 in the Sequence Listing with aspartic acid, serine, glutamic acid, asparagine, proline, lysine, serine, serine, leucine, glutamic acid, valine, tyrosine, glycine, glutamine, valine, isoleucine, lysine, and threonine, respectively, was named "h#32A1-T5L-type light chain".

[0268]

The amino acid sequence of the h#32A1-T5L-type light chain is represented by SEQ ID NO: 69 in the Sequence Listing. The sequence comprising amino acid residues 1 to 20 of the amino acid sequence of SEQ ID NO: 69, the sequence comprising amino acid residues 21 to 133 thereof, and the sequence comprising

amino acid residues 134 to 238 thereof correspond to the signal sequence, the light chain variable region, and the light chain constant region, respectively. A nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 69 is represented by SEQ ID NO: 68 in the Sequence Listing. The sequence comprising nucleotides 1 to 60 of the nucleotide sequence of SEQ ID NO: 68, the sequence comprising nucleotides 61 to 399 thereof, and the sequence comprising nucleotides 400 to 714 thereof encode the signal sequence, the light chain variable region sequence, and the light chain constant region sequence, respectively. The nucleotide sequence of SEQ ID NO: 68 and the amino acid sequence of SEQ ID NO: 69 are also shown in Fig. 36.

[0269]

c)-vi) h#32A1-T6L-type light chain:

A humanized #32A1 light chain designed by replacing amino acid numbers 29 (alanine), between 29 and 30 (i.e. inserting a residue missing from the rat framework), 36 (glutamine), 66 (glutamine), 99 (asparagine), 100 (proline), 101 (valine), 104 (aspartic acid), 106 (isoleucine), 127 (leucine), 129 (leucine), 130 (arginine), and 132 (alanine) of the #32A1 light chain represented by SEQ ID NO: 30 in the Sequence Listing with aspartic acid, serine, glutamic acid, proline, serine, serine, leucine, glutamic acid, valine, valine, isoleucine, lysine, and threonine, respectively, was named "h#32A1-T6L-type light

chain".

[0270]

The amino acid sequence of the h#32A1-T6L-type light chain is represented by SEQ ID NO: 71 in the Sequence Listing. The sequence comprising amino acid residues 1 to 20 of the amino acid sequence of SEQ ID NO: 71, the sequence comprising amino acid residues 21 to 133 thereof, and the sequence comprising amino acid residues 134 to 238 thereof correspond to the signal sequence, the light chain variable region, and the light chain constant region, respectively. A nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 71 is represented by SEQ ID NO: 70 in the Sequence Listing. The sequence comprising nucleotides 1 to 60 of the nucleotide sequence of SEQ ID NO: 70, the sequence comprising nucleotides 61 to 399 thereof, and the sequence comprising nucleotides 400 to 714 thereof encode the signal sequence, the light chain variable region sequence, and the light chain constant region sequence, respectively. The nucleotide sequence of SEQ ID NO: 70 and the amino acid sequence of SEQ ID NO: 71 are also shown in Fig. 37.

[0271]

c)-vii) h#32A1-T7L-type light chain:

A humanized #32A1 light chain designed by replacing amino acid numbers 24 (leucine), 29 (alanine), between 29 and 30 (i.e. inserting a residue missing from the rat framework), 36

(glutamine), 66 (glutamine), 68 (arginine), 81 (isoleucine), 99 (asparagine), 100 (proline), 101 (valine), 104 (aspartic acid), 106 (isoleucine), 108 (threonine), 110 (phenylalanine), 122 (alanine), 127 (leucine), 129 (leucine), 130 (arginine), and 132 (alanine) of the #32A1 light chain represented by SEQ ID NO: 30 in the Sequence Listing with methionine, aspartic acid, serine, glutamic acid, proline, lysine, valine, serine, serine, leucine, glutamic acid, valine, valine, tyrosine, glycine, valine, isoleucine, lysine, and threonine, respectively, was named "h#32A1-T7L-type light chain".

[0272]

The amino acid sequence of the h#32A1-T7L-type light chain is represented by SEQ ID NO: 78 in the Sequence Listing. The sequence comprising amino acid residues 1 to 113 of the amino acid sequence of SEQ ID NO: 78 and the sequence comprising amino acid residues 114 to 218 thereof correspond to the light chain variable region and the light chain constant region, respectively. The amino acid sequence of SEQ ID NO: 78 is also shown in Fig. 40.

[0273]

c)-viii) h#32A1-T8L-type light chain:

A humanized #32A1 light chain designed by replacing amino acid numbers 24 (leucine), 29 (alanine), between 29 and 30 (i.e. inserting a residue missing from the rat framework), 36 (glutamine), 41 (serine), 66 (glutamine), 81 (isoleucine), 99

(asparagine), 100 (proline), 101 (valine), 104 (aspartic acid), 106 (isoleucine), 108 (threonine), 110 (phenylalanine), 122 (alanine), 127 (leucine), 129 (leucine), 130 (arginine), and 132 (alanine) of the #32A1 light chain represented by SEQ ID NO: 30 in the Sequence Listing with methionine, aspartic acid, serine, glutamic acid, asparagine, proline, valine, serine, serine, leucine, glutamic acid, valine, valine, tyrosine, glycine, valine, isoleucine, lysine, and threonine, respectively, was named "h#32A1-T8L-type light chain".

[0274]

The amino acid sequence of the h#32A1-T8L-type light chain is represented by SEQ ID NO: 79 in the Sequence Listing. The sequence comprising amino acid residues 1 to 113 of the amino acid sequence of SEQ ID NO: 79 and the sequence comprising amino acid residues 114 to 218 thereof correspond to the light chain variable region and the light chain constant region, respectively. The amino acid sequence of SEQ ID NO: 79 is also shown in Fig. 40.

[0275]

c)-ix) h#32A1-T9L-type light chain:

A humanized #32A1 light chain designed by replacing amino acid numbers 24 (leucine), 29 (alanine), between 29 and 30 (i.e. inserting a residue missing from the rat framework), 36 (glutamine), 41 (serine), 66 (glutamine), 68 (arginine), 81 (isoleucine), 99 (asparagine), 100 (proline), 101 (valine),

104 (aspartic acid), 106 (isoleucine), 108 (threonine), 122 (alanine), 127 (leucine), 129 (leucine), 130 (arginine), and 132 (alanine) of the #32A1 light chain represented by SEQ ID NO: 30 in the Sequence Listing with methionine, aspartic acid, serine, glutamic acid, asparagine, proline, lysine, valine, serine, serine, leucine, glutamic acid, valine, valine, glycine, valine, isoleucine, lysine, and threonine, respectively, was named "h#32A1-T9L-type light chain".

[0276]

The amino acid sequence of the h#32A1-T9L-type light chain is represented by SEQ ID NO: 80 in the Sequence Listing. The sequence comprising amino acid residues 1 to 113 of the amino acid sequence of SEQ ID NO: 80 and the sequence comprising amino acid residues 114 to 218 thereof correspond to the light chain variable region and the light chain constant region, respectively. The amino acid sequence of SEQ ID NO: 80 is also shown in Fig. 40.

[0277]

c)-x) h#32A1-T10L-type light chain:

A humanized #32A1 light chain designed by replacing amino acid numbers 24 (leucine), 29 (alanine), between 29 and 30 (i.e. inserting a residue missing from the rat framework), 36 (glutamine), 41 (serine), 66 (glutamine), 68 (arginine), 81 (isoleucine), 99 (asparagine), 100 (proline), 101 (valine), 104 (aspartic acid), 106 (isoleucine), 108 (threonine), 110

(phenylalanine), 127 (leucine), 129 (leucine), 130 (arginine), and 132 (alanine) of the #32A1 light chain represented by SEQ ID NO: 30 in the Sequence Listing with methionine, aspartic acid, serine, glutamic acid, asparagine, proline, lysine, valine, serine, serine, leucine, glutamic acid, valine, valine, tyrosine, valine, isoleucine, lysine, and threonine, respectively, was named "h#32A1-T10L-type light chain".

[0278]

The amino acid sequence of the h#32A1-T10L-type light chain is represented by SEQ ID NO: 81 in the Sequence Listing. The sequence comprising amino acid residues 1 to 113 of the amino acid sequence of SEQ ID NO: 81 and the sequence comprising amino acid residues 114 to 218 thereof correspond to the light chain variable region and the light chain constant region, respectively. The amino acid sequence of SEQ ID NO: 81 is also shown in Fig. 40.

[0279]

c)-xi) h#32A1-T11L-type light chain:

A humanized #32A1 light chain designed by replacing amino acid numbers 24 (leucine), 29 (alanine), between 29 and 30 (i.e. inserting a residue missing from the rat framework), 36 (glutamine), 66 (glutamine), 81 (isoleucine), 99 (asparagine), 100 (proline), 101 (valine), 104 (aspartic acid), 106 (isoleucine), 108 (threonine), 110 (phenylalanine), 122 (alanine), 127 (leucine), 129 (leucine), 130 (arginine), and

132 (alanine) of the #32A1 light chain represented by SEQ ID NO: 30 in the Sequence Listing with methionine, aspartic acid, serine, glutamic acid, proline, valine, serine, serine, leucine, glutamic acid, valine, valine, tyrosine, glycine, valine, isoleucine, lysine, and threonine, respectively, was named "h#32A1-T11L-type light chain".

[0280]

The amino acid sequence of the h#32A1-T11L-type light chain is represented by SEQ ID NO: 82 in the Sequence Listing. The sequence comprising amino acid residues 1 to 113 of the amino acid sequence of SEQ ID NO: 82 and the sequence comprising amino acid residues 114 to 218 thereof correspond to the light chain variable region and the light chain constant region, respectively. The amino acid sequence of SEQ ID NO: 82 is also shown in Fig. 40.

[0281]

c)-xii) h#32A1-T12L-type light chain:

A humanized #32A1 light chain designed by replacing amino acid numbers 24 (leucine), 29 (alanine), between 29 and 30 (i.e. inserting a residue missing from the rat framework), 36 (glutamine), 66 (glutamine), 68 (arginine), 81 (isoleucine), 99 (asparagine), 100 (proline), 101 (valine), 104 (aspartic acid), 106 (isoleucine), 108 (threonine), 122 (alanine), 127 (leucine), 129 (leucine), 130 (arginine), and 132 (alanine) of the #32A1 light chain represented by SEQ ID NO: 30 in the

Sequence Listing with methionine, aspartic acid, serine, glutamic acid, proline, lysine, valine, serine, serine, leucine, glutamic acid, valine, valine, glycine, valine, isoleucine, lysine, and threonine, respectively, was named "h#32A1-T12L-type light chain".

[0282]

The amino acid sequence of the h#32A1-T12L-type light chain is represented by SEQ ID NO: 83 in the Sequence Listing. The sequence comprising amino acid residues 1 to 113 of the amino acid sequence of SEQ ID NO: 83 and the sequence comprising amino acid residues 114 to 218 thereof correspond to the light chain variable region and the light chain constant region, respectively. The amino acid sequence of SEQ ID NO: 83 is also shown in Fig. 41.

[0283]

c)-xiii) h#32A1-T13L-type light chain:

A humanized #32A1 light chain designed by replacing amino acid numbers 24 (leucine), 29 (alanine), between 29 and 30 (i.e. inserting a residue missing from the rat framework), 36 (glutamine), 66 (glutamine), 68 (arginine), 81 (isoleucine), 99 (asparagine), 100 (proline), 101 (valine), 104 (aspartic acid), 106 (isoleucine), 108 (threonine), 110 (phenylalanine), 127 (leucine), 129 (leucine), 130 (arginine), and 132 (alanine) of the #32A1 light chain represented by SEQ ID NO: 30 in the Sequence Listing with methionine, aspartic acid, serine,

glutamic acid, proline, lysine, valine, serine, serine, leucine, glutamic acid, valine, valine, tyrosine, valine, isoleucine, lysine, and threonine, respectively, was named "h#32A1-T13L-type light chain".

[0284]

The amino acid sequence of the h#32A1-T13L-type light chain is represented by SEQ ID NO: 84 in the Sequence Listing. The sequence comprising amino acid residues 1 to 113 of the amino acid sequence of SEQ ID NO: 84 and the sequence comprising amino acid residues 114 to 218 thereof correspond to the light chain variable region and the light chain constant region, respectively. The amino acid sequence of SEQ ID NO: 84 is also shown in Fig. 41.

[0285]

c)-xiv) h#32A1-T14L-type light chain:

A humanized #32A1 light chain designed by replacing amino acid numbers 24 (leucine), 29 (alanine), between 29 and 30 (i.e. inserting a residue missing from the rat framework), 36 (glutamine), 41 (serine), 66 (glutamine), 81 (isoleucine), 99 (asparagine), 100 (proline), 101 (valine), 104 (aspartic acid), 106 (isoleucine), 108 (threonine), 122 (alanine), 127 (leucine), 129 (leucine), 130 (arginine), and 132 (alanine) of the #32A1 light chain represented by SEQ ID NO: 30 in the Sequence Listing with methionine, aspartic acid, serine, glutamic acid, asparagine, proline, valine, serine, serine,

leucine, glutamic acid, valine, valine, glycine, valine, isoleucine, lysine, and threonine, respectively, was named "h#32A1-T14L-type light chain".

[0286]

The amino acid sequence of the h#32A1-T14L-type light chain is represented by SEQ ID NO: 85 in the Sequence Listing. The sequence comprising amino acid residues 1 to 113 of the amino acid sequence of SEQ ID NO: 85 and the sequence comprising amino acid residues 114 to 218 thereof correspond to the light chain variable region and the light chain constant region, respectively. The amino acid sequence of SEQ ID NO: 85 is also shown in Fig. 41.

[0287]

c)-xv) h#32A1-T15L-type light chain:

A humanized #32A1 light chain designed by replacing amino acid numbers 24 (leucine), 29 (alanine), between 29 and 30 (i.e. inserting a residue missing from the rat framework), 36 (glutamine), 41 (serine), 66 (glutamine), 81 (isoleucine), 99 (asparagine), 100 (proline), 101 (valine), 104 (aspartic acid), 106 (isoleucine), 108 (threonine), 110 (phenylalanine), 127 (leucine), 129 (leucine), 130 (arginine), and 132 (alanine) of the #32A1 light chain represented by SEQ ID NO: 30 in the Sequence Listing with methionine, aspartic acid, serine, glutamic acid, asparagine, proline, valine, serine, serine, leucine, glutamic acid, valine, valine, tyrosine, valine,

isoleucine, lysine, and threonine, respectively, was named "h#32A1-T15L-type light chain".

[0288]

The amino acid sequence of the h#32A1-T15L-type light chain is represented by SEQ ID NO: 86 in the Sequence Listing. The sequence comprising amino acid residues 1 to 113 of the amino acid sequence of SEQ ID NO: 86 and the sequence comprising amino acid residues 114 to 218 thereof correspond to the light chain variable region and the light chain constant region, respectively. The amino acid sequence of SEQ ID NO: 86 is also shown in Fig. 41.

[0289]

c)-xvi) h#32A1-T16L-type light chain:

A humanized #32A1 light chain designed by replacing amino acid numbers 24 (leucine), 29 (alanine), between 29 and 30 (i.e. inserting a residue missing from the rat framework), 36 (glutamine), 41 (serine), 66 (glutamine), 68 (arginine), 81 (isoleucine), 99 (asparagine), 100 (proline), 101 (valine), 104 (aspartic acid), 106 (isoleucine), 108 (threonine), 127 (leucine), 129 (leucine), 130 (arginine), and 132 (alanine) of the #32A1 light chain represented by SEQ ID NO: 30 in the Sequence Listing with methionine, aspartic acid, serine, glutamic acid, asparagine, proline, lysine, valine, serine, serine, leucine, glutamic acid, valine, valine, valine, isoleucine, lysine, and threonine, respectively, was named

"h#32A1-T16L-type light chain".

[0290]

The amino acid sequence of the h#32A1-T16L-type light chain is represented by SEQ ID NO: 87 in the Sequence Listing. The sequence comprising amino acid residues 1 to 113 of the amino acid sequence of SEQ ID NO: 87 and the sequence comprising amino acid residues 114 to 218 thereof correspond to the light chain variable region and the light chain constant region, respectively. The amino acid sequence of SEQ ID NO: 87 is also shown in Fig. 41.

[0291]

c)-xvii) h#32A1-T17L-type light chain:

A humanized #32A1 light chain designed by replacing amino acid numbers 24 (leucine), 29 (alanine), between 29 and 30 (i.e. inserting a residue missing from the rat framework), 36 (glutamine), 66 (glutamine), 81 (isoleucine), 99 (asparagine), 100 (proline), 101 (valine), 104 (aspartic acid), 106 (isoleucine), 108 (threonine), 122 (alanine), 127 (leucine), 129 (leucine), 130 (arginine), and 132 (alanine) of the #32A1 light chain represented by SEQ ID NO: 30 in the Sequence Listing with methionine, aspartic acid, serine, glutamic acid, proline, valine, serine, serine, leucine, glutamic acid, valine, valine, glycine, valine, isoleucine, lysine, and threonine, respectively, was named "h#32A1-T17L-type light chain".

[0292]

The amino acid sequence of the h#32A1-T17L-type light chain is represented by SEQ ID NO: 88 in the Sequence Listing. The sequence comprising amino acid residues 1 to 113 of the amino acid sequence of SEQ ID NO: 88 and the sequence comprising amino acid residues 114 to 218 thereof correspond to the light chain variable region and the light chain constant region, respectively. The amino acid sequence of SEQ ID NO: 88 is also shown in Fig. 42.

[0293]

c)-xviii) h#32A1-T18L-type light chain:

A humanized #32A1 light chain designed by replacing amino acid numbers 24 (leucine), 29 (alanine), between 29 and 30 (i.e. inserting a residue missing from the rat framework), 36 (glutamine), 66 (glutamine), 81 (isoleucine), 99 (asparagine), 100 (proline), 101 (valine), 104 (aspartic acid), 106 (isoleucine), 108 (threonine), 110 (phenylalanine), 127 (leucine), 129 (leucine), 130 (arginine), and 132 (alanine) of the #32A1 light chain represented by SEQ ID NO: 30 in the Sequence Listing with methionine, aspartic acid, serine, glutamic acid, proline, valine, serine, serine, leucine, glutamic acid, valine, valine, tyrosine, valine, isoleucine, lysine, and threonine, respectively, was named "h#32A1-T18L-type light chain".

[0294]

The amino acid sequence of the h#32A1-T18L-type light

chain is represented by SEQ ID NO: 89 in the Sequence Listing. The sequence comprising amino acid residues 1 to 113 of the amino acid sequence of SEQ ID NO: 89 and the sequence comprising amino acid residues 114 to 218 thereof correspond to the light chain variable region and the light chain constant region, respectively. The amino acid sequence of SEQ ID NO: 89 is also shown in Fig. 42.

[0295]

c)-xix) h#32A1-T19L-type light chain:

A humanized #32A1 light chain designed by replacing amino acid numbers 24 (leucine), 29 (alanine), between 29 and 30 (i.e. inserting a residue missing from the rat framework), 36 (glutamine), 66 (glutamine), 68 (arginine), 81 (isoleucine), 99 (asparagine), 100 (proline), 101 (valine), 104 (aspartic acid), 106 (isoleucine), 108 (threonine), 127 (leucine), 129 (leucine), 130 (arginine), and 132 (alanine) of the #32A1 light chain represented by SEQ ID NO: 30 in the Sequence Listing with methionine, aspartic acid, serine, glutamic acid, proline, lysine, valine, serine, serine, leucine, glutamic acid, valine, valine, valine, isoleucine, lysine, and threonine, respectively, was named "h#32A1-T19L-type light chain".

[0296]

The amino acid sequence of the h#32A1-T19L-type light chain is represented by SEQ ID NO: 90 in the Sequence Listing. The sequence comprising amino acid residues 1 to 113 of the

amino acid sequence of SEQ ID NO: 90 and the sequence comprising amino acid residues 114 to 218 thereof correspond to the light chain variable region and the light chain constant region, respectively. The amino acid sequence of SEQ ID NO: 90 is also shown in Fig. 42.

[0297]

c)-xx) h#32A1-T20L-type light chain:

A humanized #32A1 light chain designed by replacing amino acid numbers 24 (leucine), 29 (alanine), between 29 and 30 (i.e. inserting a residue missing from the rat framework), 36 (glutamine), 41 (serine), 66 (glutamine), 81 (isoleucine), 99 (asparagine), 100 (proline), 101 (valine), 104 (aspartic acid), 106 (isoleucine), 108 (threonine), 127 (leucine), 129 (leucine), 130 (arginine), and 132 (alanine) of the #32A1 light chain represented by SEQ ID NO: 30 in the Sequence Listing with methionine, aspartic acid, serine, glutamic acid, asparagine, proline, valine, serine, serine, leucine, glutamic acid, valine, valine, valine, isoleucine, lysine, and threonine, respectively, was named "h#32A1-T20L-type light chain".

[0298]

The amino acid sequence of the h#32A1-T20L-type light chain is represented by SEQ ID NO: 91 in the Sequence Listing. The sequence comprising amino acid residues 1 to 113 of the amino acid sequence of SEQ ID NO: 91 and the sequence comprising amino acid residues 114 to 218 thereof correspond to the light

chain variable region and the light chain constant region, respectively. The amino acid sequence of SEQ ID NO: 91 is also shown in Fig. 42.

[0299]

c)-xxi) h#32A1-T21L-type light chain:

A humanized #32A1 light chain designed by replacing amino acid numbers 21 (aspartic acid), 24 (leucine), between 29 and 30 (i.e. inserting a residue missing from the rat framework), 31 (alanine), 32 (valine), 34 (leucine), 36 (glutamine), 40 (isoleucine), 66 (glutamine), 99 (asparagine), 100 (proline), 101 (valine), 102 (glutamine), 103 (alanine), 104 (aspartic acid), 106 (isoleucine), 108 (threonine), 110 (phenylalanine), 122 (alanine), 123 (glycine), 127 (leucine), 129 (leucine), 130 (arginine), and 132 (alanine) of the #32A1 light chain represented by SEQ ID NO: 30 in the Sequence Listing with glutamic acid, methionine, threonine, serine, leucine, proline, glutamic acid, leucine, alanine, serine, serine, leucine, glutamic acid, proline, glutamic acid, phenylalanine, leucine, tyrosine, glycine, glutamine, valine, isoleucine, lysine, and threonine, respectively, was named "h#32A1-T21L-type light chain".

[0300]

The amino acid sequence of the h#32A1-T21L-type light chain is represented by SEQ ID NO: 92 in the Sequence Listing. The sequence comprising amino acid residues 1 to 113 of the

amino acid sequence of SEQ ID NO: 92 and the sequence comprising amino acid residues 114 to 218 thereof correspond to the light chain variable region and the light chain constant region, respectively. The amino acid sequence of SEQ ID NO: 92 is also shown in Fig. 42.

[0301]

c)-xxii) h#32A1-T22L-type light chain:

A humanized #32A1 light chain designed by replacing amino acid numbers 21 (aspartic acid), 24 (leucine), between 29 and 30 (i.e inserting a residue missing from the rat framework), 31 (alanine), 32 (valine), 34 (leucine), 36 (glutamine), 40 (isoleucine), 66 (glutamine), 99 (asparagine), 100 (proline), 101 (valine), 102 (glutamine), 103 (alanine), 104 (aspartic acid), 106 (isoleucine), 108 (threonine), 123 (glycine), 127 (leucine), 129 (leucine), 130 (arginine), and 132 (alanine) of the #32A1 light chain represented by SEQ ID NO: 30 in the Sequence Listing with glutamic acid, methionine, threonine, serine, leucine, proline, glutamic acid, leucine, alanine, serine, serine, leucine, glutamic acid, proline, glutamic acid, phenylalanine, leucine, glutamine, valine, isoleucine, lysine, and threonine, respectively, was named "h#32A1-T22L-type light chain".

[0302]

The amino acid sequence of the h#32A1-T22L-type light chain is represented by SEQ ID NO: 93 in the Sequence Listing.

The sequence comprising amino acid residues 1 to 113 of the amino acid sequence of SEQ ID NO: 93 and the sequence comprising amino acid residues 114 to 218 thereof correspond to the light chain variable region and the light chain constant region, respectively. The amino acid sequence of SEQ ID NO: 93 is also shown in Fig. 43.

[0303]

c)-xxiii) h#32A1-T23L-type light chain:

A humanized #32A1 light chain designed by replacing amino acid numbers 24 (leucine), between 29 and 30 (i.e. inserting a residue missing from the rat framework), 31 (alanine), 32 (valine), 34 (leucine), 36 (glutamine), 40 (isoleucine), 66 (glutamine), 99 (asparagine), 100 (proline), 101 (valine), 102 (glutamine), 103 (alanine), 104 (aspartic acid), 106 (isoleucine), 108 (threonine), 127 (leucine), 129 (leucine), 130 (arginine), and 132 (alanine) of the #32A1 light chain represented by SEQ ID NO: 30 in the Sequence Listing with methionine, threonine, serine, leucine, proline, glutamic acid, leucine, alanine, serine, serine, leucine, glutamic acid, proline, glutamic acid, phenylalanine, leucine, valine, isoleucine, lysine, and threonine, respectively, was named "h#32A1-T23L-type light chain".

[0304]

The amino acid sequence of the h#32A1-T23L-type light chain is represented by SEQ ID NO: 94 in the Sequence Listing.

The sequence comprising amino acid residues 1 to 113 of the amino acid sequence of SEQ ID NO: 94 and the sequence comprising amino acid residues 114 to 218 thereof correspond to the light chain variable region and the light chain constant region, respectively. The amino acid sequence of SEQ ID NO: 94 is also shown in Fig. 43.

[0305]

c)-xxiv) h#32A1-T24L-type light chain:

A humanized #32A1 light chain designed by replacing amino acid numbers 21 (aspartic acid), between 29 and 30 (i.e. inserting a residue missing from the rat framework), 31 (alanine), 32 (valine), 34 (leucine), 36 (glutamine), 40 (isoleucine), 66 (glutamine), 99 (asparagine), 100 (proline), 101 (valine), 102 (glutamine), 103 (alanine), 104 (aspartic acid), 106 (isoleucine), 108 (threonine), 110 (phenylalanine), 122 (alanine), 123 (glycine), 127 (leucine), 129 (leucine), 130 (arginine), and 132 (alanine) of the #32A1 light chain represented by SEQ ID NO: 30 in the Sequence Listing with glutamic acid, threonine, serine, leucine, proline, glutamic acid, leucine, alanine, serine, serine, leucine, glutamic acid, proline, glutamic acid, phenylalanine, leucine, tyrosine, glycine, glutamine, valine, isoleucine, lysine, and threonine, respectively, was named "h#32A1-T24L-type light chain".

[0306]

The amino acid sequence of the h#32A1-T24L-type light

chain is represented by SEQ ID NO: 95 in the Sequence Listing. The sequence comprising amino acid residues 1 to 113 of the amino acid sequence of SEQ ID NO: 95 and the sequence comprising amino acid residues 114 to 218 thereof correspond to the light chain variable region and the light chain constant region, respectively. The amino acid sequence of SEQ ID NO: 95 is also shown in Fig. 43.

[0307]

c)-xxv) h#32A1-T25L-type light chain:

A humanized #32A1 light chain designed by replacing amino acid numbers between 29 and 30 (i.e. inserting a residue missing from the rat framework), 31 (alanine), 32 (valine), 34 (leucine), 36 (glutamine), 40 (isoleucine), 99 (asparagine), 100 (proline), 101 (valine), 102 (glutamine), 103 (alanine), 104 (aspartic acid), 106 (isoleucine), 110 (phenylalanine), 127 (leucine), 129 (leucine), 130 (arginine), and 132 (alanine) of the #32A1 light chain represented by SEQ ID NO: 30 in the Sequence Listing with threonine, serine, leucine, proline, glutamic acid, leucine, serine, serine, leucine, glutamic acid, proline, glutamic acid, phenylalanine, tyrosine, valine, isoleucine, lysine, and threonine, respectively, was named "h#32A1-T25L-type light chain".

[0308]

The amino acid sequence of the h#32A1-T25L-type light chain is represented by SEQ ID NO: 96 in the Sequence Listing.

The sequence comprising amino acid residues 1 to 113 of the amino acid sequence of SEQ ID NO: 96 and the sequence comprising amino acid residues 114 to 218 thereof correspond to the light chain variable region and the light chain constant region, respectively. The amino acid sequence of SEQ ID NO: 96 is also shown in Fig. 43.

Example 23

[0309]

Production of gene of humanized antibody of rat anti-mouse Siglec-15 monoclonal antibody #32A1

a) Construction of h#32A1-T1L, h#32A1-T2L, h#32A1-T3L, h#32A1-T4L, h#32A1-T5L, and h#32A1-T6L-type light chain expression vectors

DNAs each containing a gene encoding a h#32A1-T1L, h#32A1-T2L, h#32A1-T3L, h#32A1-T4L, h#32A1-T5L, or h#32A1-T6L-type light chain variable region fused to a secretory signal represented by: amino acid numbers 1 to 133 of SEQ ID NO: 61 in the Sequence Listing; amino acid numbers 1 to 133 of SEQ ID NO: 63; amino acid numbers 1 to 133 of SEQ ID NO: 65; amino acid numbers 1 to 132 of SEQ ID NO: 67; amino acid numbers 1 to 133 of SEQ ID NO: 69; or amino acid numbers 1 to 133 of SEQ ID NO: 71 were synthesized (Medical & Biological Laboratories Co., Ltd., Artificial Gene Synthesis Service). Then, each of the DNA fragments obtained by cleaving the

synthesized DNAs with the restriction enzymes *NheI* and *BsiWI* was inserted into a universal humanized antibody light chain expression vector (pEF6KCL) at the site cleaved with the restriction enzymes *NheI* and *BsiWI*, whereby h#32A1-T1L, h#32A1-T2L, h#32A1-T3L, h#32A1-T4L, h#32A1-T5L, and h#32A1-T6L-type light chain expression vectors were constructed. The thus obtained expression vectors were named "pEF6KCL/h#32A1-T1L", "pEF6KCL/h#32A1-T2L", "pEF6KCL/h#32A1-T3L", "pEF6KCL/h#32A1-T4L", "pEF6KCL/h#32A1-T5L", and "pEF6KCL/h#32A1-T6L", respectively.

[0310]

b) Construction of h#32A1-T1H, h#32A1-T2H, h#32A1-T3H, h#32A1-T5H, and h#32A1-T6H heavy chain expression vectors

DNAs each containing a gene encoding a h#32A1-T1H, h#32A1-T2H, h#32A1-T3H, h#32A1-T5H, or h#32A1-T6H-type heavy chain variable region fused to a secretory signal represented by amino acid numbers 1 to 140 of SEQ ID NO: 51, 53, 55, 57, or 59 in the Sequence Listing were synthesized (Medical & Biological Laboratories Co., Ltd., Artificial Gene Synthesis Service). Then, each of the DNA fragments obtained by cleaving the synthesized DNAs with the restriction enzyme *BlpI* was inserted into a universal humanized antibody heavy chain expression vector (pEF1/FCCU-1) at the site cleaved with the restriction enzyme *BlpI*, whereby h#32A1-T1H, h#32A1-T2H,

h#32A1-T3H, h#32A1-T5H, and h#32A1-T6H heavy chain expression vectors were constructed. The thus obtained expression vectors were named "pEF1/FCCU/h#32A1-T1H", "pEF1/FCCU/h#32A1-T2H", "pEF1/FCCU/h#32A1-T3H", "pEF1/FCCU/h#32A1-T5H", and "pEF1/FCCU/h#32A1-T6H", respectively.

Example 24

[0311]

Preparation of humanized antibody of rat anti-mouse Siglec-15 monoclonal antibody #32A1

a) Production of humanized antibody

1.5×10^8 cells of 293 FreeStyle cells in logarithmic growth phase were seeded in 100 ml of fresh FreeStyle 293 Expression Medium (Invitrogen, Inc.) and subjected to shaking culture (125 rpm) at 37°C in an 8% CO₂ incubator. 1 mg of polyethyleneimine (manufactured by Polyscience, Inc. #24765) was dissolved in 4 ml of Opti-Pro SFM medium (manufactured by Invitrogen, Inc.), and the resulting solution was left at room temperature for 5 minutes. A heavy chain expression plasmid (0.05 mg) and a light chain expression plasmid (0.15 mg) prepared using PureLink HiPure Plasmid Kit (Invitrogen, Inc.) were suspended in 4 ml of Opti-Pro SFM medium (Invitrogen, Inc.). Then, 4 ml of the resulting expression plasmids/Opti-Pro SFM mixed liquid was added to 4 ml of the

polyethyleneimine/Opti-Pro SFM mixed liquid which had been left at room temperature for 5 minutes, and the resulting mixture was left at room temperature for an additional 5 minutes. Subsequently, 8 ml of the polyethyleneimine/the expression plasmids/Opti-Pro SFM mixed liquid was added to the 293 FreeStyle cell suspension, and the shaking culture was continued. After the cells were cultured for 7 days at 37°C in 8% CO₂, the culture supernatant was collected.

[0312]

b) Purification of humanized antibody

The culture supernatant obtained in the above a) was purified by Protein A affinity chromatography. 100 ml of the culture supernatant was put in a 500-ml stoppered flask, and 1 ml of a suspension (50% slurry) of MabSelect SuRe (manufactured by GE Healthcare Bio-science Co., Ltd.) equilibrated with PBS was added thereto. The resulting mixture was stirred overnight at 100 rpm in an incubator at 10°C. Then, the 293F culture supernatant/MabSelect SuRe suspension was applied to Zeba Spin Column empty 5 mL (PIERCE, Inc.). After all resin was poured into the column, the column was washed with 10 ml of 1 M NaCl. Subsequently, 1 ml of 1 M arginine solution (pH 4.0) was applied to the column, and a fraction containing the antibody was collected. The fraction was added to a centrifugal filter device (Amicon Ultra-4, fractional molecular weight: 50 K, Millipore Co.,

Ltd.), and liquid replacement with a citrate buffer and condensation were performed. The final volume was made up to 200 μ l, which was used as a purified sample.

[0313]

A humanized antibody of #32A1 obtained by a combination of pEF6KCL/h#32A1-T1L and pEF1/FCCU/h#32A1-T1H was named "h#32A1-T1"; a humanized antibody of #32A1 obtained by a combination of pEF6KCL/h#32A1-T2L and pEF1/FCCU/h#32A1-T2H was named "h#32A1-T2"; a humanized antibody of #32A1 obtained by a combination of pEF6KCL/h#32A1-T3L and pEF1/FCCU/h#32A1-T3H was named "h#32A1-T3"; a humanized antibody of #32A1 obtained by a combination of pEF6KCL/h#32A1-T4L and pEF1/FCCU/h#32A1-T4H was named "h#32A1-T4"; a humanized antibody of #32A1 obtained by a combination of pEF6KCL/h#32A1-T5L and pEF1/FCCU/h#32A1-T5H was named "h#32A1-T5"; and a humanized antibody of #32A1 obtained by a combination of pEF6KCL/h#32A1-T6L and pEF1/FCCU/h#32A1-T6H was named "h#32A1-T6".

Example 25

[0314]

Evaluation of binding property of humanized antibody of rat anti-mouse Siglec-15 monoclonal antibody #32A1 to mouse Siglec-15 protein

The binding property of the humanized antibodies of the

rat anti-mouse Siglec-15 #32A1 T1 to T6 to mouse Siglec-15-Fc and human Siglec-15-Fc was evaluated by the following method. The mouse Siglec-15-Fc purified in Example 4 or the human Siglec-15-Fc purified in Example 12 was diluted to 1 $\mu\text{g/ml}$ with PBS, and the diluted solution was dispensed at 100 $\mu\text{l/well}$ onto an immunoplate (manufactured by Nunc, Inc., #437111), and the plate was left to stand overnight at 4°C, whereby each protein was adsorbed to the plate. On the next day, each well was washed 5 times with a PBS-T solution (PBS, 0.05% (v/v) Tween 20), and a solution obtained by diluting skim milk (manufactured by Morinaga Milk Industry Co., Ltd.) to 5% with PBS was dispensed at 350 $\mu\text{l/well}$, and the plate was left stand at room temperature for 2 hours. The liquid in each well was removed, and each well was washed 5 times with the PBS-T solution. Thereafter, each of the purified humanized antibodies of the rat anti-mouse Siglec-15 #32A1 T1 to T6 prepared in Example 24 or the human chimeric antibody prepared in Example 19 was diluted to a final concentration of from 1 to 0.004 $\mu\text{g/ml}$ (4-fold dilution series) with a PBS solution containing 0.5% skim milk, the diluted solution was dispensed at 100 $\mu\text{l/well}$, and the plate was left to stand at room temperature for 2 hours. At this time, the concentration of each antibody was determined by performing measurement at 280 nm using a spectrophotometer DU-7400 (manufactured by Beckman Coulter, Inc.) and performing calculations based on a molar molecular extinction coefficient.

of each antibody. After each well had been washed 5 times with the PBS-T solution, alkaline phosphatase-conjugated AffiniPure goat anti-human IgG (manufactured by Jackson ImmunoResearch, Inc., #109-055-097) diluted to 2500-fold with a TBS-T solution (TBS, 0.05% (v/v) Tween 20) was added at 100 μ l/well, and the plate was left to stand at room temperature for 1 hour. The liquid in each well was removed, and each well was washed 5 times with the TBS-T solution. Thereafter, a fluorescent substrate solution (manufactured by Roche Co., Ltd., #11681982001) was added at 100 μ l/well, and a fluorescence reaction was allowed to proceed. After 10 minutes from the addition of the fluorescent substrate solution in the case of the plate having the mouse Siglec-15-Fc adsorbed thereto, and after 15 minutes in the case of the plate having the human Siglec-15-Fc adsorbed thereto, a fluorescence intensity was measured using Spectra Max M5 (manufactured by Molecular Devices, Inc.). As a result, it was confirmed that all of the examined six humanized antibodies of the rat anti-mouse Siglec-15 bind to the mouse Siglec-15 protein (Fig. 18) and the human Siglec-15 protein (Fig. 19) in an antibody concentration-dependent manner.

Example 26

[0315]

Effect of addition of chimeric antibody of rat anti-mouse

Siglec-15 monoclonal antibody #32A1 on osteoclast differentiation of mouse bone marrow nonadherent cells (stimulation with TNF α)

By using the rat anti-mouse Siglec-15 monoclonal antibody #32A1 prepared in Example 6 and the chimeric antibody of the rat anti-mouse Siglec-15 monoclonal antibody #32A1 prepared in Example 19, an effect on osteoclast differentiation of mouse bone marrow nonadherent cells by stimulation with TNF α was examined. Mouse bone marrow nonadherent cells prepared by the method of Example 8 were prepared at 1.5×10^5 cells/ml in α -MEM medium containing 10% fetal bovine serum (FBS), 10 ng/ml of M-CSF, and 2 ng/ml of TGF- β (manufactured by R&D Systems, Inc.), the resulting cell preparation was seeded in each well of a 96-well plate in an amount of 200 μ l and the cells were cultured for 2 days in a CO₂ incubator. The old culture solution in the 96-well plate was removed, and 100 μ l of MEM- α medium was added to each well, the 100 μ l of MEM- α medium containing 10% FBS to which recombinant human TNF α (manufactured by R&D Systems, Inc.) and M-CSF had been added to give final concentrations of 30 ng/ml and 10 ng/ml, respectively. To the cell culture solution, the rat anti-mouse Siglec-15 monoclonal antibody #32A1 prepared in Example 6 or the chimeric antibody of the rat anti-mouse Siglec-15 monoclonal antibody #32A1 prepared in Example 19 was added at a concentration of from 0.125 to 4 μ g/ml, and the cells

were cultured for an additional 3 days in a CO₂ incubator. At the same time, a well in which the cells were cultured by adding recombinant human OCIF/OPG prepared by the method described in the description of Patent Application Publication No. WO 96/26217 at a concentration of 100 ng/ml was also prepared. After completion of the culturing, TRAP staining was performed using a leukocyte acid phosphatase kit (manufactured by Sigma Co., Ltd.) according to the protocol accompanying the kit, and the formation of TRAP-positive multinucleated osteoclasts was observed. As a result, the formation of TRAP-positive giant multinucleated osteoclasts was inhibited by the addition of the anti-mouse Siglec-15 polyclonal antibody (Fig. 20). Although small mononuclear osteoclasts were formed even in the case where the rat anti-mouse Siglec-15 monoclonal antibody #32A1 or the chimeric antibody thereof was added, the formation of large multinucleated osteoclasts induced by TNF α was almost completely inhibited. On the other hand, even when a sufficient amount of OCIF/OPG, which is an RANKL blocker, was added, the formation of large multinucleated osteoclasts was inhibited only a little. Further, in the same manner, the activity of tartrate-resistant acid phosphatase (TRAP) of the formed osteoclasts was measured by the procedure described in Example 9. After stopping the enzymatic reaction, an absorbance of each well at 405 nm was measured, and the obtained measurement was used as an index of TRAP activity. The results

are shown in Fig. 21. A significant inhibition of TRAP activity was observed in the case of the #32A1 antibody and the chimeric antibody of #32A1 within the range of from 125 ng/ml to 4 µg/ml. From these results, it was shown that the rat anti-mouse Siglec-15 monoclonal antibody and the chimeric antibody thereof strongly inhibit the process of cell fusion in osteoclast differentiation and maturation induced by TNF α .

Example 27

[0316]

Evaluation of biological activity of rat anti-mouse Siglec-15 monoclonal antibodies #8A1 and #32A1 based on test for rat osteoclast formation

By using the rat anti-mouse Siglec-15 monoclonal antibodies #8A1 and #32A1 prepared in Example 6, an effect on osteoclast differentiation of rat bone marrow nonadherent cells was examined. Rat bone marrow nonadherent cells were prepared by modifying the method of Example 8. That is, the femur was excised from both legs of a female F344 rat at the age of 12 weeks and soft tissues were removed. Both ends of the femur were cut off, and MEM- α medium was injected using a syringe with a 23-gauge injection needle to push out bone marrow cells, which were collected in a centrifugal tube. Centrifugation was performed at room temperature for 5 minutes at 100 g, and the supernatant was removed. To the resulting

cell pellet, 1 ml of a hemolytic buffer (Red Blood Cell Lysing Buffer, manufactured by Sigma Co., Ltd.) was added to suspend it, and the resulting suspension was left at room temperature for 5 minutes. 20 ml of D-PBS was added thereto, the suspension was centrifuged at room temperature for 5 minutes at 100 g, and the supernatant was removed. To the resulting cell pellet, 10 ml of MEM- α medium (manufactured by Invitrogen, Inc.) containing 5 ng/ml of M-CSF (manufactured by R&D Systems, Inc.) and 10% fetal bovine serum (FBS) was added to suspend it. Then, the resulting suspension was passed through a cell strainer (40 μ m Nylon, manufactured by BD Falcon) to remove aggregates. The resulting cells were transferred to a 75 cm² T-flask (for the attachment of adherent cells) and cultured overnight in a CO₂ incubator. After the overnight culture, the cells which did not adhere to the T-flask were recovered and used as rat bone marrow nonadherent cells.

[0317]

The rat bone marrow nonadherent cells prepared by this method were cultured and a test for rat osteoclast formation was performed according to the method of Example 9. That is, the thus prepared rat bone marrow nonadherent cells were prepared at 1.5×10^5 cells/ml in α -MEM medium containing 10% FBS and 10 ng/ml of M-CSF (manufactured by R&D Systems, Inc.), and the resulting cell preparation was seeded in each well of a 96-well plate in an amount of 200 μ l and the cells were cultured

for 2 days in a CO₂ incubator. The old culture solution in the 96-well plate was removed, and 100 µl of MEM-α medium was added to each well, the 100 µl of MEM-α medium containing 10% FBS to which human RANKL (RANKL, manufactured by Peprotech, Inc.) and M-CSF had been added to give final concentrations of 20 ng/ml and 10 ng/ml, respectively. To the cell culture solution, the rat anti-mouse Siglec-15 monoclonal antibody #8A1 or #32A1 produced in Example 6 was added at a concentration of from 31 to 1000 ng/ml, and the cells were cultured for an additional 3 days in a CO₂ incubator. After completion of the culturing, the activity of tartrate-resistant acid phosphatase (TRAP) of the formed osteoclasts was measured by the method described in Example 9. After stopping the enzymatic reaction, an absorbance of each well at 405 nm was measured, and the obtained measurement was used as an index of TRAP activity. The results are shown in Fig. 22. In the case of the #8A1 antibody, a dose-dependent inhibition of TRAP activity was observed at a concentration of 63 ng/ml or higher, and in the case of the #32A1 antibody, a dose-dependent inhibition of TRAP activity was observed at a concentration of 31 ng/ml or higher. From these results, it was shown that the rat anti-mouse Siglec-15 monoclonal antibodies #8A1 and #32A1 strongly inhibit the rat osteoclast formation in the same manner as the mouse osteoclast formation, and the in vitro activity of inhibiting rat osteoclast formation of the #32A1 antibody is higher than that

of #8A1 antibody.

Example 28

[0318]

Designing of humanized antibody of rat anti-mouse Siglec-15 monoclonal antibody #32A1 (2)

a) Designing of humanized version of #32A1

a)-i) Designing of amino acid sequence of humanized #32A1

A humanized #32A1 antibody was constructed according to a method generally known as CDR grafting (Proc. Natl. Acad. Sci. USA 86, 10029-10033 (1989)). As for the definitions of CDR regions, the Kabat definitions (SEQUENCES OF PROTEINS OF IMMUNOLOGICAL INTEREST VOL. I, FIFTH EDITION (1991)) were used for all except for CDRH2. As for CDRH2, the sequence thereof was made shorter by five residues at the C terminus than the Kabat definition using a definition of its own. In the heavy chain sequence containing the thus defined CDRH2, the CDR sequence derived from a rat is made shorter and more of a human framework sequence is incorporated, and therefore, when it is administered to humans, it is much less likely to be recognized as a heterologous antigen. An acceptor antibody was selected based on the amino acid homology within the framework region. The sequence of the framework region of #32A1 was compared with the sequences of all human frameworks in the Kabat Database (Nuc. Acid Res. 29, 205-206 (2001)) involving antibody amino

acid sequences. As a result, for the L-chain, GF4/1.1'CL was selected as an acceptor based on a sequence homology of 71% in the framework region. As for the H-chain, M37G037'CL was selected as an acceptor based on a sequence homology of 73% in the framework region. In respect of the L-chain, the amino acid residues in the framework region of GF4/1.1'CL, and in respect of the H-chain, the amino acid residues in the framework region of M37G037'CL were aligned with the amino acid residues of #32A1, and the positions where different amino acids were used were identified. The positions of these residues were analyzed using the three-dimensional model of #32A1 constructed in a)-i) of Example 22. Then, donor residues to be grafted on the acceptor were selected according to the criteria provided by Queen et al. (Proc. Natl. Acad. Sci. USA 86, 10029-10033 (1989)). By transferring some selected donor residues to the acceptor antibody, humanized #32A1 sequences were constructed as described in the following Examples.

[0319]

a)-ii) Humanization of #32A1 heavy chain

a)-ii)-i) h#32A1-H1-1-type heavy chain:

A humanized 32A1 heavy chain designed by replacing amino acid numbers 23 (isoleucine), 24 (leucine), 26 (threonine), 32 (lysine), 43 (threonine), 61 (glutamic acid), 83 (glutamic acid), 85 (leucine), 86 (glutamic acid), 89 (valine), 95 (aspartic acid), 96 (serine), 97 (glutamic acid), 98 (serine),

100 (valine), 104 (valine), 105 (serine), 114 (isoleucine), 118 (threonine), 134 (valine), 135 (methionine), and 140 (leucine) of 32A1 represented by SEQ ID NO: 28 in the Sequence Listing with leucine, valine, serine, glutamine, alanine, glycine, alanine, valine, lysine, phenylalanine, asparagine, alanine, lysine, asparagine, leucine, methionine, asparagine, valine, alanine, threonine, leucine, and serine, respectively, was named "h#32A1-H1-1-type heavy chain".

[0320]

The amino acid sequence of the h#32A1-H1-1-type heavy chain is represented by SEQ ID NO: 99 in the Sequence Listing. The sequence comprising amino acid residues 1 to 19 of the amino acid sequence of SEQ ID NO: 99, the sequence comprising amino acid residues 20 to 140 thereof, and the sequence comprising amino acid residues 141 to 466 thereof correspond to the signal sequence, the heavy chain variable region, and the heavy chain constant region, respectively. A nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 99 is represented by SEQ ID NO: 98 in the Sequence Listing. The sequence comprising nucleotides 1 to 57 of the nucleotide sequence of SEQ ID NO: 98, the sequence comprising nucleotides 58 to 420 thereof, and the sequence comprising nucleotides 421 to 1398 thereof encode the signal sequence, the heavy chain variable region sequence, and the heavy chain constant region sequence, respectively. The nucleotide sequence of SEQ ID NO: 98 and

the amino acid sequence of SEQ ID NO: 99 are also shown in Fig. 54.

[0321]

a)-iii) Humanization of #32A1 light chain

a)-iii)-i) h#32A1-L2-15-type light chain:

A humanized 32A1 light chain designed by replacing amino acid numbers 21 (aspartic acid), 23 (valine), 24 (leucine), between 29 and 30 (i.e. inserting a residue missing from the rat framework), 31 (alanine), 32 (valine), 34 (leucine), 36 (glutamine), 40 (isoleucine), 66 (glutamine), 99 (asparagine), 100 (proline), 101 (valine), 102 (glutamine), 103 (alanine), 104 (aspartic acid), 106 (isoleucine), 108 (threonine), 110 (phenylalanine), 122 (alanine), 123 (glycine), 127 (leucine), 129 (leucine), 130 (arginine), and 132 (alanine) of 32A1 represented by SEQ ID NO: 30 in the Sequence Listing with glutamic acid, leucine, methionine, threonine, serine, leucine, proline, glutamic acid, leucine, alanine, serine, serine, leucine, glutamic acid, proline, glutamic acid, phenylalanine, leucine, tyrosine, glycine, glutamine, valine, isoleucine, lysine, and threonine, respectively, was named "h#32A1-L2-15-type light chain".

[0322]

The amino acid sequence of the h#32A1-L2-15-type light chain is represented by SEQ ID NO: 103 in the Sequence Listing. The sequence comprising amino acid residues 1 to 20 of the amino

acid sequence of SEQ ID NO: 103, the sequence comprising amino acid residues 21 to 133 thereof, and the sequence comprising amino acid residues 134 to 238 thereof correspond to the signal sequence, the light chain variable region, and the light chain constant region, respectively. A nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 103 is represented by SEQ ID NO: 102 in the Sequence Listing. The sequence comprising nucleotides 1 to 60 of the nucleotide sequence of SEQ ID NO: 102, the sequence comprising nucleotides 61 to 399 thereof, and the sequence comprising nucleotides 400 to 714 thereof encode the signal sequence, the light chain variable region sequence, and the light chain constant region sequence, respectively. The nucleotide sequence of SEQ ID NO: 102 and the amino acid sequence of SEQ ID NO: 103 are also shown in Fig. 56.

[0323]

a)-iii)-ii) h#32A1-L2-16-type light chain:

A humanized 32A1 light chain designed by replacing amino acid numbers 21 (aspartic acid), 23 (valine), 24 (leucine), between 29 and 30 (i.e. inserting a residue missing from the rat framework), 31 (alanine), 32 (valine), 34 (leucine), 36 (glutamine), 40 (isoleucine), 66 (glutamine), 99 (asparagine), 100 (proline), 101 (valine), 102 (glutamine), 103 (alanine), 104 (aspartic acid), 106 (isoleucine), 108 (threonine), 123 (glycine), 127 (leucine), 129 (leucine), 130 (arginine), and

132 (alanine) of 32A1 represented by SEQ ID NO: 30 in the Sequence Listing with glutamic acid, leucine, methionine, threonine, serine, leucine, proline, glutamic acid, leucine, alanine, serine, serine, leucine, glutamic acid, proline, glutamic acid, phenylalanine, leucine, glutamine, valine, isoleucine, lysine, and threonine, respectively, was named "h#32A1-L2-16-type light chain".

[0324]

The amino acid sequence of the h#32A1-L2-16-type light chain is represented by SEQ ID NO: 105 in the Sequence Listing. The sequence comprising amino acid residues 1 to 20 of the amino acid sequence of SEQ ID NO: 105, the sequence comprising amino acid residues 21 to 133 thereof, and the sequence comprising amino acid residues 134 to 238 thereof correspond to the signal sequence, the light chain variable region, and the light chain constant region, respectively. A nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 105 is represented by SEQ ID NO: 104 in the Sequence Listing. The sequence comprising nucleotides 1 to 60 of the nucleotide sequence of SEQ ID NO: 104, the sequence comprising nucleotides 61 to 399 thereof, and the sequence comprising nucleotides 400 to 714 thereof encode the signal sequence, the light chain variable region sequence, and the light chain constant region sequence, respectively. The nucleotide sequence of SEQ ID NO: 104 and the amino acid sequence of SEQ ID NO: 105 are also shown

in Fig. 57.

[0325]

b) Production of gene of humanized antibody of rat anti-mouse Siglec-15 monoclonal antibody #32A1

b)-i) Construction of universal human heavy chain expression vector pEG2

A DNA fragment containing a DNA sequence encoding amino acids of the signal sequence and the constant region of human IgG2 represented by SEQ ID NO: 106 was synthesized (Medical & Biological Laboratories Co., Ltd., Artificial Gene Synthesis Service), and digested with the restriction enzymes NheI and PmeI, whereby a DNA fragment of about 1100 bp was obtained. This DNA fragment was ligated to a DNA fragment of about 6200 bp obtained by digesting pEF1/FCCU-1 with NheI and PmeI and removing a DNA fragment of about 1100 bp, whereby a universal humanized antibody (hIgG2 type) heavy chain expression vector pEG2 was constructed.

[0326]

b)-ii) Construction of h#32A1-H1-1 heavy chain expression vector

A DNA fragment obtained by synthesizing a DNA containing a gene encoding the h#32A1-H1-1 heavy chain variable region fused to a secretory signal represented by amino acid numbers 1 to 140 of SEQ ID NO: 99 in the Sequence Listing (Invitrogen), and cleaving the DNA with the restriction enzyme BlnI was

inserted into the universal humanized antibody (hIgG2 type) heavy chain expression vector (pEG2) at the site cleaved with the restriction enzyme BlnI, whereby a h#32A1-H1-1 heavy chain expression vector was constructed. The thus obtained expression vector was named "pEG2/h#32A1-H1-1".

[0327]

b)-iii) Construction of h#32A1-H5 heavy chain expression vector

A humanized 32A1 heavy chain in which the signal sequence and the constant region of h#32A1-T5H-type heavy chain designed in b)-iv) of Example 22 were changed to those of IgG2 type was named "h#32A1-H5-type heavy chain".

[0328]

The amino acid sequence of the h#32A1-H5-type heavy chain is represented by SEQ ID NO: 101 in the Sequence Listing. The sequence comprising amino acid residues 1 to 19 of the amino acid sequence of SEQ ID NO: 101, the sequence comprising amino acid residues 20 to 140 thereof, and the sequence comprising amino acid residues 141 to 466 thereof correspond to the signal sequence, the heavy chain variable region, and the heavy chain constant region, respectively. A nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 101 is represented by SEQ ID NO: 100 in the Sequence Listing. The sequence comprising nucleotides 1 to 57 of the nucleotide sequence of SEQ ID NO: 100, the sequence comprising nucleotides

58 to 420 thereof, and the sequence comprising nucleotides 421 to 1398 thereof encode the signal sequence, the heavy chain variable region sequence, and the heavy chain constant region sequence, respectively. The nucleotide sequence of SEQ ID NO: 100 and the amino acid sequence of SEQ ID NO: 101 are also shown in Fig. 55.

[0329]

A DNA fragment obtained by cleaving the pEF1/FCCU/h#32A1-T5H produced in Example 23 with the restriction enzyme BspI was inserted into the universal humanized antibody (hIgG2 type) heavy chain expression vector (pEG2) at the site cleaved with the restriction enzyme BspI, whereby a h#32A1-H5 heavy chain expression vector was constructed. The thus obtained expression vector was named "pEG2/h#32A1-H5".

[0330]

b)-iv) Construction of h#32A1-L2-15 and h#32A1-L2-16-type light chain expression vectors

DNAs each containing a gene encoding a h#32A1-L2-15 or h#32A1-L2-16-type light chain variable region fused to a secretory signal represented by amino acid numbers 1 to 133 of SEQ ID NO: 103 in the Sequence Listing or amino acid numbers 1 to 133 of SEQ ID NO: 105 were synthesized (Invitrogen), and h#32A1-L2-15 and h#32A1-L2-16-type light chain expression vectors were constructed in the same manner as in Example 23.

The thus obtained expression vectors were named "pEF6KCL/h#32A1-L2-15" and "pEF6KCL/h#32A1-L2-16", respectively.

[0331]

c) Preparation of humanized antibody of rat anti-mouse Siglec-15 monoclonal antibody #32A1

c)-i) Production of humanized antibody

1.2×10^9 cells of FreeStyle 293F cells (Invitrogen) in logarithmic growth phase were seeded in 1.2 L of fresh FreeStyle 293 Expression Medium (Invitrogen) and subjected to shaking culture at 37°C in an 8% CO₂ incubator at 90 rpm for 1 hour. 3.6 mg of polyethyleneimine (Polyscience, #24765) was dissolved in 20 ml of Opti-Pro SFM medium (Invitrogen). Subsequently, an H-chain expression plasmid (0.4 mg) and an L-chain expression plasmid (0.8 mg) prepared using PureLink HiPure Plasmid Kit (Invitrogen, Inc.) were suspended in 20 ml of Opti-Pro SFM medium. Then, 20 ml of the resulting expression plasmids/Opti-Pro SFM mixed liquid was added to 20 ml of the polyethyleneimine/Opti-Pro SFM mixed liquid, and the resulting mixture was gently stirred and then left for 5 minutes. Thereafter, the mixture was added to the FreeStyle 293F cells, and shaking culture was performed for 7 days at 37°C in an 8% CO₂ incubator at 90 rpm. The resulting culture supernatant was filtered through a Disposable Capsule Filter (Advantec #CCS-045-E1H).

[0332]

A humanized antibody of #32A1 obtained by a combination of pEF6KCL/h#32A1-T5L and pEG2/h#32A1-H5 was named "h#32A1-H5/L5"; a humanized antibody of #32A1 obtained by a combination of pEF6KCL/h#32A1-T5L and pEG2/h#32A1-H1-1 was named "h#32A1-H1-1/L5"; a humanized antibody of #32A1 obtained by a combination of pEF6KCL/h#32A1-L2-15 and pEG2/h#32A1-H1-1 was named "h#32A1-H1-1/L2-15"; and a humanized antibody of #32A1 obtained by a combination of pEF6KCL/h#32A1-L2-16 and pEG2/h#32A1-H1-1 was named "h#32A1-H1-1/L2-16".

[0333]

c)-ii) Purification of humanized antibody

The culture supernatant obtained in the above c)-i) was purified by a two-step process including rProtein A affinity chromatography (at 4 to 6°C) and ceramic hydroxyapatite (at room temperature). A buffer replacement step after the purification by rProtein A affinity chromatography and after the purification by ceramic hydroxyapatite was performed at room temperature. First, 1100 to 1200 ml of the culture supernatant was applied to MabSelect SuRe (manufactured by GE Healthcare Bioscience Co., Ltd., 2 x 1 ml HiTrap columns in series) equilibrated with PBS. After all culture solution was poured into the column, the column was washed with 15 to 30 ml of PBS. Subsequently, elution was performed with 2 M arginine hydrochloride solution (pH 4.0), and a fraction

containing the antibody was collected. The fraction was applied to a desalting column (manufactured by GE Healthcare Bioscience Co., Ltd., 2 x 5 ml HiTrap desalting columns in series) and the liquid was replaced with a buffer containing 5 mM sodium phosphate, 50 mM MES, and 20 mM NaCl at pH 6.5. Further, the antibody solution subjected to the replacement with the buffer was applied to a ceramic hydroxyapatite column (Japan Bio-Rad Laboratories, Inc., Bio-Scale CHT2-1 hydroxyapatite column (2 ml volume)) equilibrated with a buffer containing 5 mM NaPi, 50 mM MES, and 20 mM NaCl at pH 6.5. Then, linear concentration gradient elution with sodium chloride was performed, and a fraction containing the antibody was collected. The fraction was applied to a desalting column (manufactured by GE Healthcare Bioscience Co., Ltd., 2 x 5 ml HiTrap desalting columns in series) and the liquid was replaced with CBS (10 mM citrate buffer containing 140 mM sodium chloride, pH 6.0). Finally, the resulting solution was concentrated using Centrifugal UF Filter Device VIVASPIN 20 (fractional molecular weight: 30 K, Sartorius Co., Ltd., at 4°C), the concentration of IgG was adjusted to 1.0 mg/ml or more, and the thus obtained solution was used as a purified sample. The volumes of the respective purified samples were as follows: h#32A1-H1-1/L5: 2.2 ml, h#32A1-H5/L5: 1.8 ml, h#32A1-H1-1/L2-16: 6.0 ml, and h#32A1-H1-1/L2-15: 2.2 ml.

Example 29

[0334]

Evaluation of biological activity of humanized antibody of rat anti-mouse Siglec-15 monoclonal antibody #32A1 based on test for mouse osteoclast formation

An inhibitory effect on mouse osteoclast formation exhibited by the humanized antibodies obtained in Examples 24 and 28 was evaluated by partially modifying the method described in Example 9. Mouse bone marrow nonadherent cells prepared by the method of Example 8 were prepared at 1.5×10^5 cells/ml in α -MEM medium containing 10% FBS and 10 ng/ml of M-CSF (manufactured by R&D Systems, Inc.), the resulting cell preparation was seeded in each well of a 96-well plate in an amount of 200 μ l and the cells were cultured for 2 days in a CO₂ incubator. The old culture solution in the 96-well plate was removed, and 100 μ l of MEM- α medium was added to each well, the 100 μ l of MEM- α medium containing 10% FBS to which human RANKL (RANKL, manufactured by Peprotech, Inc.) and M-CSF had been added to give final concentrations of 20 ng/ml and 10 ng/ml, respectively. To the cell culture solution, the rat anti-mouse Siglec-15 monoclonal antibody (#32A1 antibody) prepared in Example 6 or each of the 6 types of humanized #32A1 antibodies (h#32A1-T1, h#32A1-T2, h#32A1-T3, h#32A1-T4, h#32A1-T5, and h#32A1-T6) prepared in Example 24 was added at a concentration of from 3 to 100 ng/ml, and the cells were

cultured for an additional 3 days in a CO₂ incubator. After completion of the culturing, the activity of tartrate-resistant acid phosphatase (TRAP) of the formed osteoclasts was measured by the following procedure. The culture solution in each well of the 96-well plate was removed by suction, and 50 µl of 50 mM sodium citrate buffer (pH 6.1) containing 1% Triton X-100 was added to each well. Then, the plate was shaken for 5 minutes on a plate shaker to lyse the cells. To each well, 50 µl of a substrate solution (50 mM sodium citrate buffer (pH 6.1) containing 5 mg/ml p-nitrophenyl phosphate and 0.46% sodium tartrate) was added, and the plate was incubated at room temperature for 10 minutes. After the incubation, 50 µl of a 1 N sodium hydroxide solution was added to each well of the 96-well plate to stop the enzymatic reaction. After stopping the enzymatic reaction, an absorbance of each well at 405 nm was measured, and the obtained measurement was used as an index of TRAP activity. The results are shown in Figs. 44 and 45. Further, for the rat anti-mouse Siglec-15 monoclonal antibody (#32A1 antibody) prepared in Example 6, the human chimeric antibody of the #32A1 antibody prepared in Example 19, and 4 types of the humanized #32A1 antibodies (h#32A1-H1-1/L5, h#32A1-H5/L5, h#32A1-H1-1/L2-16, and h#32A1-H1-1/L2-15) prepared in Example 28, the biological activity was evaluated by the same method as in this test, and the results are shown in Figs. 46 and 47. In all cases of the

10 types of humanized #32A1 antibodies (h#32A1-T1, h#32A1-T2, h#32A1-T3, h#32A1-T4, h#32A1-T5, h#32A1-T6, h#32A1-H1-1/L5, h#32A1-H5/L5, h#32A1-H1-1/L2-16, and h#32A1-H1-1/L2-15) for which the activity was evaluated, a strong activity of inhibiting osteoclast formation substantially comparable to that of the rat anti-mouse Siglec-15 monoclonal antibody (#32A1 antibody) or the human chimeric antibody of the #32A1 antibody was observed.

Example 30

[0335]

Effect of addition of humanized antibody of rat anti-mouse Siglec-15 monoclonal antibody #32A1 on bone resorption activity of normal human osteoclast precursor cells (Evaluation using collagen-coated plate)

Normal human osteoclast precursor cells (Normal Human Natural Osteoclast Precursor Cells, purchased from Sanko Junyaku Co., Ltd., Cat. No. 2T-110) were seeded in a 96-well OsteoLyse cell culture plate (purchased from Sanko Junyaku Co., Ltd., Cat. No. PA-1500) at 1×10^4 cells/well according to the protocol accompanying the cells. As the medium, a minimal essential medium for osteoclast precursor cells (OPBM, purchased from Sanko Junyaku Co., Ltd., Cat. No. PT-8201) supplemented with an OPGM supplement set (purchased from Sanko Junyaku Co., Ltd., Cat. No. PT-9501) containing fetal bovine

serum (final concentration: 10%), human RANKL (final concentration: 63.8 ng/ml), human M-CSF (final concentration: 33 ng/ml), and the like was used. To the resulting culture supernatant, each of the rat anti-mouse Siglec-15 monoclonal antibody (#32A1 antibody) prepared in Example 6, the human chimeric antibody of the #32A1 antibody prepared in Example 19, and the 10 types of humanized #32A1 antibodies (h#32A1-T1, h#32A1-T2, h#32A1-T3, h#32A1-T4, h#32A1-T5, h#32A1-T6, h#32A1-H1-1/L5, h#32A1-H5/L5, h#32A1-H1-1/L2-16, and h#32A1-H1-1/L2-15) prepared in Examples 24 and 28 was added at a final concentration of 4, 20, 100, or 500 ng/ml, and the cells were cultured for 5 days in a CO₂ incubator. A 10 μ l aliquot of the culture supernatant was collected, 200 μ l of Fluorophore Releasing Reagent included in the OsteoLyse Assay Kit was added thereto, and by using a fluorescence plate reader (ARVO MX, manufactured by Perkin Elmer Inc.), time-resolved fluorometry (time-resolved fluorescence fluorometer) (Excitation: 340 nm, Emission: 615 nm) suitable for fluorescence measurement using europium was performed, whereby the amount of free fluorescent collagen fragments released in the culture supernatant was determined (Figs. 48 and 49). As a result, the amount of fluorescent collagen fragments increased by the addition of RANKL was reduced by the addition of the rat #32A1 antibody or the human chimeric #32A1 antibody in a concentration-dependent manner. In the

same manner, also by all of the examined 10 types of humanized #32A1 antibodies, a concentration-dependent inhibition was observed. From this result, it was revealed that the bone resorption activity of human osteoclasts is inhibited by the humanized #32A1 antibodies specifically binding to the Siglec-15 protein.

Example 31

[0336]

Biological evaluation of humanized antibody of rat anti-mouse Siglec-15 monoclonal antibody #32A1 using ovariectomized rats

An inhibitory effect on a decrease in bone mineral density in ovariectomized rats exhibited by the humanized antibodies obtained in Examples 24 and 28 can be evaluated by the method described in Example 15.

Example 32

[0337]

Evaluation of biological activity of humanized antibody of rat anti-mouse Siglec-15 monoclonal antibody #32A1 based on test for mouse osteoclast formation by stimulation with TNF α

An inhibitory effect on mouse osteoclast formation by stimulation with TNF α exhibited by the humanized antibodies obtained in Examples 24 and 28 can be evaluated by the method

described in Example 26.

Example 33

[0338]

Determination of thermal stability of humanized antibody using differential scanning calorimetry (DSC)

For h#32A1-H5/L5, h#32A1-H1-1/L5, h#32A1-H1-1/L2-15, and h#32A1-H1-1/L2-16, thermal stability was determined. Each of these samples was prepared at a concentration of 0.5 mg/ml (in a CBS solution), and a 400 μ l aliquot thereof was used as a sample solution for the DSC measurement. The conditions for the DSC measurement were set as follows. That is, the initial temperature was set to 20°C, the final temperature was set to 100°C, the temperature increase rate was set to 60°C/hour, and the filter time was set to 10 seconds. As a reference solution, CBS was used. As an instrument for the DSC measurement, VP-Capillary DSC platform manufactured by MicroCal Inc. USA was used. The baseline (a scanning curve obtained by filling the reference solution also in a sample cell) was subtracted from a scanning curve obtained for each sample solution, whereby baseline correction was performed. Fig. 50 shows a thermogram for h#32A1-H5/L5, Fig. 51 shows a thermogram for h#32A1-H1-1/L5, Fig. 52 shows a thermogram for h#32A1-H1-1/L2-15, and Fig. 53 shows a thermogram for h#32A1-H1-1/L2-16. When a peak top value in each thermogram

was taken as a thermal denaturation midpoint temperature (T_m) in the Fab region, the T_m value of h#32A1-H5/L5 was 81.2°C, the T_m value of h#32A1-H1-1/L5 was 84.1°C, the T_m value of h#32A1-H1-1/L2-15 was 80.0°C,, and the T_m value of h#32A1-H1-1/L2-16 (IgG2) was 77.9°C.

Industrial Applicability

[0339]

The chimeric or humanized anti-Siglec-15 antibody of the invention has an ability to inhibit osteoclast differentiation or bone resorption activity, and a pharmaceutical composition containing the anti-Siglec-15 antibody can be a therapeutic or preventive agent for a disease of abnormal bone metabolism.

Accession Number

[0340]

FERM BP-10999

SEQUENCE LISTING

<110> DAIICHI SANKYO COMPANY, LIMITED

<120> Anti-Siglec-15 antibodies

<130> SG2491A

<150> JP 2009-94613

<151> 2009-04-09

<160> 106

<170> PatentIn version 3.4

<210> 1

<211> 987

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (1)..(987)

<223> Inventor: Hiruma, Yoshiharu; Tsuda, Eisuke

<223> Inventor: Takizawa, Takeshi; Nakayama, Makiko

<400> 1

atg gaa aag tcc atc tgg ctg ctg gcc tgc ttg gcg tgg gtt ctc ccg	48
Met Glu Lys Ser Ile Trp Leu Leu Ala Cys Leu Ala Trp Val Leu Pro	
1 5 10 15	
aca ggc tca ttt gtg aga act aaa ata gat act acg gag aac ttg ctc	96
Thr Gly Ser Phe Val Arg Thr Lys Ile Asp Thr Thr Glu Asn Leu Leu	
20 25 30	
aac aca gag gtg cac agc tcg cca gcg cag cgc tgg tcc atg cag gtg	144
Asn Thr Glu Val His Ser Ser Pro Ala Gln Arg Trp Ser Met Gln Val	
35 40 45	
cca ccc gag gtg agc gcg gag gca ggc gac gcg gca gtg ctg ccc tgc	192
Pro Pro Glu Val Ser Ala Glu Ala Gly Asp Ala Val Leu Pro Cys	
50 55 60	
acc ttc acg cac ccg cac cgc cac tac gac ggg ccg ctg acg gcc atc	240
Thr Phe Thr His Pro His Arg His Tyr Asp Gly Pro Leu Thr Ala Ile	
65 70 75 80	
tgg cgc gcg ggc gag ccc tat gcg ggc ccg cag gtg ttc cgc tgc gct	288
Trp Arg Ala Gly Glu Pro Tyr Ala Gly Pro Gln Val Phe Arg Cys Ala	
85 90 95	
gcg gcg cgg ggc agc gag ctg tgc cag acg gcg ctg agc ctg cac ggc	336
Ala Ala Arg Gly Ser Glu Leu Cys Gln Thr Ala Leu Ser Leu His Gly	
100 105 110	
cgc ttc cgg ctg ctg ggc aac ccg cgc cgc aac gac ctc tcg ctg cgc	384
Arg Phe Arg Leu Leu Gly Asn Pro Arg Arg Asn Asp Leu Ser Leu Arg	
115 120 125	
gtc gag cgc ctc gcc ctg gct gac gac cgc cgc tac ttc tgc cgc gtc	432
Val Glu Arg Leu Ala Leu Ala Asp Asp Arg Arg Tyr Phe Cys Arg Val	
130 135 140	
gag ttc gcc ggc gac gtc cat gac cgc tac gag agc cgc cac ggc gtc	480
Glu Phe Ala Gly Asp Val His Asp Arg Tyr Glu Ser Arg His Gly Val	
145 150 155 160	

cgg ctg cac gtg aca gcc gcg ccg cgg atc gtc aac atc tcg gtg ctg 528
 Arg Leu His Val Thr Ala Ala Pro Arg Ile Val Asn Ile Ser Val Leu
 165 170 175
 ccc agt ccg gct cac gcc ttc cgc gcg ctc tgc act gcc gaa ggg gag 576
 Pro Ser Pro Ala His Ala Phe Arg Ala Leu Cys Thr Ala Glu Gly Glu
 180 185 190
 ccg ccg ccc gcc ctc gcc tgg tcc ggc ccg gcc ctg ggc aac agc ttg 624
 Pro Pro Pro Ala Leu Ala Trp Ser Gly Pro Ala Leu Gly Asn Ser Leu
 195 200 205
 gca gcc gtg cgg agc ccg cgt gag ggt cac ggc cac cta gtg acc gcc 672
 Ala Ala Val Arg Ser Pro Arg Glu Gly His Gly His Leu Val Thr Ala
 210 215 220
 gaa ctg ccc gca ctg acc cat gac ggc cgc tac acg tgt acg gcc gcc 720
 Glu Leu Pro Ala Leu Thr His Asp Gly Arg Tyr Thr Cys Thr Ala Ala
 225 230 235 240
 aac agc ctg ggc cgc tcc gag gcc agc gtc tac ctg ttc cgc ttc cat 768
 Asn Ser Leu Gly Arg Ser Glu Ala Ser Val Tyr Leu Phe Arg Phe His
 245 250 255
 ggc gcc agc ggg gcc tcg acg gtc gcc ctc ctg ctc ggc gct ctc gcc 816
 Gly Ala Ser Gly Ala Ser Thr Val Ala Leu Leu Leu Gly Ala Leu Gly
 260 265 270
 ttc aag gcg ctg ctg ctg ctc ggg gtc ctg gcc gcc cgc gct gcc cgc 864
 Phe Lys Ala Leu Leu Leu Leu Gly Val Leu Ala Ala Arg Ala Ala Arg
 275 280 285
 cgc cgc cca gag cat ctg gac acc ccg gac acc cca cca cgg tcc cag 912
 Arg Arg Pro Glu His Leu Asp Thr Pro Asp Thr Pro Pro Arg Ser Gln
 290 295 300
 gcc cag gag tcc aat tat gaa aat ttg agc cag atg aac ccc cgg agc 960
 Ala Gln Glu Ser Asn Tyr Glu Asn Leu Ser Gln Met Asn Pro Arg Ser
 305 310 315 320
 cca cca gcc acc atg tgc tca ccg tga 987
 Pro Pro Ala Thr Met Cys Ser Pro
 325

<210> 2
 <211> 328
 <212> PRT
 <213> Homo sapiens

<400> 2

Met Glu Lys Ser Ile Trp Leu Leu Ala Cys Leu Ala Trp Val Leu Pro
1 5 10 15

Thr Gly Ser Phe Val Arg Thr Lys Ile Asp Thr Thr Glu Asn Leu Leu
20 25 30

Asn Thr Glu Val His Ser Ser Pro Ala Gln Arg Trp Ser Met Gln Val
35 40 45

Pro Pro Glu Val Ser Ala Glu Ala Gly Asp Ala Ala Val Leu Pro Cys
50 55 60

Thr Phe Thr His Pro His Arg His Tyr Asp Gly Pro Leu Thr Ala Ile
 65 70 75 80
 Trp Arg Ala Gly Glu Pro Tyr Ala Gly Pro Gln Val Phe Arg Cys Ala
 85 90 95
 Ala Ala Arg Gly Ser Glu Leu Cys Gln Thr Ala Leu Ser Leu His Gly
 100 105 110
 Arg Phe Arg Leu Leu Gly Asn Pro Arg Arg Asn Asp Leu Ser Leu Arg
 115 120 125
 Val Glu Arg Leu Ala Leu Ala Asp Asp Arg Arg Tyr Phe Cys Arg Val
 130 135 140
 Glu Phe Ala Gly Asp Val His Asp Arg Tyr Glu Ser Arg His Gly Val
 145 150 155 160
 Arg Leu His Val Thr Ala Ala Pro Arg Ile Val Asn Ile Ser Val Leu
 165 170 175
 Pro Ser Pro Ala His Ala Phe Arg Ala Leu Cys Thr Ala Glu Gly Glu
 180 185 190
 Pro Pro Pro Ala Leu Ala Trp Ser Gly Pro Ala Leu Gly Asn Ser Leu
 195 200 205
 Ala Ala Val Arg Ser Pro Arg Glu Gly His Gly His Leu Val Thr Ala
 210 215 220
 Glu Leu Pro Ala Leu Thr His Asp Gly Arg Tyr Thr Cys Thr Ala Ala
 225 230 235 240
 Asn Ser Leu Gly Arg Ser Glu Ala Ser Val Tyr Leu Phe Arg Phe His
 245 250 255
 Gly Ala Ser Gly Ala Ser Thr Val Ala Leu Leu Leu Gly Ala Leu Gly
 260 265 270
 Phe Lys Ala Leu Leu Leu Leu Gly Val Leu Ala Ala Arg Ala Ala Arg
 275 280 285
 Arg Arg Pro Glu His Leu Asp Thr Pro Asp Thr Pro Pro Arg Ser Gln
 290 295 300
 Ala Gln Glu Ser Asn Tyr Glu Asn Leu Ser Gln Met Asn Pro Arg Ser
 305 310 315 320
 Pro Pro Ala Thr Met Cys Ser Pro
 325

<210> 3
 <211> 1026
 <212> DNA
 <213> Mus musculus

<220>
 <221> CDS
 <222> (1)..(1026)

<400> 3
 atg gag ggg tcc ctc caa ctc ctg gcc tgc ttg gcc tgt gtg ctc cag 48
 Met Glu Gly Ser Leu Gln Leu Leu Ala Cys Leu Ala Cys Val Leu Gln
 1 5 10 15
 atg gga tcc ctt gtg aaa act aga aga gac gct tcg ggg gat ctg ctc 96
 Met Gly Ser Leu Val Lys Thr Arg Arg Asp Ala Ser Gly Asp Leu Leu
 20 25 30
 aac aca gag gcg cac agt gcc ccg gcg cag cgc tgg tcc atg cag gtg 144
 Asn Thr Glu Ala His Ser Ala Pro Ala Gln Arg Trp Ser Met Gln Val
 35 40 45
 ccc gcg gag gtg aac gcg gag gct gcc gac gcg gcg gtg ctg ccc tgc 192
 Pro Ala Glu Val Asn Ala Glu Ala Gly Asp Ala Ala Val Leu Pro Cys
 50 55 60
 acc ttc acg cac ccg cac cgc cac tac gac ggg ccg ctg acg gcc atc 240
 Thr Phe Thr His Pro His Arg His Tyr Asp Gly Pro Leu Thr Ala Ile
 65 70 75 80
 tgg cgc tcg ggc gag ccg tac gcg gcc ccg cag gtg ttc cgc tgc acc 288
 Trp Arg Ser Gly Glu Pro Tyr Ala Gly Pro Gln Val Phe Arg Cys Thr
 85 90 95
 gcg gcg ccg ggc agc gag ctg tgc cag acg gcg ctg agc ctg cac gcc 336
 Ala Ala Pro Gly Ser Glu Leu Cys Gln Thr Ala Leu Ser Leu His Gly
 100 105 110
 cgc ttc cgc ctg ctg gcc aac ccg cgc cgc aac gac ctg tcc ctg cgc 384
 Arg Phe Arg Leu Leu Gly Asn Pro Arg Arg Asn Asp Leu Ser Leu Arg
 115 120 125
 gtc gag cgc ctc gcc ctg gcg gac agc gcc cgc tac ttc tgc cgc gtg 432
 Val Glu Arg Leu Ala Leu Ala Asp Ser Gly Arg Tyr Phe Cys Arg Val
 130 135 140
 gag ttc acc gcc gac gcc cac gat cgc tat gag agt cgc cat ggg gtc 480
 Glu Phe Thr Gly Asp Ala His Asp Arg Tyr Glu Ser Arg His Gly Val
 145 150 155 160
 cgt ctg cgc gtg act gct gcg ccg ccg atc gtc aac atc tcg gtg ctg 528
 Arg Leu Arg Val Thr Ala Ala Pro Arg Ile Val Asn Ile Ser Val Leu
 165 170 175
 ccg gcc ccc gcg cac gcc ttc cgc gcg ctc tgc acc gcc gag ggg gag 576
 Pro Gly Pro Ala His Ala Phe Arg Ala Leu Cys Thr Ala Glu Gly Glu
 180 185 190
 ccc ccg ccc gcc ctc gcc tgg tcg ggt ccc gcc cca gcc aac agc tcc 624
 Pro Pro Pro Ala Leu Ala Trp Ser Gly Pro Ala Pro Gly Asn Ser Ser
 195 200 205
 gct gcc ctg cag gcc cag ggt cac gcc tac cag gtg acc gcc gag ttg 672
 Ala Ala Leu Gln Gly Gln His Gly Tyr Gln Val Thr Ala Glu Leu
 210 215 220
 ccc gcg ctg acc cgc gac gcc cgc tac acg tgc acg gcg gcc aat agc 720

Pro Ala Leu Thr Arg Asp Gly Arg Tyr Thr Cys Thr Ala Ala Asn Ser
 225 230 235 240

ctg ggc cgc gcc gag gcc agc gtc tac ctg ttc cgc ttc cac ggc gcc 768
 Leu Gly Arg Ala Glu Ala Ser Val Tyr Leu Phe Arg Phe His Gly Ala
 245 250 255

ccc gga acc tcg acc cta gcg ctc ctg ctg ggc gcg ctg ggc ctc aag 816
 Pro Gly Thr Ser Thr Leu Ala Leu Leu Leu Gly Ala Leu Gly Leu Lys
 260 265 270

gcc ttg ctg ctg ctt ggc att ctg gga gcg cgt gcc acc cga cgc cga 864
 Ala Leu Leu Leu Leu Gly Ile Leu Gly Ala Arg Ala Thr Arg Arg Arg
 275 280 285

cta gat cac ctg gtc ccc cag gac acc cct cca cgg tct cag gct cag 912
 Leu Asp His Leu Val Pro Gln Asp Thr Pro Pro Arg Ser Gln Ala Gln
 290 295 300

gag tcc aat tat gaa aat ttg agc cag atg agt cct cca ggc cac cag 960
 Glu Ser Asn Tyr Glu Asn Leu Ser Gln Met Ser Pro Pro Gly His Gln
 305 310 315 320

ctg cca cgt gtt tgc tgt gag gaa ctc ctc agc cat cac cat cta gtc 1008
 Leu Pro Arg Val Cys Cys Glu Glu Leu Leu Ser His His His Leu Val
 325 330 335

att cac cat gag aaa taa 1026
 Ile His His Glu Lys
 340

<210> 4
 <211> 341
 <212> PRT
 <213> Mus musculus

<400> 4

Met Glu Gly Ser Leu Gln Leu Leu Ala Cys Leu Ala Cys Val Leu Gln
 1 5 10 15

Met Gly Ser Leu Val Lys Thr Arg Arg Asp Ala Ser Gly Asp Leu Leu
 20 25 30

Asn Thr Glu Ala His Ser Ala Pro Ala Gln Arg Trp Ser Met Gln Val
 35 40 45

Pro Ala Glu Val Asn Ala Glu Ala Gly Asp Ala Ala Val Leu Pro Cys
 50 55 60

Thr Phe Thr His Pro His Arg His Tyr Asp Gly Pro Leu Thr Ala Ile
 65 70 75 80

Trp Arg Ser Gly Glu Pro Tyr Ala Gly Pro Gln Val Phe Arg Cys Thr
 85 90 95

Ala Ala Pro Gly Ser Glu Leu Cys Gln Thr Ala Leu Ser Leu His Gly
 100 105 110

Arg Phe Arg Leu Leu Gly Asn Pro Arg Arg Asn Asp Leu Ser Leu Arg

115 120 125
 Val Glu Arg Leu Ala Leu Ala Asp Ser Gly Arg Tyr Phe Cys Arg Val
 130 135 140
 Glu Phe Thr Gly Asp Ala His Asp Arg Tyr Glu Ser Arg His Gly Val
 145 150 155 160
 Arg Leu Arg Val Thr Ala Ala Pro Arg Ile Val Asn Ile Ser Val Leu
 165 170 175
 Pro Gly Pro Ala His Ala Phe Arg Ala Leu Cys Thr Ala Glu Gly Glu
 180 185 190
 Pro Pro Pro Ala Leu Ala Trp Ser Gly Pro Ala Pro Gly Asn Ser Ser
 195 200 205
 Ala Ala Leu Gln Gly Gln Gly His Gly Tyr Gln Val Thr Ala Glu Leu
 210 215 220
 Pro Ala Leu Thr Arg Asp Gly Arg Tyr Thr Cys Thr Ala Ala Asn Ser
 225 230 235 240
 Leu Gly Arg Ala Glu Ala Ser Val Tyr Leu Phe Arg Phe His Gly Ala
 245 250 255
 Pro Gly Thr Ser Thr Leu Ala Leu Leu Leu Gly Ala Leu Gly Leu Lys
 260 265 270
 Ala Leu Leu Leu Leu Gly Ile Leu Gly Ala Arg Ala Thr Arg Arg Arg
 275 280 285
 Leu Asp His Leu Val Pro Gln Asp Thr Pro Pro Arg Ser Gln Ala Gln
 290 295 300
 Glu Ser Asn Tyr Glu Asn Leu Ser Gln Met Ser Pro Pro Gly His Gln
 305 310 315 320
 Leu Pro Arg Val Cys Cys Glu Glu Leu Leu Ser His His His Leu Val
 325 330 335
 Ile His His Glu Lys
 340

<210> 5
 <211> 774
 <212> DNA
 <213> Mus musculus

<220>
 <221> CDS
 <222> (1)..(774)

ccc gga
Pro Gly

<210> 6
 <211> 258
 <212> PRT
 <213> Mus musculus

<400> 6

Met Glu Gly Ser Leu Gln Leu Leu Ala Cys Leu Ala Cys Val Leu Gln
 1 5 10 15

Met Gly Ser Leu Val Lys Thr Arg Arg Asp Ala Ser Gly Asp Leu Leu
 20 25 30

Asn Thr Glu Ala His Ser Ala Pro Ala Gln Arg Trp Ser Met Gln Val
 35 40 45

Pro Ala Glu Val Asn Ala Glu Ala Gly Asp Ala Ala Val Leu Pro Cys
 50 55 60

Thr Phe Thr His Pro His Arg His Tyr Asp Gly Pro Leu Thr Ala Ile
 65 70 75 80

Trp Arg Ser Gly Glu Pro Tyr Ala Gly Pro Gln Val Phe Arg Cys Thr
 85 90 95

Ala Ala Pro Gly Ser Glu Leu Cys Gln Thr Ala Leu Ser Leu His Gly
 100 105 110

Arg Phe Arg Leu Leu Gly Asn Pro Arg Arg Asn Asp Leu Ser Leu Arg
 115 120 125

Val Glu Arg Leu Ala Leu Ala Asp Ser Gly Arg Tyr Phe Cys Arg Val
 130 135 140

Glu Phe Thr Gly Asp Ala His Asp Arg Tyr Glu Ser Arg His Gly Val
 145 150 155 160

Arg Leu Arg Val Thr Ala Ala Pro Arg Ile Val Asn Ile Ser Val Leu
 165 170 175

Pro Gly Pro Ala His Ala Phe Arg Ala Leu Cys Thr Ala Glu Gly Glu
 180 185 190

Pro Pro Pro Ala Leu Ala Trp Ser Gly Pro Ala Pro Gly Asn Ser Ser
 195 200 205

Ala Ala Leu Gln Gly Gln Gly His Gly Tyr Gln Val Thr Ala Glu Leu
 210 215 220

Pro Ala Leu Thr Arg Asp Gly Arg Tyr Thr Cys Thr Ala Ala Asn Ser
 225 230 235 240

Leu Gly Arg Ala Glu Ala Ser Val Tyr Leu Phe Arg Phe His Gly Ala
 245 250 255

Pro Gly

<210> 7
 <211> 55
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> PCR primer of soluble mouse Siglec-15 cDNA

<400> 7
 ggggacaagt ttgtacaaaa aagcaggctt caccatggag gggtcctcc aactc 55

<210> 8
 <211> 55
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> PCR primer of soluble mouse Siglec-15 cDNA

<400> 8
 ggggaccact ttgtacaaga aagctgggtc tccgggggcg ccgtggaagc ggaac 55

<210> 9
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Sequencing primer of soluble mouse Siglec-15 cDNA

<400> 9
 tgcgtgaagg tgcagggcag 20

<210> 10
 <211> 17
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Sequencing primer of soluble mouse Siglec-15 cDNA

<400> 10
 cctcgcttg tcgggtc 17

<210> 11
 <211> 891
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> His-tagged mouse Siglec-15 cDNA

<220>

<221>	CDS	
<222>	(1)..(891)	
<400>	11	
atg gag ggg tcc ctc caa ctc ctg gcc tgc ttg gcc tgt gtg ctc cag		48
Met Glu Gly Ser Leu Gln Leu Leu Ala Cys Leu Ala Cys Val Leu Gln		
1 5 10 15		
atg gga tcc ctt gtg aaa act aga aga gac gct tcg ggg gat ctg ctc		96
Met Gly Ser Leu Val Lys Thr Arg Arg Asp Ala Ser Gly Asp Leu Leu		
20 25 30		
aac aca gag gcg cac agt gcc ccg gcg cag cgc tgg tcc atg cag gtg		144
Asn Thr Glu Ala His Ser Ala Pro Ala Gln Arg Trp Ser Met Gln Val		
35 40 45		
ccc gcg gag gtg aac gcg gag gct gcc gac gcg gcg gtg ctg ccc tgc		192
Pro Ala Glu Val Asn Ala Glu Ala Gly Asp Ala Ala Val Leu Pro Cys		
50 55 60		
acc ttc acg cac ccg cac cgc cac tac gac ggg ccg ctg acg gcc atc		240
Thr Phe Thr His Pro His Arg His Tyr Asp Gly Pro Leu Thr Ala Ile		
65 70 75 80		
tgg cgc tcg gcc gag ccg tac gcg gcc ccg cag gtg ttc cgc tgc acc		288
Trp Arg Ser Gly Glu Pro Tyr Ala Gly Pro Gln Val Phe Arg Cys Thr		
85 90 95		
gcg gcg ccg gcc agc gag ctg tgc cag acg gcg ctg agc ctg cac gcc		336
Ala Ala Pro Gly Ser Glu Leu Cys Gln Thr Ala Leu Ser Leu His Gly		
100 105 110		
cgc ttc cgc ctg ctg gcc aac ccg cgc cgc aac gac ctg tcc ctg cgc		384
Arg Phe Arg Leu Leu Gly Asn Pro Arg Arg Asn Asp Leu Ser Leu Arg		
115 120 125		
gtc gag cgc ctc gcc ctg gcg gac agc gcc cgc tac ttc tgc cgc gtg		432
Val Glu Arg Leu Ala Leu Ala Asp Ser Gly Arg Tyr Phe Cys Arg Val		
130 135 140		
gag ttc acc gcc gac gcc cac gat cgc tat gag agt cgc cat ggg gtc		480
Glu Phe Thr Gly Asp Ala His Asp Arg Tyr Glu Ser Arg His Gly Val		
145 150 155 160		
cgt ctg cgc gtg act gct gcg ccg cgg atc gtc aac atc tcg gtg ctg		528
Arg Leu Arg Val Thr Ala Ala Pro Arg Ile Val Asn Ile Ser Val Leu		
165 170 175		
ccg gcc ccc gcg cac gcc ttc cgc gcg ctc tgc acc gcc gag ggg gag		576
Pro Gly Pro Ala His Ala Phe Arg Ala Leu Cys Thr Ala Glu Gly Glu		
180 185 190		
ccc ccg ccc gcc ctc gcc tgg tcg ggt ccc gcc cca gcc aac agc tcc		624
Pro Pro Pro Ala Leu Ala Trp Ser Gly Pro Ala Pro Gly Asn Ser Ser		
195 200 205		
gct gcc ctg cag gcc cag ggt cac gcc tac cag gtg acc gcc gag ttg		672
Ala Ala Leu Gln Gly Gln Gly His Gly Tyr Gln Val Thr Ala Glu Leu		
210 215 220		
ccc gcg ctg acc cgc gac gcc cgc tac acg tgc acg gcg gcc aat agc		720
Pro Ala Leu Thr Arg Asp Gly Arg Tyr Thr Cys Thr Ala Ala Asn Ser		
225 230 235 240		
ctg gcc cgc gcc gag gcc agc gtc tac ctg ttc cgc ttc cac gcc gcc		768
Leu Gly Arg Ala Glu Ala Ser Val Tyr Leu Phe Arg Phe His Gly Ala		
245 250 255		

ccc gga gac cca gct ttc ttg tac aaa gtg gtt gat atc gaa ggt cgt 816
 Pro Gly Asp Pro Ala Phe Leu Tyr Lys Val Val Asp Ile Glu Gly Arg
 260 265 270

ggg ggt aag cct atc cct aac cct ctc ctc ggt ctc gat tct acg cgt 864
 Gly Gly Lys Pro Ile Pro Asn Pro Leu Leu Gly Leu Asp Ser Thr Arg
 275 280 285

acc ggt cat cat cac cat cac cat tga 891
 Thr Gly His His His His His His
 290 295

<210> 12
 <211> 296
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic Construct

<400> 12

Met Glu Gly Ser Leu Gln Leu Leu Ala Cys Leu Ala Cys Val Leu Gln
 1 5 10 15

Met Gly Ser Leu Val Lys Thr Arg Arg Asp Ala Ser Gly Asp Leu Leu
 20 25 30

Asn Thr Glu Ala His Ser Ala Pro Ala Gln Arg Trp Ser Met Gln Val
 35 40 45

Pro Ala Glu Val Asn Ala Glu Ala Gly Asp Ala Ala Val Leu Pro Cys
 50 55 60

Thr Phe Thr His Pro His Arg His Tyr Asp Gly Pro Leu Thr Ala Ile
 65 70 75 80

Trp Arg Ser Gly Glu Pro Tyr Ala Gly Pro Gln Val Phe Arg Cys Thr
 85 90 95

Ala Ala Pro Gly Ser Glu Leu Cys Gln Thr Ala Leu Ser Leu His Gly
 100 105 110

Arg Phe Arg Leu Leu Gly Asn Pro Arg Arg Asn Asp Leu Ser Leu Arg
 115 120 125

Val Glu Arg Leu Ala Leu Ala Asp Ser Gly Arg Tyr Phe Cys Arg Val
 130 135 140

Glu Phe Thr Gly Asp Ala His Asp Arg Tyr Glu Ser Arg His Gly Val
 145 150 155 160

Arg Leu Arg Val Thr Ala Ala Pro Arg Ile Val Asn Ile Ser Val Leu
 165 170 175

Pro Gly Pro Ala His Ala Phe Arg Ala Leu Cys Thr Ala Glu Gly Glu

<210>	13
<211>	1512
<212>	DNA
<213>	Artificial Sequence

<220>
<223> Fc-fused mouse Siglec-15 cDNA

$\langle 220 \rangle$
 $\langle 221 \rangle$ CDS
 $\langle 222 \rangle$ (1).. (1512)

<400>	13																48
atg	gag	ggg	tcc	ctc	caa	ctc	ctg	gcc	tgc	ttg	gcc	tgt	gtg	ctc	cag		
Met	Glu	Gly	Ser	Leu	Gln	Leu	Leu	Ala	Cys	Leu	Ala	Cys	Val	Leu	Gln		
1				5					10					15			
atg	gga	tcc	ctt	gtg	aaa	act	aga	aga	gac	gct	tcg	ggg	gat	ctg	ctc		
Met	Gly	Ser	Leu	Val	Lys	Thr	Arg	Arg	Asp	Ala	Ser	Gly	Asp	Leu	Leu		
			20					25					30				
aac	aca	gag	gcg	cac	agt	gcc	ccg	gcg	cag	cgc	tgg	tcc	atg	cag	gtg		
Asn	Thr	Glu	Ala	His	Ser	Ala	Pro	Ala	Gln	Arg	Trp	Ser	Met	Gln	Val		
		35					40					45					
ccc	gcg	gag	gtg	aac	gcg	gag	gct	ggc	gac	gcg	gcg	gtg	ctg	ccc	tgc		
Pro	Ala	Glu	Val	Asn	Ala	Glu	Ala	Gly	Asp	Ala	Ala	Val	Leu	Pro	Cys		
	50					55					60						
acc	ttc	acg	cac	ccg	cac	cgc	cac	tac	gac	ggg	ccg	ctg	acg	gcc	atc		
Thr	Phe	Thr	His	Pro	His	Arg	His	Tyr	Asp	Gly	Pro	Leu	Thr	Ala	Ile		
65					70					75					80		
tgg	cgc	tcg	ggc	gag	ccg	tac	gcg	ggc	ccg	cag	gtg	ttc	cgc	tgc	acc		
Trp	Arg	Ser	Gly	Glu	Pro	Tyr	Ala	Gly	Pro	Gln	Val	Phe	Arg	Cys	Thr		
				85					90					95			

gcg gcg ccg ggc agc gag ctg tgc cag acg gcg ctg agc ctg cac ggc Ala Ala Pro Gly Ser Glu Leu Cys Gln Thr Ala Leu Ser Leu His Gly	336
100 105 110	
cgc ttc cgc ctg ctg ggc aac ccg cgc cgc aac gac ctg tcc ctg cgc Arg Phe Arg Leu Leu Gly Asn Pro Arg Arg Asn Asp Leu Ser Leu Arg	384
115 120 125	
gtc gag cgc ctc gcc ctg gcg gac agc ggc cgc tac ttc tgc cgc gtg Val Glu Arg Leu Ala Leu Ala Asp Ser Gly Arg Tyr Phe Cys Arg Val	432
130 135 140	
gag ttc acc ggc gac gcc cac gat cgc tat gag agt cgc cat ggg gtc Glu Phe Thr Gly Asp Ala His Asp Arg Tyr Glu Ser Arg His Gly Val	480
145 150 155 160	
cgt ctg cgc gtg act gct gcg ccg cgg atc gtc aac atc tcc gtg ctg Arg Leu Arg Val Thr Ala Ala Pro Arg Ile Val Asn Ile Ser Val Leu	528
165 170 175	
ccg ggc ccc gcg cac gcc ttc cgc gcg ctc tgc acc gcc gag ggg gag Pro Gly Pro Ala His Ala Phe Arg Ala Leu Cys Thr Ala Glu Gly Glu	576
180 185 190	
ccc ccg ccc gcc ctc gcc tgg tgc ggt ccc gcc cca ggc aac agc tcc Pro Pro Pro Ala Leu Ala Trp Ser Gly Pro Ala Pro Gly Asn Ser Ser	624
195 200 205	
gct gcc ctg cag ggc cag ggt cac ggc tac cag gtg acc gcc gag ttg Ala Ala Leu Gln Gly Gln Gly His Gly Tyr Gln Val Thr Ala Glu Leu	672
210 215 220	
ccc gcg ctg acc cgc gac ggc cgc tac acg tgc acc gcg gcc aat agc Pro Ala Leu Thr Arg Asp Gly Arg Tyr Thr Cys Thr Ala Ala Asn Ser	720
225 230 235 240	
ctg ggc cgc gcc gag gcc agc gtc tac ctg ttc cgc ttc cac ggc gcc Leu Gly Arg Ala Glu Ala Ser Val Tyr Leu Phe Arg Phe His Gly Ala	768
245 250 255	
ccc gga gac cca gct ttc ttg tac aaa gtg gtt gat atc cag gca gag Pro Gly Asp Pro Ala Phe Leu Tyr Lys Val Val Asp Ile Gln Ala Glu	816
260 265 270	
ccc aaa tct tgt gac aaa act cac aca tgc cca ccg tgc cca gca cct Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro	864
275 280 285	
gaa ctc ctg ggg gga ccg tca gtc ttc ctc ttc ccc cca aaa ccc aag Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys	912
290 295 300	
gac acc ctc atg atc tcc ccg acc cct gag gtc aca tgc gtg gtg gtg Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val	960
305 310 315 320	
gac gtg agc cac gaa gac cct gag gtc aag ttc aac tgg tac gtg gac Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp	1008
325 330 335	
ggc gtg gag gtg cat aat gcc aag aca aag ccg cgg gag gag cag tac Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr	1056
340 345 350	
aac agc acg tac cgt gtg gtc agc gtc ctc acc gtc ctg cac cag gac Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp	1104
355 360 365	

tgg ctg aat ggc aag gag tac aag tgc aag gtc tcc aac aaa gcc ctc 1152
 Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu
 370 375 380
 cca gcc ccc atc gag aaa acc atc tcc aaa gcc aaa ggg cag ccc cga 1200
 Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
 385 390 395 400
 gaa cca cag gtg tac acc ctg ccc cca tcc cgg gag gag atg acc aag 1248
 Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys
 405 410 415
 aac cag gtc agc ctg acc tgc ctg gtc aaa ggc ttc tat ccc agc gac 1296
 Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
 420 425 430
 atc gcc gtg gag tgg gag agc aat ggg cag ccg gag aac aac tac aag 1344
 Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys
 435 440 445
 acc acg cct ccc gtg ctg gac tcc gac ggc tcc ttc ttc ctc tat agc 1392
 Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
 450 455 460
 aag ctc acc gtg gac aag agc agg tgg cag cag ggg aac gtc ttc tca 1440
 Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser
 465 470 475 480
 tgc tcc gtg atg cat gag gct ctg cac aac cac tac acg cag aag agc 1488
 Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
 485 490 495
 ctc tcc ctg tct ccg ggt aaa taa 1512
 Leu Ser Leu Ser Pro Gly Lys
 500

<210> 14
 <211> 503
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic Construct

<400> 14

Met Glu Gly Ser Leu Gln Leu Leu Ala Cys Leu Ala Cys Val Leu Gln
1 5 10 15

Met Gly Ser Leu Val Lys Thr Arg Arg Asp Ala Ser Gly Asp Leu Leu
20 25 30

Asn Thr Glu Ala His Ser Ala Pro Ala Gln Arg Trp Ser Met Gln Val
35 40 45

Pro Ala Glu Val Asn Ala Glu Ala Gly Asp Ala Ala Val Leu Pro Cys
50 55 60

Thr Phe Thr His Pro His Arg His Tyr Asp Gly Pro Leu Thr Ala Ile
65 70 75 80

Trp Arg Ser Gly Glu Pro Tyr Ala Gly Pro Gln Val Phe Arg Cys Thr
 85 90 95
 Ala Ala Pro Gly Ser Glu Leu Cys Gln Thr Ala Leu Ser Leu His Gly
 100 105 110
 Arg Phe Arg Leu Leu Gly Asn Pro Arg Arg Asn Asp Leu Ser Leu Arg
 115 120 125
 Val Glu Arg Leu Ala Leu Ala Asp Ser Gly Arg Tyr Phe Cys Arg Val
 130 135 140
 Glu Phe Thr Gly Asp Ala His Asp Arg Tyr Glu Ser Arg His Gly Val
 145 150 155 160
 Arg Leu Arg Val Thr Ala Ala Pro Arg Ile Val Asn Ile Ser Val Leu
 165 170 175
 Pro Gly Pro Ala His Ala Phe Arg Ala Leu Cys Thr Ala Glu Gly Glu
 180 185 190
 Pro Pro Pro Ala Leu Ala Trp Ser Gly Pro Ala Pro Gly Asn Ser Ser
 195 200 205
 Ala Ala Leu Gln Gly Gln Gly His Gly Tyr Gln Val Thr Ala Glu Leu
 210 215 220
 Pro Ala Leu Thr Arg Asp Gly Arg Tyr Thr Cys Thr Ala Ala Asn Ser
 225 230 235 240
 Leu Gly Arg Ala Glu Ala Ser Val Tyr Leu Phe Arg Phe His Gly Ala
 245 250 255
 Pro Gly Asp Pro Ala Phe Leu Tyr Lys Val Val Asp Ile Gln Ala Glu
 260 265 270
 Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro
 275 280 285
 Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
 290 295 300
 Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
 305 310 315 320
 Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp
 325 330 335
 Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr
 340 345 350

Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp
355 360 365

Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu
370 375 380

Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
385 390 395 400

Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys
405 410 415

Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
420 425 430

Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys
435 440 445

Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
450 455 460

Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser
465 470 475 480

Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
485 490 495

Leu Ser Leu Ser Pro Gly Lys
500

<210> 15
<211> 780
<212> DNA
<213> Homo sapiens

<220>
<221> CDR
<222> (1)..(780)

<220>
<221> CDS
<222> (1)..(780)

<400> 15
atg gaa aag tcc atc tgg ctg ctg gcc tgc ttg gcg tgg gtt ctc ccg 48
Met Glu Lys Ser Ile Trp Leu Leu Ala Cys Leu Ala Trp Val Leu Pro
1 5 10 15
aca ggc tca ttt gtg aga act aaa ata gat act acg gag aac ttg ctc 96
Thr Gly Ser Phe Val Arg Thr Lys Ile Asp Thr Thr Glu Asn Leu Leu
20 25 30
aac aca gag gtg cac agc tcg cca gcg cag cgc tgg tcc atg cag gtg 144
Asn Thr Glu Val His Ser Ser Pro Ala Gln Arg Trp Ser Met Gln Val
35 40 45
cca ccc gag gtg agc gcg gag gca ggc gac gcg gca gtg ctg ccc tgc 192

Pro	Pro	Glu	Val	Ser	Ala	Glu	Ala	Gly	Asp	Ala	Ala	Val	Leu	Pro	Cys		
50						55				60							
acc	ttc	acg	cac	ccg	cac	cgc	cac	tac	gac	ggg	ccg	ctg	acg	gcc	atc	240	
Thr	Phe	Thr	His	Pro	His	Arg	His	Tyr	Asp	Gly	Pro	Leu	Thr	Ala	Ile		
65					70				75					80			
tgg	cgc	gcg	ggc	gag	ccc	tat	gcg	ggc	ccg	cag	gtg	ttc	cgc	tgc	gct	288	
Trp	Arg	Ala	Gly	Glu	Pro	Tyr	Ala	Gly	Pro	Gln	Val	Phe	Arg	Cys	Ala		
			85					90						95			
gcg	gcg	ccg	ggc	agc	gag	ctc	tgc	cag	acg	gcg	ctg	agc	ctg	cac	ggc	336	
Ala	Ala	Arg	Gly	Ser	Glu	Leu	Cys	Gln	Thr	Ala	Leu	Ser	Leu	His	Gly		
			100					105					110				
cgc	ttc	ccg	ctg	ctg	ggc	aac	ccg	cgc	cgc	aac	gac	ctc	tcg	ctg	cgc	384	
Arg	Phe	Arg	Leu	Leu	Gly	Asn	Pro	Arg	Arg	Asn	Asp	Leu	Ser	Leu	Arg		
		115					120					125					
gtc	gag	cgc	ctc	gcc	ctg	gct	gac	gac	cgc	cgc	tac	ttc	tgc	cgc	gtc	432	
Val	Glu	Arg	Leu	Ala	Leu	Ala	Asp	Asp	Arg	Arg	Tyr	Phe	Cys	Arg	Val		
	130					135					140						
gag	ttc	gcc	ggc	gac	gtc	cat	gac	cgc	tac	gag	agc	cgc	cac	ggc	gtc	480	
Glu	Phe	Ala	Gly	Asp	Val	His	Asp	Arg	Tyr	Glu	Ser	Arg	His	Gly	Val		
145					150					155					160		
cgg	ctg	cac	gtg	aca	gcc	gcg	ccg	cgg	atc	gtc	aac	atc	tcg	gtg	ctg	528	
Arg	Leu	His	Val	Thr	Ala	Ala	Pro	Arg	Ile	Val	Asn	Ile	Ser	Val	Leu		
				165					170					175			
ccc	agt	ccg	gct	cac	gcc	ttc	cgc	gcg	ctc	tgc	act	gcc	gaa	ggg	gag	576	
Pro	Ser	Pro	Ala	His	Ala	Phe	Arg	Ala	Leu	Cys	Thr	Ala	Glu	Gly	Glu		
			180					185					190				
ccg	ccg	ccc	gcc	ctc	gcc	tgg	tcc	ggc	ccg	gcc	ctg	ggc	aac	agc	ttg	624	
Pro	Pro	Pro	Ala	Leu	Ala	Trp	Ser	Gly	Pro	Ala	Leu	Gly	Asn	Ser	Leu		
		195					200					205					
gca	gcc	gtg	cgg	agc	ccg	cgt	gag	ggt	cac	ggc	cac	cta	gtg	acc	gcc	672	
Ala	Ala	Val	Arg	Ser	Pro	Arg	Glu	Gly	His	Gly	His	Leu	Val	Thr	Ala		
		210				215					220						
gaa	ctg	ccc	gca	ctg	acc	cat	gac	ggc	cgc	tac	acg	tgt	acg	gcc	gcc	720	
Glu	Leu	Pro	Ala	Leu	Thr	His	Asp	Gly	Arg	Tyr	Thr	Cys	Thr	Ala	Ala		
225					230					235				240			
aac	agc	ctg	ggc	cgc	tcc	gag	gcc	agc	gtc	tac	ctg	ttc	cgc	ttc	cat	768	
Asn	Ser	Leu	Gly	Arg	Ser	Glu	Ala	Ser	Val	Tyr	Leu	Phe	Arg	Phe	His		
				245					250					255			
ggc	gcc	agc	ggg													780	
Gly	Ala	Ser	Gly														
			260														

<210> 16
 <211> 260
 <212> PRT
 <213> Homo sapiens

<400> 16

Met Glu Lys Ser Ile Trp Leu Leu Ala Cys Leu Ala Trp Val Leu Pro
1 5 10 15

Thr Gly Ser Phe Val Arg Thr Lys Ile Asp Thr Thr Glu Asn Leu Leu

20 25 30
 Asn Thr Glu Val His Ser Ser Pro Ala Gln Arg Trp Ser Met Gln Val
 35 40 45
 Pro Pro Glu Val Ser Ala Glu Ala Gly Asp Ala Ala Val Leu Pro Cys
 50 55 60
 Thr Phe Thr His Pro His Arg His Tyr Asp Gly Pro Leu Thr Ala Ile
 65 70 75 80
 Trp Arg Ala Gly Glu Pro Tyr Ala Gly Pro Gln Val Phe Arg Cys Ala
 85 90 95
 Ala Ala Arg Gly Ser Glu Leu Cys Gln Thr Ala Leu Ser Leu His Gly
 100 105 110
 Arg Phe Arg Leu Leu Gly Asn Pro Arg Arg Asn Asp Leu Ser Leu Arg
 115 120 125
 Val Glu Arg Leu Ala Leu Ala Asp Asp Arg Arg Tyr Phe Cys Arg Val
 130 135 140
 Glu Phe Ala Gly Asp Val His Asp Arg Tyr Glu Ser Arg His Gly Val
 145 150 155 160
 Arg Leu His Val Thr Ala Ala Pro Arg Ile Val Asn Ile Ser Val Leu
 165 170 175
 Pro Ser Pro Ala His Ala Phe Arg Ala Leu Cys Thr Ala Glu Gly Glu
 180 185 190
 Pro Pro Pro Ala Leu Ala Trp Ser Gly Pro Ala Leu Gly Asn Ser Leu
 195 200 205
 Ala Ala Val Arg Ser Pro Arg Glu Gly His Gly His Leu Val Thr Ala
 210 215 220
 Glu Leu Pro Ala Leu Thr His Asp Gly Arg Tyr Thr Cys Thr Ala Ala
 225 230 235 240
 Asn Ser Leu Gly Arg Ser Glu Ala Ser Val Tyr Leu Phe Arg Phe His
 245 250 255
 Gly Ala Ser Gly
 260

<210> 17
 <211> 56
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> PCR primer of soluble human Siglec-15 cDNA
 <400> 17
 ggggacaagt ttgtacaaaa aagcaggctt caccatggaa aagtccatct ggctgc 56

<210> 18
 <211> 52
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> PCR primer of soluble human Siglec-15 cDNA
 <400> 18
 ggggaccact ttgtacaaga aagctgggtc cccgctggcg ccatggaagc gg 52

<210> 19
 <211> 897
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> His-tagged human Siglec-15 cDNA

<220>
 <221> CDS
 <222> (1)..(897)

<400> 19
 atg gaa aag tcc atc tgg ctg ctg gcc tgc ttg gcg tgg gtt ctc ccg 48
 Met Glu Lys Ser Ile Trp Leu Leu Ala Cys Leu Ala Trp Val Leu Pro
 1 5 10 15

aca ggc tca ttt gtg aga act aaa ata gat act acg gag aac ttg ctc 96
 Thr Gly Ser Phe Val Arg Thr Lys Ile Asp Thr Thr Glu Asn Leu Leu
 20 25 30

aac aca gag gtg cac agc tcg cca gcg cag cgc tgg tcc atg cag gtg 144
 Asn Thr Glu Val His Ser Ser Pro Ala Gln Arg Trp Ser Met Gln Val
 35 40 45

cca ccc gag gtg agc gcg gag gca ggc gac gcg gca gtg ctg ccc tgc 192
 Pro Pro Glu Val Ser Ala Glu Ala Gly Asp Ala Ala Val Leu Pro Cys
 50 55 60

acc ttc acg cac ccg cac cgc cac tac gac ggg ccg ctg acg gcc atc 240
 Thr Phe Thr His Pro His Arg His Tyr Asp Gly Pro Leu Thr Ala Ile
 65 70 75 80

tgg cgc gcg ggc gag ccc tat gcg ggc ccg cag gtg ttc cgc tgc gct 288
 Trp Arg Ala Gly Glu Pro Tyr Ala Gly Pro Gln Val Phe Arg Cys Ala
 85 90 95

gcg gcg ccg ggc agc gag ctc tgc cag acg gcg ctg agc ctg cac ggc 336
 Ala Ala Arg Gly Ser Glu Leu Cys Gln Thr Ala Leu Ser Leu His Gly
 100 105 110

cgc ttc ccg ctg ctg ggc aac ccg cgc cgc aac gac ctc tcg ctg cgc 384
 Arg Phe Arg Leu Leu Gly Asn Pro Arg Arg Asn Asp Leu Ser Leu Arg
 115 120 125

gtc gag cgc ctc gcc ctg gct gac gac cgc cgc tac ttc tgc cgc gtc 432
 Val Glu Arg Leu Ala Leu Ala Asp Asp Arg Arg Tyr Phe Cys Arg Val
 130 135 140

gag ttc gcc ggc gac gtc cat gac cgc tac gag agc cgc cac ggc gtc 480
 Glu Phe Ala Gly Asp Val His Asp Arg Tyr Glu Ser Arg His Gly Val
 145 150 155 160
 cgg ctg cac gtg aca gcc gcg ccg cgg atc gtc aac atc tcg gtg ctg 528
 Arg Leu His Val Thr Ala Ala Pro Arg Ile Val Asn Ile Ser Val Leu
 165 170 175
 ccc agt ccg gct cac gcc ttc cgc gcg ctc tgc act gcc gaa ggg gag 576
 Pro Ser Pro Ala His Ala Phe Arg Ala Leu Cys Thr Ala Glu Gly Glu
 180 185 190
 ccg ccg ccc gcc ctc gcc tgg tcc ggc ccg gcc ctg ggc aac agc ttg 624
 Pro Pro Pro Ala Leu Ala Trp Ser Gly Pro Ala Leu Gly Asn Ser Leu
 195 200 205
 gca gcc gtg cgg agc ccg cgt gag ggt cac ggc cac cta gtg acc gcc 672
 Ala Ala Val Arg Ser Pro Arg Glu Gly His Gly His Leu Val Thr Ala
 210 215 220
 gaa ctg ccc gca ctg acc cat gac ggc cgc tac acg tgt acg gcc gcc 720
 Glu Leu Pro Ala Leu Thr His Asp Gly Arg Tyr Thr Cys Thr Ala Ala
 225 230 235 240
 aac agc ctg ggc cgc tcc gag gcc agc gtc tac ctg ttc cgc ttc cat 768
 Asn Ser Leu Gly Arg Ser Glu Ala Ser Val Tyr Leu Phe Arg Phe His
 245 250 255
 ggc gcc agc ggg gac cca gct ttc ttg tac aaa gtg gtt gat atc gaa 816
 Gly Ala Ser Gly Asp Pro Ala Phe Leu Tyr Lys Val Val Asp Ile Glu
 260 265 270
 ggt cgt ggg ggt aag cct atc cct aac cct ctc ctc ggt ctc gat tct 864
 Gly Arg Gly Gly Lys Pro Ile Pro Asn Pro Leu Leu Gly Leu Asp Ser
 275 280 285
 acg cgt acc ggt cat cat cac cat cac cat tga 897
 Thr Arg Thr Gly His His His His His His
 290 295

<210> 20
 <211> 298
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic Construct

<400> 20

Met Glu Lys Ser Ile Trp Leu Leu Ala Cys Leu Ala Trp Val Leu Pro
1 5 10 15

Thr Gly Ser Phe Val Arg Thr Lys Ile Asp Thr Thr Glu Asn Leu Leu
20 25 30

Asn Thr Glu Val His Ser Ser Pro Ala Gln Arg Trp Ser Met Gln Val
35 40 45

Pro Pro Glu Val Ser Ala Glu Ala Gly Asp Ala Ala Val Leu Pro Cys
50 55 60

Thr Phe Thr His Pro His Arg His Tyr Asp Gly Pro Leu Thr Ala Ile
 65 70 75 80
 Trp Arg Ala Gly Glu Pro Tyr Ala Gly Pro Gln Val Phe Arg Cys Ala
 85 90 95
 Ala Ala Arg Gly Ser Glu Leu Cys Gln Thr Ala Leu Ser Leu His Gly
 100 105 110
 Arg Phe Arg Leu Leu Gly Asn Pro Arg Arg Asn Asp Leu Ser Leu Arg
 115 120 125
 Val Glu Arg Leu Ala Leu Ala Asp Asp Arg Arg Tyr Phe Cys Arg Val
 130 135 140
 Glu Phe Ala Gly Asp Val His Asp Arg Tyr Glu Ser Arg His Gly Val
 145 150 155 160
 Arg Leu His Val Thr Ala Ala Pro Arg Ile Val Asn Ile Ser Val Leu
 165 170 175
 Pro Ser Pro Ala His Ala Phe Arg Ala Leu Cys Thr Ala Glu Gly Glu
 180 185 190
 Pro Pro Pro Ala Leu Ala Trp Ser Gly Pro Ala Leu Gly Asn Ser Leu
 195 200 205
 Ala Ala Val Arg Ser Pro Arg Glu Gly His Gly His Leu Val Thr Ala
 210 215 220
 Glu Leu Pro Ala Leu Thr His Asp Gly Arg Tyr Thr Cys Thr Ala Ala
 225 230 235 240
 Asn Ser Leu Gly Arg Ser Glu Ala Ser Val Tyr Leu Phe Arg Phe His
 245 250 255
 Gly Ala Ser Gly Asp Pro Ala Phe Leu Tyr Lys Val Val Asp Ile Glu
 260 265 270
 Gly Arg Gly Gly Lys Pro Ile Pro Asn Pro Leu Leu Gly Leu Asp Ser
 275 280 285
 Thr Arg Thr Gly His His His His His
 290 295

<210> 21

<211> 1518

<212> DNA

<213> Artificial Sequence

<220>

<223> Fc-fused human Siglec-15 cDNA

<220>
 <221> CDS
 <222> (1)..(1518)

<400> 21

atg gaa aag tcc atc tgg ctg ctg gcc tgc ttg gcg tgg gtt ctc ccg	48
Met Glu Lys Ser Ile Trp Leu Leu Ala Cys Leu Ala Trp Val Leu Pro	
1 5 10 15	
aca ggc tca ttt gtg aga act aaa ata gat act acg gag aac ttg ctc	96
Thr Gly Ser Phe Val Arg Thr Lys Ile Asp Thr Thr Glu Asn Leu Leu	
20 25 30	
aac aca gag gtg cac agc tcg cca gcg cag cgc tgg tcc atg cag gtg	144
Asn Thr Glu Val His Ser Ser Pro Ala Gln Arg Trp Ser Met Gln Val	
35 40 45	
cca ccc gag gtg agc gcg gag gca ggc gac gcg gca gtg ctg ccc tgc	192
Pro Pro Glu Val Ser Ala Glu Ala Gly Asp Ala Ala Val Leu Pro Cys	
50 55 60	
acc ttc acg cac ccg cac cgc cac tac gac ggg ccg ctg acg gcc atc	240
Thr Phe Thr His Pro His Arg His Tyr Asp Gly Pro Leu Thr Ala Ile	
65 70 75 80	
tgg cgc gcg ggc gag ccc tat gcg ggc ccg cag gtg ttc cgc tgc gct	288
Trp Arg Ala Gly Glu Pro Tyr Ala Gly Pro Gln Val Phe Arg Cys Ala	
85 90 95	
gcg gcg ccg ggc agc gag ctg tgc cag acg gcg ctg agc ctg cac ggc	336
Ala Ala Arg Gly Ser Glu Leu Cys Gln Thr Ala Leu Ser Leu His Gly	
100 105 110	
cgc ttc ccg ctg ctg ggc aac ccg cgc cgc aac gac ctg tcg ctg cgc	384
Arg Phe Arg Leu Leu Gly Asn Pro Arg Arg Asn Asp Leu Ser Leu Arg	
115 120 125	
gtc gag cgc ctg gcc ctg gct gac gac cgc cgc tac ttc tgc cgc gtc	432
Val Glu Arg Leu Ala Leu Ala Asp Asp Arg Arg Tyr Phe Cys Arg Val	
130 135 140	
gag ttc gcc ggc gac gtc cat gac cgc tac gag agc cgc cac ggc gtc	480
Glu Phe Ala Gly Asp Val His Asp Arg Tyr Glu Ser Arg His Gly Val	
145 150 155 160	
cgg ctg cac gtg aca gcc gcg ccg ccg atc gtc aac atc tcg gtg ctg	528
Arg Leu His Val Thr Ala Ala Pro Arg Ile Val Asn Ile Ser Val Leu	
165 170 175	
ccc agt ccg gct cac gcc ttc cgc gcg ctg tgc act gcc gaa ggg gag	576
Pro Ser Pro Ala His Ala Phe Arg Ala Leu Cys Thr Ala Glu Gly Glu	
180 185 190	
ccg ccg ccc gcc ctg gcc tgg tcc ggc ccg gcc ctg ggc aac agc ttg	624
Pro Pro Pro Ala Leu Ala Trp Ser Gly Pro Ala Leu Gly Asn Ser Leu	
195 200 205	
gca gcc gtg ccg agc ccg cgt gag ggt cac ggc cac cta gtg acc gcc	672
Ala Ala Val Arg Ser Pro Arg Glu Gly His Gly His Leu Val Thr Ala	
210 215 220	
gaa ctg ccc gca ctg acc cat gac ggc cgc tac acg tgt acg gcc gcc	720
Glu Leu Pro Ala Leu Thr His Asp Gly Arg Tyr Thr Cys Thr Ala Ala	
225 230 235 240	
aac agc ctg ggc cgc tcc gag gcc agc gtc tac ctg ttc cgc ttc cat	768
Asn Ser Leu Gly Arg Ser Glu Ala Ser Val Tyr Leu Phe Arg Phe His	

245										250										255										
ggc	gcc	agc	ggg	gac	cca	gct	ttc	ttg	tac	aaa	gtg	gtt	gat	atc	cag															816
Gly	Ala	Ser	Gly	Asp	Pro	Ala	Phe	Leu	Tyr	Lys	Val	Val	Asp	Ile	Gln															
			260					265					270																	
gca	gag	ccc	aaa	tct	tgt	gac	aaa	act	cac	aca	tgc	cca	ccg	tgc	cca															864
Ala	Glu	Pro	Lys	Ser	Cys	Asp	Lys	Thr	His	Thr	Cys	Pro	Pro	Cys	Pro															
		275					280					285																		
gca	cct	gaa	ctc	ctg	ggg	gga	ccg	tca	gtc	ttc	ctc	ttc	ccc	cca	aaa															912
Ala	Pro	Glu	Leu	Leu	Gly	Gly	Pro	Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys															
	290				295						300																			
ccc	aag	gac	acc	ctc	atg	atc	tcc	cgg	acc	cct	gag	gtc	aca	tgc	gtg															960
Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	Arg	Thr	Pro	Glu	Val	Thr	Cys	Val															
305					310					315					320															
gtg	gtg	gac	gtg	agc	cac	gaa	gac	cct	gag	gtc	aag	ttc	aac	tgg	tac															1008
Val	Val	Asp	Val	Ser	His	Glu	Asp	Pro	Glu	Val	Lys	Phe	Asn	Trp	Tyr															
				325					330					335																
gtg	gac	ggc	gtg	gag	gtg	cat	aat	gcc	aag	aca	aag	ccg	cgg	gag	gag															1056
Val	Asp	Gly	Val	Glu	Val	His	Asn	Ala	Lys	Thr	Lys	Pro	Arg	Glu	Glu															
			340					345					350																	
cag	tac	aac	agc	acg	tac	cgt	gtg	gtc	agc	gtc	ctc	acc	gtc	ctg	cac															1104
Gln	Tyr	Asn	Ser	Thr	Tyr	Arg	Val	Val	Ser	Val	Leu	Thr	Val	Leu	His															
		355				360					365																			
cag	gac	tgg	ctg	aat	ggc	aag	gag	tac	aag	tgc	aag	gtc	tcc	aac	aaa															1152
Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu	Tyr	Lys	Cys	Lys	Val	Ser	Asn	Lys															
	370				375					380																				
gcc	ctc	cca	gcc	ccc	atc	gag	aaa	acc	atc	tcc	aaa	gcc	aaa	ggg	cag															1200
Ala	Leu	Pro	Ala	Pro	Ile	Glu	Lys	Thr	Ile	Ser	Lys	Ala	Lys	Gly	Gln															
385					390					395				400																
ccc	cga	gaa	cca	cag	gtg	tac	acc	ctg	ccc	cca	tcc	cgg	gag	gag	atg															1248
Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	Pro	Ser	Arg	Glu	Glu	Met															
				405				410					415																	
acc	aag	aac	cag	gtc	agc	ctg	acc	tgc	ctg	gtc	aaa	ggc	ttc	tat	ccc															1296
Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	Cys	Leu	Val	Lys	Gly	Phe	Tyr	Pro															
			420					425				430																		
agc	gac	atc	gcc	gtg	gag	tgg	gag	agc	aat	ggg	cag	ccg	gag	aac	aac															1344
Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	Ser	Asn	Gly	Gln	Pro	Glu	Asn	Asn															
		435				440					445																			
tac	aag	acc	acg	cct	ccc	gtg	ctg	gac	tcc	gac	ggc	tcc	ttc	ttc	ctc															1392
Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	Asp	Ser	Asp	Gly	Ser	Phe	Phe	Leu															
	450					455					460																			
tat	agc	aag	ctc	acc	gtg	gac	aag	agc	agg	tgg	cag	cag	ggg	aac	gtc															1440
Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys	Ser	Arg	Trp	Gln	Gln	Gly	Asn	Val															
465					470					475				480																
ttc	tca	tgc	tcc	gtg	atg	cat	gag	gct	ctg	cac	aac	cac	tac	acg	cag															1488
Phe	Ser	Cys	Ser	Val	Met	His	Glu	Ala	Leu	His	Asn	His	Tyr	Thr	Gln															
				485			490						495																	
aag	agc	ctc	tcc	ctg	tct	ccg	ggt	aaa	taa																					1518
Lys	Ser	Leu	Ser	Leu	Ser	Pro	Gly	Lys																						
			500				505																							

<211> 505
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic Construct

<400> 22

Met Glu Lys Ser Ile Trp Leu Leu Ala Cys Leu Ala Trp Val Leu Pro
 1 5 10 15

Thr Gly Ser Phe Val Arg Thr Lys Ile Asp Thr Thr Glu Asn Leu Leu
 20 25 30

Asn Thr Glu Val His Ser Ser Pro Ala Gln Arg Trp Ser Met Gln Val
 35 40 45

Pro Pro Glu Val Ser Ala Glu Ala Gly Asp Ala Ala Val Leu Pro Cys
 50 55 60

Thr Phe Thr His Pro His Arg His Tyr Asp Gly Pro Leu Thr Ala Ile
 65 70 75 80

Trp Arg Ala Gly Glu Pro Tyr Ala Gly Pro Gln Val Phe Arg Cys Ala
 85 90 95

Ala Ala Arg Gly Ser Glu Leu Cys Gln Thr Ala Leu Ser Leu His Gly
 100 105 110

Arg Phe Arg Leu Leu Gly Asn Pro Arg Arg Asn Asp Leu Ser Leu Arg
 115 120 125

Val Glu Arg Leu Ala Leu Ala Asp Asp Arg Arg Tyr Phe Cys Arg Val
 130 135 140

Glu Phe Ala Gly Asp Val His Asp Arg Tyr Glu Ser Arg His Gly Val
 145 150 155 160

Arg Leu His Val Thr Ala Ala Pro Arg Ile Val Asn Ile Ser Val Leu
 165 170 175

Pro Ser Pro Ala His Ala Phe Arg Ala Leu Cys Thr Ala Glu Gly Glu
 180 185 190

Pro Pro Pro Ala Leu Ala Trp Ser Gly Pro Ala Leu Gly Asn Ser Leu
 195 200 205

Ala Ala Val Arg Ser Pro Arg Glu Gly His Gly His Leu Val Thr Ala
 210 215 220

Glu Leu Pro Ala Leu Thr His Asp Gly Arg Tyr Thr Cys Thr Ala Ala
 225 230 235 240

Asn Ser Leu Gly Arg Ser Glu Ala Ser Val Tyr Leu Phe Arg Phe His
 245 250 255
 Gly Ala Ser Gly Asp Pro Ala Phe Leu Tyr Lys Val Val Asp Ile Gln
 260 265 270
 Ala Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro
 275 280 285
 Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys
 290 295 300
 Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val
 305 310 315 320
 Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr
 325 330 335
 Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu
 340 345 350
 Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His
 355 360 365
 Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys
 370 375 380
 Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln
 385 390 395 400
 Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met
 405 410 415
 Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro
 420 425 430
 Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn
 435 440 445
 Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu
 450 455 460
 Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val
 465 470 475 480
 Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln
 485 490 495
 Lys Ser Leu Ser Leu Ser Pro Gly Lys
 500 505

<210> 23
 <211> 33
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> PCR primer of heavy chain cDNA of rat #32A1 antibody

 <400> 23
 ggccgggtgg gctacgttgc aggtgacggt ctg 33

<210> 24
 <211> 35
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> PCR primer of light chain cDNA of rat #32A1 antibody

 <400> 24
 catgctgtac gtgctgtctt tgctgtcctg atcag 35

<210> 25
 <211> 29
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Sequencing primer of heavy chain cDNA of rat #32A1 antibody

 <400> 25
 ctccagagtt ccaggtcacg gtgactggc 29

<210> 26
 <211> 20
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Sequencing promoter of light chain cDNA of rat #32A1 antibody

 <400> 26
 tccagttgct aactgttccg 20

<210> 27
 <211> 501
 <212> DNA
 <213> Rattus norvegicus

<220>
 <221> CDA
 <222> (1)..(501)

<220>
 <221> CDS
 <222> (1)..(501)

<400> 27
 atg aag ttg tgg ttg agc tgg ata ttc ctt gtt gtt ctt ttc aaa ggt 48
 Met Lys Leu Trp Leu Ser Trp Ile Phe Leu Val Val Leu Phe Lys Gly
 1 5 10 15

gtg agg tgt gag gtg caa att ttg gag act gga gga ggc ttg gtg aag 96
 Val Arg Cys Glu Val Gln Ile Leu Glu Thr Gly Gly Gly Leu Val Lys
 20 25 30
 ccc ggt ggt tcc ctg aga ctg tct tgt gca acg tct gga ttc aat ttc 144
 Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly Phe Asn Phe
 35 40 45
 aat gat tat ttc atg aac tgg gtc cgt cag gct cca gaa aag ggg cta 192
 Asn Asp Tyr Phe Met Asn Trp Val Arg Gln Ala Pro Glu Lys Gly Leu
 50 55 60
 gag tgg gtt gct caa ata agg aac aaa att tat act tat gcc aca ttt 240
 Glu Trp Val Ala Gln Ile Arg Asn Lys Ile Tyr Thr Tyr Ala Thr Phe
 65 70 75 80
 tat gcg gag tct ttg gaa ggc aga gtc aca atc tca cga gac gat tcc 288
 Tyr Ala Glu Ser Leu Glu Gly Arg Val Thr Ile Ser Arg Asp Asp Ser
 85 90 95
 gaa agc agt gtc tac ctg caa gtg agc agt tta aga gct gaa gac act 336
 Glu Ser Ser Val Tyr Leu Gln Val Ser Ser Leu Arg Ala Glu Asp Thr
 100 105 110
 gcc att tat tac tgt aca aga tcc cta act ggg gga gac tac ttt gat 384
 Ala Ile Tyr Tyr Cys Thr Arg Ser Leu Thr Gly Gly Asp Tyr Phe Asp
 115 120 125
 tac tgg ggc caa gga gtc atg gtc aca gtc tcc tta gct gaa aca aca 432
 Tyr Trp Gly Gln Gly Val Met Val Thr Val Ser Leu Ala Glu Thr Thr
 130 135 140
 gcc cca tct gtc tat cca ctg gct cct gga act gct ctc aaa agt aac 480
 Ala Pro Ser Val Tyr Pro Leu Ala Pro Gly Thr Ala Leu Lys Ser Asn
 145 150 155 160
 tcc atg gtg acc ctg gga tgc 501
 Ser Met Val Thr Leu Gly Cys
 165

<210> 28
 <211> 167
 <212> PRT
 <213> Rattus norvegicus

<400> 28

Met Lys Leu Trp Leu Ser Trp Ile Phe Leu Val Val Leu Phe Lys Gly
 1 5 10 15
 Val Arg Cys Glu Val Gln Ile Leu Glu Thr Gly Gly Gly Leu Val Lys
 20 25 30
 Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly Phe Asn Phe
 35 40 45
 Asn Asp Tyr Phe Met Asn Trp Val Arg Gln Ala Pro Glu Lys Gly Leu
 50 55 60
 Glu Trp Val Ala Gln Ile Arg Asn Lys Ile Tyr Thr Tyr Ala Thr Phe
 65 70 75 80

Tyr Ala Glu Ser Leu Glu Gly Arg Val Thr Ile Ser Arg Asp Asp Ser
85 90 95

Glu Ser Ser Val Tyr Leu Gln Val Ser Ser Leu Arg Ala Glu Asp Thr
100 105 110

Ala Ile Tyr Tyr Cys Thr Arg Ser Leu Thr Gly Gly Asp Tyr Phe Asp
115 120 125

Tyr Trp Gly Gln Gly Val Met Val Thr Val Ser Leu Ala Glu Thr Thr
130 135 140

Ala Pro Ser Val Tyr Pro Leu Ala Pro Gly Thr Ala Leu Lys Ser Asn
145 150 155 160

Ser Met Val Thr Leu Gly Cys
165

<210> 29
<211> 417
<212> DNA
<213> Rattus norvegicus

<220>
<221> CDS
<222> (1)..(417)

<400> 29
atg gag aca gac aga ctc ctg cta tgg gca ctg ctg ctc tgg gtt cca 48
Met Glu Thr Asp Arg Leu Leu Leu Trp Ala Leu Leu Leu Trp Val Pro
1 5 10 15
ggc tcc act ggt gac att gtc ttg acc cag tct cct gct ttg gct gtg 96
Gly Ser Thr Gly Asp Ile Val Leu Thr Gln Ser Pro Ala Leu Ala Val
20 25 30
tct cta ggg cag agg gcc aca atc tcc tgt agg gcc agc caa agt gtc 144
Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Gln Ser Val
35 40 45
act att tct gga tat agt ttt ata cac tgg tac caa cag aaa cca gga 192
Thr Ile Ser Gly Tyr Ser Phe Ile His Trp Tyr Gln Gln Lys Pro Gly
50 55 60
cag caa ccc aga ctc ctc atc tat cgt gca tcc aac cta gcc tct ggg 240
Gln Gln Pro Arg Leu Leu Ile Tyr Arg Ala Ser Asn Leu Ala Ser Gly
65 70 75 80
atc ccg gcc agg ttc agt ggc agt ggg tct ggg aca gac ttc acc ctc 288
Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu
85 90 95
acc atc aat cct gtg cag gct gat gat att gca acc tat ttc tgt cag 336
Thr Ile Asn Pro Val Gln Ala Asp Asp Ile Ala Thr Tyr Phe Cys Gln
100 105 110
cag agt agg aaa tct ccg tgg acg ttc gct gga ggc acc aag ctg gaa 384
Gln Ser Arg Lys Ser Pro Trp Thr Phe Ala Gly Gly Thr Lys Leu Glu
115 120 125
ttg aga cgg gct gat gct gca cca act gta tct 417

Leu Arg Arg Ala Asp Ala Ala Pro Thr Val Ser
130 135

<210> 30
<211> 139
<212> PRT
<213> Rattus norvegicus

<400> 30

Met Glu Thr Asp Arg Leu Leu Leu Trp Ala Leu Leu Leu Trp Val Pro
1 5 10 15

Gly Ser Thr Gly Asp Ile Val Leu Thr Gln Ser Pro Ala Leu Ala Val
20 25 30

Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Gln Ser Val
35 40 45

Thr Ile Ser Gly Tyr Ser Phe Ile His Trp Tyr Gln Gln Lys Pro Gly
50 55 60

Gln Gln Pro Arg Leu Leu Ile Tyr Arg Ala Ser Asn Leu Ala Ser Gly
65 70 75 80

Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu
85 90 95

Thr Ile Asn Pro Val Gln Ala Asp Asp Ile Ala Thr Tyr Phe Cys Gln
100 105 110

Gln Ser Arg Lys Ser Pro Trp Thr Phe Ala Gly Gly Thr Lys Leu Glu
115 120 125

Leu Arg Arg Ala Asp Ala Ala Pro Thr Val Ser
130 135

<210> 31
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer EFF1

<400> 31
ccacgcgccc tgtagcggcg cattaagc

28

<210> 32
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer EFsmaR

<400> 32

aaacccggga gctttttgca aaagcctagg

30

<210> 33

<211> 1704

<212> DNA

<213> Artificial Sequence

<220>

<223> Fragment B

<400> 33

ggtaccaccc aagctggcta ggtaagcttg ctagcgccac catggtgctg cagacccagg	60
tgttcatctc cctgctgctg tggatctccg gcgcataatgg cgatatcgtg atgattaaac	120
gtacggtggc cgccccctcc gtgttcatct tccccccctc cgacgagcag ctgaagtccg	180
gcaccgcctc cgtggtgtgc ctgctgaata acttctaccc cagagaggcc aaggtgcagt	240
ggaaggtgga caacgccctg cagtccggga actcccagga gagcgtgacc gagcaggaca	300
gcaaggacag cacctacagc ctgagcagca ccctgaccct gagcaaagcc gactacgaga	360
agcacaaggt gtacgcctgc gaggtgacct accagggcct gagctcccc gtcaccaaga	420
gcttcaacag gggggagtgt taggggcccc tttaaacggg tggcatccct gtgaccctc	480
cccagtgcct ctcttgcccc tggaagtgc cactccagtg cccaccagcc ttgtccta	540
aaaattaagt tgcatacttt tgtctgacta ggtgtccttc tataatatta tggggtggag	600
gggggtggtg tggagcaagg ggcaagtgg gaagacaacc tgtaggccct gcggggtcta	660
ttgggaacca agctggagtg cagtggcaca atcttggtc actgcaatct ccgcctcctg	720
ggttcaagcg attctcctgc ctacgcctcc cgagttgttg ggattccagg catgcatgac	780
caggctcacc taatTTTTgt ttttttggtg gagacggggt ttcacatat tggccaggct	840
ggtctccaac tcctaattctc aggtgatcta cccaccttgg cctcccaa	900
acaggcgtga accactgctc cacgcgccct gtagcggcgc attaacgcgc gcgggtgtgg	960
tggttacgcg cagcgtgacc gctacacttg ccagcgccct agcgcccgct ctttcgctt	1020
tcttcccttc tttctcgcc acgttcgccg gctttccccg tcaagctcta aatcgggggc	1080
tccctttagg gttccgattt agtgctttac ggcacctcga ccccaaaaaa cttgattagg	1140
gtgatggttc acgtagtggg ccatcgccct gatagacggt ttttcgccct ttgacgttgg	1200
agtccacgtt ctttaatatg ggactcttgt tccaaactgg aacaacactc aaccctatct	1260
cggtctattc ttttgattta taagggaatt tgccgatttc ggcctatttg ttaaaaaatg	1320
agctgattta acaaaaaatt aacgcgaatt aattctgtgg aatgtgtgtc agttaggggtg	1380
tggaaagtcc ccaggctccc cagcaggcag aagtatgcaa agcatgcac tcaattagtc	1440
agcaaccagg tgtggaaagt cccaggtc cccagcaggc agaagtatgc aaagcatgca	1500
tctcaattag tcagcaacca tagtcccgc cctaactccg cccatccgc ccctaactcc	1560
gcccagttcc gccattctc cgccccatgg ctgactaatt ttttttattt atgcagaggc	1620
cgaggccgcc tctgcctctg agctattcca gaagtagtga ggaggctttt ttggaggcct	1680

aggcttttgc aaaaagctcc cggg

1704

<210> 34
 <211> 1120
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> human IgG1 signal + human IgG1 constant

<400> 34
 tgctagcgcc accatgaaac acctgtggtt cttcctcctg ctggtggcag ctcccagatg 60
 ggtgctgagc caggtgcaat tgtgcaggcg gttagctcag cctccaccaa gggcccaagc 120
 gtcttcccc tggcacccctc ctccaagagc acctctggcg gcacagccgc cctgggctgc 180
 ctggtcaagg actacttccc cgaaccctg accgtgagct ggaactcagg cgccctgacc 240
 agcggcgtgc acaccttccc cgctgtcctg cagtcctcag gactctactc cctcagcagc 300
 gtggtgaccg tgccctccag cagcttggg acccagacct acatctgcaa cgtgaatcac 360
 aagcccagca acaccaaggt ggacaagaga gttgagccca aatcttgtga caaaactcac 420
 acatgcccac cctgcccagc acctgaactc ctggggggac cctcagtctt cctcttcccc 480
 ccaaaaccca aggacaccct catgatctcc cggaccctg aggtcacatg cgtggtggtg 540
 gacgtgagcc acgaagacc tgaggtcaag ttcaactggt acgtggacgg cgtggagggtg 600
 cataatgcca agacaaagcc ccgggaggag cagtacaaca gcacgtaccg ggtggtcagc 660
 gtcctcaccg tcctgcacca ggactggctg aatggcaagg agtacaagt caaggtctcc 720
 aacaaagccc tcccagcccc catcgagaaa accatctcca aagccaaagg ccagccccgg 780
 gaaccacagg tgtacaccct gccccatcc cgggaggaga tgaccaagaa ccaggtcagc 840
 ctgacctgcc tgggtcaaagg cttctatccc agcgacatcg ccgtggagt ggagagcaat 900
 ggccagccc agaacaacta caagaccacc cctcccgtgc tggactccga cggctccttc 960
 ttctctaca gcaagctcac cgtggacaag agcagggtggc agcagggcaa cgtcttctca 1020
 tgctccgtga tgcattgaggc tctgcacaac cactacacc agaagagcct ctccctgtct 1080
 cccggcaaat gagatatcg gcccgtttaa acgggtggca 1120

<210> 35
 <211> 40
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> PCR primer of heavy chain variable region cDNA of #32A1 antibody

<400> 35
 aaagctgagc gaggtgcaaa ttttggagac tggaggaggc 40

<210> 36
 <211> 39
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> PCR primer of heavy chain variable region cDNA of #32A1 antibody

<400> 36
 aaagctgagc tgactgtgac catgactcct tggccccag 39

<210> 37
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Sequencing primer of heavy chain variable region cDNA of #32A1 antibody

<400> 37
 taatacgact cactataggg 20

<210> 38
 <211> 42
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> PCR primer of light chain variable region cDNA of #32A1 antibody

<400> 38
 aaacatatgg cgacattgtc ttgaccagc ctctgcttt gg 42

<210> 39
 <211> 37
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> PCR primer of light chain variable region cDNA of #32A1 antibody

<400> 39
 aaacgtacgt ctcaattcca gcttggtgcc tccagcg 37

<210> 40
 <211> 1413
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Chimeric heavy chain of #32A1

<220>
 <221> CDS
 <222> (1)..(1413)

<400> 40
 atg aaa cac ctg tgg ttc ttc ctc ctg ctg gtg gca gct ccc aga tgg 48
 Met Lys His Leu Trp Phe Phe Leu Leu Leu Val Ala Ala Pro Arg Trp
 1 5 10 15

gtg ctg agc gag gtg caa att ttg gag act gga gga ggc ttg gtg aag 96
 Val Leu Ser Glu Val Gln Ile Leu Glu Thr Gly Gly Gly Leu Val Lys
 20 25 30

ccc ggt ggt tcc ctg aga ctg tct tgt gca acg tct gga ttc aat ttc 144
 Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly Phe Asn Phe

35	40	45	
aat gat tat ttc atg aac tgg gtc cgt cag gct cca gaa aag ggg cta Asn Asp Tyr Phe Met Asn Trp Val Arg Gln Ala Pro Glu Lys Gly Leu 50 55 60			192
gag tgg gtt gct caa ata agg aac aaa att tat act tat gcc aca ttt Glu Trp Val Ala Gln Ile Arg Asn Lys Ile Tyr Thr Tyr Ala Thr Phe 65 70 75 80			240
tat gcg gag tct ttg gaa ggc aga gtc aca atc tca cga gac gat tcc Tyr Ala Glu Ser Leu Glu Gly Arg Val Thr Ile Ser Arg Asp Asp Ser 85 90 95			288
gaa agc agt gtc tac ctg caa gtg agc agt tta aga gct gaa gac act Glu Ser Ser Val Tyr Leu Gln Val Ser Ser Leu Arg Ala Glu Asp Thr 100 105 110			336
gcc att tat tac tgt aca aga tcc cta act ggg gga gac tac ttt gat Ala Ile Tyr Tyr Cys Thr Arg Ser Leu Thr Gly Gly Asp Tyr Phe Asp 115 120 125			384
tac tgg ggc caa gga gtc atg gtc aca gtc agc tca gcc tcc acc aag Tyr Trp Gly Gln Gly Val Met Val Thr Val Ser Ser Ala Ser Thr Lys 130 135 140			432
ggc cca agc gtc ttc ccc ctg gca ccc tcc tcc aag agc acc tct ggc Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly 145 150 155 160			480
ggc aca gcc gcc ctg ggc tgc ctg gtc aag gac tac ttc ccc gaa ccc Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro 165 170 175			528
gtg acc gtg agc tgg aac tca ggc gcc ctg acc agc ggc gtg cac acc Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr 180 185 190			576
ttc ccc gct gtc ctg cag tcc tca gga ctc tac tcc ctc agc agc gtg Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val 195 200 205			624
gtg acc gtg ccc tcc agc agc ttg ggc acc cag acc tac atc tgc aac Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn 210 215 220			672
gtg aat cac aag ccc agc aac acc aag gtg gac aag aga gtt gag ccc Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro 225 230 235 240			720
aaa tct tgt gac aaa act cac aca tgc cca ccc tgc cca gca cct gaa Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu 245 250 255			768
ctc ctg ggg gga ccc tca gtc ttc ctc ttc ccc cca aaa ccc aag gac Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp 260 265 270			816
acc ctc atg atc tcc cgg acc cct gag gtc aca tgc gtg gtg gtg gac Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp 275 280 285			864
gtg agc cac gaa gac cct gag gtc aag ttc aac tgg tac gtg gac ggc Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly 290 295 300			912
gtg gag gtg cat aat gcc aag aca aag ccc cgg gag gag cag tac aac Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn			960

305	310	315	320	
agc acg tac cgg gtg gtc agc gtc ctc acc gtc ctg cac cag gac tgg	Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp			1008
Ser Thr Tyr Arg	325	330	335	
ctg aat ggc aag gag tac aag tgc aag gtc tcc aac aaa gcc ctc cca	Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro			1056
Leu Asn	340	345	350	
gcc ccc atc gag aaa acc atc tcc aaa gcc aaa ggc cag ccc cgg gaa	Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu			1104
Ala Pro	355	360	365	
cca cag gtg tac acc ctg ccc cca tcc cgg gag gag atg acc aag aac	Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn			1152
Pro Gln	370	375	380	
cag gtc agc ctg acc tgc ctg gtc aaa ggc ttc tat ccc agc gac atc	Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile			1200
Gln Val	385	390	395	400
gcc gtg gag tgg gag agc aat ggc cag ccc gag aac aac tac aag acc	Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr			1248
Ala Val	405	410	415	
acc cct ccc gtg ctg gac tcc gac ggc tcc ttc ttc ctc tac agc aag	Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys			1296
Thr Pro	420	425	430	
ctc acc gtg gac aag agc agg tgg cag cag ggc aac gtc ttc tca tgc	Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys			1344
Leu Thr	435	440	445	
tcc gtg atg cat gag gct ctg cac aac cac tac acc cag aag agc ctc	Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu			1392
Ser Val	450	455	460	
tcc ctg tct ccc ggc aaa tga	Ser Leu Ser Pro Gly Lys			1413
Ser Leu	465	470		

<210> 41
 <211> 470
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic Construct

<400> 41

Met Lys His Leu Trp Phe Phe Leu Leu Leu Val Ala Ala Pro Arg Trp
 1 5 10 15

Val Leu Ser Glu Val Gln Ile Leu Glu Thr Gly Gly Gly Leu Val Lys
 20 25 30

Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly Phe Asn Phe
 35 40 45

Asn Asp Tyr Phe Met Asn Trp Val Arg Gln Ala Pro Glu Lys Gly Leu
 50 55 60

Glu Trp Val Ala Gln Ile Arg Asn Lys Ile Tyr Thr Tyr Ala Thr Phe
 65 70 75 80
 Tyr Ala Glu Ser Leu Glu Gly Arg Val Thr Ile Ser Arg Asp Asp Ser
 85 90 95
 Glu Ser Ser Val Tyr Leu Gln Val Ser Ser Leu Arg Ala Glu Asp Thr
 100 105 110
 Ala Ile Tyr Tyr Cys Thr Arg Ser Leu Thr Gly Gly Asp Tyr Phe Asp
 115 120 125
 Tyr Trp Gly Gln Gly Val Met Val Thr Val Ser Ser Ala Ser Thr Lys
 130 135 140
 Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly
 145 150 155 160
 Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro
 165 170 175
 Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr
 180 185 190
 Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val
 195 200 205
 Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn
 210 215 220
 Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro
 225 230 235 240
 Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu
 245 250 255
 Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp
 260 265 270
 Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
 275 280 285
 Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly
 290 295 300
 Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn
 305 310 315 320
 Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp
 325 330 335

Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro
 340 345 350

Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu
 355 360 365

Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn
 370 375 380

Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
 385 390 395 400

Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr
 405 410 415

Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys
 420 425 430

Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys
 435 440 445

Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
 450 455 460

Ser Leu Ser Pro Gly Lys
 465 470

<210> 42
 <211> 714
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Chimeric light chain of #32A1

<220>
 <221> CDS
 <222> (1)..(714)

<400> 42	
atg gtg ctg cag acc cag gtg ttc atc tcc ctg ctg ctg tgg atc tcc	48
Met Val Leu Gln Thr Gln Val Phe Ile Ser Leu Leu Leu Trp Ile Ser	
1 5 10 15	
ggc gca tat ggc gac att gtc ttg acc cag tct cct gct ttg gct gtg	96
Gly Ala Tyr Gly Asp Ile Val Leu Thr Gln Ser Pro Ala Leu Ala Val	
20 25 30	
tct cta ggg cag agg gcc aca atc tcc tgt agg gcc agc caa agt gtc	144
Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Gln Ser Val	
35 40 45	
act att tct gga tat agt ttt ata cac tgg tac caa cag aaa cca gga	192
Thr Ile Ser Gly Tyr Ser Phe Ile His Trp Tyr Gln Gln Lys Pro Gly	
50 55 60	
cag caa ccc aga ctc ctc atc tat cgt qca tcc aac cta gcc tct ggg	240

Gln Gln Pro Arg Leu Leu Ile Tyr Arg Ala Ser Asn Leu Ala Ser Gly
 65 70 75 80
 atc ccg gcc agg ttc agt ggc agt ggg tct ggg aca gac ttc acc ctc 288
 Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu
 85 90 95
 acc atc aat cct gtg cag gct gat gat att gca acc tat ttc tgt cag 336
 Thr Ile Asn Pro Val Gln Ala Asp Asp Ile Ala Thr Tyr Phe Cys Gln
 100 105 110
 cag agt agg aaa tct ccg tgg acg ttc gct gga ggc acc aag ctg gaa 384
 Gln Ser Arg Lys Ser Pro Trp Thr Phe Ala Gly Gly Thr Lys Leu Glu
 115 120 125
 ttg aga cgt acg gtg gcc gcc ccc tcc gtg ttc atc ttc ccc ccc tcc 432
 Leu Arg Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser
 130 135 140
 gac gag cag ctg aag tcc ggc acc gcc tcc gtg gtg tgc ctg ctg aat 480
 Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn
 145 150 155 160
 aac ttc tac ccc aga gag gcc aag gtg cag tgg aag gtg gac aac gcc 528
 Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala
 165 170 175
 ctg cag tcc ggg aac tcc cag gag agc gtg acc gag cag gac agc aag 576
 Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys
 180 185 190
 gac agc acc tac agc ctg agc agc acc ctg acc ctg agc aaa gcc gac 624
 Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp
 195 200 205
 tac gag aag cac aag gtg tac gcc tgc gag gtg acc cac cag ggc ctg 672
 Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu
 210 215 220
 agc tcc ccc gtc acc aag agc ttc aac agg ggg gag tgt tag 714
 Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
 225 230 235
 <210> 43
 <211> 237
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> Synthetic Construct
 <400> 43
 Met Val Leu Gln Thr Gln Val Phe Ile Ser Leu Leu Leu Trp Ile Ser
 1 5 10 15
 Gly Ala Tyr Gly Asp Ile Val Leu Thr Gln Ser Pro Ala Leu Ala Val
 20 25 30
 Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Gln Ser Val
 35 40 45
 Thr Ile Ser Gly Tyr Ser Phe Ile His Trp Tyr Gln Gln Lys Pro Gly
 50 55 60

Gln Gln Pro Arg Leu Leu Ile Tyr Arg Ala Ser Asn Leu Ala Ser Gly
 65 70 75 80
 Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu
 85 90 95
 Thr Ile Asn Pro Val Gln Ala Asp Asp Ile Ala Thr Tyr Phe Cys Gln
 100 105 110
 Gln Ser Arg Lys Ser Pro Trp Thr Phe Ala Gly Gly Thr Lys Leu Glu
 115 120 125
 Leu Arg Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser
 130 135 140
 Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn
 145 150 155 160
 Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala
 165 170 175
 Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys
 180 185 190
 Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp
 195 200 205
 Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu
 210 215 220
 Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
 225 230 235
 <210> 44
 <211> 5
 <212> PRT
 <213> Rattus norvegicus
 <400> 44
 Asp Tyr Phe Met Asn
 1 5
 <210> 45
 <211> 19
 <212> PRT
 <213> Rattus norvegicus
 <400> 45
 Gln Ile Arg Asn Lys Ile Tyr Thr Tyr Ala Thr Phe Tyr Ala Glu Ser
 1 5 10 15

Leu Glu Gly

<210> 46
 <211> 10
 <212> PRT
 <213> Rattus norvegicus

<400> 46

Ser Leu Thr Gly Gly Asp Tyr Phe Asp Tyr
 1 5 10

<210> 47
 <211> 15
 <212> PRT
 <213> Rattus norvegicus

<400> 47

Arg Ala Ser Gln Ser Val Thr Ile Ser Gly Tyr Ser Phe Ile His
 1 5 10 15

<210> 48
 <211> 7
 <212> PRT
 <213> Rattus norvegicus

<400> 48

Arg Ala Ser Asn Leu Ala Ser
 1 5

<210> 49
 <211> 9
 <212> PRT
 <213> Rattus norvegicus

<400> 49

Gln Gln Ser Arg Lys Ser Pro Trp Thr
 1 5

<210> 50
 <211> 1410
 <212> DNA
 <213> Artificial sequence

<220>
 <223> h#32A1-T1H

<220>
 <221> CDS
 <222> (1)..(1410)

<400> 50

atg aaa cac ctg tgg ttc ttc ctc ctg ctg gtg gca gct ccc aga tgg
 Met Lys His Leu Trp Phe Phe Leu Leu Leu Val Ala Ala Pro Arg Trp
 1 5 10 15

48

gtg ctg agc gag gtg caa ctg gtg gag agc ggc ggc gga ctt gtg caa
 Val Leu Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln

96

20	25	30	
cct ggc ggc tcc ctg aga ctt agc tgt gcc gcc tcc ggc ttc aac ttc Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Phe 35 40 45			144
aac gac tac ttc atg aac tgg gtg aga caa gcc cct ggc aag ggc ctg Asn Asp Tyr Phe Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu 50 55 60			192
gag tgg gtg gcc caa atc aga aac aag atc tac acc tac gcc acc ttc Glu Trp Val Ala Gln Ile Arg Asn Lys Ile Tyr Thr Tyr Ala Thr Phe 65 70 75 80			240
tac gcc gag agc ctt gag ggc aga ttc acc atc tcc aga gac aac gcc Tyr Ala Glu Ser Leu Glu Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala 85 90 95			288
aag aac agc ctg tac ctt caa atg aac tcc ctg aga gcc gag gac acc Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr 100 105 110			336
gcc gtg tac tac tgt gcc aga agc ctt acc ggc ggc gac tac ttc gac Ala Val Tyr Tyr Cys Ala Arg Ser Leu Thr Gly Gly Asp Tyr Phe Asp 115 120 125			384
tac tgg ggc caa ggc acc ctg gtg acc gtg agc tca gcc tcc acc aag Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala Ser Thr Lys 130 135 140			432
ggc cca agc gtc ttc ccc ctg gca ccc tcc tcc aag agc acc tct ggc Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly 145 150 155 160			480
ggc aca gcc gcc ctg ggc tgc ctg gtc aag gac tac ttc ccc gaa ccc Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro 165 170 175			528
gtg acc gtg agc tgg aac tca ggc gcc ctg acc agc ggc gtg cac acc Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr 180 185 190			576
ttc ccc gct gtc ctg cag tcc tca gga ctc tac tcc ctc agc agc gtg Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val 195 200 205			624
gtg acc gtg ccc tcc agc agc ttg ggc acc cag acc tac atc tgc aac Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn 210 215 220			672
gtg aat cac aag ccc agc aac acc aag gtg gac aag aga gtt gag ccc Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro 225 230 235 240			720
aaa tct tgt gac aaa act cac aca tgc cca ccc tgc cca gca cct gaa Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu 245 250 255			768
ctc ctg ggg gga ccc tca gtc ttc ctc ttc ccc cca aaa ccc aag gac Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp 260 265 270			816
acc ctc atg atc tcc cgg acc cct gag gtc aca tgc gtg gtg gtg gac Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp 275 280 285			864
gtg agc cac gaa gac cct gag gtc aag ttc aac tgg tac gtg gac ggc Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly			912

290	295	300	
gtg gag gtg cat aat gcc aag aca aag ccc cgg gag gag cag tac aac Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn 305 310 315 320			960
agc acg tac cgg gtg gtc agc gtc ctc acc gtc ctg cac cag gac tgg Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp 325 330 335			1008
ctg aat ggc aag gag tac aag tgc aag gtc tcc aac aaa gcc ctc cca Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro 340 345 350			1056
gcc ccc atc gag aaa acc atc tcc aaa gcc aaa ggc cag ccc cgg gaa Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu 355 360 365			1104
cca cag gtg tac acc ctg ccc cca tcc cgg gag gag atg acc aag aac Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn 370 375 380			1152
cag gtc agc ctg acc tgc ctg gtc aaa ggc ttc tat ccc agc gac atc Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile 385 390 395 400			1200
gcc gtg gag tgg gag agc aat ggc cag ccc gag aac aac tac aag acc Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr 405 410 415			1248
acc cct ccc gtg ctg gac tcc gac ggc tcc ttc ttc ctc tac agc aag Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys 420 425 430			1296
ctc acc gtg gac aag agc agg tgg cag cag ggc aac gtc ttc tca tgc Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys 435 440 445			1344
tcc gtg atg cat gag gct ctg cac aac cac tac acc cag aag agc ctc Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu 450 455 460			1392
tcc ctg tct ccc ggc aaa Ser Leu Ser Pro Gly Lys 465 470			1410

<210> 51
 <211> 470
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic Construct

<400> 51

Met Lys His Leu Trp Phe Phe Leu Leu Val Ala Ala Pro Arg Trp
1 5 10 15

Val Leu Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln
20 25 30

Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Phe
35 40 45

Asn Asp Tyr Phe Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
 50 55 60
 Glu Trp Val Ala Gln Ile Arg Asn Lys Ile Tyr Thr Tyr Ala Thr Phe
 65 70 75 80
 Tyr Ala Glu Ser Leu Glu Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala
 85 90 95
 Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr
 100 105 110
 Ala Val Tyr Tyr Cys Ala Arg Ser Leu Thr Gly Gly Asp Tyr Phe Asp
 115 120 125
 Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys
 130 135 140
 Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly
 145 150 155 160
 Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro
 165 170 175
 Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr
 180 185 190
 Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val
 195 200 205
 Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn
 210 215 220
 Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro
 225 230 235 240
 Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu
 245 250 255
 Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp
 260 265 270
 Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
 275 280 285
 Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly
 290 295 300
 Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn
 305 310 315 320

Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp
325 330 335

Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro
340 345 350

Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu
355 360 365

Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn
370 375 380

Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
385 390 395 400

Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr
405 410 415

Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys
420 425 430

Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys
435 440 445

Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
450 455 460

Ser Leu Ser Pro Gly Lys
465 470

<210>	52
<211>	1410
<212>	DNA
<213>	Artificial Sequence

<220>
<223> h#32A1-T2H

<220>
<221> CDS
<222> (1)..(1410)

[illegible]

Asn	Asp	Tyr	Phe	Met	Asn	Trp	Val	Arg	Gln	Ala	Pro	Glu	Lys	Gly	Leu	
50						55					60					
gag	tgg	gtg	gcc	caa	atc	aga	aac	aag	atc	tac	acc	tac	gcc	acc	ttc	240
Glu	Trp	Val	Ala	Gln	Ile	Arg	Asn	Lys	Ile	Tyr	Thr	Tyr	Ala	Thr	Phe	
65					70					75					80	
tac	gcc	gag	agc	ctg	gag	ggc	aga	gtg	acc	atc	tcc	aga	gac	aac	gcc	288
Tyr	Ala	Glu	Ser	Leu	Glu	Gly	Arg	Val	Thr	Ile	Ser	Arg	Asp	Asn	Ala	
				85					90					95		
aag	aac	agc	ctg	tac	ctg	caa	atg	tcc	tcc	ctg	aga	gcc	gag	gac	acc	336
Lys	Asn	Ser	Leu	Tyr	Leu	Gln	Met	Ser	Ser	Leu	Arg	Ala	Glu	Asp	Thr	
			100					105					110			
gcc	gtg	tac	tac	tgt	gcc	aga	agc	ctg	acc	ggc	ggc	gac	tac	ttc	gac	384
Ala	Val	Tyr	Tyr	Cys	Ala	Arg	Ser	Leu	Thr	Gly	Gly	Asp	Tyr	Phe	Asp	
		115					120					125				
tac	tgg	ggc	caa	ggc	acc	ctg	gtg	acc	gtg	agc	tca	gcc	tcc	acc	aag	432
Tyr	Trp	Gly	Gln	Gly	Thr	Leu	Val	Thr	Val	Ser	Ser	Ala	Ser	Thr	Lys	
	130					135					140					
ggc	cca	agc	gtc	ttc	ccc	ctg	gca	ccc	tcc	tcc	aag	agc	acc	tct	ggc	480
Gly	Pro	Ser	Val	Phe	Pro	Leu	Ala	Pro	Ser	Ser	Lys	Ser	Thr	Ser	Gly	
145					150					155					160	
ggc	aca	gcc	gcc	ctg	ggc	tgc	ctg	gtc	aag	gac	tac	ttc	ccc	gaa	ccc	528
Gly	Thr	Ala	Ala	Leu	Gly	Cys	Leu	Val	Lys	Asp	Tyr	Phe	Pro	Glu	Pro	
				165					170					175		
gtg	acc	gtg	agc	tgg	aac	tca	ggc	gcc	ctg	acc	agc	ggc	gtg	cac	acc	576
Val	Thr	Val	Ser	Trp	Asn	Ser	Gly	Ala	Leu	Thr	Ser	Gly	Val	His	Thr	
			180					185					190			
ttc	ccc	gct	gtc	ctg	cag	tcc	tca	gga	ctc	tac	tcc	ctc	agc	agc	gtg	624
Phe	Pro	Ala	Val	Leu	Gln	Ser	Ser	Gly	Leu	Tyr	Ser	Leu	Ser	Ser	Val	
		195					200					205				
gtg	acc	gtg	ccc	tcc	agc	agc	ttg	ggc	acc	cag	acc	tac	atc	tgc	aac	672
Val	Thr	Val	Pro	Ser	Ser	Ser	Leu	Gly	Thr	Gln	Thr	Tyr	Ile	Cys	Asn	
	210					215					220					
gtg	aat	cac	aag	ccc	agc	aac	acc	aag	gtg	gac	aag	aga	gtt	gag	ccc	720
Val	Asn	His	Lys	Pro	Ser	Asn	Thr	Lys	Val	Asp	Lys	Arg	Val	Glu	Pro	
225					230					235				240		
aaa	tct	tgt	gac	aaa	act	cac	aca	tgc	cca	ccc	tgc	cca	gca	cct	gaa	768
Lys	Ser	Cys	Asp	Lys	Thr	His	Thr	Cys	Pro	Pro	Cys	Pro	Ala	Pro	Glu	
				245					250					255		
ctc	ctg	ggg	gga	ccc	tca	gtc	ttc	ctc	ttc	ccc	cca	aaa	ccc	aag	gac	816
Leu	Leu	Gly	Gly	Pro	Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	
			260					265					270			
acc	ctc	atg	atc	tcc	cgg	acc	cct	gag	gtc	aca	tgc	gtg	gtg	gtg	gac	864
Thr	Leu	Met	Ile	Ser	Arg	Thr	Pro	Glu	Val	Thr	Cys	Val	Val	Val	Asp	
		275					280					285				
gtg	agc	cac	gaa	gac	cct	gag	gtc	aag	ttc	aac	tgg	tac	gtg	gac	ggc	912
Val	Ser	His	Glu	Asp	Pro	Glu	Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly	
	290					295					300					
gtg	gag	gtg	cat	aat	gcc	aag	aca	aag	ccc	cgg	gag	gag	cag	tac	aac	960
Val	Glu	Val	His	Asn	Ala	Lys	Thr	Lys	Pro	Arg	Glu	Glu	Gln	Tyr	Asn	
305					310					315					320	
agc	acg	tac	cgg	gtg	gtc	agc	gtc	ctc	acc	gtc	ctg	cac	cag	gac	tgg	1008

Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp
 325 330 335
 ctg aat ggc aag gag tac aag tgc aag gtc tcc aac aaa gcc ctc cca 1056
 Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro
 340 345 350
 gcc ccc atc gag aaa acc atc tcc aaa gcc aaa ggc cag ccc cgg gaa 1104
 Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu
 355 360 365
 cca cag gtg tac acc ctg ccc cca tcc cgg gag gag atg acc aag aac 1152
 Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn
 370 375 380
 cag gtc agc ctg acc tgc ctg gtc aaa ggc ttc tat ccc agc gac atc 1200
 Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
 385 390 395 400
 gcc gtg gag tgg gag agc aat ggc cag ccc gag aac aac tac aag acc 1248
 Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr
 405 410 415
 acc cct ccc gtg ctg gac tcc gac ggc tcc ttc ttc ctc tac agc aag 1296
 Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys
 420 425 430
 ctc acc gtg gac aag agc agg tgg cag cag ggc aac gtc ttc tca tgc 1344
 Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys
 435 440 445
 tcc gtg atg cat gag gct ctg cac aac cac tac acc cag aag agc ctc 1392
 Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
 450 455 460
 tcc ctg tct ccc ggc aaa 1410
 Ser Leu Ser Pro Gly Lys
 465 470

<210> 53
 <211> 470
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic Construct

<400> 53

Met Lys His Leu Trp Phe Phe Leu Leu Leu Val Ala Ala Pro Arg Trp
1 5 10 15

Val Leu Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln
20 25 30

Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Phe
35 40 45

Asn Asp Tyr Phe Met Asn Trp Val Arg Gln Ala Pro Glu Lys Gly Leu
50 55 60

Glu Trp Val Ala Gln Ile Arg Asn Lys Ile Tyr Thr Tyr Ala Thr Phe
65 70 75 80

Tyr Ala Glu Ser Leu Glu Gly Arg Val Thr Ile Ser Arg Asp Asn Ala
 85 90 95

Lys Asn Ser Leu Tyr Leu Gln Met Ser Ser Leu Arg Ala Glu Asp Thr
 100 105 110

Ala Val Tyr Tyr Cys Ala Arg Ser Leu Thr Gly Gly Asp Tyr Phe Asp
 115 120 125

Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys
 130 135 140

Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly
 145 150 155 160

Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro
 165 170 175

Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr
 180 185 190

Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val
 195 200 205

Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn
 210 215 220

Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro
 225 230 235 240

Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu
 245 250 255

Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp
 260 265 270

Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
 275 280 285

Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly
 290 295 300

Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn
 305 310 315 320

Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp
 325 330 335

Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro
 340 345 350

Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu
355 360 365

Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn
370 375 380

Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
385 390 395 400

Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr
405 410 415

Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys
420 425 430

Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys
435 440 445

Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
450 455 460

Ser Leu Ser Pro Gly Lys
465 470

<210> 54
<211> 1410
<212> DNA
<213> Artificial Sequence

<220>
<223> h#32A1-T3H

<220>
<221> CDS
<222> (1)..(1410)

<400> 54	
atg aaa cac ctg tgg ttc ttc ctc ctg ctg gtg gca gct ccc aga tgg	48
Met Lys His Leu Trp Phe Phe Leu Leu Leu Val Ala Ala Pro Arg Trp	
1 5 10 15	
gtg ctg agc gag gtg cag atc gtg gag agc ggc ggc gga ctt gtg cag	96
Val Leu Ser Glu Val Gln Ile Val Glu Ser Gly Gly Gly Leu Val Gln	
20 25 30	
cct ggc ggc tcc ctg aga ctt agc tgt gcc acc tcc ggc ttc aac ttc	144
Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly Phe Asn Phe	
35 40 45	
aac gac tac ttc atg aac tgg gtg aga cag gcc cct gag aag ggc ctg	192
Asn Asp Tyr Phe Met Asn Trp Val Arg Gln Ala Pro Glu Lys Gly Leu	
50 55 60	
gag tgg gtg gcc cag atc aga aac aag atc tac acc tac gcc acc ttc	240
Glu Trp Val Ala Gln Ile Arg Asn Lys Ile Tyr Thr Tyr Ala Thr Phe	
65 70 75 80	

tac gcc gag agc ctt gag ggc aga gtg acc atc tcc aga gac gac agc Tyr Ala Glu Ser Leu Glu Gly Arg Val Thr Ile Ser Arg Asp Asp Ser	288
gag tcc agc gtg tac ctt cag atg tcc agc ctg aga gcc gag gac acc Glu Ser Ser Val Tyr Leu Gln Met Ser Ser Leu Arg Ala Glu Asp Thr	336
gcc gtg tac tac tgt acc aga agc ctt acc ggc ggc gac tac ttc gac Ala Val Tyr Tyr Cys Thr Arg Ser Leu Thr Gly Gly Asp Tyr Phe Asp	384
tac tgg ggc cag ggc acc ctg gtg acc gtg agc tca gcc tcc acc aag Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala Ser Thr Lys	432
ggc cca agc gtc ttc ccc ctg gca ccc tcc tcc aag agc acc tct ggc Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly	480
ggc aca gcc gcc ctg ggc tgc ctg gtc aag gac tac ttc ccc gaa ccc Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro	528
gtg acc gtg agc tgg aac tca ggc gcc ctg acc agc ggc gtg cac acc Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr	576
ttc ccc gct gtc ctg cag tcc tca gga ctc tac tcc ctc agc agc gtg Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val	624
gtg acc gtg ccc tcc agc agc ttg ggc acc cag acc tac atc tgc aac Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn	672
gtg aat cac aag ccc agc aac acc aag gtg gac aag aga gtt gag ccc Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro	720
aaa tct tgt gac aaa act cac aca tgc cca ccc tgc cca gca cct gaa Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu	768
ctc ctg ggg gga ccc tca gtc ttc ctc ttc ccc cca aaa ccc aag gac Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp	816
acc ctc atg atc tcc cgg acc cct gag gtc aca tgc gtg gtg gtg gac Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp	864
gtg agc cac gaa gac cct gag gtc aag ttc aac tgg tac gtg gac ggc Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly	912
gtg gag gtg cat aat gcc aag aca aag ccc cgg gag gag cag tac aac Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn	960
agc acg tac cgg gtg gtc agc gtc ctc acc gtc ctg cac cag gac tgg Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp	1008
ctg aat ggc aag gag tac aag tgc aag gtc tcc aac aaa gcc ctc cca Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro	1056

gcc ccc atc gag aaa acc atc tcc aaa gcc aaa ggc cag ccc cgg gaa 1104
 Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu
 355 360 365
 cca cag gtg tac acc ctg ccc cca tcc cgg gag gag atg acc aag aac 1152
 Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn
 370 375 380
 cag gtc agc ctg acc tgc ctg gtc aaa ggc ttc tat ccc agc gac atc 1200
 Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
 385 390 395 400
 gcc gtg gag tgg gag agc aat ggc cag ccc gag aac aac tac aag acc 1248
 Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr
 405 410 415
 acc cct ccc gtg ctg gac tcc gac ggc tcc ttc ttc ctc tac agc aag 1296
 Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys
 420 425 430
 ctc acc gtg gac aag agc agg tgg cag cag ggc aac gtc ttc tca tgc 1344
 Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys
 435 440 445
 tcc gtg atg cat gag gct ctg cac aac cac tac acc cag aag agc ctc 1392
 Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
 450 455 460
 tcc ctg tct ccc ggc aaa 1410
 Ser Leu Ser Pro Gly Lys
 465 470

<210> 55
 <211> 470
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic Construct

<400> 55

Met Lys His Leu Trp Phe Phe Leu Leu Leu Val Ala Ala Pro Arg Trp
1 5 10 15

Val Leu Ser Glu Val Gln Ile Val Glu Ser Gly Gly Gly Leu Val Gln
20 25 30

Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly Phe Asn Phe
35 40 45

Asn Asp Tyr Phe Met Asn Trp Val Arg Gln Ala Pro Glu Lys Gly Leu
50 55 60

Glu Trp Val Ala Gln Ile Arg Asn Lys Ile Tyr Thr Tyr Ala Thr Phe
65 70 75 80

Tyr Ala Glu Ser Leu Glu Gly Arg Val Thr Ile Ser Arg Asp Asp Ser
85 90 95

Glu Ser Ser Val Tyr Leu Gln Met Ser Ser Leu Arg Ala Glu Asp Thr

100	105	110
Ala Val Tyr Tyr Cys Thr Arg Ser Leu Thr Gly Gly Asp Tyr Phe Asp		
115	120	125
Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys		
130	135	140
Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly		
145	150	155
Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro		
165	170	175
Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr		
180	185	190
Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val		
195	200	205
Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn		
210	215	220
Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro		
225	230	235
Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu		
245	250	255
Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp		
260	265	270
Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp		
275	280	285
Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly		
290	295	300
Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn		
305	310	315
Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp		
325	330	335
Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro		
340	345	350
Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu		
355	360	365
Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn		

370

375

380

Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
 385 390 395 400

Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr
 405 410 415

Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys
 420 425 430

Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys
 435 440 445

Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
 450 455 460

Ser Leu Ser Pro Gly Lys
 465 470

<210> 56
 <211> 1410
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> h#32A1-T5H

<220>
 <221> CDS
 <222> (1)..(1410)

<400> 56
 atg aaa cac ctg tgg ttc ttc ctc ctg ctg gtg gca gct ccc aga tgg 48
 Met Lys His Leu Trp Phe Phe Leu Leu Leu Val Ala Ala Pro Arg Trp
 1 5 10 15
 gtg ctg agc gag gtg cag gtg gtg gag agc ggc ggc gga ctt gtg cag 96
 Val Leu Ser Glu Val Gln Val Val Glu Ser Gly Gly Gly Leu Val Gln
 20 25 30
 cct ggc ggc tcc ctg aga ctt agc tgt gcc acc tcc ggc ttc aac ttc 144
 Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly Phe Asn Phe
 35 40 45
 aac gac tac ttc atg aac tgg gtg aga cag gcc cct ggc aag ggc ctg 192
 Asn Asp Tyr Phe Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
 50 55 60
 gag tgg gtg gcc cag atc aga aac aag atc tac acc tac gcc acc ttc 240
 Glu Trp Val Ala Gln Ile Arg Asn Lys Ile Tyr Thr Tyr Ala Thr Phe
 65 70 75 80
 tac gcc gag agc ctt gag ggc aga ttc acc atc tcc aga gac aac agc 288
 Tyr Ala Glu Ser Leu Glu Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser
 85 90 95
 aag tcc acc gtg tac ctt cag atg aac tcc ctg aga gcc gag gac acc 336
 Lys Ser Thr Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr
 100 105 110

gcc	gtg	tac	tac	tgt	acc	aga	agc	ctt	acc	ggc	ggc	gac	tac	ttc	gac	384
Ala	Val	Tyr	Tyr	Cys	Thr	Arg	Ser	Leu	Thr	Gly	Gly	Asp	Tyr	Phe	Asp	
		115					120					125				
tac	tgg	ggc	cag	ggc	acc	ctg	gtg	acc	gtg	agc	tca	gcc	tcc	acc	aag	432
Tyr	Trp	Gly	Gln	Gly	Thr	Leu	Val	Thr	Val	Ser	Ser	Ala	Ser	Thr	Lys	
	130					135					140					
ggc	cca	agc	gtc	ttc	ccc	ctg	gca	ccc	tcc	tcc	aag	agc	acc	tct	ggc	480
Gly	Pro	Ser	Val	Phe	Pro	Leu	Ala	Pro	Ser	Ser	Lys	Ser	Thr	Ser	Gly	
145					150					155					160	
ggc	aca	ggc	ggc	ctg	ggc	tgc	ctg	gtc	aag	gac	tac	ttc	ccc	gaa	ccc	528
Gly	Thr	Ala	Ala	Leu	Gly	Cys	Leu	Val	Lys	Asp	Tyr	Phe	Pro	Glu	Pro	
				165					170					175		
gtg	acc	gtg	agc	tgg	aac	tca	ggc	ggc	ctg	acc	agc	ggc	gtg	cac	acc	576
Val	Thr	Val	Ser	Trp	Asn	Ser	Gly	Ala	Leu	Thr	Ser	Gly	Val	His	Thr	
			180				185						190			
ttc	ccc	gct	gtc	ctg	cag	tcc	tca	gga	ctc	tac	tcc	ctc	agc	agc	gtg	624
Phe	Pro	Ala	Val	Leu	Gln	Ser	Ser	Gly	Leu	Tyr	Ser	Leu	Ser	Ser	Val	
		195					200					205				
gtg	acc	gtg	ccc	tcc	agc	agc	ttg	ggc	acc	cag	acc	tac	atc	tgc	aac	672
Val	Thr	Val	Pro	Ser	Ser	Ser	Leu	Gly	Thr	Gln	Thr	Tyr	Ile	Cys	Asn	
		210				215					220					
gtg	aat	cac	aag	ccc	agc	aac	acc	aag	gtg	gac	aag	aga	gtt	gag	ccc	720
Val	Asn	His	Lys	Pro	Ser	Asn	Thr	Lys	Val	Asp	Lys	Arg	Val	Glu	Pro	
225					230					235					240	
aaa	tct	tgt	gac	aaa	act	cac	aca	tgc	cca	ccc	tgc	cca	gca	cct	gaa	768
Lys	Ser	Cys	Asp	Lys	Thr	His	Thr	Cys	Pro	Pro	Cys	Pro	Ala	Pro	Glu	
				245					250					255		
ctc	ctg	ggg	gga	ccc	tca	gtc	ttc	ctc	ttc	ccc	cca	aaa	ccc	aag	gac	816
Leu	Leu	Gly	Gly	Pro	Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	
			260					265					270			
acc	ctc	atg	atc	tcc	cgg	acc	cct	gag	gtc	aca	tgc	gtg	gtg	gtg	gac	864
Thr	Leu	Met	Ile	Ser	Arg	Thr	Pro	Glu	Val	Thr	Cys	Val	Val	Val	Asp	
		275					280					285				
gtg	agc	cac	gaa	gac	cct	gag	gtc	aag	ttc	aac	tgg	tac	gtg	gac	ggc	912
Val	Ser	His	Glu	Asp	Pro	Glu	Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly	
	290				295						300					
gtg	gag	gtg	cat	aat	gcc	aag	aca	aag	ccc	cgg	gag	gag	cag	tac	aac	960
Val	Glu	Val	His	Asn	Ala	Lys	Thr	Lys	Pro	Arg	Glu	Glu	Gln	Tyr	Asn	
305					310					315					320	
agc	acg	tac	cgg	gtg	gtc	agc	gtc	ctc	acc	gtc	ctg	cac	cag	gac	tgg	1008
Ser	Thr	Tyr	Arg	Val	Val	Ser	Val	Leu	Thr	Val	Leu	His	Gln	Asp	Trp	
				325					330					335		
ctg	aat	ggc	aag	gag	tac	aag	tgc	aag	gtc	tcc	aac	aaa	gcc	ctc	cca	1056
Leu	Asn	Gly	Lys	Glu	Tyr	Lys	Cys	Lys	Val	Ser	Asn	Lys	Ala	Leu	Pro	
			340					345					350			
gcc	ccc	atc	gag	aaa	acc	atc	tcc	aaa	gcc	aaa	ggc	cag	ccc	cgg	gaa	1104
Ala	Pro	Ile	Glu	Lys	Thr	Ile	Ser	Lys	Ala	Lys	Gly	Gln	Pro	Arg	Glu	
		355					360					365				
cca	cag	gtg	tac	acc	ctg	ccc	cca	tcc	cgg	gag	gag	atg	acc	aag	aac	1152
Pro	Gln	Val	Tyr	Thr	Leu	Pro	Pro	Ser	Arg	Glu	Glu	Met	Thr	Lys	Asn	
		370				375					380					

cag gtc agc ctg acc tgc ctg gtc aaa ggc ttc tat ccc agc gac atc 1200
 Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
 385 390 395 400

gcc gtg gag tgg gag agc aat ggc cag ccc gag aac aac tac aag acc 1248
 Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr
 405 410 415

acc cct ccc gtg ctg gac tcc gac ggc tcc ttc ttc ctc tac agc aag 1296
 Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys
 420 425 430

ctc acc gtg gac aag agc agg tgg cag cag ggc aac gtc ttc tca tgc 1344
 Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys
 435 440 445

tcc gtg atg cat gag gct ctg cac aac cac tac acc cag aag agc ctc 1392
 Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
 450 455 460

tcc ctg tct ccc ggc aaa 1410
 Ser Leu Ser Pro Gly Lys
 465 470

<210> 57
 <211> 470
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic Construct

<400> 57

Met Lys His Leu Trp Phe Phe Leu Leu Leu Val Ala Ala Pro Arg Trp
 1 5 10 15

Val Leu Ser Glu Val Gln Val Val Glu Ser Gly Gly Gly Leu Val Gln
 20 25 30

Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly Phe Asn Phe
 35 40 45

Asn Asp Tyr Phe Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
 50 55 60

Glu Trp Val Ala Gln Ile Arg Asn Lys Ile Tyr Thr Tyr Ala Thr Phe
 65 70 75 80

Tyr Ala Glu Ser Leu Glu Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser
 85 90 95

Lys Ser Thr Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr
 100 105 110

Ala Val Tyr Tyr Cys Thr Arg Ser Leu Thr Gly Gly Asp Tyr Phe Asp
 115 120 125

Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys
 130 135 140
 Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly
 145 150 155 160
 Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro
 165 170 175
 Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr
 180 185 190
 Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val
 195 200 205
 Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn
 210 215 220
 Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro
 225 230 235 240
 Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu
 245 250 255
 Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp
 260 265 270
 Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
 275 280 285
 Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly
 290 295 300
 Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn
 305 310 315 320
 Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp
 325 330 335
 Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro
 340 345 350
 Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu
 355 360 365
 Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn
 370 375 380
 Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
 385 390 395 400

Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr
 405 410 415

Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys
 420 425 430

Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys
 435 440 445

Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
 450 455 460

Ser Leu Ser Pro Gly Lys
 465 470

<210> 58
 <211> 1410
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> h#32A1-T6H

<220>
 <221> CDS
 <222> (1)..(1410)

<400> 58
 atg aaa cac ctg tgg ttc ttc ctc ctg ctg gtg gca gct ccc aga tgg 48
 Met Lys His Leu Trp Phe Phe Leu Leu Leu Val Ala Ala Pro Arg Trp
 1 5 10 15
 gtg ctg agc gag gtg cag gtg gtg gag agc ggc ggc gga ctt gtg cag 96
 Val Leu Ser Glu Val Gln Val Val Glu Ser Gly Gly Gly Leu Val Gln
 20 25 30
 cct ggc ggc tcc ctg aga ctt agc tgt gcc acc tcc ggc ttc aac ttc 144
 Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly Phe Asn Phe
 35 40 45
 aac gac tac ttc atg aac tgg gtg aga cag gcc cct gag aag ggc ctg 192
 Asn Asp Tyr Phe Met Asn Trp Val Arg Gln Ala Pro Glu Lys Gly Leu
 50 55 60
 gag tgg gtg gcc cag atc aga aac aag atc tac acc tac gcc acc ttc 240
 Glu Trp Val Ala Gln Ile Arg Asn Lys Ile Tyr Thr Tyr Ala Thr Phe
 65 70 75 80
 tac gcc gag agc ctt gag ggc aga gtg acc atc tcc aga gac aac agc 288
 Tyr Ala Glu Ser Leu Glu Gly Arg Val Thr Ile Ser Arg Asp Asn Ser
 85 90 95
 aag tcc acc gtg tac ctt cag atg tcc agc ctt aga gcc gag gac acc 336
 Lys Ser Thr Val Tyr Leu Gln Met Ser Ser Leu Arg Ala Glu Asp Thr
 100 105 110
 gcc gtg tac tac tgt acc aga agc ctt acc ggc ggc gac tac ttc gac 384
 Ala Val Tyr Tyr Cys Thr Arg Ser Leu Thr Gly Gly Asp Tyr Phe Asp
 115 120 125
 tac tgg ggc cag ggc acc ctt gtg aca gtg agc tca gcc tcc acc aag 432
 Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys

130	135	140	
ggc cca agc gtc ttc ccc ctg gca ccc tcc tcc aag agc acc tct ggc Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly 145 150 155 160			480
ggc aca gcc gcc ctg ggc tgc ctg gtc aag gac tac ttc ccc gaa ccc Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro 165 170 175			528
gtg acc gtg agc tgg aac tca ggc gcc ctg acc agc ggc gtg cac acc Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr 180 185 190			576
ttc ccc gct gtc ctg cag tcc tca gga ctc tac tcc ctc agc agc gtg Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val 195 200 205			624
gtg acc gtg ccc tcc agc agc ttg ggc acc cag acc tac atc tgc aac Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn 210 215 220			672
gtg aat cac aag ccc agc aac acc aag gtg gac aag aga gtt gag ccc Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro 225 230 235 240			720
aaa tct tgt gac aaa act cac aca tgc cca ccc tgc cca gca cct gaa Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu 245 250 255			768
ctc ctg ggg gga ccc tca gtc ttc ctc ttc ccc cca aaa ccc aag gac Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp 260 265 270			816
acc ctc atg atc tcc cgg acc cct gag gtc aca tgc gtg gtg gtg gac Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp 275 280 285			864
gtg agc cac gaa gac cct gag gtc aag ttc aac tgg tac gtg gac ggc Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly 290 295 300			912
gtg gag gtg cat aat gcc aag aca aag ccc cgg gag gag cag tac aac Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn 305 310 315 320			960
agc acg tac cgg gtg gtc agc gtc ctc acc gtc ctg cac cag gac tgg Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp 325 330 335			1008
ctg aat ggc aag gag tac aag tgc aag gtc tcc aac aaa gcc ctc cca Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro 340 345 350			1056
gcc ccc atc gag aaa acc atc tcc aaa gcc aaa ggc cag ccc cgg gaa Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu 355 360 365			1104
cca cag gtg tac acc ctg ccc cca tcc cgg gag gag atg acc aag aac Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn 370 375 380			1152
cag gtc agc ctg acc tgc ctg gtc aaa ggc ttc tat ccc agc gac atc Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile 385 390 400			1200
gcc gtg gag tgg gag agc aat ggc cag ccc gag aac aac tac aag acc Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr			1248

	405		410		415	
acc cct ccc gtg ctg gac tcc gac ggc tcc ttc ttc ctc tac agc aag						1296
Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys						
	420		425		430	
ctc acc gtg gac aag agc agg tgg cag cag ggc aac gtc ttc tca tgc						1344
Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys						
	435		440		445	
tcc gtg atg cat gag gct ctg cac aac cac tac acc cag aag agc ctc						1392
Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu						
	450		455		460	
tcc ctg tct ccc ggc aaa						1410
Ser Leu Ser Pro Gly Lys						
	465		470			

<210> 59
 <211> 470
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic Construct

<400> 59

Met Lys His Leu Trp Phe Phe Leu Leu Leu Val Ala Ala Pro Arg Trp
 1 5 10 15

Val Leu Ser Glu Val Gln Val Val Glu Ser Gly Gly Gly Leu Val Gln
 20 25 30

Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly Phe Asn Phe
 35 40 45

Asn Asp Tyr Phe Met Asn Trp Val Arg Gln Ala Pro Glu Lys Gly Leu
 50 55 60

Glu Trp Val Ala Gln Ile Arg Asn Lys Ile Tyr Thr Tyr Ala Thr Phe
 65 70 75 80

Tyr Ala Glu Ser Leu Glu Gly Arg Val Thr Ile Ser Arg Asp Asn Ser
 85 90 95

Lys Ser Thr Val Tyr Leu Gln Met Ser Ser Leu Arg Ala Glu Asp Thr
 100 105 110

Ala Val Tyr Tyr Cys Thr Arg Ser Leu Thr Gly Gly Asp Tyr Phe Asp
 115 120 125

Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys
 130 135 140

Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly
 145 150 155 160

Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro
 165 170 175
 Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr
 180 185 190
 Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val
 195 200 205
 Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn
 210 215 220
 Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro
 225 230 235 240
 Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu
 245 250 255
 Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp
 260 265 270
 Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
 275 280 285
 Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly
 290 295 300
 Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn
 305 310 315 320
 Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp
 325 330 335
 Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro
 340 345 350
 Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu
 355 360 365
 Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn
 370 375 380
 Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
 385 390 395 400
 Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr
 405 410 415
 Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys
 420 425 430

Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys
 435 440 445

Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
 450 455 460

Ser Leu Ser Pro Gly Lys
 465 470

<210> 60
 <211> 714
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> h#32A1-T1L

<220>
 <221> CDS
 <222> (1)..(714)

<400> 60
 atg gtg ctg cag acc cag gtg ttc atc tcc ctg ctg ctg tgg atc tcc 48
 Met Val Leu Gln Thr Gln Val Phe Ile Ser Leu Leu Leu Trp Ile Ser
 1 5 10 15
 ggc gca tat ggc gac atc gtg atg acc cag agc cct gac tcc ctt gcc 96
 Gly Ala Tyr Gly Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala
 20 25 30
 gtg tcc ctg ggc gag aga gcc acc atc aac tgt aga gcc tcc cag agc 144
 Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Arg Ala Ser Gln Ser
 35 40 45
 gtg acc atc tcc ggc tac agc ttc atc cac tgg tac cag cag aag cct 192
 Val Thr Ile Ser Gly Tyr Ser Phe Ile His Trp Tyr Gln Gln Lys Pro
 50 55 60
 ggc cag cct cct aag ctt ctg atc tac aga gcc tcc aac ctt gcc agc 240
 Gly Gln Pro Pro Lys Leu Ile Tyr Arg Ala Ser Asn Leu Ala Ser
 65 70 75 80
 ggc gtg cct gcc aga ttc tcc ggc agc ggc tcc ggc acc gac ttc acc 288
 Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
 85 90 95
 ctg acc atc agc tcc ctt cag gcc gag gac gtg gcc gtg tac tac tgt 336
 Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys
 100 105 110
 cag cag agc aga aag tcc cct tgg acc ttc ggc ggc ggc acc aag gtg 384
 Gln Gln Ser Arg Lys Ser Pro Trp Thr Phe Gly Gly Gly Thr Lys Val
 115 120 125
 gag atc aag cgt acg gtg gcc gcc ccc tcc gtg ttc atc ttc ccc ccc 432
 Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro
 130 135 140
 tcc gac gag cag ctg aag tcc ggc acc gcc tcc gtg gtg tgc ctg ctg 480
 Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu
 145 150 155 160
 aat aac ttc tac ccc aga gag gcc aag gtg cag tgg aag gtg gac aac 528

Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn
 165 170 175
 gcc ctg cag tcc ggg aac tcc cag gag agc gtg acc gag cag gac agc 576
 Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser
 180 185 190
 aag gac agc acc tac agc ctg agc agc acc ctg acc ctg agc aaa gcc 624
 Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala
 195 200 205
 gac tac gag aag cac aag gtg tac gcc tgc gag gtg acc cac cag gcc 672
 Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly
 210 215 220
 ctg agc tcc ccc gtc acc aag agc ttc aac agg ggg gag tgt 714
 Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
 225 230 235

<210> 61
 <211> 238
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic Construct

<400> 61

Met Val Leu Gln Thr Gln Val Phe Ile Ser Leu Leu Leu Trp Ile Ser
 1 5 10 15
 Gly Ala Tyr Gly Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala
 20 25 30
 Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Arg Ala Ser Gln Ser
 35 40 45
 Val Thr Ile Ser Gly Tyr Ser Phe Ile His Trp Tyr Gln Gln Lys Pro
 50 55 60
 Gly Gln Pro Pro Lys Leu Leu Ile Tyr Arg Ala Ser Asn Leu Ala Ser
 65 70 75 80
 Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
 85 90 95
 Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys
 100 105 110
 Gln Gln Ser Arg Lys Ser Pro Trp Thr Phe Gly Gly Gly Thr Lys Val
 115 120 125
 Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro
 130 135 140
 Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu
 145 150 155 160

Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn
165 170 175

Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser
180 185 190

Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala
195 200 205

Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly
210 215 220

Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
225 230 235

<210> 62
<211> 714
<212> DNA
<213> Artificial Sequence

<220>
<223> h#32A1-T2L

<220>
<221> CDS
<222> (1)..(714)

<400> 62
atg gtg ctg cag acc cag gtg ttc atc tcc ctg ctg ctg tgg atc tcc 48
Met Val Leu Gln Thr Gln Val Phe Ile Ser Leu Leu Leu Trp Ile Ser
1 5 10 15
ggc gca tat ggc gac atc gtg atg acc cag agc cct gac tcc ctt gcc 96
Gly Ala Tyr Gly Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala
20 25 30
gtg tcc ctg ggc gag aga gcc acc atc agc tgt aga gcc tcc cag agc 144
Val Ser Leu Gly Glu Arg Ala Thr Ile Ser Cys Arg Ala Ser Gln Ser
35 40 45
gtg acc atc tcc ggc tac agc ttc atc cac tgg tac cag cag aag cct 192
Val Thr Ile Ser Gly Tyr Ser Phe Ile His Trp Tyr Gln Gln Lys Pro
50 55 60
ggc cag cct cct aga ctt ctg atc tac aga gcc tcc aac ctt gcc agc 240
Gly Gln Pro Pro Arg Leu Leu Ile Tyr Arg Ala Ser Asn Leu Ala Ser
65 70 75 80
ggc gtg cct gcc aga ttc tcc ggc agc ggc tcc ggc acc gac ttc acc 288
Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
85 90 95
ctg acc atc agc tcc ctt cag gcc gag gac gtg gcc gtg tac ttc tgt 336
Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Phe Cys
100 105 110
cag cag agc aga aag tcc cct tgg acc ttc gcc ggc ggc acc aag gtg 384
Gln Gln Ser Arg Lys Ser Pro Trp Thr Phe Ala Gly Gly Thr Lys Val
115 120 125

gag atc aag cgt acg gtg gcc gcc ccc tcc gtg ttc atc ttc ccc ccc 432
 Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro
 130 135 140
 tcc gac gag cag ctg aag tcc ggc acc gcc tcc gtg gtg tgc ctg ctg 480
 Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu
 145 150 155 160
 aat aac ttc tac ccc aga gag gcc aag gtg cag tgg aag gtg gac aac 528
 Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn
 165 170 175
 gcc ctg cag tcc ggg aac tcc cag gag agc gtg acc gag cag gac agc 576
 Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser
 180 185 190
 aag gac agc acc tac agc ctg agc agc acc ctg acc ctg agc aaa gcc 624
 Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala
 195 200 205
 gac tac gag aag cac aag gtg tac gcc tgc gag gtg acc cac cag gcc 672
 Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly
 210 215 220
 ctg agc tcc ccc gtc acc aag agc ttc aac agg ggg gag tgt 714
 Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
 225 230 235

<210> 63
 <211> 238
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic Construct

<400> 63

Met Val Leu Gln Thr Gln Val Phe Ile Ser Leu Leu Leu Trp Ile Ser
1 5 10 15

Gly Ala Tyr Gly Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala
20 25 30

Val Ser Leu Gly Glu Arg Ala Thr Ile Ser Cys Arg Ala Ser Gln Ser
35 40 45

Val Thr Ile Ser Gly Tyr Ser Phe Ile His Trp Tyr Gln Gln Lys Pro
50 55 60

Gly Gln Pro Pro Arg Leu Leu Ile Tyr Arg Ala Ser Asn Leu Ala Ser
65 70 75 80

Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
85 90 95

Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Phe Cys
100 105 110

Gln Gln Ser Arg Lys Ser Pro Trp Thr Phe Ala Gly Gly Thr Lys Val

115 120 125
 Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro
 130 135 140
 Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu
 145 150 155 160
 Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn
 165 170 175
 Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser
 180 185 190
 Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala
 195 200 205
 Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly
 210 215 220
 Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
 225 230 235

<210> 64
 <211> 714
 <212> DNA
 <213> Artificial sequence

<220>
 <223> h#32A1-T3L

<220>
 <221> CDS
 <222> (1)..(714)

<400> 64
 atg gtg ctg cag acc cag gtg ttc atc tcc ctg ctg ctg tgg atc tcc 48
 Met Val Leu Gln Thr Gln Val Phe Ile Ser Leu Leu Leu Trp Ile Ser
 1 5 10 15
 ggc gca tat ggc gac atc gtg ctt acc cag agc cct gac tcc ctt gcc 96
 Gly Ala Tyr Gly Asp Ile Val Leu Thr Gln Ser Pro Asp Ser Leu Ala
 20 25 30
 gtg tcc ctg ggc gag aga gcc acc atc agc tgt aga gcc tcc cag agc 144
 Val Ser Leu Gly Glu Arg Ala Thr Ile Ser Cys Arg Ala Ser Gln Ser
 35 40 45
 gtg acc atc tcc ggc tac agc ttc atc cac tgg tac cag cag aag cct 192
 Val Thr Ile Ser Gly Tyr Ser Phe Ile His Trp Tyr Gln Gln Lys Pro
 50 55 60
 ggc cag cag cct aga ctt ctg atc tac aga gcc tcc aac ctt gcc agc 240
 Gly Gln Gln Pro Arg Leu Leu Ile Tyr Arg Ala Ser Asn Leu Ala Ser
 65 70 75 80
 ggc atc cct gcc aga ttc tcc ggc agc ggc tcc ggc acc gac ttc acc 288
 Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
 85 90 95

ctg acc atc agc tcc ctt cag gcc gag gac gtg gcc acc tac ttc tgt 336
 Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Thr Tyr Phe Cys
 100 105 110
 cag cag agc aga aag tcc cct tgg acc ttc gcc gcc ggc acc aag gtg 384
 Gln Gln Ser Arg Lys Ser Pro Trp Thr Phe Ala Gly Gly Thr Lys Val
 115 120 125
 gag atc aag cgt acg gtg gcc gcc ccc tcc gtg ttc atc ttc ccc ccc 432
 Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro
 130 135 140
 tcc gac gag cag ctg aag tcc gcc acc gcc tcc gtg gtg tgc ctg ctg 480
 Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu
 145 150 155
 aat aac ttc tac ccc aga gag gcc aag gtg cag tgg aag gtg gac aac 528
 Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn
 165 170 175
 gcc ctg cag tcc ggg aac tcc cag gag agc gtg acc gag cag gac agc 576
 Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser
 180 185 190
 aag gac agc acc tac agc ctg agc agc acc ctg acc ctg agc aaa gcc 624
 Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala
 195 200 205
 gac tac gag aag cac aag gtg tac gcc tgc gag gtg acc cac cag gcc 672
 Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly
 210 215 220
 ctg agc tcc ccc gtc acc aag agc ttc aac agg ggg gag tgt 714
 Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
 225 230 235

<210> 65
 <211> 238
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic Construct

<400> 65

Met Val Leu Gln Thr Gln Val Phe Ile Ser Leu Leu Leu Trp Ile Ser
1 5 10 15

Gly Ala Tyr Gly Asp Ile Val Leu Thr Gln Ser Pro Asp Ser Leu Ala
20 25 30

Val Ser Leu Gly Glu Arg Ala Thr Ile Ser Cys Arg Ala Ser Gln Ser
35 40 45

Val Thr Ile Ser Gly Tyr Ser Phe Ile His Trp Tyr Gln Gln Lys Pro
50 55 60

Gly Gln Gln Pro Arg Leu Leu Ile Tyr Arg Ala Ser Asn Leu Ala Ser
65 70 75 80

Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
85 90 95

Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Thr Tyr Phe Cys
100 105 110

Gln Gln Ser Arg Lys Ser Pro Trp Thr Phe Ala Gly Gly Thr Lys Val
115 120 125

Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro
130 135 140

Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu
145 150 155 160

Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn
165 170 175

Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser
180 185 190

Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala
195 200 205

Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly
210 215 220

Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
225 230 235

<210> 66
<211> 711
<212> DNA
<213> Artificial Sequence

<220>
<223> h#32A1-T4L

<220>
<221> CDS
<222> (1)..(711)

<400> 66
atg gtg ctg cag acc cag gtg ttc atc tcc ctg ctg ctg tgg atc tcc 48
Met Val Leu Gln Thr Gln Val Phe Ile Ser Leu Leu Leu Trp Ile Ser
1 5 10 15
ggc gca tat ggc gac atc gtg ctt acc cag agc cct gcc ctt gcc gtg 96
Gly Ala Tyr Gly Asp Ile Val Leu Thr Gln Ser Pro Ala Leu Ala Val
20 25 30
tcc ctg ggc gag aga gcc acc atc agc tgt aga gcc tcc cag agc gtg 144
Ser Leu Gly Glu Arg Ala Thr Ile Ser Cys Arg Ala Ser Gln Ser Val
35 40 45
acc atc tcc ggc tac agc ttc atc cac tgg tac cag cag aag cct gcc 192
Thr Ile Ser Gly Tyr Ser Phe Ile His Trp Tyr Gln Gln Lys Pro Gly

50	55	60	
cag Gln 65	cag cct aga ctt Gln Pro Arg Leu 70	ctg atc tac aga gcc tcc Leu Ile Tyr Arg Ala Ser 75	240
atc Ile	cct gcc aga ttc Pro Ala Arg Phe 85	tcc ggc agc ggc tcc ggc Ser Gly Ser Gly Ser 90	288
acc Thr	atc agc tcc ctt Ile Ser Ser Leu 100	cag gcc gag gac gtg Gln Ala Glu Asp Val 105	336
cag Gln	agc aga aag tcc Ser Arg Lys Ser 115	cct tgg acc ttc gcc Pro Trp Thr Phe Ala 120	384
atc Ile	aag cgt acg gtg Lys Arg Thr Val 130	gcc gcc ccc tcc Ala Ala Pro Ser 135	432
gac Asp 145	gag cag ctg aag Glu Gln Leu Lys 150	gcc acc gcc tcc Ala Thr Ala Ser 155	480
aac Asn	ttc tac ccc aga Phe Tyr Pro Arg 165	gag gcc aag gtg Glu Ala Lys Val 170	528
ctg Leu	cag tcc ggc aac Gln Ser Ser Asn 180	gtg acc gag ctg Val Thr Glu Gln 190	576
gac Asp	agc acc tac agc Ser Thr Tyr Ser 195	ctg agc acc ctg Leu Thr Leu Ser 205	624
tac Tyr 210	gag aag cac aag Glu Lys His Lys 215	gtg tgc gag gtg Val Cys Glu Val 220	672
agc Ser 225	tcc ccc gtc acc Ser Pro Val Thr 230	aag agc ttc aac Lys Ser Phe Asn 235	711

<210> 67
 <211> 237
 <212> PRT
 <213> Artificial sequence

<220>
 <223> Synthetic Construct

<400> 67

Met val Leu Gln Thr Gln val Phe ile Ser Leu Leu Leu Trp ile Ser
1 5 10 15

Gly Ala Tyr Gly Asp ile val Leu Thr Gln Ser Pro Ala Leu Ala val
20 25 30

Ser Leu gly Glu Arg Ala Thr ile Ser Cys Arg Ala Ser Gln Ser val
35 40 45

Thr Ile Ser Gly Tyr Ser Phe Ile His Trp Tyr Gln Gln Lys Pro Gly
50 55 60

Gln Gln Pro Arg Leu Leu Ile Tyr Arg Ala Ser Asn Leu Ala Ser Gly
65 70 75 80

Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu
85 90 95

Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Thr Tyr Phe Cys Gln
100 105 110

Gln Ser Arg Lys Ser Pro Trp Thr Phe Ala Gly Gly Thr Lys Leu Glu
115 120 125

Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser
130 135 140

Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn
145 150 155 160

Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala
165 170 175

Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys
180 185 190

Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp
195 200 205

Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu
210 215 220

Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
225 230 235

<210> 68
<211> 714
<212> DNA
<213> Artificial Sequence

<220>
<223> h#32A1-T5L

<220>
<221> CDS
<222> (1)..(714)

<400> 68
atg gtg ctg cag acc cag gtg ttc atc tcc ctg ctg ctg tgg atc tcc 48
Met Val Leu Gln Thr Gln Val Phe Ile Ser Leu Leu Leu Trp Ile Ser
1 5 10 15
ggc gca tat ggc gac atc gtg ctt acc cag agc cct gac tcc ctt gcc 96

Gly	Ala	Tyr	Gly	Asp	Ile	Val	Leu	Thr	Gln	Ser	Pro	Asp	Ser	Leu	Ala	
			20					25					30			
gtg	tcc	ctg	ggc	gag	aga	gcc	acc	atc	aac	tgt	aga	gcc	tcc	cag	agc	144
Val	Ser	Leu	Gly	Glu	Arg	Ala	Thr	Ile	Asn	Cys	Arg	Ala	Ser	Gln	Ser	
		35				40						45				
gtg	acc	atc	tcc	ggc	tac	agc	ttc	atc	cac	tgg	tac	cag	cag	aag	cct	192
Val	Thr	Ile	Ser	Gly	Tyr	Ser	Phe	Ile	His	Trp	Tyr	Gln	Gln	Lys	Pro	
	50					55				60						
ggc	cag	cct	cct	aag	ctt	ctg	atc	tac	aga	gcc	tcc	aac	ctt	gcc	agc	240
Gly	Gln	Pro	Pro	Lys	Leu	Leu	Ile	Tyr	Arg	Ala	Ser	Asn	Leu	Ala	Ser	
65				70					75					80		
ggc	atc	cct	gcc	aga	ttc	tcc	ggc	agc	ggc	tcc	ggc	acc	gac	ttc	acc	288
Gly	Ile	Pro	Ala	Arg	Phe	Ser	Gly	Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	
			85					90						95		
ctg	acc	atc	agc	tcc	ctt	cag	gcc	gag	gac	gtg	gcc	acc	tac	tac	tgt	336
Leu	Thr	Ile	Ser	Ser	Leu	Gln	Ala	Glu	Asp	Val	Ala	Thr	Tyr	Tyr	Cys	
			100				105						110			
cag	cag	agc	aga	aag	tcc	cct	tgg	acc	ttc	ggc	cag	ggc	acc	aag	gtg	384
Gln	Gln	Ser	Arg	Lys	Ser	Pro	Trp	Thr	Phe	Gly	Gln	Gly	Thr	Lys	Val	
		115				120						125				
gag	atc	aag	cgt	acg	gtg	gcc	gcc	ccc	tcc	gtg	ttc	atc	ttc	ccc	ccc	432
Glu	Ile	Lys	Arg	Thr	Val	Ala	Ala	Pro	Ser	Val	Phe	Ile	Phe	Pro	Pro	
	130					135				140						
tcc	gac	gag	cag	ctg	aag	tcc	ggc	acc	gcc	tcc	gtg	gtg	tgc	ctg	ctg	480
Ser	Asp	Glu	Gln	Leu	Lys	Ser	Gly	Thr	Ala	Ser	Val	Val	Cys	Leu	Leu	
145				150					155					160		
aat	aac	ttc	tac	ccc	aga	gag	gcc	aag	gtg	cag	tgg	aag	gtg	gac	aac	528
Asn	Asn	Phe	Tyr	Pro	Arg	Glu	Ala	Lys	Val	Gln	Trp	Lys	Val	Asp	Asn	
			165					170						175		
gcc	ctg	cag	tcc	ggg	aac	tcc	cag	gag	agc	gtg	acc	gag	cag	gac	agc	576
Ala	Leu	Gln	Ser	Gly	Asn	Ser	Gln	Glu	Ser	Val	Thr	Glu	Gln	Asp	Ser	
			180				185						190			
aag	gac	agc	acc	tac	agc	ctg	agc	agc	acc	ctg	acc	ctg	agc	aaa	gcc	624
Lys	Asp	Ser	Thr	Tyr	Ser	Leu	Ser	Ser	Thr	Leu	Thr	Leu	Ser	Lys	Ala	
		195				200						205				
gac	tac	gag	aag	cac	aag	gtg	tac	gcc	tgc	gag	gtg	acc	cac	cag	ggc	672
Asp	Tyr	Glu	Lys	His	Lys	Val	Tyr	Ala	Cys	Glu	Val	Thr	His	Gln	Gly	
	210					215					220					
ctg	agc	tcc	ccc	gtc	acc	aag	agc	ttc	aac	agg	ggg	gag	tgt			714
Leu	Ser	Ser	Pro	Val	Thr	Lys	Ser	Phe	Asn	Arg	Gly	Glu	Cys			
225				230					235							

<210> 69
 <211> 238
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic Construct

<400> 69

Met	Val	Leu	Gln	Thr	Gln	Val	Phe	Ile	Ser	Leu	Leu	Leu	Trp	Ile	Ser
1				5					10					15	

Gly Ala Tyr Gly Asp Ile Val Leu Thr Gln Ser Pro Asp Ser Leu Ala
 20 25 30
 Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Arg Ala Ser Gln Ser
 35 40 45
 Val Thr Ile Ser Gly Tyr Ser Phe Ile His Trp Tyr Gln Gln Lys Pro
 50 55 60
 Gly Gln Pro Pro Lys Leu Leu Ile Tyr Arg Ala Ser Asn Leu Ala Ser
 65 70 75 80
 Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
 85 90 95
 Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Thr Tyr Tyr Cys
 100 105 110
 Gln Gln Ser Arg Lys Ser Pro Trp Thr Phe Gly Gln Gly Thr Lys Val
 115 120 125
 Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro
 130 135 140
 Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu
 145 150 155 160
 Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn
 165 170 175
 Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser
 180 185 190
 Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala
 195 200 205
 Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly
 210 215 220
 Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
 225 230 235

<210> 70
 <211> 714
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> h#32A1-T6L

<220>

<221> CDS
 <222> (1)..(714)
 <400> 70
 atg gtg ctg cag acc cag gtg ttc atc tcc ctg ctg ctg tgg atc tcc 48
 Met Val Leu Gln Thr Gln Val Phe Ile Ser Leu Leu Leu Trp Ile Ser
 1 5 10 15
 ggc gca tat ggc gac atc gtg ctt acc cag agc cct gac tcc ctt gcc 96
 Gly Ala Tyr Gly Asp Ile Val Leu Thr Gln Ser Pro Asp Ser Leu Ala
 20 25 30
 gtg tcc ctg ggc gag aga gcc acc atc agc tgt aga gcc tcc cag agc 144
 Val Ser Leu Gly Glu Arg Ala Thr Ile Ser Cys Arg Ala Ser Gln Ser
 35 40 45
 gtg acc atc tcc ggc tac agc ttc atc cac tgg tac cag cag aag cct 192
 Val Thr Ile Ser Gly Tyr Ser Phe Ile His Trp Tyr Gln Gln Lys Pro
 50 55 60
 ggc cag cct cct aga ctg ctg atc tac aga gcc tcc aac ctt gcc agc 240
 Gly Gln Pro Pro Arg Leu Leu Ile Tyr Arg Ala Ser Asn Leu Ala Ser
 65 70 75 80
 ggc atc cct gcc aga ttc tcc ggc agc ggc tcc ggc acc gac ttc acc 288
 Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
 85 90 95
 ctg acc atc agc tcc ctt cag gcc gag gac gtg gcc acc tac ttc tgt 336
 Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Thr Tyr Phe Cys
 100 105 110
 cag cag agc aga aag tcc cct tgg acc ttc gcc ggc ggc acc aag gtg 384
 Gln Gln Ser Arg Lys Ser Pro Trp Thr Phe Ala Gly Gly Thr Lys Val
 115 120 125
 gag atc aag cgt acg gtg gcc gcc ccc tcc gtg ttc atc ttc ccc ccc 432
 Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro
 130 135 140
 tcc gac gag cag ctg aag tcc ggc acc gcc tcc gtg gtg tgc ctg ctg 480
 Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu
 145 150 155 160
 aat aac ttc tac ccc aga gag gcc aag gtg cag tgg aag gtg gac aac 528
 Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn
 165 170 175
 gcc ctg cag tcc ggc aac tcc cag gag agc gtg acc gag cag gac agc 576
 Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser
 180 185 190
 aag gac agc acc tac agc ctg agc agc acc ctg acc ctg agc aaa gcc 624
 Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala
 195 200 205
 gac tac gag aag cac aag gtg tac gcc tgc gag gtg acc cac cag ggc 672
 Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly
 210 215 220
 ctg agc tcc ccc gtc acc aag agc ttc aac agg ggc gag tgt 714
 Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
 225 230 235
 <210> 71
 <211> 238
 <212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic Construct

<400> 71

Met Val Leu Gln Thr Gln Val Phe Ile Ser Leu Leu Leu Trp Ile Ser
1 5 10 15

Gly Ala Tyr Gly Asp Ile Val Leu Thr Gln Ser Pro Asp Ser Leu Ala
20 25 30

Val Ser Leu Gly Glu Arg Ala Thr Ile Ser Cys Arg Ala Ser Gln Ser
35 40 45

Val Thr Ile Ser Gly Tyr Ser Phe Ile His Trp Tyr Gln Gln Lys Pro
50 55 60

Gly Gln Pro Pro Arg Leu Leu Ile Tyr Arg Ala Ser Asn Leu Ala Ser
65 70 75 80

Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
85 90 95

Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Thr Tyr Phe Cys
100 105 110

Gln Gln Ser Arg Lys Ser Pro Trp Thr Phe Ala Gly Gly Thr Lys Val
115 120 125

Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro
130 135 140

Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu
145 150 155 160

Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn
165 170 175

Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser
180 185 190

Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala
195 200 205

Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly
210 215 220

Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
225 230 235

<210> 72

<211> 451
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> h#32A1-T7H

<400> 72

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Phe Asn Asp Tyr
 20 25 30

Phe Met Asn Trp Val Arg Gln Ala Pro Glu Lys Gly Leu Glu Trp Val
 35 40 45

Ala Gln Ile Arg Asn Lys Ile Tyr Thr Tyr Ala Thr Phe Tyr Ala Glu
 50 55 60

Ser Leu Glu Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser
 65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr
 85 90 95

Tyr Cys Ala Arg Ser Leu Thr Gly Gly Asp Tyr Phe Asp Tyr Trp Gly
 100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
 115 120 125

Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala
 130 135 140

Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
 145 150 155 160

Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
 165 170 175

Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
 180 185 190

Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His
 195 200 205

Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys
 210 215 220

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
 225 230 235 240

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
245 250 255

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
260 265 270

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
275 280 285

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
290 295 300

Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
305 310 315 320

Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
325 330 335

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
340 345 350

Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser
355 360 365

Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
370 375 380

Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
385 390 395 400

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
405 410 415

Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
420 425 430

His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
435 440 445

Pro Gly Lys
450

<210> 73
<211> 451
<212> PRT
<213> Artificial Sequence

<220>
<223> h#32A1-T8H

<400> 73

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

1	5	10	15
Ser	Leu	Arg	Leu
	20	Ser	Cys
		Ala	Ala
		25	Ser
		Gly	Phe
		Asn	Phe
		30	Asn
		Asp	Tyr
Phe	Met	Asn	Trp
	35	Val	Arg
		Gln	Ala
		40	Pro
		Gly	Lys
		Gly	Leu
		45	Glu
		Trp	Val
Ala	Gln	Ile	Arg
	50	Asn	Lys
		55	Ile
		Tyr	Thr
		Tyr	Ala
		60	Thr
		Phe	Tyr
		Ala	Glu
Ser	Leu	Glu	Gly
	65	Arg	Val
		70	Thr
		Ile	Ser
		Arg	Asp
		75	Asn
		Ala	Lys
		Asn	Ser
		80	
Leu	Tyr	Leu	Gln
		85	Met
		Asn	Ser
		Leu	Arg
		90	Ala
		Glu	Asp
		Thr	Ala
		95	Val
		Tyr	
Tyr	Cys	Ala	Arg
		100	Ser
		Leu	Thr
		Gly	Gly
		105	Asp
		Tyr	Phe
		Asp	Tyr
		110	Trp
		Gly	
Gln	Gly	Thr	Leu
		115	Val
		Thr	Val
		120	Ser
		Ser	Ala
		Ser	Thr
		125	Lys
		Gly	Pro
		Ser	
Val	Phe	Pro	Leu
	130	Ala	Pro
		135	Ser
		Ser	Lys
		Ser	Thr
		140	Ser
		Gly	Gly
		Thr	Ala
Ala	Leu	Gly	Cys
	145	Leu	Val
		150	Lys
		Asp	Tyr
		Phe	Pro
		155	Glu
		Pro	Val
		Thr	Val
		160	
Ser	Trp	Asn	Ser
		165	Gly
		Ala	Leu
		Thr	Ser
		170	Gly
		Val	His
		Thr	Phe
		175	Pro
		Ala	
Val	Leu	Gln	Ser
		180	Ser
		Gly	Leu
		Tyr	Ser
		185	Leu
		Ser	Ser
		Val	Val
		190	Thr
		Val	
Pro	Ser	Ser	Ser
	195	Leu	Gly
		Thr	Gln
		200	Thr
		Tyr	Ile
		Cys	Asn
		205	Val
		Asn	His
Lys	Pro	Ser	Asn
	210	Thr	Lys
		Val	Val
		215	Asp
		Lys	Arg
		Val	Glu
		220	Pro
		Lys	Ser
		Cys	
Asp	Lys	Thr	His
	225	Thr	Cys
		230	Pro
		Pro	Cys
		Pro	Ala
		235	Pro
		Glu	Leu
		Leu	Gly
		240	
Gly	Pro	Ser	Val
		245	Phe
		Leu	Phe
		Pro	Pro
		250	Lys
		Pro	Lys
		Asp	Thr
		Leu	Met
		255	
Ile	Ser	Arg	Thr
		260	Pro
		Glu	Val
		Thr	Cys
		265	Val
		Val	Val
		Val	Asp
		270	Val
		Ser	His
Glu	Asp	Pro	Glu
		Val	Lys
		Phe	Asn
		Trp	Tyr
		Val	Asp
		Gly	Val
		Glu	Val

[illegible]

<210>	74
<211>	451
<212>	PRT
<213>	Artificial Sequence

<220>
<223> h#32A1-T9H

<400> 74

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Phe Asn Asp Tyr
20 25 30

Phe Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ala Gln Ile Arg Asn Lys Ile Tyr Thr Tyr Ala Thr Phe Tyr Ala Glu
 50 55 60
 Ser Leu Glu Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser
 65 70 75 80
 Leu Tyr Leu Gln Met Ser Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr
 85 90 95
 Tyr Cys Ala Arg Ser Leu Thr Gly Gly Asp Tyr Phe Asp Tyr Trp Gly
 100 105 110
 Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
 115 120 125
 Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala
 130 135 140
 Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
 145 150 155 160
 Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
 165 170 175
 Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
 180 185 190
 Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His
 195 200 205
 Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys
 210 215 220
 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
 225 230 235 240
 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
 245 250 255
 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
 260 265 270
 Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
 275 280 285
 His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
 290 295 300
 Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
 305 310 315 320

Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
 325 330 335

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
 340 345 350

Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser
 355 360 365

Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
 370 375 380

Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
 385 390 395 400

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
 405 410 415

Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
 420 425 430

His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
 435 440 445

Pro Gly Lys
 450

<210> 75
 <211> 451
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> h#32A1-T10H

<400> 75

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Phe Asn Asp Tyr
 20 25 30

Phe Met Asn Trp Val Arg Gln Ala Pro Glu Lys Gly Leu Glu Trp Val
 35 40 45

Ala Gln Ile Arg Asn Lys Ile Tyr Thr Tyr Ala Thr Phe Tyr Ala Glu
 50 55 60

Ser Leu Glu Gly Arg Val Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser
 65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr

85

90

95

Tyr Cys Ala Arg Ser Leu Thr Gly Gly Asp Tyr Phe Asp Tyr Trp Gly
 100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
 115 120 125

Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala
 130 135 140

Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
 145 150 155 160

Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
 165 170 175

Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
 180 185 190

Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His
 195 200 205

Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys
 210 215 220

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
 225 230 235 240

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
 245 250 255

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
 260 265 270

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
 275 280 285

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
 290 295 300

Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
 305 310 315 320

Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
 325 330 335

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
 340 345 350

Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser

355

360

365

Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
 370 375 380

Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
 385 390 395 400

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
 405 410 415

Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
 420 425 430

His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
 435 440 445

Pro Gly Lys
 450

<210> 76
 <211> 451
 <212> PRT
 <213> Artificial sequence

<220>
 <223> h#32A1-T11H

<400> 76

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Phe Asn Asp Tyr
 20 25 30

Phe Met Asn Trp Val Arg Gln Ala Pro Glu Lys Gly Leu Glu Trp Val
 35 40 45

Ala Gln Ile Arg Asn Lys Ile Tyr Thr Tyr Ala Thr Phe Tyr Ala Glu
 50 55 60

Ser Leu Glu Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser
 65 70 75 80

Leu Tyr Leu Gln Met Ser Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr
 85 90 95

Tyr Cys Ala Arg Ser Leu Thr Gly Gly Asp Tyr Phe Asp Tyr Trp Gly
 100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
 115 120 125

Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala
 130 135 140
 Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
 145 150 155 160
 Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
 165 170 175
 Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
 180 185 190
 Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His
 195 200 205
 Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys
 210 215 220
 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
 225 230 235 240
 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
 245 250 255
 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
 260 265 270
 Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
 275 280 285
 His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
 290 295 300
 Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
 305 310 315 320
 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
 325 330 335
 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
 340 345 350
 Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser
 355 360 365
 Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
 370 375 380
 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
 385 390 395 400

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
 405 410 415

Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
 420 425 430

His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
 435 440 445

Pro Gly Lys
 450

<210> 77
 <211> 451
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> h#32A1-T12H

<400> 77

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Phe Asn Asp Tyr
 20 25 30

Phe Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

Ala Gln Ile Arg Asn Lys Ile Tyr Thr Tyr Ala Thr Phe Tyr Ala Glu
 50 55 60

Ser Leu Glu Gly Arg Val Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser
 65 70 75 80

Leu Tyr Leu Gln Met Ser Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr
 85 90 95

Tyr Cys Ala Arg Ser Leu Thr Gly Gly Asp Tyr Phe Asp Tyr Trp Gly
 100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
 115 120 125

Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala
 130 135 140

Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
 145 150 155 160

Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala

165 170 175
 Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
 180 185 190
 Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His
 195 200 205
 Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys
 210 215 220
 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
 225 230 235 240
 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
 245 250 255
 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
 260 265 270
 Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
 275 280 285
 His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
 290 295 300
 Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
 305 310 315 320
 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
 325 330 335
 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
 340 345 350
 Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser
 355 360 365
 Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
 370 375 380
 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
 385 390 395 400
 Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
 405 410 415
 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
 420 425 430
 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser

435

440

445

Pro Gly Lys
450

<210> 78
 <211> 218
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> h#32A1-T7L

<400> 78

Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
 1 5 10 15

Glu Arg Ala Thr Ile Ser Cys Arg Ala Ser Gln Ser Val Thr Ile Ser
 20 25 30

Gly Tyr Ser Phe Ile His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro
 35 40 45

Lys Leu Leu Ile Tyr Arg Ala Ser Asn Leu Ala Ser Gly Val Pro Ala
 50 55 60

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
 65 70 75 80

Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Ser Arg
 85 90 95

Lys Ser Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg
 100 105 110

Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln
 115 120 125

Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr
 130 135 140

Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser
 145 150 155 160

Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr
 165 170 175

Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys
 180 185 190

His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro
 195 200 205

Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
 210 215

<210> 79
 <211> 218
 <212> PRT
 <213> Artificial sequence

<220>
 <223> h#32A1-T8L

<400> 79

Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
 1 5 10 15

Glu Arg Ala Thr Ile Asn Cys Arg Ala Ser Gln Ser Val Thr Ile Ser
 20 25 30

Gly Tyr Ser Phe Ile His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro
 35 40 45

Arg Leu Leu Ile Tyr Arg Ala Ser Asn Leu Ala Ser Gly Val Pro Ala
 50 55 60

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
 65 70 75 80

Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Ser Arg
 85 90 95

Lys Ser Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg
 100 105 110

Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln
 115 120 125

Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr
 130 135 140

Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser
 145 150 155 160

Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr
 165 170 175

Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys
 180 185 190

His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro
 195 200 205

Val Thr Lys Ser Phe Asn Arg Gly Glu Cys

210

215

<210> 80
 <211> 218
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> h#32A1-T9L

<400> 80

Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
 1 5 10 15

Glu Arg Ala Thr Ile Asn Cys Arg Ala Ser Gln Ser Val Thr Ile Ser
 20 25 30

Gly Tyr Ser Phe Ile His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro
 35 40 45

Lys Leu Leu Ile Tyr Arg Ala Ser Asn Leu Ala Ser Gly Val Pro Ala
 50 55 60

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
 65 70 75 80

Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Phe Cys Gln Gln Ser Arg
 85 90 95

Lys Ser Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg
 100 105 110

Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln
 115 120 125

Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr
 130 135 140

Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser
 145 150 155 160

Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr
 165 170 175

Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys
 180 185 190

His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro
 195 200 205

Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
 210 215

<210> 81
 <211> 218
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> h#32A1-T10L

<400> 81

Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
 1 5 10 15

Glu Arg Ala Thr Ile Asn Cys Arg Ala Ser Gln Ser Val Thr Ile Ser
 20 25 30

Gly Tyr Ser Phe Ile His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro
 35 40 45

Lys Leu Leu Ile Tyr Arg Ala Ser Asn Leu Ala Ser Gly Val Pro Ala
 50 55 60

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
 65 70 75 80

Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Ser Arg
 85 90 95

Lys Ser Pro Trp Thr Phe Ala Gly Gly Thr Lys Val Glu Ile Lys Arg
 100 105 110

Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln
 115 120 125

Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr
 130 135 140

Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser
 145 150 155 160

Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr
 165 170 175

Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys
 180 185 190

His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro
 195 200 205

Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
 210 215

<210> 82

<211> 218
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> h#32A1-T11L

<400> 82

Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
 1 5 10 15

Glu Arg Ala Thr Ile Ser Cys Arg Ala Ser Gln Ser Val Thr Ile Ser
 20 25 30

Gly Tyr Ser Phe Ile His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro
 35 40 45

Arg Leu Leu Ile Tyr Arg Ala Ser Asn Leu Ala Ser Gly Val Pro Ala
 50 55 60

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
 65 70 75 80

Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Ser Arg
 85 90 95

Lys Ser Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg
 100 105 110

Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln
 115 120 125

Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr
 130 135 140

Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser
 145 150 155 160

Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr
 165 170 175

Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys
 180 185 190

His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro
 195 200 205

Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
 210 215

<210> 83
 <211> 218
 <212> PRT

<213> Artificial Sequence

<220>

<223> h#32A1-T12L

<400> 83

Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
1 5 10 15

Glu Arg Ala Thr Ile Ser Cys Arg Ala Ser Gln Ser Val Thr Ile Ser
20 25 30

Gly Tyr Ser Phe Ile His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro
35 40 45

Lys Leu Leu Ile Tyr Arg Ala Ser Asn Leu Ala Ser Gly Val Pro Ala
50 55 60

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
65 70 75 80

Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Phe Cys Gln Gln Ser Arg
85 90 95

Lys Ser Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg
100 105 110

Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln
115 120 125

Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr
130 135 140

Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser
145 150 155 160

Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr
165 170 175

Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys
180 185 190

His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro
195 200 205

Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
210 215

<210> 84

<211> 218

<212> PRT

<213> Artificial Sequence

<220>

<223> h#32A1-T13L

<400> 84

Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
 1 5 10 15

Glu Arg Ala Thr Ile Ser Cys Arg Ala Ser Gln Ser Val Thr Ile Ser
 20 25 30

Gly Tyr Ser Phe Ile His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro
 35 40 45

Lys Leu Leu Ile Tyr Arg Ala Ser Asn Leu Ala Ser Gly Val Pro Ala
 50 55 60

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
 65 70 75 80

Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Ser Arg
 85 90 95

Lys Ser Pro Trp Thr Phe Ala Gly Gly Thr Lys Val Glu Ile Lys Arg
 100 105 110

Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln
 115 120 125

Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr
 130 135 140

Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser
 145 150 155 160

Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr
 165 170 175

Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys
 180 185 190

His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro
 195 200 205

Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
 210 215

<210> 85

<211> 218

<212> PRT

<213> Artificial Sequence

<220>

<223> h#32A1-T14L

<400> 85

Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
 1 5 10 15

Glu Arg Ala Thr Ile Asn Cys Arg Ala Ser Gln Ser Val Thr Ile Ser
 20 25 30

Gly Tyr Ser Phe Ile His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro
 35 40 45

Arg Leu Leu Ile Tyr Arg Ala Ser Asn Leu Ala Ser Gly Val Pro Ala
 50 55 60

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
 65 70 75 80

Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Phe Cys Gln Gln Ser Arg
 85 90 95

Lys Ser Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg
 100 105 110

Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln
 115 120 125

Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr
 130 135 140

Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser
 145 150 155 160

Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr
 165 170 175

Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys
 180 185 190

His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro
 195 200 205

Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
 210 215

<210> 86

<211> 218

<212> PRT

<213> Artificial Sequence

<220>

<223> h#32A1-T15L

<400> 86

Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
 1 5 10 15
 Glu Arg Ala Thr Ile Asn Cys Arg Ala Ser Gln Ser Val Thr Ile Ser
 20 25 30
 Gly Tyr Ser Phe Ile His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro
 35 40 45
 Arg Leu Leu Ile Tyr Arg Ala Ser Asn Leu Ala Ser Gly Val Pro Ala
 50 55 60
 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
 65 70 75 80
 Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Ser Arg
 85 90 95
 Lys Ser Pro Trp Thr Phe Ala Gly Gly Thr Lys Val Glu Ile Lys Arg
 100 105 110
 Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln
 115 120 125
 Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr
 130 135 140
 Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser
 145 150 155 160
 Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr
 165 170 175
 Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys
 180 185 190
 His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro
 195 200 205
 Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
 210 215

<210> 87
 <211> 218
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> h#32A1-T16L

<400> 87

Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly

1 5 10 15
 Glu Arg Ala Thr Ile Asn Cys Arg Ala Ser Gln Ser Val Thr Ile Ser
 20 25 30
 Gly Tyr Ser Phe Ile His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro
 35 40 45
 Lys Leu Leu Ile Tyr Arg Ala Ser Asn Leu Ala Ser Gly Val Pro Ala
 50 55 60
 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
 65 70 75 80
 Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Phe Cys Gln Gln Ser Arg
 85 90 95
 Lys Ser Pro Trp Thr Phe Ala Gly Gly Thr Lys Val Glu Ile Lys Arg
 100 105 110
 Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln
 115 120 125
 Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr
 130 135 140
 Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser
 145 150 155 160
 Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr
 165 170 175
 Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys
 180 185 190
 His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro
 195 200 205
 Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
 210 215

<210> 88
 <211> 218
 <212> PRT
 <213> Artificial sequence

<220>
 <223> h#32A1-T17L

<400> 88

Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
 1 5 10 15

Glu Arg Ala Thr Ile Ser Cys Arg Ala Ser Gln Ser Val Thr Ile Ser
20 25 30

Gly Tyr Ser Phe Ile His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro
35 40 45

Arg Leu Leu Ile Tyr Arg Ala Ser Asn Leu Ala Ser Gly Val Pro Ala
50 55 60

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
65 70 75 80

Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Phe Cys Gln Gln Ser Arg
85 90 95

Lys Ser Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg
100 105 110

Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln
115 120 125

Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr
130 135 140

Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser
145 150 155 160

Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr
165 170 175

Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys
180 185 190

His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro
195 200 205

Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
210 215

<210> 89
<211> 218
<212> PRT
<213> Artificial Sequence

<220>
<223> h#32A1-T18L

<400> 89

Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
1 5 10 15

Glu Arg Ala Thr Ile Ser Cys Arg Ala Ser Gln Ser Val Thr Ile Ser

20 25 30
 Gly Tyr Ser Phe Ile His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro
 35 40 45
 Arg Leu Leu Ile Tyr Arg Ala Ser Asn Leu Ala Ser Gly Val Pro Ala
 50 55 60
 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
 65 70 75 80
 Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Ser Arg
 85 90 95
 Lys Ser Pro Trp Thr Phe Ala Gly Gly Thr Lys Val Glu Ile Lys Arg
 100 105 110
 Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln
 115 120 125
 Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr
 130 135 140
 Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser
 145 150 155 160
 Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr
 165 170 175
 Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys
 180 185 190
 His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro
 195 200 205
 Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
 210 215

<210> 90
 <211> 218
 <212> PRT
 <213> Artificial sequence

<220>
 <223> h#32A1-T19L

<400> 90

Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
 1 5 10 15
 Glu Arg Ala Thr Ile Ser Cys Arg Ala Ser Gln Ser Val Thr Ile Ser
 20 25 30

Gly Tyr Ser Phe Ile His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro
 35 40 45
 Lys Leu Leu Ile Tyr Arg Ala Ser Asn Leu Ala Ser Gly Val Pro Ala
 50 55 60
 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
 65 70 75 80
 Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Phe Cys Gln Gln Ser Arg
 85 90 95
 Lys Ser Pro Trp Thr Phe Ala Gly Gly Thr Lys Val Glu Ile Lys Arg
 100 105 110
 Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln
 115 120 125
 Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr
 130 135 140
 Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser
 145 150 155 160
 Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr
 165 170 175
 Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys
 180 185 190
 His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro
 195 200 205
 Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
 210 215

<210> 91
 <211> 218
 <212> PRT
 <213> Artificial sequence

<220>
 <223> h#32A1-T20L

<400> 91

Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
 1 5 10 15
 Glu Arg Ala Thr Ile Asn Cys Arg Ala Ser Gln Ser Val Thr Ile Ser
 20 25 30
 Gly Tyr Ser Phe Ile His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro

35 40 45
 Arg Leu Leu Ile Tyr Arg Ala Ser Asn Leu Ala Ser Gly Val Pro Ala
 50 55 60
 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
 65 70 75 80
 Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Phe Cys Gln Gln Ser Arg
 85 90 95
 Lys Ser Pro Trp Thr Phe Ala Gly Gly Thr Lys Val Glu Ile Lys Arg
 100 105 110
 Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln
 115 120 125
 Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr
 130 135 140
 Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser
 145 150 155 160
 Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr
 165 170 175
 Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys
 180 185 190
 His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro
 195 200 205
 Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
 210 215

<210> 92
 <211> 218
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> h#32A1-T21L

<400> 92

Glu Ile Leu Met Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
 1 5 10 15
 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Thr Ile Ser
 20 25 30
 Gly Tyr Ser Phe Ile His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro
 35 40 45

Arg Leu Leu Ile Tyr Arg Ala Ser Asn Leu Ala Ser Gly Ile Pro Ala
50 55 60

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
65 70 75 80

Ser Leu Glu Pro Glu Asp Phe Ala Leu Tyr Tyr Cys Gln Gln Ser Arg
85 90 95

Lys Ser Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
100 105 110

Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln
115 120 125

Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr
130 135 140

Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser
145 150 155 160

Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr
165 170 175

Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys
180 185 190

His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro
195 200 205

Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
210 215

<210> 93
<211> 218
<212> PRT
<213> Artificial sequence

<220>
<223> h#32A1-T22L

<400> 93

Glu Ile Leu Met Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Thr Ile Ser
20 25 30

Gly Tyr Ser Phe Ile His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro
35 40 45

Arg Leu Leu Ile Tyr Arg Ala Ser Asn Leu Ala Ser Gly Ile Pro Ala

50 55 60
 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
 65 70 75 80
 Ser Leu Glu Pro Glu Asp Phe Ala Leu Tyr Phe Cys Gln Gln Ser Arg
 85 90 95
 Lys Ser Pro Trp Thr Phe Ala Gln Gly Thr Lys Val Glu Ile Lys Arg
 100 105 110
 Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln
 115 120 125
 Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr
 130 135 140
 Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser
 145 150 155 160
 Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr
 165 170 175
 Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys
 180 185 190
 His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro
 195 200 205
 Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
 210 215

<210> 94
 <211> 218
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> h#32A1-T23L

<400> 94

Glu Ile Leu Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
 1 5 10 15
 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Thr Ile Ser
 20 25 30
 Gly Tyr Ser Phe Ile His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro
 35 40 45
 Arg Leu Leu Ile Tyr Arg Ala Ser Asn Leu Ala Ser Gly Ile Pro Ala
 50 55 60

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
65 70 75 80

Ser Leu Glu Pro Glu Asp Phe Ala Leu Tyr Tyr Cys Gln Gln Ser Arg
85 90 95

Lys Ser Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
100 105 110

Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln
115 120 125

Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr
130 135 140

Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser
145 150 155 160

Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr
165 170 175

Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys
180 185 190

His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro
195 200 205

Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
210 215

<210> 95
<211> 218
<212> PRT
<213> Artificial Sequence

<220>
<223> h#32A1-T24L

<400> 95

Glu Ile Leu Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Thr Ile Ser
20 25 30

Gly Tyr Ser Phe Ile His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro
35 40 45

Arg Leu Leu Ile Tyr Arg Ala Ser Asn Leu Ala Ser Gly Ile Pro Ala
50 55 60

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser

65 70 75 80
 Ser Leu Glu Pro Glu Asp Phe Ala Leu Tyr Tyr Cys Gln Gln Ser Arg
 85 90 95
 Lys Ser Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
 100 105 110
 Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln
 115 120 125
 Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr
 130 135 140
 Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser
 145 150 155 160
 Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr
 165 170 175
 Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys
 180 185 190
 His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro
 195 200 205
 Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
 210 215

<210> 96
 <211> 218
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> h#32A1-T25L

<400> 96

Asp Ile Leu Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
 1 5 10 15
 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Thr Ile Ser
 20 25 30
 Gly Tyr Ser Phe Ile His Trp Tyr Gln Gln Lys Pro Gly Gln Gln Pro
 35 40 45
 Arg Leu Leu Ile Tyr Arg Ala Ser Asn Leu Ala Ser Gly Ile Pro Ala
 50 55 60
 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
 65 70 75 80

Ser Leu Glu Pro Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Ser Arg
85 90 95

Lys Ser Pro Trp Thr Phe Ala Gly Gly Thr Lys Val Glu Ile Lys Arg
100 105 110

Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln
115 120 125

Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr
130 135 140

Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser
145 150 155 160

Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr
165 170 175

Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys
180 185 190

His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro
195 200 205

Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
210 215

<210> 97
<211> 14
<212> PRT
<213> Rattus norvegicus

<400> 97

Gln Ile Arg Asn Lys Ile Tyr Thr Tyr Ala Thr Phe Tyr Ala
1 5 10

<210> 98
<211> 1398
<212> DNA
<213> Artificial sequence

<220>
<223> h#32A1-H1-1

<220>
<221> CDS
<222> (1)..(1398)

<400> 98
atg aaa cac ctg tgg ttc ttc ctc ctg ctg gtg gca gct ccc aga tgg 48
Met Lys His Leu Trp Phe Phe Leu Leu Leu Val Ala Ala Pro Arg Trp
1 5 10 15

gtg ctg agc gaa gtc cag ctt gtg gaa agc gga ggg gga ctc gtt cag 96
Val Leu Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln

20	25	30	
cca gga ggc tct ctg cgc ctg tca tgc gct gcc agc gga ttt aat ttc Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Phe 35 40 45			144
aat gat tat ttt atg aac tgg gtc agg cag gct ccg gga aaa ggg ctg Asn Asp Tyr Phe Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu 50 55 60			192
gaa tgg gtc gcc cag atc aga aac aag atc tat act tac gct aca ttc Glu Trp Val Ala Gln Ile Arg Asn Lys Ile Tyr Thr Tyr Ala Thr Phe 65 70 75 80			240
tac gcc gca tct gta aag ggg agg ttt aca att agt cgc gac aat gca Tyr Ala Ala Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala 85 90 95			288
aaa aat agt ctg tat ctc caa atg aac tcc ctc cgc gca gag gat act Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr 100 105 110			336
gct gtc tac tac tgc gcc agg tcc ttg act ggc ggc gac tat ttt gat Ala Val Tyr Tyr Cys Ala Arg Ser Leu Thr Gly Gly Asp Tyr Phe Asp 115 120 125			384
tac tgg gga cag ggc acc ctg gtg acg gtg agc tca gcc agc acc aag Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys 130 135 140			432
ggc cct tcc gtg ttc cct ctg gcc cct tgt agc cgt tcc acc agc gag Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu 145 150 155 160			480
tcc acc gcc gcc ctt ggc tgt ctg gtg aag gac tac ttc cct gag cct Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro 165 170 175			528
gtg acc gtg agc tgg aac tcc gga gcc ctt acc agc ggc gtg cac acc Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr 180 185 190			576
ttc cct gcc gtg ctg cag tcc agc ggc ctt tac tcc ctg agc tcc gtg Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val 195 200 205			624
gtg acc gtg cct agc tcc aac ttc ggc acc caa acc tac acc tgt aac Val Thr Val Pro Ser Ser Asn Phe Gly Thr Gln Thr Tyr Thr Cys Asn 210 215 220			672
gtg gac cac aag cct agc aac acc aag gtg gac aag acc gtg gag cgt Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Thr Val Glu Arg 225 230 235 240			720
aag tgt tgt gtg gag tgt cct cct tgt cct gcc cct cct gtg gcc gga Lys Cys Cys Val Glu Cys Pro Pro Cys Pro Ala Pro Pro Val Ala Gly 245 250 255			768
cct tcc gtg ttc ctt ttc cct cct aag cct aag gac acc ctg atg atc Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 260 265 270			816
agc cgt acc cct gag gtg acc tgt gtg gtg gtg gac gtg tcc cac gag Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 275 280 285			864
gac cct gag gtg cag ttc aac tgg tac gtg gac ggc gtg gag gtg cac Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 290 295 300			912

290	295	300	
aac gcc aag acc aag cct cgt gag gag caa ttc aac agc acc ttc cgt Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Phe Arg 305 310 315 320			960
gtg gtg tcc gtg ctt acc gtg gtg cac caa gac tgg ctg aac ggc aag Val Val Ser Val Leu Thr Val Val His Gln Asp Trp Leu Asn Gly Lys 325 330 335			1008
gag tac aag tgt aag gtg agc aac aag gga ctt cct gcc cct atc gag Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ala Pro Ile Glu 340 345 350			1056
aag acc atc tcc aag acc aag ggc caa cct cgt gag cct caa gtg tac Lys Thr Ile Ser Lys Thr Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 355 360 365			1104
acc ctt cct cct agc cgt gag gag atg acc aag aac caa gtg tcc ctt Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu 370 375 380			1152
acc tgt ctg gtg aag ggc ttc tac cct agc gac atc gcc gtg gag tgg Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 385 390 395 400			1200
gag tcc aac gga caa cct gag aac aac tac aag acc acc cct cct atg Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Met 405 410 415			1248
ctt gac agc gac ggc tcc ttc ttc ctg tac agc aag ctg acc gtg gac Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 420 425 430			1296
aag tcc cgt tgg caa caa ggc aac gtg ttc agc tgt tcc gtg atg cac Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His 435 440 445			1344
gag gcc ctg cac aac cac tac acc caa aag agc ctt tcc ctg agc cct Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro 450 455 460			1392
gga aag Gly Lys 465			1398

<210> 99
 <211> 466
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic Construct

<400> 99

Met Lys His Leu Trp Phe Phe Leu Leu Leu Val Ala Ala Pro Arg Trp
 1 5 10 15

Val Leu Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln
 20 25 30

Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Phe
 35 40 45

Asn Asp Tyr Phe Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
 50 55 60
 Glu Trp Val Ala Gln Ile Arg Asn Lys Ile Tyr Thr Tyr Ala Thr Phe
 65 70 75 80
 Tyr Ala Ala Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala
 85 90 95
 Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr
 100 105 110
 Ala Val Tyr Tyr Cys Ala Arg Ser Leu Thr Gly Gly Asp Tyr Phe Asp
 115 120 125
 Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys
 130 135 140
 Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu
 145 150 155 160
 Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro
 165 170 175
 Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr
 180 185 190
 Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val
 195 200 205
 Val Thr Val Pro Ser Ser Asn Phe Gly Thr Gln Thr Tyr Thr Cys Asn
 210 215 220
 Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Thr Val Glu Arg
 225 230 235 240
 Lys Cys Cys Val Glu Cys Pro Pro Cys Pro Ala Pro Pro Val Ala Gly
 245 250 255
 Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
 260 265 270
 Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu
 275 280 285
 Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His
 290 295 300
 Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Phe Arg
 305 310 315 320

Val Val Ser Val Leu Thr Val Val His Gln Asp Trp Leu Asn Gly Lys
 325 330 335
 Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ala Pro Ile Glu
 340 345 350
 Lys Thr Ile Ser Lys Thr Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr
 355 360 365
 Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu
 370 375 380
 Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
 385 390 395 400
 Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Met
 405 410 415
 Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp
 420 425 430
 Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His
 435 440 445
 Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro
 450 455 460
 Gly Lys
 465

<210> 100
 <211> 1398
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> h#32A1-H5

<220>
 <221> CDS
 <222> (1)..(1398)

<400> 100	
atg aaa cac ctg tgg ttc ttc ctc ctg ctg gtg gca gct ccc aga tgg	48
Met Lys His Leu Trp Phe Phe Leu Leu Leu Val Ala Ala Pro Arg Trp	
1 5 10 15	
gtg ctg agc gag gtg cag gtg gtg gag agc ggc ggc gga ctt gtg cag	96
Val Leu Ser Glu Val Gln Val Val Glu Ser Gly Gly Gly Leu Val Gln	
20 25 30	
cct ggc ggc tcc ctg aga ctt agc tgt gcc acc tcc ggc ttc aac ttc	144
Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly Phe Asn Phe	
35 40 45	
aac gac tac ttc atg aac tgg gtg aga cag gcc cct ggc aag ggc ctg	192

Asn	Asp	Tyr	Phe	Met	Asn	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	
50						55					60					
gag	tgg	gtg	gcc	cag	atc	aga	aac	aag	atc	tac	acc	tac	gcc	acc	ttc	240
Glu	Trp	Val	Ala	Gln	Ile	Arg	Asn	Lys	Ile	Tyr	Thr	Tyr	Ala	Thr	Phe	
65					70					75					80	
tac	gcc	gag	agc	ctt	gag	ggc	aga	ttc	acc	atc	tcc	aga	gac	aac	agc	288
Tyr	Ala	Glu	Ser	Leu	Glu	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	Ser	
				85					90					95		
aag	tcc	acc	gtg	tac	ctt	cag	atg	aac	tcc	ctg	aga	gcc	gag	gac	acc	336
Lys	Ser	Thr	Val	Tyr	Leu	Gln	Met	Asn	Ser	Leu	Arg	Ala	Glu	Asp	Thr	
			100					105					110			
gcc	gtg	tac	tac	tgt	acc	aga	agc	ctt	acc	ggc	ggc	gac	tac	ttc	gac	384
Ala	Val	Tyr	Tyr	Cys	Thr	Arg	Ser	Leu	Thr	Gly	Gly	Asp	Tyr	Phe	Asp	
		115					120					125				
tac	tgg	ggc	cag	ggc	acc	ctg	gtg	acc	gtg	agc	tca	gcc	agc	acc	aag	432
Tyr	Trp	Gly	Gln	Gly	Thr	Leu	Val	Thr	Val	Ser	Ser	Ala	Ser	Thr	Lys	
	130					135					140					
ggc	cct	tcc	gtg	ttc	cct	ctg	gcc	cct	tgt	agc	cgt	tcc	acc	agc	gag	480
Gly	Pro	Ser	Val	Phe	Pro	Leu	Ala	Pro	Cys	Ser	Arg	Ser	Thr	Ser	Glu	
145					150					155					160	
tcc	acc	gcc	gcc	ctt	ggc	tgt	ctg	gtg	aag	gac	tac	ttc	cct	gag	cct	528
Ser	Thr	Ala	Ala	Leu	Gly	Cys	Leu	Val	Lys	Asp	Tyr	Phe	Pro	Glu	Pro	
				165					170					175		
gtg	acc	gtg	agc	tgg	aac	tcc	gga	gcc	ctt	acc	agc	ggc	gtg	cac	acc	576
Val	Thr	Val	Ser	Trp	Asn	Ser	Gly	Ala	Leu	Thr	Ser	Gly	Val	His	Thr	
			180				185						190			
ttc	cct	gcc	gtg	ctg	cag	tcc	agc	ggc	ctt	tac	tcc	ctg	agc	tcc	gtg	624
Phe	Pro	Ala	Val	Leu	Gln	Ser	Ser	Gly	Leu	Tyr	Ser	Leu	Ser	Ser	Val	
		195				200						205				
gtg	acc	gtg	cct	agc	tcc	aac	ttc	ggc	acc	caa	acc	tac	acc	tgt	aac	672
Val	Thr	Val	Pro	Ser	Ser	Asn	Phe	Gly	Thr	Gln	Thr	Tyr	Thr	Cys	Asn	
	210					215					220					
gtg	gac	cac	aag	cct	agc	aac	acc	aag	gtg	gac	aag	acc	gtg	gag	cgt	720
Val	Asp	His	Lys	Pro	Ser	Asn	Thr	Lys	Val	Asp	Lys	Thr	Val	Glu	Arg	
225					230				235						240	
aag	tgt	tgt	gtg	gag	tgt	cct	cct	tgt	cct	gcc	cct	cct	gtg	gcc	gga	768
Lys	Cys	Cys	Val	Glu	Cys	Pro	Pro	Cys	Pro	Ala	Pro	Pro	Val	Ala	Gly	
				245					250					255		
cct	tcc	gtg	ttc	ctt	ttc	cct	cct	aag	cct	aag	gac	acc	ctg	atg	atc	816
Pro	Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu	Met	Ile	
			260					265					270			
agc	cgt	acc	cct	gag	gtg	acc	tgt	gtg	gtg	gtg	gac	gtg	tcc	cac	gag	864
Ser	Arg	Thr	Pro	Glu	Val	Thr	Cys	Val	Val	Val	Asp	Val	Ser	His	Glu	
		275					280					285				
gac	cct	gag	gtg	cag	ttc	aac	tgg	tac	gtg	gac	ggc	gtg	gag	gtg	cac	912
Asp	Pro	Glu	Val	Gln	Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu	Val	His	
	290					295					300					
aac	gcc	aag	acc	aag	cct	cgt	gag	gag	caa	ttc	aac	agc	acc	ttc	cgt	960
Asn	Ala	Lys	Thr	Lys	Pro	Arg	Glu	Glu	Gln	Phe	Asn	Ser	Thr	Phe	Arg	
305					310					315					320	
gtg	gtg	tcc	gtg	ctt	acc	gtg	gtg	cac	caa	gac	tgg	ctg	aac	ggc	aag	1008

Val Val Ser Val Leu Thr Val Val His Gln Asp Trp Leu Asn Gly Lys
 325 330 335
 gag tac aag tgt aag gtg agc aac aag gga ctt cct gcc cct atc gag 1056
 Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ala Pro Ile Glu
 340 345 350
 aag acc atc tcc aag acc aag ggc caa cct cgt gag cct caa gtg tac 1104
 Lys Thr Ile Ser Lys Thr Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr
 355 360 365
 acc ctt cct cct agc cgt gag gag atg acc aag aac caa gtg tcc ctt 1152
 Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu
 370 375 380
 acc tgt ctg gtg aag ggc ttc tac cct agc gac atc gcc gtg gag tgg 1200
 Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
 385 390 395 400
 gag tcc aac gga caa cct gag aac aac tac aag acc acc cct cct atg 1248
 Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Met
 405 410 415
 ctt gac agc gac ggc tcc ttc ttc ctg tac agc aag ctg acc gtg gac 1296
 Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp
 420 425 430
 aag tcc cgt tgg caa caa ggc aac gtg ttc agc tgt tcc gtg atg cac 1344
 Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His
 435 440 445
 gag gcc ctg cac aac cac tac acc caa aag agc ctt tcc ctg agc cct 1392
 Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro
 450 455 460
 gga aag
 Gly Lys 1398
 465

<210> 101
 <211> 466
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic Construct

<400> 101

Met Lys His Leu Trp Phe Phe Leu Leu Leu Val Ala Ala Pro Arg Trp
 1 5 10 15

Val Leu Ser Glu Val Gln Val Val Glu Ser Gly Gly Gly Leu Val Gln
 20 25 30

Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly Phe Asn Phe
 35 40 45

Asn Asp Tyr Phe Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
 50 55 60

Glu Trp Val Ala Gln Ile Arg Asn Lys Ile Tyr Thr Tyr Ala Thr Phe
 65 70 75 80

Tyr Ala Glu Ser Leu Glu Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser
 85 90 95
 Lys Ser Thr Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr
 100 105 110
 Ala Val Tyr Tyr Cys Thr Arg Ser Leu Thr Gly Gly Asp Tyr Phe Asp
 115 120 125
 Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys
 130 135 140
 Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu
 145 150 155 160
 Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro
 165 170 175
 Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr
 180 185 190
 Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val
 195 200 205
 Val Thr Val Pro Ser Ser Asn Phe Gly Thr Gln Thr Tyr Thr Cys Asn
 210 215 220
 Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Thr Val Glu Arg
 225 230 235 240
 Lys Cys Cys Val Glu Cys Pro Pro Cys Pro Ala Pro Pro Val Ala Gly
 245 250 255
 Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
 260 265 270
 Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu
 275 280 285
 Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His
 290 295 300
 Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Phe Arg
 305 310 315 320
 Val Val Ser Val Leu Thr Val Val His Gln Asp Trp Leu Asn Gly Lys
 325 330 335
 Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ala Pro Ile Glu
 340 345 350

Lys Thr Ile Ser Lys Thr Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr
355 360 365

Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu
370 375 380

Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
385 390 395 400

Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Met
405 410 415

Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp
420 425 430

Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His
435 440 445

Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro
450 455 460

Gly Lys
465

<210> 102
<211> 714
<212> DNA
<213> Artificial Sequence

<220>
<223> h#32A1-L2-15

<220>
<221> CDS
<222> (1)..(714)

<400> 102
atg gtg ctg cag acc cag gtg ttc atc tcc ctg ctg ctg tgg atc tcc 48
Met Val Leu Gln Thr Gln Val Phe Ile Ser Leu Leu Leu Trp Ile Ser
1 5 10 15
ggc gca tat ggc gaa att ctg atg acg cag agt cct gca act ctt agt 96
Gly Ala Tyr Gly Glu Ile Leu Met Thr Gln Ser Pro Ala Thr Leu Ser
20 25 30
ctg tca cct ggc gag aga gcc aca ctc agc tgc cga gcg tcc cag tcc 144
Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser
35 40 45
gtg acc att agc ggc tat tct ttt att cat tgg tat cag caa aag cct 192
Val Thr Ile Ser Gly Tyr Ser Phe Ile His Trp Tyr Gln Gln Lys Pro
50 55 60
gga cag gcg cca agg ctg ctc att tac aga gca agc aac ctt gcc tct 240
Gly Gln Ala Pro Arg Leu Leu Ile Tyr Arg Ala Ser Asn Leu Ala Ser
65 70 75 80

ggc att cca gca aga ttc agc ggg agc gga tca ggg aca gat ttc acc 288
 Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
 85 90 95
 ttg acc atc tcc tcc ctg gag ccg gag gat ttc gcg ttg tat tat tgt 336
 Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Leu Tyr Tyr Cys
 100 105 110
 cag caa tct agg aag agt cca tgg aca ttt ggc cag ggc acc aaa gtg 384
 Gln Gln Ser Arg Lys Ser Pro Trp Thr Phe Gly Gln Gly Thr Lys Val
 115 120 125
 gag atc aag cgt acg gtg gcc gcc ccc tcc gtg ttc atc ttc ccc ccc 432
 Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro
 130 135 140
 tcc gac gag cag ctg aag tcc ggc acc gcc tcc gtg gtg tgc ctg ctg 480
 Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu
 145 150 155 160
 aat aac ttc tac ccc aga gag gcc aag gtg cag tgg aag gtg gac aac 528
 Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn
 165 170 175
 gcc ctg cag tcc ggg aac tcc cag gag agc gtg acc gag cag gac agc 576
 Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser
 180 185 190
 aag gac agc acc tac agc ctg agc agc acc ctg acc ctg agc aaa gcc 624
 Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala
 195 200 205
 gac tac gag aag cac aag gtg tac gcc tgc gag gtg acc cac cag ggc 672
 Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly
 210 215 220
 ctg agc tcc ccc gtc acc aag agc ttc aac agg ggg gag tgt 714
 Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
 225 230 235

<210> 103
 <211> 238
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic Construct

<400> 103

Met Val Leu Gln Thr Gln Val Phe Ile Ser Leu Leu Leu Trp Ile Ser
1 5 10 15

Gly Ala Tyr Gly Glu Ile Leu Met Thr Gln Ser Pro Ala Thr Leu Ser
20 25 30

Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser
35 40 45

Val Thr Ile Ser Gly Tyr Ser Phe Ile His Trp Tyr Gln Gln Lys Pro
50 55 60

Gly Gln Ala Pro Arg Leu Leu Ile Tyr Arg Ala Ser Asn Leu Ala Ser

<220>
<223> h#32A1-L2-16

<220>
<221> CDS
<222> (1)..(714)

<400>	104																		
atg	gtg	ctg	cag	acc	cag	gtg	ttc	atc	tcc	ctg	ctg	ctg	tgg	atc	tcc				
Met	Val	Leu	Gln	Thr	Gln	Val	Phe	Ile	Ser	Leu	Leu	Leu	Trp	Ile	Ser				48
1				5					10					15					
ggc	gca	tat	ggc	gaa	atc	ctg	atg	aca	cag	agt	cct	gcg	acc	ctc	tcc				
Gly	Ala	Tyr	Gly	Glu	Ile	Leu	Met	Thr	Gln	Ser	Pro	Ala	Thr	Leu	Ser				96
			20					25					30						
ctc	tca	cca	ggc	gag	agg	gcc	acc	ctg	tct	tgt	aga	gcc	agc	cag	tca				
Leu	Ser	Pro	Gly	Glu	Arg	Ala	Thr	Leu	Ser	Cys	Arg	Ala	Ser	Gln	Ser				144
		35					40					45							

gtc act att agt gga tac tca ttt atc cat tgg tat caa cag aaa cca 192
 Val Thr Ile Ser Gly Tyr Ser Phe Ile His Trp Tyr Gln Gln Lys Pro
 50 55 60
 gga cag gcg cct cgg ctt ctg atc tac cgc gcc tca aac ctt gcc tct 240
 Gly Gln Ala Pro Arg Leu Leu Ile Tyr Arg Ala Ser Asn Leu Ala Ser
 65 70 75 80
 ggc atc ccc gcg agg ttc tct ggc tct ggc agc ggt acc gat ttt aca 288
 Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
 85 90 95
 ctg act atc tca agc ctc gaa cct gaa gac ttc gca ctg tac ttt tgc 336
 Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Leu Tyr Phe Cys
 100 105 110
 cag cag agc agg aag tcc ccc tgg act ttt gca cag gga acc aaa gtc 384
 Gln Gln Ser Arg Lys Ser Pro Trp Thr Phe Ala Gln Gly Thr Lys Val
 115 120 125
 gaa atc aag cgt acg gtg gcc gcc ccc tcc gtg ttc atc ttc ccc ccc 432
 Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro
 130 135 140
 tcc gac gag cag ctg aag tcc ggc acc gcc tcc gtg gtg tgc ctg ctg 480
 Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu
 145 150 155 160
 aat aac ttc tac ccc aga gag gcc aag gtg cag tgg aag gtg gac aac 528
 Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn
 165 170 175
 gcc ctg cag tcc ggg aac tcc cag gag agc gtg acc gag cag gac agc 576
 Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser
 180 185 190
 aag gac agc acc tac agc ctg agc agc acc ctg acc ctg agc aaa gcc 624
 Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala
 195 200 205
 gac tac gag aag cac aag gtg tac gcc tgc gag gtg acc cac cag gcc 672
 Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly
 210 215 220
 ctg agc tcc ccc gtc acc aag agc ttc aac agg ggg gag tgt 714
 Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
 225 230 235

<210> 105
 <211> 238
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic Construct

<400> 105

Met Val Leu Gln Thr Gln Val Phe Ile Ser Leu Leu Leu Trp Ile Ser
1 5 10 15

Gly Ala Tyr Gly Glu Ile Leu Met Thr Gln Ser Pro Ala Thr Leu Ser
20 25 30

Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser
 35 40 45
 Val Thr Ile Ser Gly Tyr Ser Phe Ile His Trp Tyr Gln Gln Lys Pro
 50 55 60
 Gly Gln Ala Pro Arg Leu Leu Ile Tyr Arg Ala Ser Asn Leu Ala Ser
 65 70 75 80
 Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
 85 90 95
 Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Leu Tyr Phe Cys
 100 105 110
 Gln Gln Ser Arg Lys Ser Pro Trp Thr Phe Ala Gln Gly Thr Lys Val
 115 120 125
 Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro
 130 135 140
 Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu
 145 150 155 160
 Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn
 165 170 175
 Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser
 180 185 190
 Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala
 195 200 205
 Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly
 210 215 220
 Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
 225 230 235

 <210> 106
 <211> 1111
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Nucleic acid sequence coding signal peptide and constant region of
 human IgG2 heavy chain

 <400> 106
 aagcttgcta gcgccaccat gaaacacctg tggttcttcc tcctgctggt ggcagctccc 60
 agatgggtgc tgagccaggt gcaattgtgc aggcggtag ctacgccagc accaagggcc 120
 cttccgtgtt ccctctggcc cctttagacc gttccaccag cgagtccaac gccgccttg 180

gctgtctggt gaaggactac ttccctgagc ctgtgaccgt gagctggaac tccggagccc	240
ttaccagcgg cgtgcacacc ttccctgccg tgctgcagtc cagcggcctt tactccctga	300
gctccgtggt gaccgtgcct agctccaact tcggcaccca aacctacacc tgtaacgtgg	360
accacaagcc tagcaacacc aagggtggaca agaccgtgga gcgtaagtgt tgtgtggagt	420
gtcctccttg tcctgcccct cctgtggccg gaccttccgt gttccttttc ctcctaagc	480
ctaaggacac cctgatgac agccgtaccc ctgaggtgac ctgtgtggtg gtggacgtgt	540
cccacgagga ccctgaggtg cagttcaact ggtacgtgga cggcgtggag gtgcacaacg	600
ccaagaccaa gcctcgtgag gagcaattca acagcacctt ccgtgtggtg tccgtgctta	660
ccgtggtgca ccaagactgg ctgaacggca aggagtacaa gtgtaagggtg agcaacaagg	720
gacttcctgc ccctatcgag aagaccatct ccaagaccaa gggccaacct cgtgagcctc	780
aagtgtacac ctttcctcct agccgtgagg agatgaccaa gaaccaagtg tcccttacct	840
gtctggtgaa gggcttctac cctagcgaca tcgccgtgga gtgggagtcc aacggacaac	900
ctgagaacaa ctacaagacc acccctccta tgcttgacag cgacggctcc ttcttcctgt	960
acagcaagct gaccgtggac aagtcccgtt ggcaacaagg caacgtgttc agctgttccg	1020
tgatgcacga ggccctgcac aaccactaca cccaaaagag cttttccctg agccctggaa	1080
agtgatatcg ggcccgttta aacgggtggc a	1111

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. An isolated antibody which binds to a polypeptide comprising amino acid residues 39 to 165 of an amino acid sequence represented by SEQ ID NO: 2 and inhibits osteoclast formation and/or osteoclastic bone resorption, or a functional fragment of the antibody, wherein the antibody or functional fragment thereof comprises:

a heavy chain sequence containing a variable region having CDRH1, CDRH2, and CDRH3, and the CDRH1 comprises an amino acid sequence represented by SEQ ID NO: 44, the CDRH2 comprises any one of amino acid sequences represented by SEQ ID NO: 45 and SEQ ID NO: 97, and the CDRH3 comprises an amino acid sequence represented by SEQ ID NO: 46; and

a light chain sequence containing a variable region having CDRL1, CDRL2, and CDRL3, and the CDRL1 comprises an amino acid sequence represented by SEQ ID NO: 47, the CDRL2 comprises an amino acid sequence represented by SEQ ID NO: 48, and the CDRL3 comprises an amino acid sequence represented by SEQ ID NO: 49, and

wherein the antibody is not:

(i) the antibody produced by hybridoma FERM BP-10999 or a functional fragment, humanised variant or chimeric variant of the antibody produced by hybridoma FERM BP-10999 ; or

(ii) a polyspecific antibody derived from the antibody produced by hybridoma FERM BP-10999 or a functional fragment, humanised variant or chimeric variant thereof.

2. The antibody or a functional fragment of the antibody according to claim 1, which contains a heavy chain variable

region sequence comprising amino acid residues 20 to 140 of an amino acid sequence represented by SEQ ID NO: 41 and a light chain variable region sequence comprising amino acid residues 21 to 132 of an amino acid sequence represented by SEQ ID NO: 43; and wherein the heavy chain has a constant region of a human immunoglobulin G2 heavy chain and the light chain has a constant region of a human immunoglobulin K light chain.

3. The functional fragment of the isolated antibody according to claim 1 which is selected from the group consisting of Fab, F(ab')₂, Fab' and Fv.
4. The isolated antibody according to claim 1 or claim 2, wherein the antibody is an scFv.
5. The isolated antibody or a functional fragment of the isolated antibody according to any one of claims 1 to 3, wherein the antibody is a chimeric antibody.
6. The isolated antibody or a functional fragment of the isolated antibody according to any one of claims 1 to 3, or 5, wherein the antibody is humanized.
7. The isolated antibody according to claim 6 when dependent from claims 1, 3 or 5, wherein the heavy chain has a constant region of a human immunoglobulin G2 heavy chain and the light chain has a constant region of a human immunoglobulin K light chain.
8. A pharmaceutical composition, wherein said pharmaceutical composition comprises at least one of the antibodies or functional fragments of the antibodies according to any one of claims 1 to 7.

9. The pharmaceutical composition according to claim 8, wherein said pharmaceutical composition is a therapeutic and/or preventive agent for abnormal bone metabolism.

10. A pharmaceutical composition for treating and/or preventing abnormal bone metabolism, which comprises at least one of the antibodies or functional fragments of the antibodies according to any one of claims 1 to 7 and at least one member selected from the group consisting of bisphosphonates, active vitamin D3, calcitonin and derivatives thereof, hormones, SERMs (selective estrogen receptor modulators), ipriflavone, vitamin K2 (menatetrenone), calcium preparations, PTH (parathyroid hormone), nonsteroidal anti-inflammatory agents, soluble TNF receptors, anti-TNF- α antibodies or functional fragments of the antibodies, anti-PTHrP (parathyroid hormone-related protein) antibodies or functional fragments of the antibodies, IL-1 receptor antagonists, anti-IL-6 receptor antibodies or functional fragments of the antibodies, anti-RANKL antibodies or functional fragments of the antibodies, and OCIF (osteoclastogenesis inhibitory factor).

11. The pharmaceutical composition according to claim 9 or claim 10, wherein the abnormal bone metabolism is selected from the group consisting of osteoporosis, bone destruction accompanying rheumatoid arthritis, cancerous hypercalcemia, bone destruction accompanying multiple myeloma or cancer metastasis to bone, giant cell tumor, osteopenia, tooth loss due to periodontitis, osteolysis around a prosthetic joint, bone destruction in chronic osteomyelitis, Paget's disease of bone, renal osteodystrophy, and osteogenesis imperfecta.

12. The pharmaceutical composition according to claim 11, wherein the abnormal bone metabolism is osteoporosis, bone

destruction accompanying rheumatoid arthritis, or bone destruction accompanying cancer metastasis to bone.

13. The pharmaceutical composition according to claim 12, wherein the abnormal bone metabolism is osteoporosis.

14. The pharmaceutical composition according to claim 12, wherein the osteoporosis is postmenopausal osteoporosis, senile osteoporosis, secondary osteoporosis due to the use of a therapeutic agent, or osteoporosis accompanying rheumatoid arthritis.

15. Use of an antibody according to any one of claims 1 to 7 or a functional fragment thereof for the manufacture of a medicament for treating and/or preventing abnormal bone metabolism.

16. Use of an antibody according to any one of claims 1 to 7 or a functional fragment thereof for the manufacture of a medicament for treating and/or preventing abnormal bone metabolism, wherein said medicament is for simultaneous or successive administration with at least one member selected from the group consisting of bisphosphonates, active vitamin D₃, calcitonin and derivatives thereof, hormones, SERMs (selective estrogen receptor modulators), ipriflavone, vitamin K₂ (menatetrenone), calcium preparations, PTH (parathyroid hormone), nonsteroidal anti-inflammatory agents, soluble TNF receptors, anti-TNF- α antibodies or functional fragments of the antibodies, anti-PTHrP (parathyroid hormone-related protein) antibodies or functional fragments of the antibodies, IL-1 receptor antagonists, anti-IL-6 receptor antibodies or functional fragments of the antibodies, anti-RANKL antibodies or functional fragments of the antibodies, and OCIF (osteoclastogenesis inhibitory factor).

17. The use according to claim 15 or claim 16, wherein the abnormal bone metabolism is osteoporosis, bone destruction accompanying rheumatoid arthritis, or bone destruction accompanying cancer metastasis to bone.

18. The use according to claim 17, wherein the abnormal bone metabolism is osteoporosis.

19. The use according to claim 18, wherein the osteoporosis is postmenopausal osteoporosis, senile osteoporosis, secondary osteoporosis due to the use of a therapeutic agent, or osteoporosis accompanying rheumatoid arthritis.

20. The pharmaceutical composition according to any one of claims 10 to 14, or the use according to claim 15, wherein the hormones are estradiol.

21. The pharmaceutical composition according to claim 14 or the use according to claim 19 wherein the therapeutic agent is a steroid or an immunosuppressant.

22. An isolated polynucleotide encoding the antibody according to claim 2.

23. The isolated polynucleotide according to claim 22, wherein said polynucleotide contains a nucleotide sequence comprising nucleotides 58 to 420 of a nucleotide sequence represented by SEQ ID NO: 40 and a nucleotide sequence comprising nucleotides 61 to 396 of a nucleotide sequence represented by SEQ ID NO: 42.

24. The isolated polynucleotide according to claim 23, wherein said polynucleotide contains a nucleotide sequence comprising nucleotides 58 to 1410 of a nucleotide sequence represented by SEQ ID NO: 40 and a nucleotide sequence comprising nucleotides

61 to 711 of a nucleotide sequence represented by SEQ ID NO: 42.

25. A vector, comprising any one of the polynucleotides according to any one of claims 22 to 24.

26. A transformed host cell, comprising any one of the polynucleotides according to any one of claims 22 to 24.

27. A transformed host cell, comprising the vector according to claim 25.

28. A method of producing the antibody according to claim 2, comprising culturing the host cell according to claim 26 or claim 27, and purifying an antibody from the resulting culture product.